1
00:00:05,956 --> 00:00:09,893
THE NHLBI TO WELCOME YOU TO THIS

2
00:00:09,893 --> 00:00:13,097
311th MEETING OF THE NATIONAL

3
00:00:13,097 --> 00:00:16,467
HEART, LUNG AND BLOOD ADVISORY

4
00:00:16,467 --> 00:00:19,303
COUNCIL AND EXPRESS OUR SINCERE

5
00:00:19,303 --> 00:00:21,038
APPRECIATION TO MEMBERS OF

6
00:00:21,038 --> 00:00:22,973
COUNCIL FOR SHARING THEIR

7
00:00:22,973 --> 00:00:24,108
PRECIOUS TIME AND BRAIN POWER

8
00:00:24,108 --> 00:00:28,112
WITH US AS WE CONDUCT THE

9
00:00:28,112 --> 00:00:30,414
BUSINESS OF NHLBI MISSION AND

10
00:00:30,414 --> 00:00:31,348
WITHOUT FURTHER ADO, LET ME TURN

11
00:00:31,348 --> 00:00:37,521
IT OVER TO OUR EXECUTIVE

12
00:00:37,521 --> 00:00:40,858
SECRETARY DR. CHARISEE LAMAR TO

13
00:00:40,858 --> 00:00:43,393
LEAD US THROUGH THE OPENING

14
00:00:43,393 --> 00:00:45,129
SESSION, AND MY GAVEL IN 1 HAND,

15
00:00:45,129 --> 00:00:46,430
1 HAND ON THE MICROPHONE AND THE

16
00:00:46,430 --> 00:00:48,432
OTHER ON THE GAVEL, THANK YOU.

17
00:00:48,432 --> 00:00:50,167
>> THANK YOU DR. GIBBONS
AND

18
00:00:50,167 --> 00:00:51,468
GOOD MORNING AND WELCOME, OR

19
00:00:51,468 --> 00:00:52,603
GOOD AFTERNOON AND WELCOME

20
00:00:52,603 --> 00:00:53,804
DEPENDING ON YOUR TIME ZONE.

21
00:00:53,804 --> 00:00:56,006
WE ARE DELIGHTED TO HAVE YOU

22
00:00:56,006 --> 00:00:56,540
JOIN US TODAY.

23
00:00:56,540 --> 00:00:58,375
SO AS WE GET STARTED I LOOLD

24
00:00:58,375 --> 00:01:01,145
TOIK TO MAKE A FEW

25
00:01:01,145 --> 00:01:01,745
ADMINISTRATIVE ANNOUNCEMENTS.

26
00:01:01,745 --> 00:01:03,514
THE NOTICE OF THIS SCHEDULED

27
00:01:03,514 --> 00:01:06,383
MEETING WAS PUBLISHED IN THE

28
00:01:06,383 --> 00:01:07,317
FEDERAL REGISTER, PLEASE RNL,

29
00:01:07,317 --> 00:01:08,585
THIS IS AN OPEN SESSION TODAY

30
00:01:08,585 --> 00:01:10,554
AND IT IS BEING RECORDED.

31
00:01:10,554 --> 00:01:12,389
THE VIDEO OF THE SESSION WILL BE

32
00:01:12,389 --> 00:01:13,490
ARCHIVED AND REMAIN AVAILABLE TO

33
00:01:13,490 --> 00:01:16,560
THE PUBLIC AND NIH COLLEAGUES.

34
00:01:16,560 --> 00:01:19,429
TO REVIEW BRIEFLY OUR AGENDA FOR

35
00:01:19,429 --> 00:01:20,964
TODAY, WE WILL, AFTER MY

36
00:01:20,964 --> 00:01:22,466
ANNOUNCEMENTS, WE WILL HAVE

37
00:01:22,466 --> 00:01:25,536
DR. GIBBONS GIVE HIS DIRECTOR'S

38
00:01:25,536 --> 00:01:25,769
REPORT.

39
00:01:25,769 --> 00:01:27,171
WE WILL HAVE LUNCH AND THEN WE

40
00:01:27,171 --> 00:01:33,143
WILL HAVE A PRESENTATION BY

41
00:01:33,143 --> 00:01:34,311
DR. MUZUNO FROM THE INTRAMURAL

42
00:01:34,311 --> 00:01:35,145
RESEARCH PROGRAM AND THEN WE

43
00:01:35,145 --> 00:01:38,115
WILL FOLLOW UP WITH A BRIEF

44
00:01:38,115 --> 00:01:40,350
REFRESHER ON THE DECISION LENS

45
00:01:40,350 --> 00:01:42,986
AND THEN REMOVE INTO REVIEW FOR

46
00:01:42,986 --> 00:01:44,154
CONCEPTS FOR COUNSELS AND I WILL

47
00:01:44,154 --> 00:01:45,989
ADJOURN AFTER WE HAVE THOSE

48
00:01:45,989 --> 00:01:46,790
DISCUSSIONS.

49
00:01:46,790 --> 00:01:47,524
SO WITHOUT FURTHER ADO, I WILL

50
00:01:47,524 --> 00:01:49,393
TURN IT OVER TO DR. GIBBONS SO

51
00:01:49,393 --> 00:01:51,662
HE CAN GIVE HIS DIRECTOR'S

52
00:01:51,662 --> 00:02:01,805
REPORT. 

53
00:02:04,241 --> 00:02:04,474
DR. GIBBONS?

54
00:02:04,474 --> 00:02:06,076
>> ALL RIGHT.

55
00:02:06,076 --> 00:02:09,947
WELL, THANK YOU, AUDIO'S OKAY,

56
00:02:09,947 --> 00:02:10,847
YOU CAN HEAR?

57
00:02:10,847 --> 00:02:11,548
OKAY, GREAT.

58
00:02:11,548 --> 00:02:17,287
WELL, THANK YOU AND WE CAN GO TO

59
00:02:17,287 --> 00:02:18,555
THE NEXT SLIDE.

60
00:02:18,555 --> 00:02:20,090
THE DIRECTOR'S REPORT, AGAIN IN

61
00:02:20,090 --> 00:02:23,126
OUR USUAL 2 SECTIONS, I WILL

62
00:02:23,126 --> 00:02:25,329
START OFF WITH ACCOUNTABLE

63
00:02:25,329 --> 00:02:28,065
STEWARDSHIP AND MOVE MORE TOWARD

64
00:02:28,065 --> 00:02:30,000
OUR SCIENTIFIC PORTFOLIO

65
00:02:30,000 --> 00:02:31,034
PRIORITIES.

66
00:02:31,034 --> 00:02:36,707
NEXT. 

67
00:02:36,707 --> 00:02:40,577
NEXT SLIDE, PLEASE.

68
00:02:40,577 --> 00:02:43,380
FIRST I WANTED TO EXPRESS

69
00:02:43,380 --> 00:02:48,919
APPRECIATION TO OUR BOARD OF

70
00:02:48,919 --> 00:02:50,153
SCIENTIFIC COUNSELORS, SORT OF

71
00:02:50,153 --> 00:02:52,522
AN EXTENSION OF OUR FACA

72
00:02:52,522 --> 00:02:53,890
ACCOUNTABILITY, PARTICULARLY IN

73
00:02:53,890 --> 00:02:56,727
THIS CASE, FOCUSED IN ON OUR

74
00:02:56,727 --> 00:02:59,663
INTRA MAURI OSHEROFFAL PROGRAM

75
00:02:59,663 --> 00:03:01,798
AND INSURING THAT WE'RE

76
00:03:01,798 --> 00:03:07,437
MAINTAINING A HIGH STANDARD AND

77
00:03:07,437 --> 00:03:09,039
CONSTITUTES ABOUT PERHAPS 6 OR

78
00:03:09,039 --> 00:03:13,610
7 PERCENT OF THE OVERALL NHLBI

79
00:03:13,610 --> 00:03:17,748
BUDGET BUT IT IS AN IMPORTANT

80
00:03:17,748 --> 00:03:19,483
AND COMPLIMENTARY COMPONENT TO

81
00:03:19,483 --> 00:03:21,051
OUR SCIENTIFIC PORTFOLIO RELATED

82
00:03:21,051 --> 00:03:24,054
TO THE DISTINKTSIVENESS OF THE

83
00:03:24,054 --> 00:03:25,022
INTRAMURAL PROGRAM IN PART BY

84
00:03:25,022 --> 00:03:28,058
THE CLINICAL CENTER WHICH IS THE

85
00:03:28,058 --> 00:03:30,093
WORLD'S LARGEST RESEARCH

86
00:03:30,093 --> 00:03:32,029
HOSPITAL AND INCLUDES A BREDTH

87
00:03:32,029 --> 00:03:35,198
OF SCIENCE, OF BASIC EARLY

88
00:03:35,198 --> 00:03:36,266
TRANSLATION, CLINICAL POPULATION

89
00:03:36,266 --> 00:03:39,536
SCIENCE AND SO THAT UNDERGOES A

90
00:03:39,536 --> 00:03:41,038
REVIEW AND GENERALLY IN JUNE

91
00:03:41,038 --> 00:03:44,107
COUNCIL WE GET THOSE VERY CYCLES

92
00:03:44,107 --> 00:03:46,843
OF REVIEWS OF OUR VARIOUS

93
00:03:46,843 --> 00:03:51,181
INVESTIGATORS AND THEY UNDERGO A

94
00:03:51,181 --> 00:03:54,051
RIGOROUS EVALUATION BY THIS BSC.

95
00:03:54,051 --> 00:03:57,454
I MIGHT ALSO TAKE THIS MOMENT

96
00:03:57,454 --> 00:03:59,122
NOT ONLY TO THANK THOSE ON THE

97
00:03:59,122 --> 00:04:01,391
BSC WHO HAVE SERVED AND HAVE

98
00:04:01,391 --> 00:04:03,026
BEEN PART OF A CLOSED SESSION

99
00:04:03,026 --> 00:04:06,330
REVIEW OF ALL THE PIs THAT

100
00:04:06,330 --> 00:04:11,735
CAME UP IN THIS CYCLE, WITH OUR

101
00:04:11,735 --> 00:04:14,538
ADVISORY COUNCIL BUT ALSO TO

102
00:04:14,538 --> 00:04:17,774
EXPRESS PUBLICLY, MY

103
00:04:17,774 --> 00:04:19,376
APPRECIATION FOR DR. ALEXIS

104
00:04:19,376 --> 00:04:23,347
THOMPSON WHO HAS BEEN A MEMBER

105
00:04:23,347 --> 00:04:26,650
OF OUR BSC BUT RELATED TO SOME

106
00:04:26,650 --> 00:04:29,619
OF THE ACTIVITIES OF THE NEW

107
00:04:29,619 --> 00:04:30,754
ADMINISTRATION TRANSITION AND

108
00:04:30,754 --> 00:04:35,492
THE REVIEW OF ALL OUR FACA

109
00:04:35,492 --> 00:04:38,395
COMMITTEES WHICH IS THE

110
00:04:38,395 --> 00:04:42,132
PREROGATIVE OF THE

111
00:04:42,132 --> 00:04:42,499
ADMINISTRATION.

112
00:04:42,499 --> 00:04:44,067
THE DECISION WAS MADE TO

113
00:04:44,067 --> 00:04:53,176
TERMINATE HER SERVICE A COUPLE

114
00:04:53,176 --> 00:04:54,478
TIME EARLIER, SHE'S BEEN

115
00:04:54,478 --> 00:04:55,545
EXEMPLARY IN HER SERVICE, SO

116
00:04:55,545 --> 00:05:02,018
THERE'S NO CAUSE THAT WE COULD

117
00:05:02,018 --> 00:05:04,054
DISCERN SO WE EXPRESS OUR

118
00:05:04,054 --> 00:05:06,289
GRATITUDE TO HER AND HER

119
00:05:06,289 --> 00:05:08,425
SERVICE. 

120
00:05:08,425 --> 00:05:10,160
I MIGHT JUST POINT OUT

121
00:05:10,160 --> 00:05:11,561
PARENTHETICALLY THAT THIS WAS A

122
00:05:11,561 --> 00:05:13,630
PROCESS THAT OCCURRED THROUGHOUT

123
00:05:13,630 --> 00:05:20,804
A NUMBER OF BSCs WITHIN THE

124
00:05:20,804 --> 00:05:21,738
INTRAMURAL PROGRAM, MANY OF YOU

125
00:05:21,738 --> 00:05:32,215
MAY HAVE SEEN REPORTS AND WE

126
00:05:38,321 --> 00:05:43,193
WANTED TO THANK HER FOR HER

127
00:05:43,193 --> 00:05:43,427
SERVICE.

128
00:05:43,427 --> 00:05:47,898
AND AGAIN AS PART OF THAT REVIEW

129
00:05:47,898 --> 00:05:49,833
OF OUR INTRAMURAL PROGRAM, WE

130
00:05:49,833 --> 00:05:53,737
ALSO LIKE TO TAKE THE

131
00:05:53,737 --> 00:05:56,573
OPPORTUNITY TO SHOWCASE AN

132
00:05:56,573 --> 00:05:58,175
INVESTIGATOR WITHIN THE DIR SO

133
00:05:58,175 --> 00:05:59,643
THAT OVERALL COUNSELS AND I WILL

134
00:05:59,643 --> 00:06:01,378
QUITE FRANKLY OUR EXTRAMURAL

135
00:06:01,378 --> 00:06:02,646
COMMUNITY GETS A WINDOW INTO

136
00:06:02,646 --> 00:06:04,648
SOME OF OUR OUTSTANDING

137
00:06:04,648 --> 00:06:05,882
SCIENTISTS THAT ARE BEING

138
00:06:05,882 --> 00:06:09,386
REVIEWED, AND SO WE LOOK FORWARD

139
00:06:09,386 --> 00:06:14,024
TO THE PRESENTATION TODAY OF

140
00:06:14,024 --> 00:06:16,092
DR. MIZUNO, A WORLD CLASS

141
00:06:16,092 --> 00:06:18,528
EXPERTS IN CRYOEM, AND VERY

142
00:06:18,528 --> 00:06:21,531
EXCITED ABOUT THE CENTER THAT

143
00:06:21,531 --> 00:06:31,942
SHE'S CREATED WITHIN THE

144
00:06:34,010 --> 00:06:35,111
INTRAMURAL PROGRAM.

145
00:06:35,111 --> 00:06:38,415
OKAY, HOPE THAT'S A LITTLE

146
00:06:38,415 --> 00:06:38,648
BETTER.

147
00:06:38,648 --> 00:06:40,851
OKAY, SO WE LOOK FORWARD TO HER

148
00:06:40,851 --> 00:06:41,785
PRESENTATION, AS AGAIN, GIVING

149
00:06:41,785 --> 00:06:44,654
YOU A TASTE OF THE INTRAMURAL

150
00:06:44,654 --> 00:06:46,723
PROGRAM NOW AND ANNUAL WORK

151
00:06:46,723 --> 00:06:48,158
THAT'S BEING DONE THERE.

152
00:06:48,158 --> 00:06:48,859
NEXT SLIDE, PLEASE.

153
00:06:48,859 --> 00:06:51,628
SO WITH THAT, ON THE INTRAMURAL

154
00:06:51,628 --> 00:06:57,033
SIDE, LET ME EXPAND OUT ON THE

155
00:06:57,033 --> 00:06:57,601
EXTRAMURAL ACCOUNTABLE

156
00:06:57,601 --> 00:06:59,769
STEWARDSHIP AND NO SURPRISE TO

157
00:06:59,769 --> 00:07:01,538
ALL OF YOU, YOU ARE AWARE WE'RE

158
00:07:01,538 --> 00:07:03,907
IN WHAT'S CALLED A FULL YEAR

159
00:07:03,907 --> 00:07:08,245
CONTINUING RESOLUTION WHICH IS

160
00:07:08,245 --> 00:07:12,048
IN ESSENCE CONGRESS DIDN'T PUT

161
00:07:12,048 --> 00:07:13,550
TOGETHER AN APPROPRIATION FOR

162
00:07:13,550 --> 00:07:14,851
FY25 THAT GOES THROUGH REGULAR

163
00:07:14,851 --> 00:07:19,155
ORDER AND IT REVIEWS AND

164
00:07:19,155 --> 00:07:21,791
REALLOCATES, BUT RATHER IS

165
00:07:21,791 --> 00:07:26,463
EXTENDING BASICALLY THE FY24

166
00:07:26,463 --> 00:07:28,832
GUIDANCE AND SO THAT KEEPS US

167
00:07:28,832 --> 00:07:35,238
FLAT, IN TERMS OF FY24 TO 25 AND

168
00:07:35,238 --> 00:07:40,377
YOU'VE SEEN OUR PUBLISHED

169
00:07:40,377 --> 00:07:44,080
FUNDING APPROACH WHICH THIS YEAR

170
00:07:44,080 --> 00:07:45,382
WE STRIVE TO MAINTAIN THE PAY

171
00:07:45,382 --> 00:07:47,117
LINE AS MUCH AS WE CAN BUT AS

172
00:07:47,117 --> 00:07:50,453
ALL OF YOU ARE AWARE, EVEN IN A

173
00:07:50,453 --> 00:07:52,756
FLAT BUDGET, GIVEN THE INFLATION

174
00:07:52,756 --> 00:07:54,558
AS PART OF DOING RESEARCH AND

175
00:07:54,558 --> 00:07:56,026
EVERYTHING ELSE THAT YOU'RE

176
00:07:56,026 --> 00:07:58,662
AWARE OF, EVEN WITH A FLAT

177
00:07:58,662 --> 00:08:00,196
BUDGET IT PUTS A LOT OF PRESSURE

178
00:08:00,196 --> 00:08:04,334
SUCH THAT IT'S HARD TO DO THE

179
00:08:04,334 --> 00:08:06,736
SAME AMOUNT OF WORK WITHOUT THE

180
00:08:06,736 --> 00:08:08,171
SAME AMOUNT OF MONEY GIVEN THE

181
00:08:08,171 --> 00:08:09,673
INCREASING COSTS OF DOING

182
00:08:09,673 --> 00:08:09,940
RESEARCH.

183
00:08:09,940 --> 00:08:13,009
WE'RE TRYING TO DO OUR BEST TO

184
00:08:13,009 --> 00:08:15,412
MAINTAIN THAT 12 PERCENTILE AND

185
00:08:15,412 --> 00:08:20,650
THEN A 10-POINT BONUS BUMP FOR

186
00:08:20,650 --> 00:08:25,889
ESIs AND MAKING RECOLLECT

187
00:08:25,889 --> 00:08:27,624
ADJUSTMENTS TO STRETCH THOSE

188
00:08:27,624 --> 00:08:28,992
RESOURCES, THAT'S WHERE WE ARE

189
00:08:28,992 --> 00:08:30,961
WITH 25 AND OBVIOUSLY DESPITE

190
00:08:30,961 --> 00:08:35,999
ALL THE THINGS HAPPENING WITH

191
00:08:35,999 --> 00:08:37,300
THE EXECUTIVE TRANSITION AND A

192
00:08:37,300 --> 00:08:39,269
LOT OF SHIFTS BEING MADE IN HOW

193
00:08:39,269 --> 00:08:42,405
FUNDING IS DONE OR AWARDS ARE

194
00:08:42,405 --> 00:08:44,407
BEING MADE, WE'RE NEVERTHELESS

195
00:08:44,407 --> 00:08:45,809
TRYING TO MAKE PROGRESS IN

196
00:08:45,809 --> 00:08:48,178
GETTING THOSE AWARDS OUT IN

197
00:08:48,178 --> 00:08:49,346
ACCORDANCE WITH THESE

198
00:08:49,346 --> 00:08:53,249
GUIDELINES. 

199
00:08:53,249 --> 00:08:53,950
NEXT SLIDE, PLEASE.

200
00:08:53,950 --> 00:08:55,552
AND TOWARD THAT END, I THINK

201
00:08:55,552 --> 00:09:00,256
IT'S ALWAYS IMPORTANT TO

202
00:09:00,256 --> 00:09:01,891
ACKNOWLEDGE WHAT'S HAPPENING AND

203
00:09:01,891 --> 00:09:03,727
ADDRESS THE ELEPHANT IN THE ROOM

204
00:09:03,727 --> 00:09:05,528
OF THE NEW ADMINISTRATION

205
00:09:05,528 --> 00:09:07,530
TRANSITIONS AND HOW THAT'S

206
00:09:07,530 --> 00:09:09,499
AFFECTING OUR OPERATIONS AND HOW

207
00:09:09,499 --> 00:09:13,236
IT'S AFFECTING YOU AS PART OF

208
00:09:13,236 --> 00:09:14,004
THE EXTRAMURAL COMMUNITY.

209
00:09:14,004 --> 00:09:18,308
I'M SURE YOU ARE AWARE THE

210
00:09:18,308 --> 00:09:22,512
PRESIDENT'S BUDGET AS WELL AS

211
00:09:22,512 --> 00:09:24,014
THE ADMINISTRATION'S INTENTION

212
00:09:24,014 --> 00:09:27,417
TO PROPOSE REORGANIZATION OF NIH

213
00:09:27,417 --> 00:09:29,619
IN WAYS YOU HAVE PROBABLY SEEN

214
00:09:29,619 --> 00:09:35,191
MODELS LIKE THIS BEFORE, AS I

215
00:09:35,191 --> 00:09:37,594
RECALL HAROLD VARMIS EVEN

216
00:09:37,594 --> 00:09:38,428
CONSIDERED VARIOUS

217
00:09:38,428 --> 00:09:39,462
ORGANIZATIONAL STRATEGIES, THESE

218
00:09:39,462 --> 00:09:42,966
THINGS SEEM TO COME UP EVERY

219
00:09:42,966 --> 00:09:46,236
5-10 YEARS AND THIS IS THE MOST

220
00:09:46,236 --> 00:09:48,004
RECENT 1.

221
00:09:48,004 --> 00:09:49,973
I SUPPOSE WE'RE BEING FOLDED

222
00:09:49,973 --> 00:09:52,342
INTO SOMETHING CALLED WHAT IS IT

223
00:09:52,342 --> 00:09:55,512
BODY SYSTEMS ALONG WITH MY GOOD

224
00:09:55,512 --> 00:09:58,381
FRIENDS AT DDK AND AMS, BUT

225
00:09:58,381 --> 00:10:00,250
THESE ARE PROPOSALS REMINISCENT

226
00:10:00,250 --> 00:10:02,952
OF THINGS THAT HAVE BEEN OUT

227
00:10:02,952 --> 00:10:05,188
WITH ROGERS IN CONGRESS, IT'S

228
00:10:05,188 --> 00:10:06,456
REMINISCENT OF THINGS THAT ARE

229
00:10:06,456 --> 00:10:08,992
WRITTEN UP IN PROJECT 2025

230
00:10:08,992 --> 00:10:10,860
DOCUMENTS, ET CETERA, SO, THESE

231
00:10:10,860 --> 00:10:14,364
MODELS HAVE BEEN OUT THERE BUT

232
00:10:14,364 --> 00:10:16,032
IT'S IMPORTANT FOR US TO

233
00:10:16,032 --> 00:10:18,201
APPRECIATE THAT IT'S REALLY UP

234
00:10:18,201 --> 00:10:21,671
TO CONGRESS TO AUTHORIZE ANY

235
00:10:21,671 --> 00:10:22,338
RESTRUCTURING OR REORGANIZATION.

236
00:10:22,338 --> 00:10:25,108
THE FACT THAT THERE'S 27 ICs,

237
00:10:25,108 --> 00:10:29,145
IS IN FACT A CREATION OF

238
00:10:29,145 --> 00:10:31,514
CONGRESS, THAT'S ITS WORK AND

239
00:10:31,514 --> 00:10:34,350
THEN IT AUTHORIZED THAT

240
00:10:34,350 --> 00:10:35,485
STRUCTURE AND APPROPRIATES

241
00:10:35,485 --> 00:10:37,787
ACCORDING TO THOSE EXISTING

242
00:10:37,787 --> 00:10:38,722
STRUCTURES SO AGAIN, I KNOW

243
00:10:38,722 --> 00:10:42,358
THERE MIGHT BE A LOT OF CONCERNS

244
00:10:42,358 --> 00:10:44,828
HERE, BUT AT THIS STAGE STILL

245
00:10:44,828 --> 00:10:48,465
JUST A PROPOSAL. 

246
00:10:48,465 --> 00:10:51,801
THERE ARE PROCESSES, SOME

247
00:10:51,801 --> 00:10:53,269
INVOLVING STRATEGIC MANAGEMENT

248
00:10:53,269 --> 00:10:57,574
REVIEW BOARD OR SMRB, THAT'S

249
00:10:57,574 --> 00:10:59,109
CONGRESSALLY -- YEAH, I THINK

250
00:10:59,109 --> 00:11:02,812
MANDATED AS A MECHANISM BY WHICH

251
00:11:02,812 --> 00:11:05,682
THESE SORTS OF CONSIDERATIONS

252
00:11:05,682 --> 00:11:08,852
ARE ADJUDICATED AS A SYSTEMATIC

253
00:11:08,852 --> 00:11:13,790
THOUGHTFUL PROCESS BY NIH, AND

254
00:11:13,790 --> 00:11:16,459
SO WE'RE HOPEFUL THEIR NEW NIH

255
00:11:16,459 --> 00:11:18,595
DIRECTOR OF LEVERAGE THAT

256
00:11:18,595 --> 00:11:20,096
MECHANISM TO EVEN CONTEMPLATE

257
00:11:20,096 --> 00:11:22,265
THIS SORT OF CONSIDERATION AND

258
00:11:22,265 --> 00:11:27,504
THAT HAS BEEN DONE BEFORE WITH I

259
00:11:27,504 --> 00:11:30,740
BELIEVE A MERGER OF NIDA AND

260
00:11:30,740 --> 00:11:34,144
NIAAA, IN TERMS OF ALCOHOL AND

261
00:11:34,144 --> 00:11:37,981
DRUG ABUSE THROUGH THAT

262
00:11:37,981 --> 00:11:38,314
MECHANISM.

263
00:11:38,314 --> 00:11:41,384
SO THERE IS PRECEDENT FOR THIS

264
00:11:41,384 --> 00:11:43,686
AND THAT'S WHY I ENCOURAGE US TO

265
00:11:43,686 --> 00:11:45,855
KEEP THE ANXIETY DOWN UNTIL

266
00:11:45,855 --> 00:11:48,725
THOSE SORT OF PROCESSES PLAY

267
00:11:48,725 --> 00:11:49,192
OUT.

268
00:11:49,192 --> 00:11:50,193
NEVERTHELESS, PROBABLY THE MORE

269
00:11:50,193 --> 00:11:54,164
STRIKING PART OF THE PRESIDENT'S

270
00:11:54,164 --> 00:11:56,699
BUDGET WAS THE 40 +% CUT OVER

271
00:11:56,699 --> 00:11:58,868
ALL, A LOSS OF OVER 18 BILLION

272
00:11:58,868 --> 00:12:03,139
DOLLARS, BACK TO A BASE OF 27

273
00:12:03,139 --> 00:12:04,073
FOR NIH.

274
00:12:04,073 --> 00:12:07,744
AND FOR THOSE WHO WATCH THE NIH

275
00:12:07,744 --> 00:12:11,981
DIRECTOR'S HEARING WITH THE

276
00:12:11,981 --> 00:12:13,683
APPROPRIATIONS RECOGNIZE THAT

277
00:12:13,683 --> 00:12:14,984
BOTH SIDES OF THE AISLE QUITE

278
00:12:14,984 --> 00:12:16,486
FRANKLY ARE CONCERNED ABOUT THE

279
00:12:16,486 --> 00:12:18,955
DEPTH OF THOSE CUTS AND THE

280
00:12:18,955 --> 00:12:19,989
IMPLICATIONS OF IT.

281
00:12:19,989 --> 00:12:23,526
SIMILARLY, I DON'T NEED TO TELL

282
00:12:23,526 --> 00:12:25,328
THIS GROUP 1 OF THE EXECUTIVE

283
00:12:25,328 --> 00:12:26,696
ORDERS OF THIS NEW

284
00:12:26,696 --> 00:12:34,637
ADMINISTRATION WAS TO PUT A CAP

285
00:12:34,637 --> 00:12:36,840
ON INDIRECT COSTS AT 15%, THOSE

286
00:12:36,840 --> 00:12:38,141
THINGS ARE BEING CHALLENGED IN

287
00:12:38,141 --> 00:12:39,309
COURT AND IT'S NOTABLE THAT AS

288
00:12:39,309 --> 00:12:42,078
FAR AS I KNOW AND WE'VE GONE

289
00:12:42,078 --> 00:12:43,580
THROUGH THIS BEFORE, THE NIH

290
00:12:43,580 --> 00:12:47,550
DOESN'T HAVE ANY KIND OF

291
00:12:47,550 --> 00:12:49,619
SOLITTORY, STATUTORY AUTHORITY

292
00:12:49,619 --> 00:12:54,190
TO JUST UNILATERALLY CHANGE THE

293
00:12:54,190 --> 00:12:54,858
INDIRECT COST RATE.

294
00:12:54,858 --> 00:12:57,360
AND SO THAT'S PART OF WHAT IS

295
00:12:57,360 --> 00:12:58,061
BEING CHALLENGED.

296
00:12:58,061 --> 00:13:00,196
I DON'T THINK NIH EVEN WORKS

297
00:13:00,196 --> 00:13:05,668
THROUGH THE CALCULATIONS OF ALL

298
00:13:05,668 --> 00:13:09,606
THOSE SORTS OF ELEMENTS AND SO,

299
00:13:09,606 --> 00:13:12,108
THIS IS AN AREA WHERE I WOULDN'T

300
00:13:12,108 --> 00:13:12,642
GET IMMEDIATELY PANICKED.

301
00:13:12,642 --> 00:13:15,945
THIS IS SOMETHING THAT WILL BE

302
00:13:15,945 --> 00:13:18,348
IN PLACE IN THE VERY NEAR TERM

303
00:13:18,348 --> 00:13:21,384
THOUGH IT WILL BE SOMETHING THAT

304
00:13:21,384 --> 00:13:24,454
I SUSPECT WILL BE EXAMINED,

305
00:13:24,454 --> 00:13:26,656
HOPEFULLY IN A MORE THOUGHTFUL

306
00:13:26,656 --> 00:13:29,559
WAY. 

307
00:13:29,559 --> 00:13:30,727
AGAIN, WE'RE PERHAPS IT IS TIME

308
00:13:30,727 --> 00:13:32,395
TO STEP BACK AND INSURE WE HAVE

309
00:13:32,395 --> 00:13:34,163
THE BEST MODEL, WE HAVE THE BEST

310
00:13:34,163 --> 00:13:35,899
CRITERIA, WE HAVE THE BEST

311
00:13:35,899 --> 00:13:40,169
PROCESS, AND QUITE FRANKLY FOR

312
00:13:40,169 --> 00:13:41,971
INSTITUTIONS TO THINK HOW THEY

313
00:13:41,971 --> 00:13:45,141
MIGHT BE MORE ACCOUNTABLE

314
00:13:45,141 --> 00:13:46,109
STEWARDS BY TRANSPARENCY ABOUT

315
00:13:46,109 --> 00:13:47,310
WHERE THAT MONEY GOES AND

316
00:13:47,310 --> 00:13:52,215
INSURING THAT IT IS RELATED TO

317
00:13:52,215 --> 00:13:54,617
REAL RESEARCH COSTS THAT ARE

318
00:13:54,617 --> 00:13:56,252
ASSOCIATED WITH THESE PROGRAMS

319
00:13:56,252 --> 00:14:02,392
AND SO, THAT SCENARIO OF I THINK

320
00:14:02,392 --> 00:14:03,693
COLLECTIVE RESPONSIBILITY THAT

321
00:14:03,693 --> 00:14:04,861
THE WHOLE ECOSYSTEM SHOULD BE

322
00:14:04,861 --> 00:14:07,263
LOOKING AT IS HOW DO WE SUSTAIN

323
00:14:07,263 --> 00:14:09,465
THE WORLD'S GREATEST RESEARCH

324
00:14:09,465 --> 00:14:10,466
INFRASTRUCTURE AND PARTNERSHIP

325
00:14:10,466 --> 00:14:12,902
BETWEEN THE GOVERNMENT AND

326
00:14:12,902 --> 00:14:14,938
ACADEMIC INSTITUTIONS AND THEIR

327
00:14:14,938 --> 00:14:16,439
INVESTIGATORS TO FUEL LEADING

328
00:14:16,439 --> 00:14:18,474
EDGE SCIENCE AND SO WE HOPE

329
00:14:18,474 --> 00:14:20,209
THERE WILL BE A THOUGHTFUL

330
00:14:20,209 --> 00:14:28,518
DIALOGUE ABOUT THAT WITH THE

331
00:14:28,518 --> 00:14:29,152
COMMUNITY MOVING FORWARD.

332
00:14:29,152 --> 00:14:30,320
CERTAINLY YOU HAVE ALSO SEEN

333
00:14:30,320 --> 00:14:34,657
WITH THE NEW ADMINISTRATION

334
00:14:34,657 --> 00:14:37,493
TRANSITION, VARIOUS PRIORITIES,

335
00:14:37,493 --> 00:14:40,430
MANY RELATED TO CHRONIC DISEASE

336
00:14:40,430 --> 00:14:43,399
AND THE SLOWING RATE OF INCREASE

337
00:14:43,399 --> 00:14:48,604
OF LIFE EXPECTANCY, AND THAT THE

338
00:14:48,604 --> 00:14:49,172
ADMINISTRATION HAS EXPRESSED

339
00:14:49,172 --> 00:14:51,474
INTEREST IN CERTAIN TOPIC AREAS

340
00:14:51,474 --> 00:14:53,943
LIKE NUTRITION, ENVIRONMENTAL

341
00:14:53,943 --> 00:14:56,346
FACTORS, TOXINS, AND EXPOSURES,

342
00:14:56,346 --> 00:14:58,915
ALL OF WHICH MAY INFLUENCE

343
00:14:58,915 --> 00:14:59,682
CHRONIC CONDITIONS, MANY OF

344
00:14:59,682 --> 00:15:02,585
WHICH ARE IN OUR MISSIONARY, AND

345
00:15:02,585 --> 00:15:10,159
IN OUR PORTFOLIO, SO WE LOOK

346
00:15:10,159 --> 00:15:12,462
FORWARD TO LEARNING MORE ABOUT

347
00:15:12,462 --> 00:15:13,596
THIS ADMINISTRATION'S PRIORITY

348
00:15:13,596 --> 00:15:15,331
AREAS IN PART BECAUSE I THINK WE

349
00:15:15,331 --> 00:15:17,867
MIGHT FIND A GREAT DEAL OF

350
00:15:17,867 --> 00:15:19,535
ALIGNMENT WITH A LOT OF THINGS

351
00:15:19,535 --> 00:15:23,206
WE'VE BEEN PURSUING AT THE NHLBI

352
00:15:23,206 --> 00:15:26,476
RELATED TO PRECISION PREVENTION

353
00:15:26,476 --> 00:15:27,510
AND PREEMPTION OF CHRONIC

354
00:15:27,510 --> 00:15:28,177
DISEASE.

355
00:15:28,177 --> 00:15:32,915
AND SO I REMAIN HOPEFUL AND

356
00:15:32,915 --> 00:15:34,984
OPTIMISTIC THAT AS STAKEHOLDERS

357
00:15:34,984 --> 00:15:37,487
ARE ENGAGED WITH CONGRESS AND WE

358
00:15:37,487 --> 00:15:38,521
FIND OUR APPROPRIATION, THAT

359
00:15:38,521 --> 00:15:41,491
THERE'S A LOT WE CAN DO TO

360
00:15:41,491 --> 00:15:43,793
ADVANCE THAT ASPECT OF THIS

361
00:15:43,793 --> 00:15:44,494
ADMINISTRATION'S AGENDA AND WE

362
00:15:44,494 --> 00:15:48,798
LOOK FORWARD TO THAT.

363
00:15:48,798 --> 00:15:53,202
NEXT SLIDE. 

364
00:15:53,202 --> 00:15:56,906
TOWARD THAT END, THE KEY THING

365
00:15:56,906 --> 00:15:59,976
THAT I HOPE WE AS AGAIN A CIRCLE

366
00:15:59,976 --> 00:16:03,279
OF PARTNERS AND AN ECOSYSTEM IS

367
00:16:03,279 --> 00:16:07,784
TO ADDRESS THE VALUE PROPOSITION

368
00:16:07,784 --> 00:16:11,554
FOR THE SHARED SUSTAINABLE

369
00:16:11,554 --> 00:16:13,356
COMMITMENT TO A GROWING

370
00:16:13,356 --> 00:16:15,491
INVESTORMENT IN BIOMEDICAL

371
00:16:15,491 --> 00:16:16,159
RESEARCH THAT OUTPACES INFLATION

372
00:16:16,159 --> 00:16:18,628
IN A WAY THAT CAN MAKE AN IMPACT

373
00:16:18,628 --> 00:16:24,367
SUCH THAT WE CAN REDUCE THE

374
00:16:24,367 --> 00:16:28,204
BURDEN OF DISEASE IN THIS

375
00:16:28,204 --> 00:16:28,438
COUNTRY.

376
00:16:28,438 --> 00:16:29,739
SO IT'S 1 OF THE THINGS THAT

377
00:16:29,739 --> 00:16:33,743
WE'RE HOPING THAT STAKEHOLDERS

378
00:16:33,743 --> 00:16:36,612
WILL PURSUE, WITH CONGRESS IS

379
00:16:36,612 --> 00:16:39,082
HOW TO INDEED ACHIEVE THAT END

380
00:16:39,082 --> 00:16:43,219
AND FOR THOSE OF YOU WHO HEARD

381
00:16:43,219 --> 00:16:46,589
THE HEARING YESTERDAY, THERE'S

382
00:16:46,589 --> 00:16:49,092
BEEN A COMMITMENT, SENATOR

383
00:16:49,092 --> 00:16:49,826
DURBIN ARTICULATED VERY WELL

384
00:16:49,826 --> 00:16:53,429
THAT LED TO THE UPSLOPE DURING

385
00:16:53,429 --> 00:16:55,398
THE LAST OH 7, 8 YEARS AND THE

386
00:16:55,398 --> 00:16:57,366
KEY THING IS REALLY TO MAINTAIN

387
00:16:57,366 --> 00:16:59,335
THAT MOMENTUM AND GET BACK TO IT

388
00:16:59,335 --> 00:17:01,404
AND CERTAINLY NOT GO BACKWARDS

389
00:17:01,404 --> 00:17:02,238
WITH A 40% CUT.

390
00:17:02,238 --> 00:17:05,775
SO I HOPE THAT WE CAN WORK

391
00:17:05,775 --> 00:17:07,677
COLLECTIVELY TO PUT US BACK ON

392
00:17:07,677 --> 00:17:15,318
THAT TRACK. 

393
00:17:15,318 --> 00:17:15,952
NEXT SLIDE, PLEASE.

394
00:17:15,952 --> 00:17:17,687
I ALSO WANT TO ADDRESS THE

395
00:17:17,687 --> 00:17:18,554
REALITIES AND THE ELEPHANT IN

396
00:17:18,554 --> 00:17:24,627
THE ROOM IN TERMS OF A LOT OF

397
00:17:24,627 --> 00:17:28,564
THE THINGS RELATED TO CHANGES

398
00:17:28,564 --> 00:17:32,401
OVER LAST 5 MONTHS WHERE YOU HAD

399
00:17:32,401 --> 00:17:34,137
CERTAIN FOLKS WITH CHAIN SAWS

400
00:17:34,137 --> 00:17:39,308
AND EVERYONE HERE BY NOW HAS

401
00:17:39,308 --> 00:17:42,945
HEARD OF DOGE, AND THEIR

402
00:17:42,945 --> 00:17:45,414
APPROACH TO CHANGING THE FEDERAL

403
00:17:45,414 --> 00:17:49,218
GOVERNMENT AND THIS IS RESULTED

404
00:17:49,218 --> 00:17:53,256
IN WHAT'S CALLED REDUCTIONS IN

405
00:17:53,256 --> 00:17:55,658
FORCE IMPLEMENTED BY DOJO THAT

406
00:17:55,658 --> 00:18:01,230
HAS HAD AN IMPACT ON OUR STAFF

407
00:18:01,230 --> 00:18:08,271
AND STAFFING WHERE WE'VE LOST A

408
00:18:08,271 --> 00:18:10,773
NUMBER OF STAFF, OTHER SORTS OF

409
00:18:10,773 --> 00:18:12,708
TERMINATIONS AND THAT'S HAD AN

410
00:18:12,708 --> 00:18:14,977
IMPACT ACROSS OUR ORGANIZATION

411
00:18:14,977 --> 00:18:20,116
AND IS INDEED INCLUDED CERTAIN

412
00:18:20,116 --> 00:18:25,388
SUBUNITS OF OUR INSTITUTE.

413
00:18:25,388 --> 00:18:27,089
THESE ARE THINGS THAT ALSO

414
00:18:27,089 --> 00:18:32,295
INVOLVE A SHIFT IN THE BALANCE

415
00:18:32,295 --> 00:18:33,329
REPORTEDLY BETWEEN FUNCTIONS OF

416
00:18:33,329 --> 00:18:35,731
THE AGENCY THAT WILL BE DONE IN

417
00:18:35,731 --> 00:18:37,800
THE OFFICE OF THE DIRECTOR

418
00:18:37,800 --> 00:18:39,101
RELATIVE TO FUNCTIONS AND

419
00:18:39,101 --> 00:18:40,803
ACTIVITIES THAT ARE DONE IN EACH

420
00:18:40,803 --> 00:18:45,141
OF THE 27 ICs AND OVER TIME

421
00:18:45,141 --> 00:18:48,211
THOSE THINGS -- THERE'S ALSO A

422
00:18:48,211 --> 00:18:49,478
BALANCE INTENTION BUT FOR THE

423
00:18:49,478 --> 00:18:51,514
MOST PART THE ICs HAVE

424
00:18:51,514 --> 00:18:52,949
MAINTAINED AT LEAST SOME

425
00:18:52,949 --> 00:18:54,116
FUNCTIONALITY AND KEY THINGS

426
00:18:54,116 --> 00:18:57,086
CRITICAL TO THE BUSINESS OF

427
00:18:57,086 --> 00:19:01,257
SCIENCE AND EXECUTING ON THAT

428
00:19:01,257 --> 00:19:05,628
AND THAT'S HAD AN EXAMPLE ON OUR

429
00:19:05,628 --> 00:19:09,665
FOIA OFFICE, ETHICS,

430
00:19:09,665 --> 00:19:10,833
COMMUNICATIONS, OUR PLANNING AND

431
00:19:10,833 --> 00:19:12,235
EVALUATION, SO A NUMBER OF

432
00:19:12,235 --> 00:19:14,737
FUNCTIONAL AREAS THAT ARE

433
00:19:14,737 --> 00:19:16,239
IMPORTANT FOR US TO DO THE

434
00:19:16,239 --> 00:19:18,441
BUSINESS OF SCIENCE OF NHLBI OR

435
00:19:18,441 --> 00:19:21,611
BEING MOVED INTO A CENTRAL

436
00:19:21,611 --> 00:19:25,881
SITUATION AND OUR STAFFING HAS

437
00:19:25,881 --> 00:19:27,717
BEEN REDUCED AND THERE WAS A

438
00:19:27,717 --> 00:19:31,220
THREAT FOR THAT TO ALSO HAPPEN

439
00:19:31,220 --> 00:19:32,755
FOR OUR ACQUISITIONS AND IT RUNS

440
00:19:32,755 --> 00:19:35,124
OUR RESEARCH AND DEVELOPMENT

441
00:19:35,124 --> 00:19:36,626
CONTRACTS THAT OFTEN SUPPORTS

442
00:19:36,626 --> 00:19:38,594
ALL OUR COHORT STUDIES, ET

443
00:19:38,594 --> 00:19:42,765
CETERA OF MOVING THAT DOWN TO

444
00:19:42,765 --> 00:19:44,467
GENERAL SERVICES ADMINISTRATION

445
00:19:44,467 --> 00:19:49,405
AS IF, YOU KNOW RUNNING THE ARIC

446
00:19:49,405 --> 00:19:51,574
STUDY WAS SIMILAR TO ORDERING

447
00:19:51,574 --> 00:19:59,348
PENCILS AND PAPER FOR THE AGENCY

448
00:19:59,348 --> 00:20:00,750
AND HOPEFULLY, COMMON SENSE HAS

449
00:20:00,750 --> 00:20:02,485
PREVAILED IN A RECOGNITION THAT

450
00:20:02,485 --> 00:20:05,388
THESE ARE COMPLEX THINGS THAT

451
00:20:05,388 --> 00:20:08,090
REQUIRE CLOSE SCIENTIFIC

452
00:20:08,090 --> 00:20:10,793
EXPERTISE AS WELL AND SO FAR,

453
00:20:10,793 --> 00:20:14,864
WE'VE BEEN ABLE TO SUSTAIN OR

454
00:20:14,864 --> 00:20:17,433
OTHER TRANSACTIONAL AUTHORITY

455
00:20:17,433 --> 00:20:19,635
OFFICE AND ACQUISITION.

456
00:20:19,635 --> 00:20:21,404
THOUGH, AGAIN, HOW THE REPORTING

457
00:20:21,404 --> 00:20:23,472
FUNCTIONS ARE GOING TO WORK

458
00:20:23,472 --> 00:20:25,207
REMAINS TO BE SEEN.

459
00:20:25,207 --> 00:20:28,611
SIMILAR CHANGES ARE HAPPENING IN

460
00:20:28,611 --> 00:20:29,345
OUR INFORMATION TECHNOLOGY.

461
00:20:29,345 --> 00:20:31,881
SO I WON'T BORE YOU WITH ALL THE

462
00:20:31,881 --> 00:20:33,049
SAUSAGE MAKING EXCEPT TO SAY

463
00:20:33,049 --> 00:20:38,688
THAT ALL OF THESE THINGS HAVE AN

464
00:20:38,688 --> 00:20:39,889
EFFECT ON OUR FUNCTIONALITY AS

465
00:20:39,889 --> 00:20:41,257
AN INSTITUTE AND THEREFORE MAY

466
00:20:41,257 --> 00:20:44,260
AFFECT YOU ALL AS WE ENGAGE YOU

467
00:20:44,260 --> 00:20:47,663
AS STAKEHOLDERS AND AWARDEES AND

468
00:20:47,663 --> 00:20:50,933
APPLICANTS AS THESE CHANGES AND

469
00:20:50,933 --> 00:20:52,468
LOSSES IN STAFFING WILL HAVE AN

470
00:20:52,468 --> 00:20:54,937
IMPACT ON OUR OPERATIONS.

471
00:20:54,937 --> 00:21:00,042
THE OTHER THAN I WILL MENTION IS

472
00:21:00,042 --> 00:21:05,848
THE OFFICE OF SCIENTIFIC POLICY

473
00:21:05,848 --> 00:21:08,551
WHERE EDUCATION AND ENGAGEMENT

474
00:21:08,551 --> 00:21:19,095
WHERE A LOT OF OUR   STAKEHOLDER

475
00:21:20,262 --> 00:21:21,630
INTERACTIONS MEET AND RESIDE,

476
00:21:21,630 --> 00:21:23,899
THAT'S WHERE A SMALL SICKLE CELL

477
00:21:23,899 --> 00:21:27,103
PROGRAM OR AN ORGANIZATION, ALL

478
00:21:27,103 --> 00:21:32,074
OUR --  OVERA HUNDRED PATIENT

479
00:21:32,074 --> 00:21:33,609
INTEREST GROUPS WERE ENGAGED IN

480
00:21:33,609 --> 00:21:35,010
THE OFFICE AND WE'VE LOST A LOT

481
00:21:35,010 --> 00:21:37,213
OF STAFF THERE AND THAT'S GOING

482
00:21:37,213 --> 00:21:41,283
TO HAVE IMPLICATIONS WITH HOW WE

483
00:21:41,283 --> 00:21:42,318
INTERACT WITH THE VARIOUS

484
00:21:42,318 --> 00:21:43,285
COMMUNITIES WE SERVE.

485
00:21:43,285 --> 00:21:45,621
SO WE'RE HOPEFUL THERE WILL BE A

486
00:21:45,621 --> 00:21:46,322
GREATER RECOGNITION, THE

487
00:21:46,322 --> 00:21:48,691
IMPORTANCE OF SUSTAINING THAT

488
00:21:48,691 --> 00:21:51,761
ACTIVITY AT THE LEVEL OF

489
00:21:51,761 --> 00:21:55,831
INSTITUTE BUT THAT'S AN ONGOING

490
00:21:55,831 --> 00:21:56,132
DISCUSSION.

491
00:21:56,132 --> 00:21:57,933
FINALLY, ON THE OTHER SIDE

492
00:21:57,933 --> 00:22:01,170
THERE, YOU SEE THAT SOME OF THE

493
00:22:01,170 --> 00:22:02,805
EXTRAMURAL PROGRAMS HAD A LOSS,

494
00:22:02,805 --> 00:22:04,407
THAT'S PARTICULARLY BEEN FELT

495
00:22:04,407 --> 00:22:06,809
NOW IN PROGRAM DIVISIONS BUT

496
00:22:06,809 --> 00:22:10,679
ALSO IN OUR DIVISION OF

497
00:22:10,679 --> 00:22:12,014
EXTRAMURAL RESEARCH ACTIVITIES

498
00:22:12,014 --> 00:22:15,351
AND PARTICULARLY OUR SCIENTIFIC

499
00:22:15,351 --> 00:22:17,953
REVIEW SECTION WHICH IS

500
00:22:17,953 --> 00:22:22,491
UNDERGONE A SHIFT OVER TO CSR AS

501
00:22:22,491 --> 00:22:26,495
THAT SCIENTIFIC REVIEW GETS

502
00:22:26,495 --> 00:22:26,962
CENTRALIZED IN CSR.

503
00:22:26,962 --> 00:22:29,932
SO JUST TO HAVE A SENSE OF

504
00:22:29,932 --> 00:22:31,300
SOMEBODY IMPACTING OF THESE

505
00:22:31,300 --> 00:22:34,036
TRANSITIONS AND THE DOGE CUTS

506
00:22:34,036 --> 00:22:37,440
AND RIFTS ON OUR STRUCTURE AND

507
00:22:37,440 --> 00:22:39,275
FUNCTIONALITY FOR YOUR

508
00:22:39,275 --> 00:22:39,875
AWARENESS. 

509
00:22:39,875 --> 00:22:44,380
NEXT SLIDE, PLEASE.

510
00:22:44,380 --> 00:22:47,583
SIMILARLY, ANYONE WHO'S BEEN

511
00:22:47,583 --> 00:22:48,951
AWAKE RECOGNIZES THAT THERE HAVE

512
00:22:48,951 --> 00:22:50,820
BEEN A FLURRY OF EXECUTIVE

513
00:22:50,820 --> 00:22:53,122
ORDERS AS PART OF THIS NEW

514
00:22:53,122 --> 00:22:57,893
ADMINISTRATION AND MANY OF THEM

515
00:22:57,893 --> 00:23:00,396
DO RELATE TO OUR RESEARCH

516
00:23:00,396 --> 00:23:00,896
PORTFOLIO.

517
00:23:00,896 --> 00:23:05,267
THIS IS JUST A SAMPLING OF SOME

518
00:23:05,267 --> 00:23:05,968
OF THEM.

519
00:23:05,968 --> 00:23:11,106
HOPEFULLY YOU CAN READ FOR

520
00:23:11,106 --> 00:23:13,609
YOURSELF WHAT THEY'RE FOCUSED IN

521
00:23:13,609 --> 00:23:20,549
ON AND THIS PROVIDES YOU A TEXT

522
00:23:20,549 --> 00:23:26,055
OF THE TERMINATION LETTERS OF

523
00:23:26,055 --> 00:23:28,023
DOGE AND OTHERS HAVE AFFIXED TO

524
00:23:28,023 --> 00:23:31,093
THAT TERMINATION IN ALIGNMENT

525
00:23:31,093 --> 00:23:36,665
WITH THE EXECUTIVE ORDERS.

526
00:23:36,665 --> 00:23:40,803
I WON'T READ THIS TO THE EXTENT

527
00:23:40,803 --> 00:23:43,839
THAT QUITE FRANKLY IT DOESN'T

528
00:23:43,839 --> 00:23:44,807
REFLECT A SENSIBILITY THAT I

529
00:23:44,807 --> 00:23:47,443
HAVE OR THAT I THINK IS

530
00:23:47,443 --> 00:23:50,179
APPROPRIATE FOR A RESEARCH

531
00:23:50,179 --> 00:23:52,414
AGENCY BUT NEVERTHELESS, WE'RE

532
00:23:52,414 --> 00:23:56,151
BEING TRANSPARENT ABOUT WHAT IS

533
00:23:56,151 --> 00:23:59,955
HAPPENING AND WHAT YOU WILL SEE

534
00:23:59,955 --> 00:24:10,366
AS A CONSEQUENCE, NEXT SLIDE,

535
00:24:10,366 --> 00:24:11,467
PLEASE.

536
00:24:11,467 --> 00:24:14,069
NEXT SLIDE.

537
00:24:14,069 --> 00:24:16,305
TOWARD THAT END, THERE'S CERTAIN

538
00:24:16,305 --> 00:24:17,940
CHANGES THAT HAVE BEEN MADE THAT

539
00:24:17,940 --> 00:24:19,208
AGAIN, I THINK THE RESEARCH

540
00:24:19,208 --> 00:24:22,478
COMMUNITY SHOULD BE AWARE OF.

541
00:24:22,478 --> 00:24:23,412
CLEARLY YOU'RE ALREADY FEELING

542
00:24:23,412 --> 00:24:28,551
SOME OF THE GRANT AWARD

543
00:24:28,551 --> 00:24:31,420
TERMINATIONS AND THE PATTERN

544
00:24:31,420 --> 00:24:34,356
RELATED TO SPECIFIC PRIORITIES

545
00:24:34,356 --> 00:24:37,059
OR AREAS OF DEPRIORITIZATION

546
00:24:37,059 --> 00:24:38,928
THAT THE NEW ADMINISTRATION I

547
00:24:38,928 --> 00:24:41,196
THINK ARE FAIRLY MANIFEST TO YOU

548
00:24:41,196 --> 00:24:45,034
AND IN WAYS THAT ARE RAISING

549
00:24:45,034 --> 00:24:48,470
QUESTIONS ABOUT HOW WE PURSUE

550
00:24:48,470 --> 00:24:49,171
RESEARCH AFFECTING CERTAIN

551
00:24:49,171 --> 00:24:53,008
SUBGROUPS AND SPECIAL

552
00:24:53,008 --> 00:24:56,245
POPULATIONS AND GROUPS THAT ARE

553
00:24:56,245 --> 00:24:57,179
DISPROPORTIONATELY AFFECTED AS

554
00:24:57,179 --> 00:24:58,547
AMERICANS IN HEALTH AND DISEASE,

555
00:24:58,547 --> 00:25:01,817
WE THINK THAT'S STILL IMPORTANT

556
00:25:01,817 --> 00:25:03,285
IN FULFILLING OUR MISSION AND

557
00:25:03,285 --> 00:25:05,321
SERVING THE AMERICAN PEOPLE, ALL

558
00:25:05,321 --> 00:25:11,327
THE AMERICAN PEOPLE AND THAT OUR

559
00:25:11,327 --> 00:25:12,861
SCIENCE SHOULD REFLECT THAT

560
00:25:12,861 --> 00:25:17,566
SERVICE TO ALL INCLUDING VARIOUS

561
00:25:17,566 --> 00:25:21,837
GROUPS WHO HAVE DIFFERENT HEALTH

562
00:25:21,837 --> 00:25:22,838
OUTCOMES AND SO THAT'S SOMETHING

563
00:25:22,838 --> 00:25:26,942
WE WILL CONTINUE TO WORK THROUGH

564
00:25:26,942 --> 00:25:31,747
ALONG WITH MANY OTHER AREAS OF

565
00:25:31,747 --> 00:25:33,515
OUR WORKFORCE IN ENSURING WE

566
00:25:33,515 --> 00:25:34,450
HAVE INCLUSIVE EXCELLENCE AS

567
00:25:34,450 --> 00:25:39,989
PART OF WHAT WE DO, RECOGNIZING

568
00:25:39,989 --> 00:25:41,357
THAT TALENT COMES FROM

569
00:25:41,357 --> 00:25:43,192
EVERYWHERE AND WE'RE ABOUT

570
00:25:43,192 --> 00:25:45,694
PROMOTING THAT OPPORTUNITY TO

571
00:25:45,694 --> 00:25:49,798
EVERYONE IN SERVICE TO ALL

572
00:25:49,798 --> 00:25:50,099
COMMUNITIES.

573
00:25:50,099 --> 00:25:52,034
SO REALLY I'VE ALREADY ALLUDED

574
00:25:52,034 --> 00:25:54,670
TO THE CENTRALIZATION OF CSR

575
00:25:54,670 --> 00:25:57,640
REVIEW, IT'S ALWAYS BEEN CSR IS

576
00:25:57,640 --> 00:26:03,612
THE BULK OF PROBABLY LIKE 80% OF

577
00:26:03,612 --> 00:26:04,546
 OF

578
00:26:04,546 --> 00:26:05,147
REVIEW, BUT INSTITUTES,

579
00:26:05,147 --> 00:26:07,082
CERTAINLY OURS IS A STATUTORY

580
00:26:07,082 --> 00:26:09,685
AUTHORITY TO DO ITS OWN REVIEWS,

581
00:26:09,685 --> 00:26:12,388
AND WE HAVE WITH OUR OWN SPECIAL

582
00:26:12,388 --> 00:26:13,856
EMPHASIS PANELS SO FOR EXAMPLE,

583
00:26:13,856 --> 00:26:16,525
AN AREA SUCH AS CLINICAL TRIALS,

584
00:26:16,525 --> 00:26:19,662
THAT'S NOW SOMETHING THAT'S GONE

585
00:26:19,662 --> 00:26:23,232
AWAY AND WILL HAVE TO WORK

586
00:26:23,232 --> 00:26:24,299
THROUGH HOW WE MIGHT ADAPT TO

587
00:26:24,299 --> 00:26:25,701
THAT BUT THAT WILL BE A

588
00:26:25,701 --> 00:26:28,504
TRANSITION AND THAT WILL AFFECT

589
00:26:28,504 --> 00:26:30,339
OUR CLINICAL RESEARCH PORTFOLIO

590
00:26:30,339 --> 00:26:34,510
AS WE FIGURE OUT HOW TO WORK

591
00:26:34,510 --> 00:26:36,612
UNDER A CSR SYSTEM RELATIVE TO

592
00:26:36,612 --> 00:26:40,649
AN IC BASED PEER REVIEWED SYSTEM

593
00:26:40,649 --> 00:26:42,284
INSTEAD OF NOFOs.

594
00:26:42,284 --> 00:26:44,486
TOWARD THAT END, YOU SHOULD BE

595
00:26:44,486 --> 00:26:47,923
AWARE OF THE COMMUNICATION

596
00:26:47,923 --> 00:26:48,624
CENTRALIZATION, I'VE ALREADY

597
00:26:48,624 --> 00:26:53,362
KIND OF ALLUDED TO IT THAT HOW

598
00:26:53,362 --> 00:26:56,932
WE DO PUBLIC EDUCATION, HOW WE

599
00:26:56,932 --> 00:27:01,670
DO HIGHLIGHTING, THE ACTIVITIES

600
00:27:01,670 --> 00:27:03,038
OF NHLBI INVESTIGATORS AND

601
00:27:03,038 --> 00:27:06,608
PROBABLY MOST IMPORTANTLY HOW WE

602
00:27:06,608 --> 00:27:08,343
ENGAGE OUR COMMUNITY OR OUR

603
00:27:08,343 --> 00:27:10,379
PROFESSIONAL SOCIETIES AND

604
00:27:10,379 --> 00:27:12,414
PUBLIC INTEREST GROUPS WILL BE

605
00:27:12,414 --> 00:27:13,916
CHANGED BY THESE TRANSITIONS AND

606
00:27:13,916 --> 00:27:16,785
IT WILL HAVE AN IMPACT.

607
00:27:16,785 --> 00:27:24,359
AND FINALLY, AGAIN, I'VE ALREADY

608
00:27:24,359 --> 00:27:26,061
ALLUDED TO IT, SUBSTANTIAL

609
00:27:26,061 --> 00:27:30,199
CHANGES IN HOW WE GO ABOUT

610
00:27:30,199 --> 00:27:31,133
SOLICITING NOFOs, AND

611
00:27:31,133 --> 00:27:32,868
PROVIDING YOU WITH FUNDING

612
00:27:32,868 --> 00:27:37,106
OPPORTUNITY ANNOUNCE  ANNOUNCEMD

613
00:27:37,106 --> 00:27:39,541
THERE IS AN EFFORT TO REDUCE THE

614
00:27:39,541 --> 00:27:41,076
NUMBER OF ACTIVE NOFOs BY

615
00:27:41,076 --> 00:27:43,112
HALF, I THINK IT WAS SOMETHING

616
00:27:43,112 --> 00:27:44,747
LIKE 7 OR 800 ARE OUT THERE AND

617
00:27:44,747 --> 00:27:49,818
THEY ARE TRYING TO AIM IT DOWN

618
00:27:49,818 --> 00:27:50,753
TO MAYBE 400, 500.

619
00:27:50,753 --> 00:27:54,089
SO EACH IC MAY HAVE A CAP ON THE

620
00:27:54,089 --> 00:27:59,428
NUMBER OF ACTIVE NOFOs, SO YOU

621
00:27:59,428 --> 00:28:04,032
CAN  IMAGINE THAT WILL HAVE AN

622
00:28:04,032 --> 00:28:06,435
IMPACT TO WHAT YOU MAY BE

623
00:28:06,435 --> 00:28:10,172
SEEING, SPECIFICALLY TO IC

624
00:28:10,172 --> 00:28:10,405
NOFO,s.

625
00:28:10,405 --> 00:28:12,141
ONE STRATEGY IS TO DO THIS, OR

626
00:28:12,141 --> 00:28:15,177
MORE COLLABORATION OR CLUSTERING

627
00:28:15,177 --> 00:28:18,046
OF NOFOs IN VARIOUS AREAS OF

628
00:28:18,046 --> 00:28:19,848
CLINICAL TRIALS RATHER THAN EACH

629
00:28:19,848 --> 00:28:21,049
IC HAVE ITS OWN SUITE.

630
00:28:21,049 --> 00:28:26,588
SO THOSE ARE THE THINGS, THE

631
00:28:26,588 --> 00:28:28,090
SAUSAGE MAKING THAT DWELL ON AS

632
00:28:28,090 --> 00:28:29,825
WE ADAPT TO THE NEW

633
00:28:29,825 --> 00:28:30,759
ADMINISTRATION AND SOME OF ITS

634
00:28:30,759 --> 00:28:32,494
CHANGES IN HOW IT WANTS TO

635
00:28:32,494 --> 00:28:33,896
MANAGE THINGS. 

636
00:28:33,896 --> 00:28:37,933
NEXT SLIDE, PLEASE.

637
00:28:37,933 --> 00:28:40,269
AND I JUST WANT TO CONVEY OR

638
00:28:40,269 --> 00:28:45,541
WELCOMING TO OUR NEW NIH

639
00:28:45,541 --> 00:28:47,276
DIRECTOR JAY BHATTACHARYA, HE

640
00:28:47,276 --> 00:28:50,879
HAS BEEN HERE I GUESS ALMOST A

641
00:28:50,879 --> 00:28:53,015
COUPLE MONTHS NOW AND WE'RE

642
00:28:53,015 --> 00:28:56,919
HOPEFUL TO GET HIM TO COME TO

643
00:28:56,919 --> 00:28:57,753
OUR COUNCIL.

644
00:28:57,753 --> 00:29:00,255
HE'S A LITTLE BUSY THIS WEEK AND

645
00:29:00,255 --> 00:29:03,525
COULDN'T MAKE THIS GIIVE HE HAD

646
00:29:03,525 --> 00:29:05,727
A SENATE HEARING YESTERDAY BUT

647
00:29:05,727 --> 00:29:06,762
WE'RE HOPEFUL THAT EITHER

648
00:29:06,762 --> 00:29:08,330
OCTOBER OR SOMETIME IN THE NEAR

649
00:29:08,330 --> 00:29:10,399
FUTURE WE COULD HAVE HIM COME

650
00:29:10,399 --> 00:29:13,602
AND ADDRESS THE NHLBI COMMUNITY.

651
00:29:13,602 --> 00:29:15,137
YOU'VE HEARD OF HIS VERY HIGH

652
00:29:15,137 --> 00:29:23,245
LEVEL VISION AND ISSUES, VERY

653
00:29:23,245 --> 00:29:26,748
MUCH INCLINED TOWARD

654
00:29:26,748 --> 00:29:30,052
APPRECIATING AND RECONCILING AND

655
00:29:30,052 --> 00:29:32,588
RECKONING WITH WHAT HE PERCEIVES

656
00:29:32,588 --> 00:29:34,189
AS CERTAIN CHALLENGES RELATED TO

657
00:29:34,189 --> 00:29:38,460
THE COVID PANDEMIC AND ISSUES OF

658
00:29:38,460 --> 00:29:42,397
TRUST THAT HAVE BEEN COMPROMISED

659
00:29:42,397 --> 00:29:50,038
RELATED TO THAT AND THAT'S 1 OF

660
00:29:50,038 --> 00:29:51,440
HIS PRIORITIES IN PART BY

661
00:29:51,440 --> 00:29:52,841
FOCUSING ON SCIENCE THAT MATTERS

662
00:29:52,841 --> 00:29:54,710
TO THE PUBLIC IN THAT WAY

663
00:29:54,710 --> 00:29:58,914
ALIGNING WITH THE FOCUS ON

664
00:29:58,914 --> 00:30:01,516
ADDRESSING CHRONIC DISEASE AND

665
00:30:01,516 --> 00:30:04,319
ADDRESSING ADVANCES IN THAT

666
00:30:04,319 --> 00:30:06,989
SPACE AS PART OF MAKING AMERICA

667
00:30:06,989 --> 00:30:17,132
HEALTHY 

668
00:30:24,373 --> 00:30:29,745
I BELIEVE HE WANTS ANY TO FUND

669
00:30:29,745 --> 00:30:30,846
REPLICATION, AND REPLICATION

670
00:30:30,846 --> 00:30:32,781
STUDIES, REPLICATION OF WORK AND

671
00:30:32,781 --> 00:30:36,985
DATA SHARING IN WAYS THAT ARE

672
00:30:36,985 --> 00:30:38,854
MORE TRANSPARENT.

673
00:30:38,854 --> 00:30:41,857
SIMILARLY, WE'VE HEARD HIM

674
00:30:41,857 --> 00:30:43,058
TALKING ABOUT MAKING BIG

675
00:30:43,058 --> 00:30:45,327
ADVANCES. 

676
00:30:45,327 --> 00:30:49,131
BY THAT I THINK HE'S ADVANCED A

677
00:30:49,131 --> 00:30:53,168
THESIS WHERE THERE'S MAYBE TOO

678
00:30:53,168 --> 00:30:55,304
MUCH GROUP THINK, INCREMENTALISM

679
00:30:55,304 --> 00:31:00,008
THAT MAY BE PART OF THE PEER

680
00:31:00,008 --> 00:31:01,777
REVIEW AND FUNDING SYSTEM.

681
00:31:01,777 --> 00:31:04,079
THOSE CAMPAIGNS HAVE BEEN

682
00:31:04,079 --> 00:31:05,881
RAISED, ENSURING HIGH RISK, HIGH

683
00:31:05,881 --> 00:31:09,051
REWARD, LEADING EDGE WORK AND WE

684
00:31:09,051 --> 00:31:16,358
LOOK FORWARD TO SEEING HOW HE

685
00:31:16,358 --> 00:31:17,759
FLESHES THAT OUT.

686
00:31:17,759 --> 00:31:22,931
WORKING WITH HIM TO SEE HOW WE

687
00:31:22,931 --> 00:31:28,103
CAN DO THAT. 

688
00:31:28,103 --> 00:31:30,572
HIS ANALYSIS BOILS DOWN TO

689
00:31:30,572 --> 00:31:32,240
FUNDING MORE EARLY STAGE

690
00:31:32,240 --> 00:31:35,911
INVESTIGATORS EARLIER, SOMETHING

691
00:31:35,911 --> 00:31:36,912
NOT A PARTICULARLY NOVEL

692
00:31:36,912 --> 00:31:37,579
INTENTION.

693
00:31:37,579 --> 00:31:40,248
BUT ONE WE HAVE TO CONTINUALLY

694
00:31:40,248 --> 00:31:40,849
WORK ON.

695
00:31:40,849 --> 00:31:42,317
INDEED, PROBABLY ONE OF THE BEST

696
00:31:42,317 --> 00:31:48,457
WAYS TO DO THAT IS MAINTAIN A

697
00:31:48,457 --> 00:31:50,158
PAYLINE AND 10-POINT BONUS AND

698
00:31:50,158 --> 00:31:52,327
ENSURE WE GET THEM OFF TO A

699
00:31:52,327 --> 00:31:53,462
START THAT'S SUSTAINABLE.

700
00:31:53,462 --> 00:31:57,666
AND NOT SCARE THEM WITH A 40%

701
00:31:57,666 --> 00:31:57,833
CUT.

702
00:31:57,833 --> 00:32:01,003
BUT THAT'S AN AREA THAT I HOPE

703
00:32:01,003 --> 00:32:06,241
WE CAN, AGAIN, ADDRESS TOGETHER.

704
00:32:06,241 --> 00:32:08,677
AND THEN FINALLY SAFETY AND

705
00:32:08,677 --> 00:32:11,079
TRANSPARENCY, AGAIN TO A CERTAIN

706
00:32:11,079 --> 00:32:14,149
EXTENT RELATES TO DATA AND DATA

707
00:32:14,149 --> 00:32:16,651
SHARING AS WELL AS FINALLY

708
00:32:16,651 --> 00:32:18,553
ACADEMIC FREEDOM.

709
00:32:18,553 --> 00:32:21,490
AND A DIVERSITY OF VIEWPOINTS

710
00:32:21,490 --> 00:32:24,526
AND DEBATE AND DISSENT, AND THAT

711
00:32:24,526 --> 00:32:27,329
SORT OF DIALOGUE THAT ALL

712
00:32:27,329 --> 00:32:29,031
SCIENTISTS ENGAGE IN NATURALLY

713
00:32:29,031 --> 00:32:30,098
AND ONE WHERE I DON'T THINK

714
00:32:30,098 --> 00:32:33,301
THERE WILL BE A LOT OF

715
00:32:33,301 --> 00:32:33,835
DISAGREEMENT ON.

716
00:32:33,835 --> 00:32:37,105
I THINK WHERE THERE'S SOMETIMES

717
00:32:37,105 --> 00:32:41,109
A CHALLENGE IS I DON'T THINK

718
00:32:41,109 --> 00:32:48,250
THAT ANY OF US ARE WELL SERVED

719
00:32:48,250 --> 00:32:51,820
ADVANCING SCIENCE THE MORE WE

720
00:32:51,820 --> 00:32:57,926
POLITICIZE SCIENCE BECAUSE IT'S

721
00:32:57,926 --> 00:32:59,394
ALREADY HYPERPARTISANSHIP THAT'S

722
00:32:59,394 --> 00:33:00,862
GIVING THESE VIEWPOINTS AND I

723
00:33:00,862 --> 00:33:02,831
THINK UNDERGIRDS ISSUES OF TRUST

724
00:33:02,831 --> 00:33:05,333
WITH CERTAIN COMMUNITIES THAT WE

725
00:33:05,333 --> 00:33:11,373
NEED TO ENGAGE BETTER WITH.

726
00:33:11,373 --> 00:33:14,209
AND URGING ACADEMIC FREEDOM IS

727
00:33:14,209 --> 00:33:17,946
REALLY OPENING UP DIALOGUE AS

728
00:33:17,946 --> 00:33:20,982
OPPOSED TO TERMINATING GRANTS

729
00:33:20,982 --> 00:33:23,685
THAT DON'T HAVE THE IDEOLOGY

730
00:33:23,685 --> 00:33:24,386
THAT AN INCUMBENT ADMINISTRATION

731
00:33:24,386 --> 00:33:24,786
MAY HAVE.

732
00:33:24,786 --> 00:33:30,425
I HOPE WE'RE NOT ON A PENDULUM

733
00:33:30,425 --> 00:33:33,428
GOING TO WOKE AND ANTI-WOKE AS

734
00:33:33,428 --> 00:33:35,931
OPPOSED TO JUST FOCUSING ON THE

735
00:33:35,931 --> 00:33:41,703
SCIENCE AND TONING DOWN SOME OF

736
00:33:41,703 --> 00:33:42,637
THE PARTISANSHIP BECAUSE THAT'S

737
00:33:42,637 --> 00:33:44,306
REALLY WHERE SUSTAINED FUNDING

738
00:33:44,306 --> 00:33:50,378
AND SUPPORT OF NIH HAS ALWAYS

739
00:33:50,378 --> 00:33:51,046
BEEN NONPARTISAN, BICAMERAL,

740
00:33:51,046 --> 00:33:55,217
BIPARTISAN IN TERMS OF THAT

741
00:33:55,217 --> 00:33:57,552
STRUCTURE, AND IT'S BECAUSE

742
00:33:57,552 --> 00:33:59,154
SCIENCE AND HEALTH DON'T KNOW

743
00:33:59,154 --> 00:34:01,957
RED STATES OR BLUE STATES,

744
00:34:01,957 --> 00:34:05,594
PATIENTS YOU CARE FOR, YOU DON'T

745
00:34:05,594 --> 00:34:07,129
CARE WHAT POLITICAL AFFILIATION

746
00:34:07,129 --> 00:34:08,430
IS; YOU'RE THERE TO ADDRESS

747
00:34:08,430 --> 00:34:09,664
THEIR SUFFERING.

748
00:34:09,664 --> 00:34:10,932
SCIENCE IS LIKEWISE NOT ABOUT

749
00:34:10,932 --> 00:34:11,967
RED AND BLUE.

750
00:34:11,967 --> 00:34:18,640
I HOPE WE CAN GET TO THAT STAGE.

751
00:34:18,640 --> 00:34:19,875
NEXT SLIDE.

752
00:34:19,875 --> 00:34:24,646
TOWARD THAT END, ONE OF THE

753
00:34:24,646 --> 00:34:26,515
THINGS THAT ACTUALLY JAY

754
00:34:26,515 --> 00:34:29,885
PRESENTED IN ONE OF HIS TALKS

755
00:34:29,885 --> 00:34:32,754
WAS ON THE LEFT-HAND SIDE, WHERE

756
00:34:32,754 --> 00:34:36,424
HE BUILDS IN THAT ARGUMENT THAT

757
00:34:36,424 --> 00:34:37,759
DURING COVID THERE WAS THAT

758
00:34:37,759 --> 00:34:40,395
CLEAR SLIPPAGE IN TERMS OF

759
00:34:40,395 --> 00:34:45,333
SURVEYS OF AN ELEMENT OF THAT

760
00:34:45,333 --> 00:34:45,967
TRUST.

761
00:34:45,967 --> 00:34:50,472
WE DIG A LITTLE BIT DEEPER INTO

762
00:34:50,472 --> 00:34:52,107
THAT SAME STUDY, ALTHOUGH THE

763
00:34:52,107 --> 00:34:56,144
AGGREGATE LOOKS LIKE IT'S A

764
00:34:56,144 --> 00:34:58,079
GENERAL SHIFT DOWN, ACTUALLY

765
00:34:58,079 --> 00:34:59,714
THAT NEXT LAYER OF ANALYSIS

766
00:34:59,714 --> 00:35:02,584
WOULD SUGGEST THAT IT'S STILL

767
00:35:02,584 --> 00:35:04,786
PRETTY HIGH AMONG CERTAIN

768
00:35:04,786 --> 00:35:08,056
SEGMENTS OF OUR POPULATION.

769
00:35:08,056 --> 00:35:09,357
AND, YOU KNOW, HAD A LITTLE BUMP

770
00:35:09,357 --> 00:35:12,194
RELATED TO COVID BUT NOTHING

771
00:35:12,194 --> 00:35:14,696
THAT COULDN'T BE RECOVERED.

772
00:35:14,696 --> 00:35:17,365
AND YOU CAN SEE THE MARKED

773
00:35:17,365 --> 00:35:19,367
DIFFERENCE, AGAIN, BY RED AND

774
00:35:19,367 --> 00:35:19,734
BLUE.

775
00:35:19,734 --> 00:35:22,170
AND SO I THINK THAT'S MORE OF

776
00:35:22,170 --> 00:35:27,309
WHAT WE MAY NEED TO THINK ABOUT

777
00:35:27,309 --> 00:35:29,778
IS HOW WE'RE ENGAGING ALL PARTS

778
00:35:29,778 --> 00:35:32,147
OF THE AMERICAN POPULATION AND

779
00:35:32,147 --> 00:35:35,650
NOT SLIPPING SCIENCE INTO THE

780
00:35:35,650 --> 00:35:36,218
SAME DIVISIVENESS.

781
00:35:36,218 --> 00:35:39,588
ON THE RIGHT YOU CAN SEE AGAIN

782
00:35:39,588 --> 00:35:42,991
PART OF THIS ANALYSIS, CERTAINLY

783
00:35:42,991 --> 00:35:44,726
IN ONE GROUP EDUCATION

784
00:35:44,726 --> 00:35:45,860
ATTAINMENT MIGHT PLAY A ROLE IN

785
00:35:45,860 --> 00:35:49,431
TERMS OF TRUST IN SCIENCE, TRUST

786
00:35:49,431 --> 00:35:52,367
IN SCIENTISTS.

787
00:35:52,367 --> 00:35:55,036
BUT THAT'S NOT UNIFORM.

788
00:35:55,036 --> 00:35:57,606
AND, AGAIN, RAISES SOME QUESTION

789
00:35:57,606 --> 00:35:59,441
HOW WE'RE REACHING ALL

790
00:35:59,441 --> 00:36:01,676
COMMUNITIES AND HOW WE'RE

791
00:36:01,676 --> 00:36:03,645
PERCEIVED AS TRUSTWORTHY BY

792
00:36:03,645 --> 00:36:04,512
VARIOUS COMMUNITIES.

793
00:36:04,512 --> 00:36:07,682
AND WHAT WE MAY NEED TO DO TO

794
00:36:07,682 --> 00:36:10,018
REGAIN THAT SENSE OF

795
00:36:10,018 --> 00:36:15,223
TRUSTWORTHINESS WITH THOSE

796
00:36:15,223 --> 00:36:15,757
COMMUNITIES.

797
00:36:15,757 --> 00:36:16,057
NEXT SLIDE.

798
00:36:16,057 --> 00:36:19,894
AND I THINK THEY ARE TELLING US

799
00:36:19,894 --> 00:36:25,867
SOMETHING ABOUT HOW WE MAY THINK

800
00:36:25,867 --> 00:36:26,568
ABOUT APPROACHING ALL

801
00:36:26,568 --> 00:36:28,503
COMMUNITIES AND ALL THAT WE

802
00:36:28,503 --> 00:36:32,774
SERVE, PERHAPS IN A MORE

803
00:36:32,774 --> 00:36:33,275
EFFECTIVE WAY.

804
00:36:33,275 --> 00:36:38,880
THIS IS SOMETHING WHERE THE

805
00:36:38,880 --> 00:36:39,848
PUBLIC SURVEY ABOUT SCIENTISTS,

806
00:36:39,848 --> 00:36:41,049
THEY TRUST US TO DO THE RIGHT

807
00:36:41,049 --> 00:36:44,119
THING FOR THE PUBLIC, BUT WHAT

808
00:36:44,119 --> 00:36:45,520
DO THEY THINK ABOUT US?

809
00:36:45,520 --> 00:36:48,056
THEY GIVE US PROPS FOR WHAT WE

810
00:36:48,056 --> 00:36:48,523
DO.

811
00:36:48,523 --> 00:36:52,227
WE'RE ALL SMART PEOPLE.

812
00:36:52,227 --> 00:36:55,930
AND THAT'S GREAT. 

813
00:36:55,930 --> 00:36:57,265
AND THEY APPRECIATE OUR SKILLS

814
00:36:57,265 --> 00:37:02,404
IN THAT WAY, BUT YOU CAN SEE THE

815
00:37:02,404 --> 00:37:04,039
THINGS WE FALL BELOW 50 THAT

816
00:37:04,039 --> 00:37:05,340
WE'RE TALKING ABOUT THIS

817
00:37:05,340 --> 00:37:06,775
EARLIER, YOU KNOW, I THINK WE

818
00:37:06,775 --> 00:37:09,878
NEED TO GET BETTER AT

819
00:37:09,878 --> 00:37:10,378
COMMUNICATING OUR VALUE

820
00:37:10,378 --> 00:37:13,882
PROPOSITION AND HOW WE CAN BE

821
00:37:13,882 --> 00:37:15,550
HELPFUL TO THE AMERICAN PUBLIC.

822
00:37:15,550 --> 00:37:17,886
AND SO I THINK ALL OF US CAN

823
00:37:17,886 --> 00:37:20,689
BECOME BETTER COMMUNICATORS OF

824
00:37:20,689 --> 00:37:23,892
WHAT WE DO TO ENGENDER THAT

825
00:37:23,892 --> 00:37:28,430
SENSE OF TRUST AND SERVICE TO

826
00:37:28,430 --> 00:37:28,763
THE COMMUNITY.

827
00:37:28,763 --> 00:37:34,869
ANOTHER THING ABOUT US BEING

828
00:37:34,869 --> 00:37:35,637
ALOOF, OLD, UNAPPROACHABLE,

829
00:37:35,637 --> 00:37:37,439
KNOW-IT-ALLS, AND WE ALL ARE

830
00:37:37,439 --> 00:37:40,442
SAGES ON THE STAGE AND WE KNOW

831
00:37:40,442 --> 00:37:41,776
WHAT EVERYONE OUGHT TO DO.

832
00:37:41,776 --> 00:37:43,345
AND WE TELL THEM.

833
00:37:43,345 --> 00:37:49,584
AND SO THOSE ARE THINGS I THINK

834
00:37:49,584 --> 00:37:53,054
WE DEAL WITH THIS CHALLENGE TO

835
00:37:53,054 --> 00:37:54,589
INSTITUTIONS INCLUDING ALL THE

836
00:37:54,589 --> 00:37:56,124
REALLY ACADEMIC INSTITUTIONS

837
00:37:56,124 --> 00:38:03,031
WHICH ARE ALSO UNDER DECLINE IN

838
00:38:03,031 --> 00:38:04,866
TRUST THAT WE DO INTROSPECTION

839
00:38:04,866 --> 00:38:06,201
ABOUT WHAT WE COULD BE DOING

840
00:38:06,201 --> 00:38:10,238
BETTER IN THIS SPACE AS OPPOSED

841
00:38:10,238 --> 00:38:12,874
TO CHANGE, ACKNOWLEDGE WE DO

842
00:38:12,874 --> 00:38:14,342
HAVE A PROBLEM, AND START TO

843
00:38:14,342 --> 00:38:18,046
WORK ON HOW WE CAN BE MORE

844
00:38:18,046 --> 00:38:20,382
EFFECTIVE AT SERVING THE PUBLIC.

845
00:38:20,382 --> 00:38:21,516
AND ENGENDER THEIR TRUST.

846
00:38:21,516 --> 00:38:24,419
AND, AGAIN, YOU CAN SEE SOME

847
00:38:24,419 --> 00:38:31,893
POLARITIES IN THIS REGARD.

848
00:38:31,893 --> 00:38:32,327
NEXT SLIDE.

849
00:38:32,327 --> 00:38:33,962
SO I WANTED TO WALK THROUGH THAT

850
00:38:33,962 --> 00:38:43,705
AS WE TRY TO ADAPT AND NAVIGATE

851
00:38:43,705 --> 00:38:45,907
THIS CHANGE, THAT WE APPROACH IT

852
00:38:45,907 --> 00:38:49,644
WITH A SENSE OF HUMILITY THAT WE

853
00:38:49,644 --> 00:38:52,046
HAVEN'T GOTTEN IT ALL RIGHT ALL

854
00:38:52,046 --> 00:38:52,447
THE TIME.

855
00:38:52,447 --> 00:38:54,015
THERE ARE THINGS THAT I THINK WE

856
00:38:54,015 --> 00:38:57,085
DO NEED TO GET BETTER AT,

857
00:38:57,085 --> 00:38:59,154
PROBABLY HAVE TO LISTEN MORE.

858
00:38:59,154 --> 00:39:02,223
AND AGAIN COME WITH THAT CULTURE

859
00:39:02,223 --> 00:39:03,992
OF HUMILITY IN ADDRESSING A LOT

860
00:39:03,992 --> 00:39:07,362
OF THESE COMMUNITIES THAT DON'T

861
00:39:07,362 --> 00:39:08,062
TRUST US.

862
00:39:08,062 --> 00:39:13,168
AND WHAT WE MAY NEED TO DO TO

863
00:39:13,168 --> 00:39:14,269
ENGENDER MORE TRUST.

864
00:39:14,269 --> 00:39:16,438
AND I THINK THAT WILL BE PART OF

865
00:39:16,438 --> 00:39:20,308
OUR CHALLENGE OVER THESE NEXT

866
00:39:20,308 --> 00:39:21,843
COUPLE YEARS TO EXTEND THAT IT'S

867
00:39:21,843 --> 00:39:24,446
GOING TO BE CRITICAL FOR US TO

868
00:39:24,446 --> 00:39:26,114
FULFILL THE MISSION AND ACTUALLY

869
00:39:26,114 --> 00:39:28,817
THE PRIORITIES OF THIS

870
00:39:28,817 --> 00:39:30,852
ADMINISTRATION BECAUSE IT'S MANY

871
00:39:30,852 --> 00:39:32,454
OF THOSE SAME COMMUNITIES THAT

872
00:39:32,454 --> 00:39:33,388
ARE SUFFERING THE MOST.

873
00:39:33,388 --> 00:39:35,390
I DON'T KNOW THAT THEY ARE

874
00:39:35,390 --> 00:39:38,293
GETTING THE BENEFITS OF THE

875
00:39:38,293 --> 00:39:39,127
SCIENCE WE'RE DOING.

876
00:39:39,127 --> 00:39:42,063
AND IF THEY ARE NOT, AND THAT'S

877
00:39:42,063 --> 00:39:43,765
PART OF THEIR LACK OF TRUST,

878
00:39:43,765 --> 00:39:46,601
AGAIN, I THINK THAT MIGHT BE ON

879
00:39:46,601 --> 00:39:48,703
US AS TO HOW WELL WE'RE

880
00:39:48,703 --> 00:39:51,539
ADDRESSING THEIR NEEDS AND

881
00:39:51,539 --> 00:39:54,676
LISTENING TO THEIR NEEDS AND

882
00:39:54,676 --> 00:39:56,144
BRINGING SCIENCE TO BEAR IN A

883
00:39:56,144 --> 00:40:00,748
WAY THAT BENEFITS THEM AND THEIR

884
00:40:00,748 --> 00:40:01,049
COMMUNITIES.

885
00:40:01,049 --> 00:40:01,616
NEXT SLIDE.

886
00:40:01,616 --> 00:40:03,418
NEXT SLIDE.

887
00:40:03,418 --> 00:40:08,423
SO, I'LL START TO WRAP UP WITH

888
00:40:08,423 --> 00:40:12,260
WHAT I HOPE IS A RESEARCH AGENDA

889
00:40:12,260 --> 00:40:14,662
THAT ALIGNS WITH WHAT THE NEW

890
00:40:14,662 --> 00:40:17,065
ADMINISTRATION HAS SAID ARE ITS

891
00:40:17,065 --> 00:40:20,802
PRIORITIES, AND ITS CONCERNS.

892
00:40:20,802 --> 00:40:23,605
AND ONE IS THIS LIFE EXPECTANCY

893
00:40:23,605 --> 00:40:27,108
AND HOW IN OUR COMPARABLE

894
00:40:27,108 --> 00:40:29,911
WEALTHY NATIONS IT'S HAD A MORE

895
00:40:29,911 --> 00:40:33,181
RAPID UPSLOPE THAN IN THE U.S.

896
00:40:33,181 --> 00:40:35,016
AND OBVIOUSLY THAT DIP AT THE

897
00:40:35,016 --> 00:40:37,118
END WAS COVID THAT WE'RE STILL

898
00:40:37,118 --> 00:40:41,656
TRYING TO BOUNCE BACK FROM.

899
00:40:41,656 --> 00:40:43,691
I ALSO THOUGHT IT'S IMPORTANT WE

900
00:40:43,691 --> 00:40:46,661
TALK ABOUT LIFE EXPECTANCY

901
00:40:46,661 --> 00:40:49,397
DIFFERENCES THAT THOSE ARE MORE

902
00:40:49,397 --> 00:40:50,431
EXPERT THAN I RECOGNIZE IF

903
00:40:50,431 --> 00:40:53,434
YOU'RE GOING TO CHANGE THAT LIFE

904
00:40:53,434 --> 00:40:56,271
EXPECTANCY CURVE, THE BIGGEST

905
00:40:56,271 --> 00:40:58,072
CHANGES HAPPEN EARLIER ON IN

906
00:40:58,072 --> 00:41:01,209
TERMS OF LOSSES AND PREMATURE

907
00:41:01,209 --> 00:41:01,876
DEATHS, PER SE.

908
00:41:01,876 --> 00:41:06,481
SO I THINK IT IS NOTABLE THAT IF

909
00:41:06,481 --> 00:41:07,715
YOU LOOK AT WHAT HAS ALSO

910
00:41:07,715 --> 00:41:09,817
HAPPENED OVER THAT TIME PERIOD,

911
00:41:09,817 --> 00:41:13,388
THE PREVALENCE OF TWO OR MORE

912
00:41:13,388 --> 00:41:15,223
CHRONIC CONDITIONS AMONGST

913
00:41:15,223 --> 00:41:17,926
RELATIVELY YOUNGER ADULTS IS ON

914
00:41:17,926 --> 00:41:19,561
THE UPSLOPE, PROBABLY IN PART

915
00:41:19,561 --> 00:41:21,396
RELATED TO OBESITY, ET CETERA,

916
00:41:21,396 --> 00:41:24,532
BUT I THINK THIS IS AN AREA OF

917
00:41:24,532 --> 00:41:26,234
CONCERN THAT IS GOING TO

918
00:41:26,234 --> 00:41:27,502
CONTINUE TO DRIVE CHRONIC

919
00:41:27,502 --> 00:41:28,503
DISEASE IN THIS COUNTRY THAT

920
00:41:28,503 --> 00:41:32,807
DOES NEED TO BE ADDRESSED.

921
00:41:32,807 --> 00:41:35,243
NEXT SLIDE.

922
00:41:35,243 --> 00:41:37,912
AND TOWARD THAT END, I THINK

923
00:41:37,912 --> 00:41:39,847
IT'S ALSO IMPORTANT TO

924
00:41:39,847 --> 00:41:41,549
APPRECIATE THE DIVERSITY OF OUR

925
00:41:41,549 --> 00:41:43,885
COUNTRY AND THE VARIOUS

926
00:41:43,885 --> 00:41:44,185
COMMUNITIES.

927
00:41:44,185 --> 00:41:45,153
ALTHOUGH THAT AGGREGATE LIFE

928
00:41:45,153 --> 00:41:47,155
EXPECTANCY CURVE HAS A CERTAIN

929
00:41:47,155 --> 00:41:49,857
SHAPE, IT'S OBVIOUSLY A FAMILY

930
00:41:49,857 --> 00:41:52,727
OF CURVES, AND THERE ARE

931
00:41:52,727 --> 00:41:54,596
SUBPOPULATIONS IN AMERICA THAT

932
00:41:54,596 --> 00:41:56,864
DON'T HAVE THE SAME LEVEL OF

933
00:41:56,864 --> 00:41:58,399
LIFE EXPECTANCY OR EVEN SLOPE.

934
00:41:58,399 --> 00:41:59,901
SOME OF THOSE CURVES ARE GOING

935
00:41:59,901 --> 00:42:01,202
IN THE WRONG DIRECTION ACTUALLY.

936
00:42:01,202 --> 00:42:05,106
AND SO IF WE'RE GOING TO ADDRESS

937
00:42:05,106 --> 00:42:06,741
PANDEMIC OF CHRONIC DISEASE, IF

938
00:42:06,741 --> 00:42:11,145
YOU WILL, I THINK WE HAVE TO

939
00:42:11,145 --> 00:42:11,813
APPRECIATE THE DIFFERENT

940
00:42:11,813 --> 00:42:12,547
POPULATIONS, PARTICULARLY IF

941
00:42:12,547 --> 00:42:13,681
WE'RE GOING TO REDRESS IT.

942
00:42:13,681 --> 00:42:18,920
NEXT SLIDE.

943
00:42:18,920 --> 00:42:22,724
INDEED AS PART OF THAT ANALYSIS

944
00:42:22,724 --> 00:42:23,958
COMPARED TO OTHER WEALTHY

945
00:42:23,958 --> 00:42:27,762
NATIONS, YOU CAN SEE THAT

946
00:42:27,762 --> 00:42:29,430
DECLINE IN CARDIOVASCULAR DEATHS

947
00:42:29,430 --> 00:42:31,165
PARTICULARLY FOR THOSE UNDER AGE

948
00:42:31,165 --> 00:42:33,701
70, YOU CAN SEE OUR SLOPE IS

949
00:42:33,701 --> 00:42:35,737
KIND OF FLATTENED OUT RELATIVE

950
00:42:35,737 --> 00:42:39,674
TO OTHER COUNTRIES, AND IF YOU

951
00:42:39,674 --> 00:42:45,713
PULL OUT THOSE AGED 15 TO 49,

952
00:42:45,713 --> 00:42:47,749
SUBSTANTIAL DIFFERENCE IN CVD

953
00:42:47,749 --> 00:42:50,351
DEATHS, IN THIS REALLY PREMATURE

954
00:42:50,351 --> 00:42:54,288
POPULATION THAT AT LEAST I FOUND

955
00:42:54,288 --> 00:42:56,224
QUITE DISTURBING RELATIVE TO

956
00:42:56,224 --> 00:42:57,025
PEER NATIONS.

957
00:42:57,025 --> 00:42:58,226
IN ADDITION THERE ARE OBVIOUSLY

958
00:42:58,226 --> 00:43:00,828
OTHER FACTORS IN THIS COUNTRY IN

959
00:43:00,828 --> 00:43:03,364
TERMS OF LOSSES FROM GUN

960
00:43:03,364 --> 00:43:04,799
VIOLENCE AND DRUG OVERDOSES THAT

961
00:43:04,799 --> 00:43:06,768
MAY BE VERY DIFFERENT FROM OUR

962
00:43:06,768 --> 00:43:09,904
PEER COUNTRIES THAT AFFECTS LIFE

963
00:43:09,904 --> 00:43:11,806
EXPECTANCY CURVES, BUT GIVEN OUR

964
00:43:11,806 --> 00:43:14,142
PORTFOLIO THIS KEY ONE THAT I

965
00:43:14,142 --> 00:43:15,376
THINK WE SHOULD BE PAYING

966
00:43:15,376 --> 00:43:18,046
ATTENTION TO.

967
00:43:18,046 --> 00:43:20,114
NEXT SLIDE.

968
00:43:20,114 --> 00:43:22,216
AND TOWARD THAT END, I THINK

969
00:43:22,216 --> 00:43:23,918
IT'S, AGAIN, IMPORTANT TO

970
00:43:23,918 --> 00:43:25,486
APPRECIATE THAT, YES, THOSE

971
00:43:25,486 --> 00:43:27,955
CURVES OF THE AGGREGATE FOR OUR

972
00:43:27,955 --> 00:43:29,657
NATION RELATIVE TO WEALTHY

973
00:43:29,657 --> 00:43:31,259
NATIONS HAS THAT DIFFERENT SLOPE

974
00:43:31,259 --> 00:43:34,796
BUT EVEN THE SLOPES WITHIN THIS

975
00:43:34,796 --> 00:43:38,599
COUNTRY ARE DIFFERENT, AND YOU

976
00:43:38,599 --> 00:43:40,902
CAN SEE DIFFERENT PATTERNS AND

977
00:43:40,902 --> 00:43:44,906
HOW IN FACT WITH A LENS OF

978
00:43:44,906 --> 00:43:49,477
SOCIAL DETERMINANTS AND SOCIAL

979
00:43:49,477 --> 00:43:51,546
DEPRIVATION THE RELATIONSHIP

980
00:43:51,546 --> 00:43:53,481
BETWEEN THOSE FACTORS AND

981
00:43:53,481 --> 00:43:54,282
CARDIOVASCULAR MORBIDITY AND

982
00:43:54,282 --> 00:43:57,051
MORTALITY, AND YOU CAN SEE THE

983
00:43:57,051 --> 00:44:05,193
CLEAR GRADIENT RELATED TO SOCIAL

984
00:44:05,193 --> 00:44:07,395
DEPRIVATION AND EVEN SOCIAL

985
00:44:07,395 --> 00:44:09,897
DETERMINANTS YOU CAN SEE, AGAIN,

986
00:44:09,897 --> 00:44:11,666
INTERACTION THERE AS WELL.

987
00:44:11,666 --> 00:44:16,571
SO, CLEARLY IF WE'RE GOING TO

988
00:44:16,571 --> 00:44:17,371
ADDRESS THIS CHRONIC DISEASE

989
00:44:17,371 --> 00:44:21,609
BURDEN, WE HAVE TO BE THINKING

990
00:44:21,609 --> 00:44:23,878
ABOUT THESE SOCIAL, GEOGRAPHIC,

991
00:44:23,878 --> 00:44:27,248
AND PLACE MATTER ISSUES IN

992
00:44:27,248 --> 00:44:31,052
COMBINATION AND AT MULTIPLE

993
00:44:31,052 --> 00:44:33,721
LEVELS. 

994
00:44:33,721 --> 00:44:36,424
NEXT SLIDE.

995
00:44:36,424 --> 00:44:37,024
INDEED, DRILLING INTO

996
00:44:37,024 --> 00:44:39,927
HYPERTENSION, THIS IS ONE OF THE

997
00:44:39,927 --> 00:44:43,564
AREAS WHERE THIS MAY BE MOST

998
00:44:43,564 --> 00:44:45,032
CRITICAL, WE'VE LOOKED TOWARD

999
00:44:45,032 --> 00:44:47,635
THOSE YOUNGER ADULTS AND START

1000
00:44:47,635 --> 00:44:49,604
TO SEE DIFFERENCES, PARTICULARLY

1001
00:44:49,604 --> 00:44:53,908
IN CERTAIN POPULATIONS, AND IN

1002
00:44:53,908 --> 00:44:55,877
CERTAIN GEOGRAPHIES, WHERE THIS

1003
00:44:55,877 --> 00:44:58,579
PARTICULAR BURDEN OF RISK

1004
00:44:58,579 --> 00:45:01,315
FACTORS AMONG THE YOUNGER ADULTS

1005
00:45:01,315 --> 00:45:04,519
THAT HAS ALREADY MANIFEST AND

1006
00:45:04,519 --> 00:45:06,120
POTENTIALLY DRIVING SOME EARLY

1007
00:45:06,120 --> 00:45:10,458
RISK AND PREMATURE DEATHS.

1008
00:45:10,458 --> 00:45:12,193
NEXT SLIDE PLEASE.

1009
00:45:12,193 --> 00:45:13,895
AND APPRECIATING, AGAIN, THAT

1010
00:45:13,895 --> 00:45:19,267
THE INTERACTIONS OF THE VARIOUS

1011
00:45:19,267 --> 00:45:21,602
FACTORS, GENETICS, ENVIRONMENTAL

1012
00:45:21,602 --> 00:45:24,906
EXPOSURES, VARIOUS LOCAL SOCIAL

1013
00:45:24,906 --> 00:45:25,406
DETERMINANTS, NUTRITION,

1014
00:45:25,406 --> 00:45:26,974
EXERCISE, ACCESS TO HEALTHY

1015
00:45:26,974 --> 00:45:28,776
LIFESTYLE, ALL THESE FACTORS ARE

1016
00:45:28,776 --> 00:45:30,912
GOING TO INTERACT IF WE'RE GOING

1017
00:45:30,912 --> 00:45:33,781
TO ADDRESS THIS CHRONIC DISEASE

1018
00:45:33,781 --> 00:45:36,417
BURDEN IN THIS COUNTRY AND

1019
00:45:36,417 --> 00:45:37,985
RECOGNIZE THAT THERE ARE

1020
00:45:37,985 --> 00:45:39,520
POPULATIONS WHERE WE HAVE AN

1021
00:45:39,520 --> 00:45:43,691
EARLIER ONSET OF A LOT OF THESE

1022
00:45:43,691 --> 00:45:45,560
RISK FACTORS AND COMORBID

1023
00:45:45,560 --> 00:45:47,328
CONDITIONS PREDISPOSED TO

1024
00:45:47,328 --> 00:45:48,229
PREMATURE DEATHS, HYPERTENSION

1025
00:45:48,229 --> 00:45:51,399
BEING SHOWN HERE.

1026
00:45:51,399 --> 00:45:52,667
NEXT SLIDE PLEASE.

1027
00:45:52,667 --> 00:45:54,235
COMBINED WITH OBESITY.

1028
00:45:54,235 --> 00:45:55,469
SO THAT'S WHERE WE'RE HOPEFUL

1029
00:45:55,469 --> 00:45:57,772
THAT A LOT OF THE APPROACHES

1030
00:45:57,772 --> 00:46:00,241
WE'VE BEEN STARTING TO BUILD

1031
00:46:00,241 --> 00:46:04,712
TOWARD OF TAKING A HOLISTIC

1032
00:46:04,712 --> 00:46:07,048
MULTI-LEVEL SYSTEMS APPROACH TO

1033
00:46:07,048 --> 00:46:10,952
REDUCING THE BURDEN OF CHRONIC

1034
00:46:10,952 --> 00:46:11,352
DISEASE, TYPICALLY

1035
00:46:11,352 --> 00:46:13,020
CARDIOVASCULAR RISK ACROSS THE

1036
00:46:13,020 --> 00:46:17,992
LIFE COURSE, HAS BEEN A CORE OF

1037
00:46:17,992 --> 00:46:20,528
OUR STRATEGIC VISION AND

1038
00:46:20,528 --> 00:46:21,662
CERTAINLY IMPLEMENTATION PLAN,

1039
00:46:21,662 --> 00:46:23,331
BUT ALSO LEVERAGING OTHER

1040
00:46:23,331 --> 00:46:26,300
ELEMENTS OF THE INSTITUTE LIKE

1041
00:46:26,300 --> 00:46:28,603
CTRIS, CEAL, IN WAYS THAT WE CAN

1042
00:46:28,603 --> 00:46:31,706
HOPEFULLY DO A HOLISTIC AND

1043
00:46:31,706 --> 00:46:35,343
MULTI-LAYERED STRATEGY TO

1044
00:46:35,343 --> 00:46:38,212
ADDRESS THAT, BUT LEVERAGE A

1045
00:46:38,212 --> 00:46:40,648
SOCIOECOLOGICAL MODEL.

1046
00:46:40,648 --> 00:46:41,515
NEXT SLIDE.

1047
00:46:41,515 --> 00:46:44,685
AND IN THAT REGARD, I THINK

1048
00:46:44,685 --> 00:46:46,888
WE'RE WELL POSITIONED TO ADDRESS

1049
00:46:46,888 --> 00:46:48,656
MAKING AMERICA HEALTHY AGAIN IN

1050
00:46:48,656 --> 00:46:51,592
MANY WAYS BY LEVERAGING SOME OF

1051
00:46:51,592 --> 00:46:52,760
THE PLATFORMS THAT WE CREATED,

1052
00:46:52,760 --> 00:46:55,429
INDEED IN THE CONTEXT OF COVID,

1053
00:46:55,429 --> 00:46:57,098
WHEN IT WAS REALLY IMPORTANT TO

1054
00:46:57,098 --> 00:46:59,533
GET ON THE GROUND IN THESE

1055
00:46:59,533 --> 00:47:05,539
COMMUNITIES, MEET THEM WHERE

1056
00:47:05,539 --> 00:47:07,742
THEY ARE, LISTEN, CO-CREATE

1057
00:47:07,742 --> 00:47:10,111
COMMUNITY-ENGAGED SOLUTIONS TO

1058
00:47:10,111 --> 00:47:11,612
THE CHALLENGES THEY SEE, AND

1059
00:47:11,612 --> 00:47:15,116
START TO MAKE AN IMPACT ON THOSE

1060
00:47:15,116 --> 00:47:16,584
COMMUNITIES, WITH THOSE

1061
00:47:16,584 --> 00:47:20,988
COMMUNITIES, WITH THAT STRATEGY.

1062
00:47:20,988 --> 00:47:25,893
NEXT SLIDE PLEASE.

1063
00:47:25,893 --> 00:47:27,595
INDEED, THERE'S SUGGESTION THAT

1064
00:47:27,595 --> 00:47:31,565
PARTICULARLY USING HYPERTENSION

1065
00:47:31,565 --> 00:47:34,302
AS A PARADIGM THAT WE'VE MADE

1066
00:47:34,302 --> 00:47:36,270
PROGRESS IN SOME OF OUR HEALTH

1067
00:47:36,270 --> 00:47:38,539
EDUCATION AND PUBLIC EDUCATION

1068
00:47:38,539 --> 00:47:40,007
EFFORTS RAISING AWARENESS, BUT

1069
00:47:40,007 --> 00:47:41,809
WE STILL HAVEN'T QUITE GOT THERE

1070
00:47:41,809 --> 00:47:44,645
WITH TREATMENT AND CONTROL.

1071
00:47:44,645 --> 00:47:47,648
WE'VE DONE GREAT EFFICACY

1072
00:47:47,648 --> 00:47:49,383
TRIALS, WITH SPRINT WE NOW KNOW

1073
00:47:49,383 --> 00:47:56,157
WE CAN  PREVENT HEART ATTACKS,

1074
00:47:56,157 --> 00:47:56,924
STROKES, WITH OPTIMAL BLOOD

1075
00:47:56,924 --> 00:47:57,291
PRESSURE.

1076
00:47:57,291 --> 00:47:59,894
YET WHEN WE LOOK AT WHERE WE

1077
00:47:59,894 --> 00:48:03,798
ARE, WITH TREATMENT AND CONTROL,

1078
00:48:03,798 --> 00:48:04,899
WE'RE NOT THERE.

1079
00:48:04,899 --> 00:48:06,667
AND, AGAIN, THERE'S CERTAIN

1080
00:48:06,667 --> 00:48:07,468
COMMUNITIES THAT ARE LAGGING

1081
00:48:07,468 --> 00:48:08,035
BEHIND.

1082
00:48:08,035 --> 00:48:16,444
SO SOME OF THE BENEFITS OF

1083
00:48:16,444 --> 00:48:17,778
GETTING TO THOSE COMMUNITIES

1084
00:48:17,778 --> 00:48:20,715
THAT NEED IT THE MOST.

1085
00:48:20,715 --> 00:48:21,816
NEXT SLIDE PLEASE.

1086
00:48:21,816 --> 00:48:24,919
AND THAT'S WHERE I'M HOPING THAT

1087
00:48:24,919 --> 00:48:29,690
WE'LL DOUBLE DOWN ON SOME OF THE

1088
00:48:29,690 --> 00:48:30,558
COMMUNITY-ENGAGED RESEARCH AND

1089
00:48:30,558 --> 00:48:32,760
IMPLEMENTATION SCIENCE THAT IS

1090
00:48:32,760 --> 00:48:36,797
COMMUNITY EMBEDDED IN WAYS THAT

1091
00:48:36,797 --> 00:48:40,768
TAKES NOVEL APPROACHES TO

1092
00:48:40,768 --> 00:48:44,605
COMMUNICATING WITH FOLKS, AND

1093
00:48:44,605 --> 00:48:46,107
LEVERAGING TRUSTED MESSENGERS

1094
00:48:46,107 --> 00:48:48,275
WITHIN COMMUNITY TO ENGAGE WITH

1095
00:48:48,275 --> 00:48:52,246
PEERS IN WAYS THAT DOES RAISE

1096
00:48:52,246 --> 00:48:53,247
AWARENESS, PROMOTES TREATMENT,

1097
00:48:53,247 --> 00:48:54,682
PROMOTES CONTROL IN A

1098
00:48:54,682 --> 00:48:59,620
COORDINATED SORT OF WAY,

1099
00:48:59,620 --> 00:49:01,722
DEMONSTRATED BY RIGOROUS STUDY.

1100
00:49:01,722 --> 00:49:04,759
AND SO CAN WE SCALE THESE SORTS

1101
00:49:04,759 --> 00:49:09,730
OF ACTIVITIES BECOMES THE

1102
00:49:09,730 --> 00:49:10,498
QUESTION.

1103
00:49:10,498 --> 00:49:12,633
NEXT SLIDE.

1104
00:49:12,633 --> 00:49:13,634
THAT'S WHERE WE'RE HOPEFUL WE'LL

1105
00:49:13,634 --> 00:49:15,836
CONTINUE TO BUILD ON THE CEAL

1106
00:49:15,836 --> 00:49:17,872
PLATFORM AN ELEMENT LINKED TO

1107
00:49:17,872 --> 00:49:19,607
PRIMARY CARE WHICH OBVIOUSLY IS

1108
00:49:19,607 --> 00:49:21,275
PART OF RISK FACTOR MANAGEMENT.

1109
00:49:21,275 --> 00:49:25,079
IF WE'RE GOING TO MAKE A DENT

1110
00:49:25,079 --> 00:49:26,080
MAKING AMERICA HEALTHY AGAIN,

1111
00:49:26,080 --> 00:49:28,849
AFFECTING AND ADDRESSING THIS IN

1112
00:49:28,849 --> 00:49:30,384
COMMUNITIES THAT LACK AND HAVE

1113
00:49:30,384 --> 00:49:33,154
THESE DISPARITIES AND NEED THIS

1114
00:49:33,154 --> 00:49:34,622
THE MOST, THEN ENGAGING THESE

1115
00:49:34,622 --> 00:49:39,126
COMMUNITIES WHERE THEY ARE AND

1116
00:49:39,126 --> 00:49:42,196
COUPLING WITH COMMUNITY EMBEDDED

1117
00:49:42,196 --> 00:49:44,899
CLINICAL OPPORTUNITIES AND AREAS

1118
00:49:44,899 --> 00:49:46,734
OF RISK FACTOR MANAGEMENT WHERE

1119
00:49:46,734 --> 00:49:49,203
HOPEFULLY WE CREATE SCALABLE

1120
00:49:49,203 --> 00:49:49,437
MODELS.

1121
00:49:49,437 --> 00:49:50,938
NEXT SLIDE.

1122
00:49:50,938 --> 00:49:53,274
AND SO, PROGRESS IS BEING MADE

1123
00:49:53,274 --> 00:49:55,209
TO BUILD OUT THAT CONNECTION OF

1124
00:49:55,209 --> 00:49:58,646
CEAL WITH THE PRIMARY CARE BASED

1125
00:49:58,646 --> 00:50:00,414
RESEARCH NETWORKS, AND

1126
00:50:00,414 --> 00:50:01,549
DEVELOPING DATA EXCHANGES SUCH

1127
00:50:01,549 --> 00:50:03,751
THAT, AGAIN, WE HAVE A SENSE IN

1128
00:50:03,751 --> 00:50:05,786
THOSE COMMUNITIES AND THOSE

1129
00:50:05,786 --> 00:50:08,089
PRACTICES OF THE CHALLENGES OF

1130
00:50:08,089 --> 00:50:09,423
RISK FACTOR AND HEALTHY

1131
00:50:09,423 --> 00:50:10,958
LIFESTYLE MANAGEMENT.

1132
00:50:10,958 --> 00:50:11,759
NEXT SLIDE.

1133
00:50:11,759 --> 00:50:13,894
AND AS WE HAVE THOSE DATA

1134
00:50:13,894 --> 00:50:17,898
RESOURCES, WE CAN THEN START TO

1135
00:50:17,898 --> 00:50:21,969
ASSESS ARE THERE STRATEGIES WITH

1136
00:50:21,969 --> 00:50:22,603
IMPLEMENTATION SCIENCE,

1137
00:50:22,603 --> 00:50:23,237
COMMUNITY-ENGAGED RESEARCH WHERE

1138
00:50:23,237 --> 00:50:24,538
WE CAN HELP THOSE COMMUNITIES

1139
00:50:24,538 --> 00:50:27,141
WHERE THEY HAVE THE HIGHEST

1140
00:50:27,141 --> 00:50:28,709
PREVALENCE OF BLOOD PRESSURE,

1141
00:50:28,709 --> 00:50:34,381
BUT ALSO BLOOD PRESSURE IS NOT

1142
00:50:34,381 --> 00:50:36,050
ADEQUATELY CONTROLLED AND LOOK

1143
00:50:36,050 --> 00:50:40,321
AT RISK FACTORS, SO MANY

1144
00:50:40,321 --> 00:50:41,889
AFFECTING POPULATIONS, SOCIAL

1145
00:50:41,889 --> 00:50:44,692
DETERMINANTS,  NEW PROVIDESSERS.

1146
00:50:44,692 --> 00:50:47,328
IF WE'RE GOING TO MAKE AN IMPACT

1147
00:50:47,328 --> 00:50:48,462
THIS HOLISTIC APPROACH WE THINK

1148
00:50:48,462 --> 00:50:49,897
WILL BE CRITICAL.

1149
00:50:49,897 --> 00:50:50,564
NEXT SLIDE.

1150
00:50:50,564 --> 00:50:55,402
INDEED AS PART OF THE EARLY

1151
00:50:55,402 --> 00:50:57,805
PILOT STUDY IN THAT CEAL CARE

1152
00:50:57,805 --> 00:51:02,276
NET THEY ARE DOING A RANDOMIZED

1153
00:51:02,276 --> 00:51:07,047
CLUSTER DESIGN TRIAL INVOLVING

1154
00:51:07,047 --> 00:51:08,649
MULTIPLE CLINICS IN THAT NETWORK

1155
00:51:08,649 --> 00:51:12,219
TO TAKE AN APPROACH WHERE

1156
00:51:12,219 --> 00:51:13,654
THEYIVELY USING HOPEFULLY EHR

1157
00:51:13,654 --> 00:51:16,657
SCREENING WHAT PATIENTS HAVE

1158
00:51:16,657 --> 00:51:19,293
UNCONTROLLED HYPERTENSION OR

1159
00:51:19,293 --> 00:51:21,662
DIABETES AND LINKING TO SOCIAL

1160
00:51:21,662 --> 00:51:24,965
VULNERABILITY AND DOING A SOCIAL

1161
00:51:24,965 --> 00:51:25,799
VULNERABILITY SUPPORT WITH

1162
00:51:25,799 --> 00:51:28,536
COMMUNITY HEALTH WORKERS AND

1163
00:51:28,536 --> 00:51:30,538
HOPING HELPING THEM NAVIGATE

1164
00:51:30,538 --> 00:51:34,475
ISSUES OF ACCESS OR ADHERENCE OR

1165
00:51:34,475 --> 00:51:36,477
SOCIAL SUPPORT IN OTHER WAYS AND

1166
00:51:36,477 --> 00:51:38,212
TO SEE WHETHER THAT COULD BE

1167
00:51:38,212 --> 00:51:40,281
DONE AT THAT CLINIC LEVEL IS A

1168
00:51:40,281 --> 00:51:41,482
TEST OF THIS.

1169
00:51:41,482 --> 00:51:44,218
SO THIS IS KIND OF A TEST OF THE

1170
00:51:44,218 --> 00:51:45,986
MODEL, BUT HOPEFULLY STARTS TO

1171
00:51:45,986 --> 00:51:48,355
BRING TOGETHER THE COMMUNITY

1172
00:51:48,355 --> 00:51:49,723
ENGAGED RESEARCH, PRIMARY CARE

1173
00:51:49,723 --> 00:51:55,296
NETWORK, AND HOW WE'RE WRAPPING

1174
00:51:55,296 --> 00:51:55,963
AROUND HOLISTICALLY SOCIAL

1175
00:51:55,963 --> 00:51:58,365
DETERMINANTS OF HEALTH IN A

1176
00:51:58,365 --> 00:52:01,535
HOPEFULLY RIGOROUS AND WAY AND

1177
00:52:01,535 --> 00:52:02,836
EVIDENCE-BASED WAY WE HOPE CAN

1178
00:52:02,836 --> 00:52:04,605
SCALE.

1179
00:52:04,605 --> 00:52:04,905
NEXT SLIDE.

1180
00:52:04,905 --> 00:52:09,710
TOWARD THAT END, WE SEE THIS AS

1181
00:52:09,710 --> 00:52:13,047
PART OF THAT VIRTUOUS CYCLE OF

1182
00:52:13,047 --> 00:52:14,848
DISCOVERY THAT THEN HAS PUBLIC

1183
00:52:14,848 --> 00:52:18,485
HEALTH IMPACT IN WHICH THERE'S

1184
00:52:18,485 --> 00:52:20,688
THIS INTEGRATION OF COMPONENTS

1185
00:52:20,688 --> 00:52:21,655
INCLUDING THE IMPLEMENTATION

1186
00:52:21,655 --> 00:52:23,691
SCIENCE TOWARD A HEALTH OUTCOME.

1187
00:52:23,691 --> 00:52:26,093
SO I'VE TALKED ABOUT THE

1188
00:52:26,093 --> 00:52:28,862
COMMUNITY ENGAGEMENT PART BUT

1189
00:52:28,862 --> 00:52:31,232
THERE'S ALSO A POSITION THAT

1190
00:52:31,232 --> 00:52:32,866
EVEN CAN OCCUR WITH EARLY

1191
00:52:32,866 --> 00:52:33,801
TRANSLATION IN BASIC SCIENCE AS

1192
00:52:33,801 --> 00:52:39,673
WELL AS PART OF THE WHOLE CYCLE.

1193
00:52:39,673 --> 00:52:40,207
NEXT SLIDE.

1194
00:52:40,207 --> 00:52:43,143
AND ONE OF THE EXAMPLES I'LL GO

1195
00:52:43,143 --> 00:52:45,913
BACK TO SOME REAL WORLD SCIENCE,

1196
00:52:45,913 --> 00:52:56,423
THE AREA I WAS INVOLVED IN, I

1197
00:52:57,191 --> 00:52:59,660
STILL REMEMBER OLIVER SMITHIES

1198
00:52:59,660 --> 00:53:01,528
PAPER, SHOWING A DOSE DEPENDENT

1199
00:53:01,528 --> 00:53:07,768
EFFECT OF EACH COPY ON BLOOD

1200
00:53:07,768 --> 00:53:08,535
PRESSURE, HIGHLIGHTING THE

1201
00:53:08,535 --> 00:53:19,013
CRITICAL COAL AS PART OF THE

1202
00:53:20,014 --> 00:53:21,148
CASCADE, ANGIOTENSEINOGEN,

1203
00:53:21,148 --> 00:53:23,851
SETTING THE STAGE OF

1204
00:53:23,851 --> 00:53:28,689
FUNDAMENTALLY FOR TRANSLATING

1205
00:53:28,689 --> 00:53:29,590
THAT INTO NOVEL THERAPEUTIC, AND

1206
00:53:29,590 --> 00:53:36,764
MANY ARE FAMILIAR WITH SOME OF

1207
00:53:36,764 --> 00:53:39,633
THE STUDIES WHERE KNOCKING DOWN

1208
00:53:39,633 --> 00:53:42,102
ANGIOTENSEINOGEN BY A LIVER

1209
00:53:42,102 --> 00:53:42,670
TARGETED THERAPY COULD LOWER

1210
00:53:42,670 --> 00:53:45,039
BLOOD PRESSURE AGAIN IN ANIMALS,

1211
00:53:45,039 --> 00:53:47,841
NOW IN PHASE 2, MOVING TO PHASE

1212
00:53:47,841 --> 00:53:51,245
3 STUDIES, IN AN AGE OF IT TAKES

1213
00:53:51,245 --> 00:53:54,715
AN RNA INTERFERON STRATEGY SRNA

1214
00:53:54,715 --> 00:53:57,718
AND HOPEFULLY KNOCKS DOWN THE

1215
00:53:57,718 --> 00:54:01,855
ANGIOTENSEINOGEN GENE, DELIVERED

1216
00:54:01,855 --> 00:54:03,290
BY A GlcNAc POLYMER TO THE

1217
00:54:03,290 --> 00:54:04,625
LEVEL WHICH GENERALLY WORKS WELL

1218
00:54:04,625 --> 00:54:07,361
AND YOU CAN SEE SIX-MONTH DROP

1219
00:54:07,361 --> 00:54:10,964
WITH ONE TREATMENT IN BLOOD

1220
00:54:10,964 --> 00:54:11,565
PRESSURE FOR THIS AGENT.

1221
00:54:11,565 --> 00:54:15,269
THIS IS ALSO WHERE WE'RE EXCITED

1222
00:54:15,269 --> 00:54:16,870
THAT ANOTHER CHAPTER OF

1223
00:54:16,870 --> 00:54:20,307
PREEMPTIVE THERAPY MAY BE THE

1224
00:54:20,307 --> 00:54:23,344
ABILITY TO TARGET GENE THERAPIES

1225
00:54:23,344 --> 00:54:26,280
IN THIS CASE RNA INTERFERONS AS

1226
00:54:26,280 --> 00:54:27,715
STRATEGIES TO INFLUENCE PATHWAYS

1227
00:54:27,715 --> 00:54:30,751
THAT NOW WE HAVE GREAT MOLECULAR

1228
00:54:30,751 --> 00:54:32,986
TARGETS TO, AND WHICH WE CAN

1229
00:54:32,986 --> 00:54:37,291
START TO THINK ABOUT PREVENTING

1230
00:54:37,291 --> 00:54:38,592
OR PREEMPTING HYPERTENSION.

1231
00:54:38,592 --> 00:54:42,963
AND SO WE'RE VERY EXCITED OF

1232
00:54:42,963 --> 00:54:43,697
ADVANCING THOSE TECHNOLOGIES,

1233
00:54:43,697 --> 00:54:47,401
ACTUALLY WILL BE REVIEWING ONE

1234
00:54:47,401 --> 00:54:48,702
OF OUR INNOVATION PLATFORMS

1235
00:54:48,702 --> 00:54:51,038
CATALYZE IN WHICH WE'RE LOOKING

1236
00:54:51,038 --> 00:54:54,675
FORWARD TO EFFORTS TO BUILD UP

1237
00:54:54,675 --> 00:54:58,011
THE CAPABILITIES OF THIS IN VIVO

1238
00:54:58,011 --> 00:54:59,913
GENETIC ENGINEERING AND

1239
00:54:59,913 --> 00:55:03,617
CELL-BASED THERAPIES REMINISCENT

1240
00:55:03,617 --> 00:55:11,725
OF WHAT WE DID WITH SICKLE CELL

1241
00:55:11,725 --> 00:55:12,960
AND BONE MARROW TRANSPLANT, IN

1242
00:55:12,960 --> 00:55:17,197
SITU, IN CASE THE LIVER FOR

1243
00:55:17,197 --> 00:55:18,432
HYPERTENSION AND FRANKLY LDL,

1244
00:55:18,432 --> 00:55:19,833
THERE ARE COMPANIES WORKING ON

1245
00:55:19,833 --> 00:55:22,369
THESE STRATEGIES BUT DEVELOPING

1246
00:55:22,369 --> 00:55:25,906
THE NEXT GENERATION OF VECTORS

1247
00:55:25,906 --> 00:55:27,674
AND HOMING VECTORS,

1248
00:55:27,674 --> 00:55:29,309
SUFFICIENCIES AND EFFECTIVENESS

1249
00:55:29,309 --> 00:55:30,644
OF THESE APPROACHES, WE SEE THIS

1250
00:55:30,644 --> 00:55:32,913
AS AN EXCITING AREA FOR

1251
00:55:32,913 --> 00:55:34,615
PREEMPTION AND PREVENTION OF

1252
00:55:34,615 --> 00:55:43,223
CHRONIC DISEASE.

1253
00:55:43,223 --> 00:55:44,425
NEXT SLIDE.

1254
00:55:44,425 --> 00:55:48,362
LET ME SHIFT AND CLOSE WITH

1255
00:55:48,362 --> 00:55:51,999
MATERNAL HEALTH AS ANOTHER AREA

1256
00:55:51,999 --> 00:55:56,036
WHERE AGAIN YOU CAN SEE MAJOR

1257
00:55:56,036 --> 00:55:58,305
DISPARITIES WITH OUR COMPARABLE

1258
00:55:58,305 --> 00:55:59,373
NATIONS, AND A MAJOR PROBLEM

1259
00:55:59,373 --> 00:56:02,876
THAT WE NEED TO ADDRESS IN THIS

1260
00:56:02,876 --> 00:56:03,844
COUNTRY, AND THAT I THINK THAT,

1261
00:56:03,844 --> 00:56:08,182
AGAIN, IS PART OF MAKING

1262
00:56:08,182 --> 00:56:09,583
AMERICAN HEALTHY AGAIN,

1263
00:56:09,583 --> 00:56:12,286
RECOGNIZING WOMEN IN THEIR

1264
00:56:12,286 --> 00:56:14,488
REPRODUCTIVE YEARS, AND HOW THAT

1265
00:56:14,488 --> 00:56:18,992
HAS AN IMPACT PARTICULARLY IN

1266
00:56:18,992 --> 00:56:20,694
PREGNANCY ON THE DEVELOPMENTAL

1267
00:56:20,694 --> 00:56:24,398
ORIGINS OF CHRONIC DISEASE AS WE

1268
00:56:24,398 --> 00:56:25,566
RECOGNIZE THAT IN UTERO

1269
00:56:25,566 --> 00:56:28,969
EXPOSURES MAY BE SETTING THE

1270
00:56:28,969 --> 00:56:30,437
STAGE FOR CHRONIC DISEASE LATER

1271
00:56:30,437 --> 00:56:33,373
IN CHILDHOOD AND IN ADULT LIFE.

1272
00:56:33,373 --> 00:56:36,577
NEXT SLIDE.

1273
00:56:36,577 --> 00:56:38,679
AND THIS ALSO REPRESENTS AN

1274
00:56:38,679 --> 00:56:42,583
OPPORTUNITY TO ADDRESS THAT LIFE

1275
00:56:42,583 --> 00:56:43,484
EXPECTANCY AND CHRONIC DISEASE

1276
00:56:43,484 --> 00:56:45,886
CURVE BECAUSE WE KNOW THE

1277
00:56:45,886 --> 00:56:51,492
LONG-TERM SEQUELAE OF THESE

1278
00:56:51,492 --> 00:56:56,063
ADVERSE PREGNANCY OUTCOMES LIKE

1279
00:56:56,063 --> 00:56:56,964
PREECLAMPSIA, HYPERTENSION LATER

1280
00:56:56,964 --> 00:57:02,202
IN LIFE AND IN THE CHILD, WE CAN

1281
00:57:02,202 --> 00:57:03,504
SEE THIS INTERGENERATIONAL

1282
00:57:03,504 --> 00:57:04,705
EFFECT IN MANY POPULATIONS.

1283
00:57:04,705 --> 00:57:05,439
NEXT SLIDE.

1284
00:57:05,439 --> 00:57:08,509
AND THAT MAY BE A VERY RIPE AREA

1285
00:57:08,509 --> 00:57:11,478
FOR US TO DO FURTHER STUDY OF

1286
00:57:11,478 --> 00:57:14,848
DEFINING WHO IS MOST AT RISK,

1287
00:57:14,848 --> 00:57:16,817
AND LEVERAGING SOME OF THE TOOLS

1288
00:57:16,817 --> 00:57:20,053
AND TECHNOLOGIES IN GENETICS TO

1289
00:57:20,053 --> 00:57:21,588
PREDICT THAT AND BIOMARKERS AS

1290
00:57:21,588 --> 00:57:23,290
WELL, WE SEE THAT AS ANOTHER

1291
00:57:23,290 --> 00:57:24,625
PROMISING AREA OF RESEARCH ABOUT

1292
00:57:24,625 --> 00:57:27,294
WHERE WE CAN, AGAIN, BE MORE

1293
00:57:27,294 --> 00:57:29,630
PREDICTIVE AND PRECISE IN

1294
00:57:29,630 --> 00:57:30,397
PREVENTING THESE COMPLICATIONS

1295
00:57:30,397 --> 00:57:33,901
BY IDENTIFYING WHO IS AT

1296
00:57:33,901 --> 00:57:37,771
GREATEST RISK.

1297
00:57:37,771 --> 00:57:39,740
NEXT SLIDE.

1298
00:57:39,740 --> 00:57:41,909
WITH THAT END, WE SEE AN

1299
00:57:41,909 --> 00:57:43,911
OPPORTUNITY TO MAKE

1300
00:57:43,911 --> 00:57:47,581
INTERVENTIONS, IN THIS CASE THE

1301
00:57:47,581 --> 00:57:52,019
CHAPS TRIAL, LOWERING BLOOD

1302
00:57:52,019 --> 00:57:53,020
PRESSURE, REDUCING PRE-ECLAMPSIA

1303
00:57:53,020 --> 00:57:55,422
AND OTHER COMPLICATIONS SO

1304
00:57:55,422 --> 00:57:56,490
HOPEFULLY WE'RE CHANGING THAT IN

1305
00:57:56,490 --> 00:57:59,660
THE HISTORY BOTH FOR MOM AND THE

1306
00:57:59,660 --> 00:58:07,200
CHILD BY THOSE INTERVENTIONS.

1307
00:58:07,200 --> 00:58:07,501
NEXT SLIDE.

1308
00:58:07,501 --> 00:58:09,970
PERHAPS EGGING ON MY COLLEAGUES

1309
00:58:09,970 --> 00:58:12,439
TO THINK ABOUT WHAT'S CHAPs

1310
00:58:12,439 --> 00:58:21,748
2.0, WHAT WE SHOULD BE DOING

1311
00:58:21,748 --> 00:58:24,585
NEXT SYSTOLIC 140 FOR A PREGNANT

1312
00:58:24,585 --> 00:58:26,019
WOMAN DOESN'T SOUND THE BEST,

1313
00:58:26,019 --> 00:58:28,021
COULD WE DO MORE?

1314
00:58:28,021 --> 00:58:29,523
ARE THERE LIFESTYLE CHANGES IN

1315
00:58:29,523 --> 00:58:32,125
ADDITION TO THE DRUGS THAT COULD

1316
00:58:32,125 --> 00:58:33,660
BE ENHANCING MOM'S HEALTH AND

1317
00:58:33,660 --> 00:58:35,162
PERHAPS BABY'S HEALTH AS WELL

1318
00:58:35,162 --> 00:58:38,365
THAT MIGHT HAVE LONG-TERM

1319
00:58:38,365 --> 00:58:38,966
SEQUELAE.

1320
00:58:38,966 --> 00:58:44,371
AND INDEED WE'VE ALREADY CREATED

1321
00:58:44,371 --> 00:58:45,572
A DIETARY PATTERN, DASH,

1322
00:58:45,572 --> 00:58:47,074
AFFECTED IN THIS CONTEXT.

1323
00:58:47,074 --> 00:58:48,208
YET SCRAPED AROUND WITH OUR

1324
00:58:48,208 --> 00:58:52,045
TEAM, I DON'T KNOW IN A THERE'S

1325
00:58:52,045 --> 00:58:53,914
BEEN A ROBUST DASH-LIKE

1326
00:58:53,914 --> 00:58:57,050
INTERVENTION IN WOMEN WHO ARE

1327
00:58:57,050 --> 00:58:59,786
PREGNANT GIVEN HOW IMPORTANT

1328
00:58:59,786 --> 00:59:00,754
BLOOD PRESSURE IS.

1329
00:59:00,754 --> 00:59:03,991
AND SO I'LL LEAVE THAT OUT TO

1330
00:59:03,991 --> 00:59:05,359
PROGRAM TO BE THINKING ABOUT

1331
00:59:05,359 --> 00:59:08,228
WHAT WE MIGHT BE ABLE TO DO IN

1332
00:59:08,228 --> 00:59:09,696
THAT SPACE.

1333
00:59:09,696 --> 00:59:11,231
IT'S HARD TO IMAGINE DASH DIET

1334
00:59:11,231 --> 00:59:14,468
WOULD DO A LOT OF HARM, PROBABLY

1335
00:59:14,468 --> 00:59:16,737
GOOD NOT ONLY FOR MOM BUT BABY

1336
00:59:16,737 --> 00:59:19,106
AS WELL, SO THAT MAY BE

1337
00:59:19,106 --> 00:59:24,745
IMPORTANT HYPOTHESIS TO TEST.

1338
00:59:24,745 --> 00:59:25,512
NEXT SLIDE.

1339
00:59:25,512 --> 00:59:28,248
NEXT SLIDE PLEASE.

1340
00:59:28,248 --> 00:59:34,054
AND SO WHEN WE TRY TO WALK

1341
00:59:34,054 --> 00:59:38,392
THROUGH TODAY, OPPORTUNITIES IN

1342
00:59:38,392 --> 00:59:41,628
THAT VIRTUOUS CYCLE THAT WE

1343
00:59:41,628 --> 00:59:45,432
THINK COULD BE VERY WELL

1344
00:59:45,432 --> 00:59:46,933
ASSIGNED WITH THE NEW

1345
00:59:46,933 --> 00:59:49,136
ADMINISTRATION'S MAKE AMERICA

1346
00:59:49,136 --> 00:59:50,837
HEALTHY AGAIN AGENDA TO ADDRESS,

1347
00:59:50,837 --> 01:00:00,380
PREVENT, IF NOT PREEMPT CHRONIC

1348
01:00:00,380 --> 01:00:02,049
DISEASE RELATIVE WITH OUR

1349
01:00:02,049 --> 01:00:02,749
PORTFOLIO, AND WE'VE STARTED

1350
01:00:02,749 --> 01:00:04,518
WITH THE COMMUNITY TO HAVE

1351
01:00:04,518 --> 01:00:06,687
TOOLS, PLATFORMS, WHERE THE

1352
01:00:06,687 --> 01:00:08,188
COMMUNITY TO RISE TO THE

1353
01:00:08,188 --> 01:00:09,623
CHALLENGE AND MAKE A DIFFERENCE

1354
01:00:09,623 --> 01:00:10,691
AND GET CURVES SHIFTED BACK THE

1355
01:00:10,691 --> 01:00:13,393
WAY THEY NEED TO BE.

1356
01:00:13,393 --> 01:00:15,595
NEXT SLIDE.

1357
01:00:15,595 --> 01:00:17,531
ALL THIS WILL BE CRITICAL BUT

1358
01:00:17,531 --> 01:00:22,335
ONLY IF WE WORK TOGETHER AS

1359
01:00:22,335 --> 01:00:23,303
PARTNERS IN THAT WAY, AND FIRST

1360
01:00:23,303 --> 01:00:25,839
OF ALL BE SURE WE GET THE

1361
01:00:25,839 --> 01:00:28,341
RESOURCES WE NEED TO PURSUE THAT

1362
01:00:28,341 --> 01:00:28,575
AGENDA.

1363
01:00:28,575 --> 01:00:30,410
IF WE DO, I THINK THERE'S A LOT

1364
01:00:30,410 --> 01:00:32,079
OF EXCITING WORK WE CAN DO

1365
01:00:32,079 --> 01:00:33,413
TOGETHER. 

1366
01:00:33,413 --> 01:00:36,983
WITH THAT, I'LL CLOSE.

1367
01:00:36,983 --> 01:00:50,831
THANKS. 

1368
01:00:50,831 --> 01:01:01,308
>> COMMENTS FROM COUNCIL? 

1369
01:01:07,547 --> 01:01:09,416
SEEING NO HANDS RAISED

1370
01:01:09,416 --> 01:01:10,951
VIRTUALLY, WE'LL BREAK FOR
LUNCH.

1371
01:01:10,951 --> 01:01:11,151
WE'LL TAKE THE 30 MINUTES AND
COME BACK AND RECONVENE THE

1372
01:01:11,151 --> 01:01:19,962
PRESENTATION FROM DR. MIZUNO,
INTRAMURAL RESEARCH.

1373
01:01:19,962 --> 01:01:23,466
WE'RE DELIGHTED TO HAVE WITH US

1374
01:01:23,466 --> 01:01:29,539
THE NEXT SPEAKER, DR. MIZUNO,

1375
01:01:29,539 --> 01:01:34,277
SENIOR INVESTIGATOR, INTRAMURAL

1376
01:01:34,277 --> 01:01:36,245
RESEARCH AT NHLBI.

1377
01:01:36,245 --> 01:01:38,848
FROM UNIVERSITY OF TOKYO,

1378
01:01:38,848 --> 01:01:39,849
Ph.D. IN BIOPHYSICS THROUGH

1379
01:01:39,849 --> 01:01:42,285
JOINT PROGRAM WITH UNIVERSITY OF

1380
01:01:42,285 --> 01:01:44,854
TOKYO AND UNIVERSITY OF TEXAS

1381
01:01:44,854 --> 01:01:46,355
SOUTHWESTERN MEDICAL CENTER,

1382
01:01:46,355 --> 01:01:48,724
PRIOR TO JOINING NHLBI SHE LED

1383
01:01:48,724 --> 01:01:51,060
INDEPENDENT GROUP FOR 8 YEARS AT

1384
01:01:51,060 --> 01:01:52,962
THE MAX PLANCK INSTITUTE OF

1385
01:01:52,962 --> 01:01:56,499
BIOCHEMISTRY IN GERMANY AND ALSO

1386
01:01:56,499 --> 01:01:59,302
RECEIVED NUMEROUS EUROPEAN

1387
01:01:59,302 --> 01:02:09,612
HONORS INCLUDING EMBO YOUNG

1388
01:02:09,612 --> 01:02:11,380
INVESTIGATOR AWARD, AND ERC

1389
01:02:11,380 --> 01:02:14,050
CONSOLIDATED GRANT, SERVED AS

1390
01:02:14,050 --> 01:02:16,485
EDITOR OF FEB LETTERS AND

1391
01:02:16,485 --> 01:02:18,955
EVALUATOR OF THE EUROPEAN UNION

1392
01:02:18,955 --> 01:02:23,559
HORIZON 2020 PROGRAM.

1393
01:02:23,559 --> 01:02:23,793
WELCOME.

1394
01:02:23,793 --> 01:02:32,868
>> THANK YOU VERY MUCH,
I'M

1395
01:02:32,868 --> 01:02:34,036
NAOKO MIZUNO.

1396
01:02:34,036 --> 01:02:36,005
I'M INCREDIBLY HONORED TO BE

1397
01:02:36,005 --> 01:02:38,341
HERE TO GIVE MY PRESENTATION TO

1398
01:02:38,341 --> 01:02:42,244
YOU ALL FOR THE INTRODUCTION OF

1399
01:02:42,244 --> 01:02:44,981
OUR RESEARCH PROGRAM ON EXCITING

1400
01:02:44,981 --> 01:02:52,989
FINDS HAPPENING IN MY

1401
01:02:52,989 --> 01:02:53,289
LABORATORY.

1402
01:02:53,289 --> 01:03:03,833
MY LAB USED TO BE AT MAX PLANCK

1403
01:03:05,067 --> 01:03:07,236
INSTITUTE, FIVE YEARS AGO MOVED

1404
01:03:07,236 --> 01:03:09,605
TO NIH, STARTED EXPOUNDING

1405
01:03:09,605 --> 01:03:12,575
LOOKING AT INTERESTING AND ALSO

1406
01:03:12,575 --> 01:03:14,110
IMPORTANT CLINICAL AND MEDICAL

1407
01:03:14,110 --> 01:03:14,510
PROGRAMS.

1408
01:03:14,510 --> 01:03:17,313
SO I'M GOING TO TELL YOU A

1409
01:03:17,313 --> 01:03:23,185
LITTLE BIT OF ONGOING PROGRESS,

1410
01:03:23,185 --> 01:03:33,696
ALSO ONE INTERESTING COMPLETE

1411
01:03:33,929 --> 01:03:34,330
PROJECT. 

1412
01:03:34,330 --> 01:03:43,806
JUST A MOMENT, OKAY. 

1413
01:03:43,806 --> 01:03:44,874
IT WORKS.

1414
01:03:44,874 --> 01:03:49,211
SO HERE YOU CAN SEE THIS IS KIND

1415
01:03:49,211 --> 01:03:52,481
OF THEME OF MY LABORATORY,

1416
01:03:52,481 --> 01:03:54,116
INTEGRATIVE IMAGING, WHICH MEANS

1417
01:03:54,116 --> 01:03:56,552
THAT WE ARE USING DIFFERENT TYPE

1418
01:03:56,552 --> 01:04:02,992
OF THE  MAGNIFYING LENS TO

1419
01:04:02,992 --> 01:04:03,559
DESCRIBE THE PHENOMENA WE'RE

1420
01:04:03,559 --> 01:04:06,862
INTERESTED IN FOR EXAMPLE

1421
01:04:06,862 --> 01:04:10,032
STUDDING MOLECULAR ORGANIZATION,

1422
01:04:10,032 --> 01:04:12,201
WE CAN ALSO DESCRIBE NEAR ATOMIC

1423
01:04:12,201 --> 01:04:14,270
OR ATOMIC INFORMATION.

1424
01:04:14,270 --> 01:04:17,473
YOU CAN SEE IN CELLULAR

1425
01:04:17,473 --> 01:04:19,442
ORGANIZATION MORPHOLOGY, TISSUE

1426
01:04:19,442 --> 01:04:21,177
ORGANIZATION, USING DIFFERENT

1427
01:04:21,177 --> 01:04:22,445
MAGNIFIERS CAN COMBINE

1428
01:04:22,445 --> 01:04:23,846
INFORMATION AND FINALLY OUR GOAL

1429
01:04:23,846 --> 01:04:25,881
IS TO HAVE A COMPREHENSIVE

1430
01:04:25,881 --> 01:04:27,783
UNDERSTANDING OF THE PHENOMENA

1431
01:04:27,783 --> 01:04:29,118
THAT WE ARE INTERESTED.

1432
01:04:29,118 --> 01:04:31,821
I'M GOING TO TELL YOU A LITTLE

1433
01:04:31,821 --> 01:04:34,123
BIT MORE ABOUT THIS LATER.

1434
01:04:34,123 --> 01:04:36,992
FOR NOW LET'S MOVE ON.

1435
01:04:36,992 --> 01:04:40,362
WHAT I MEAN BY DIFFERENT LENS IS

1436
01:04:40,362 --> 01:04:41,831
FOLLOWING.

1437
01:04:41,831 --> 01:04:44,200
WE ARE THE IMAGING LAB, LOOK

1438
01:04:44,200 --> 01:04:45,000
INTO IMAGING TECHNOLOGIES.

1439
01:04:45,000 --> 01:04:48,804
YOU CAN SEE HERE THIS TABLE IS

1440
01:04:48,804 --> 01:04:51,207
SHOWING THE LINEUP OF DIFFERENT

1441
01:04:51,207 --> 01:04:52,007
TYPE OF MICROSCOPES DEPENDING

1442
01:04:52,007 --> 01:04:53,242
WHAT RESOLUTION YOU WANT TO

1443
01:04:53,242 --> 01:04:55,311
ACHIEVE OR WHAT KIND OF CONTEXT

1444
01:04:55,311 --> 01:04:58,047
FOR THE SIZE OF THE SAMPLE YOU

1445
01:04:58,047 --> 01:04:58,447
HAVE.

1446
01:04:58,447 --> 01:05:01,517
YOU CAN SEE HERE THIS IS QUITE

1447
01:05:01,517 --> 01:05:03,652
NICELY COVERED BUT THIS WAS NOT

1448
01:05:03,652 --> 01:05:06,355
THE CASE 10 YEARS AGO.

1449
01:05:06,355 --> 01:05:09,291
SO, MY LAB IS WORKING ON

1450
01:05:09,291 --> 01:05:12,094
CryoEM, AND MYSELF I HAVE BEEN

1451
01:05:12,094 --> 01:05:14,530
WORKING ON CryoEM SINCE 1999.

1452
01:05:14,530 --> 01:05:16,665
SO THIS IS REALLY MY EXPERTISE.

1453
01:05:16,665 --> 01:05:19,468
BUT IF YOU LOOK AT THIS PORTION,

1454
01:05:19,468 --> 01:05:21,570
THIS IS A CryoEM.

1455
01:05:21,570 --> 01:05:23,272
WE DID THE TECHNOLOGY.

1456
01:05:23,272 --> 01:05:26,776
THIS WAS NOT A VARIABLE OR AT

1457
01:05:26,776 --> 01:05:29,478
LEAST WASN'T A PRIME METHOD

1458
01:05:29,478 --> 01:05:31,180
UNTIL 2015.

1459
01:05:31,180 --> 01:05:34,550
AROUND THAT TIME THERE WAS

1460
01:05:34,550 --> 01:05:35,518
TECHNOLOGY BREAKTHROUGH IN THE

1461
01:05:35,518 --> 01:05:43,359
FIELD, THAT  ALLOWED LARGE

1462
01:05:43,359 --> 01:05:46,662
CONTEXTUAL AT NEAR ATOMIC

1463
01:05:46,662 --> 01:05:47,530
RESOLUTION CHANGING HOW PEOPLE

1464
01:05:47,530 --> 01:05:49,098
LOOK AT STRUCTURE AND

1465
01:05:49,098 --> 01:05:50,065
INTERACTIONS ENOUGH WITHIN TWO

1466
01:05:50,065 --> 01:05:52,034
YEARS THE PIONEERS IN THE FIELD

1467
01:05:52,034 --> 01:05:52,735
GOT NOBEL PRIZE.

1468
01:05:52,735 --> 01:05:56,872
SO IT WAS A BIG DEAL.

1469
01:05:56,872 --> 01:05:59,141
AFTERWARDS NOW WHAT WE ARE

1470
01:05:59,141 --> 01:06:01,911
EXPERIENCING IS THE NEXT PHASE

1471
01:06:01,911 --> 01:06:12,354
OF THE REVOLUTION OR BREAK

1472
01:06:13,823 --> 01:06:15,724
THROUGH, IN SITU, CryoEM, WE

1473
01:06:15,724 --> 01:06:17,593
CAN START LOOKING INTO WHAT'S

1474
01:06:17,593 --> 01:06:23,465
GOING ON IN THE CELL, USING

1475
01:06:23,465 --> 01:06:27,903
CryoEM METHOD, WE HAVE

1476
01:06:27,903 --> 01:06:28,904
POTENTIAL OF INFORMATION.

1477
01:06:28,904 --> 01:06:30,906
NOW, LOOKING AT THE FUTURE, I

1478
01:06:30,906 --> 01:06:34,310
WANT TO ADD ONE MORE DIMENSION.

1479
01:06:34,310 --> 01:06:36,378
THIS IS AN IMAGING DIMENSION BUT

1480
01:06:36,378 --> 01:06:39,615
THEN WE CAN ALSO ADD ONE MORE SO

1481
01:06:39,615 --> 01:06:43,052
WE CAN START ASKING MORE OF THE

1482
01:06:43,052 --> 01:06:44,887
INFORMATION AND COMPREHENSION.

1483
01:06:44,887 --> 01:06:46,589
BUT THIS SOMETIMES IS HAPPENING,

1484
01:06:46,589 --> 01:06:47,756
NOT ALL THE TIME, BUT IN THE

1485
01:06:47,756 --> 01:06:49,625
FUTURE IT'S GOOD TO HAVE AN EYE

1486
01:06:49,625 --> 01:06:50,192
ON IT.

1487
01:06:50,192 --> 01:06:54,230
FOR EXAMPLE, HOW CAN WE CONNECT

1488
01:06:54,230 --> 01:06:54,730
IMAGING INFORMATION WITH

1489
01:06:54,730 --> 01:06:56,699
DYNAMICS IN VIVO IMAGING OR GIVE

1490
01:06:56,699 --> 01:07:00,603
THE CONTEXT OF THE DISEASE OR

1491
01:07:00,603 --> 01:07:06,942
EVEN THE APPLICATION, SO HOW TO

1492
01:07:06,942 --> 01:07:08,377
PREVENT THE DISEASE, DEVELOPING

1493
01:07:08,377 --> 01:07:12,181
DRUG USING METHOD OF IMAGING.

1494
01:07:12,181 --> 01:07:13,048
OKAY.

1495
01:07:13,048 --> 01:07:16,652
SO, WHAT WE HAVE BEEN DOING

1496
01:07:16,652 --> 01:07:17,920
UNTIL RECENTLY THE PROTEIN

1497
01:07:17,920 --> 01:07:23,425
ANALYSIS, YOU CAN SEE HERE THIS

1498
01:07:23,425 --> 01:07:27,796
IS PROTEIN COMPLEX, ADHESION

1499
01:07:27,796 --> 01:07:31,500
MACHINERY, A MACHINERY THAT IS

1500
01:07:31,500 --> 01:07:34,136
PERIPHERY, MAKING A DECISION

1501
01:07:34,136 --> 01:07:38,040
WHAT CELLS SHOULD BE DOING,

1502
01:07:38,040 --> 01:07:39,041
DEVELOP CANCER, MIGRATE,

1503
01:07:39,041 --> 01:07:41,210
POLARIZE, THINGS LIKE THIS

1504
01:07:41,210 --> 01:07:42,845
HAPPENING BECAUSE OF THIS

1505
01:07:42,845 --> 01:07:44,246
RECEPTOR CALLED INTEGRIN.

1506
01:07:44,246 --> 01:07:46,081
IT'S VERY IMPORTANT THAT IT'S

1507
01:07:46,081 --> 01:07:50,219
ALSO ON THE ONE TARGET OR THE

1508
01:07:50,219 --> 01:07:51,120
TREATMENT.

1509
01:07:51,120 --> 01:07:54,390
SO INTEGRIN IS HERE, IT IS DOING

1510
01:07:54,390 --> 01:07:55,791
SURVEILLANCE OUTSIDE OF THE

1511
01:07:55,791 --> 01:07:59,495
CELL, SO THIS IS ECM, AND YOU

1512
01:07:59,495 --> 01:08:02,631
CAN SEE THOSE ARE THE PROTEINS

1513
01:08:02,631 --> 01:08:08,470
INSIDE THE CELL, THAT MAKES THIS

1514
01:08:08,470 --> 01:08:09,672
COMPLEX.

1515
01:08:09,672 --> 01:08:10,406
EVENTUALLY COMPLEX IS INITIATOR

1516
01:08:10,406 --> 01:08:13,175
ON DEVELOPING TO HUNDREDS OF

1517
01:08:13,175 --> 01:08:15,010
PROTEINS MAKING A DRUG, CHANGED

1518
01:08:15,010 --> 01:08:19,281
THE BEHAVIOR OF THE CELL.

1519
01:08:19,281 --> 01:08:20,783
SO, WE CAN ADDRESS A LOT OF

1520
01:08:20,783 --> 01:08:23,218
THINGS, QUITE NICE THAT WE HAVE

1521
01:08:23,218 --> 01:08:25,354
A PRECISE CONTROL AND WE HAVE

1522
01:08:25,354 --> 01:08:27,156
PRECISE UNDERSTANDING OF THE

1523
01:08:27,156 --> 01:08:27,623
MOLECULES.

1524
01:08:27,623 --> 01:08:30,626
BUT THEN THE MAIN CHALLENGE OR

1525
01:08:30,626 --> 01:08:31,994
THE CHALLENGE REMAINS WHICH IS

1526
01:08:31,994 --> 01:08:34,997
IS IT NOT HAPPENING ALONE, IT IS

1527
01:08:34,997 --> 01:08:36,832
HAPPENING IN THE CONTEXT OF THE

1528
01:08:36,832 --> 01:08:38,901
CELL, SO CELL HAS A LOT MORE

1529
01:08:38,901 --> 01:08:43,238
GOING ON THAN ON OUR LITTLE

1530
01:08:43,238 --> 01:08:44,940
COMPLEX SHOWN HERE.

1531
01:08:44,940 --> 01:08:47,109
SO QUESTION, ISN'T IT NICE, WE

1532
01:08:47,109 --> 01:08:48,110
CAN ADDRESS THE SAME THING IN

1533
01:08:48,110 --> 01:08:52,181
THE CONTEXT IN THE LARGER

1534
01:08:52,181 --> 01:08:53,749
CONTEXT AND WITHIN THE CONTEXT,

1535
01:08:53,749 --> 01:08:55,384
WITHIN THE COMMUNICATION, WITH

1536
01:08:55,384 --> 01:08:57,152
THE CELL, BETWEEN THE OUTSIDE,

1537
01:08:57,152 --> 01:08:58,320
INSIDE THE CELL, WITHIN THE

1538
01:08:58,320 --> 01:09:04,259
CELL, SO THAT'S WHAT WE WANT TO

1539
01:09:04,259 --> 01:09:04,426
DO.

1540
01:09:04,426 --> 01:09:05,694
THEREFORE, I THINK MORE THAN

1541
01:09:05,694 --> 01:09:11,800
FIVE YEARS AGO DECIDED TO MOVE,

1542
01:09:11,800 --> 01:09:20,876
JUMP IN THE FIELD OF IN SITU

1543
01:09:20,876 --> 01:09:23,679
CryoEM, OR CRYO-ET.

1544
01:09:23,679 --> 01:09:24,580
IT LEADS TO UNEXPECTED DISCOVERY

1545
01:09:24,580 --> 01:09:27,549
SO IT'S BEEN FUN TO FIND

1546
01:09:27,549 --> 01:09:31,820
SOMETHING THAT WE NEVER THOUGHT

1547
01:09:31,820 --> 01:09:32,721
WE WOULD FIND.

1548
01:09:32,721 --> 01:09:37,626
NOW I'M GOING TO TELL YOU TWO

1549
01:09:37,626 --> 01:09:39,628
EXAMPLES OF THE ONGOING

1550
01:09:39,628 --> 01:09:41,230
EXPLORATION AND ALSO ONE

1551
01:09:41,230 --> 01:09:42,698
COMPLETE EXAMPLE, BUT I THINK

1552
01:09:42,698 --> 01:09:45,434
IT'S QUITE AMAZING THAT WE

1553
01:09:45,434 --> 01:09:45,901
MANAGED.

1554
01:09:45,901 --> 01:09:47,903
SO, I THINK I ALREADY MENTIONED

1555
01:09:47,903 --> 01:09:53,409
ABOUT WHAT WE ARE INTERESTED IN,

1556
01:09:53,409 --> 01:09:54,676
DECISION-MAKING PROCESS OF CELL,

1557
01:09:54,676 --> 01:10:01,350
SO YOU CAN SEE HERE BASICALLY

1558
01:10:01,350 --> 01:10:02,985
THE FORMATION, IT SOUNDS LIKE A

1559
01:10:02,985 --> 01:10:04,586
SHAPING OF THE CELL, BUT

1560
01:10:04,586 --> 01:10:06,255
ACTUALLY THIS MEANS IT'S A

1561
01:10:06,255 --> 01:10:09,625
DECISION-MAKING PROCESS OF THE

1562
01:10:09,625 --> 01:10:12,661
CELL.

1563
01:10:12,661 --> 01:10:16,899
SO, THIS EXAMPLE SHOWS

1564
01:10:16,899 --> 01:10:17,166
ACTIVATING

1565
01:10:17,166 --> 01:10:25,507
IT'S GOING TO CHANGE THE SHAPE,

1566
01:10:25,507 --> 01:10:27,376
SHIELD THE WOUND, DECISION

1567
01:10:27,376 --> 01:10:29,078
MAKING, SO DIVIDING, AFTER

1568
01:10:29,078 --> 01:10:30,245
DIVIDING PORTION THERE'S A LOT

1569
01:10:30,245 --> 01:10:31,280
GOING ON HERE.

1570
01:10:31,280 --> 01:10:34,149
SO A LOT OF CONTROL, A LOT OF

1571
01:10:34,149 --> 01:10:36,251
SIGNALING HAPPENING.

1572
01:10:36,251 --> 01:10:37,553
AND MOST PROMINENT EXAMPLE OF

1573
01:10:37,553 --> 01:10:39,555
THE CELL THAT'S CHANGING SHAPE

1574
01:10:39,555 --> 01:10:44,426
IS THE NEURONAL CELL OR SHAPING

1575
01:10:44,426 --> 01:10:50,365
PROCESS. 

1576
01:10:50,365 --> 01:10:52,701
SO THE NEURON, ELONGATE, A LOT

1577
01:10:52,701 --> 01:10:56,004
OF LOCAL CONTROL IS HAPPENING.

1578
01:10:56,004 --> 01:10:59,875
I'M NOT A NEURAL SCIENTIST, BUT

1579
01:10:59,875 --> 01:11:01,977
I'M A BASIC SCIENTIST INTERESTED

1580
01:11:01,977 --> 01:11:05,848
IN THE SHAPING PROCESS, WE ALSO

1581
01:11:05,848 --> 01:11:11,086
LOOK INTO THE NEURONAL CELL

1582
01:11:11,086 --> 01:11:12,554
SHAPE PROCESS.

1583
01:11:12,554 --> 01:11:15,457
AND NOW BEING AT NIH WE'RE ALSO

1584
01:11:15,457 --> 01:11:16,758
FOCUSING ON WHAT IF THE FINE

1585
01:11:16,758 --> 01:11:18,961
PROCESS OF THE CELL SHAPE

1586
01:11:18,961 --> 01:11:20,929
FORMATION IS NOT WORKING, WHICH

1587
01:11:20,929 --> 01:11:24,633
MEANS THAT THE DISEASE IS

1588
01:11:24,633 --> 01:11:25,367
HAPPENING QUITE DIRECTLY OUT OF

1589
01:11:25,367 --> 01:11:27,569
THE CONTROL, OUT OF THE

1590
01:11:27,569 --> 01:11:28,237
HOMEOSTASIS.

1591
01:11:28,237 --> 01:11:31,106
FOR EXAMPLE, CANCER CELL, IF YOU

1592
01:11:31,106 --> 01:11:33,609
LOOK AT THIS KIND OF LEGS, THE

1593
01:11:33,609 --> 01:11:36,211
TIP OF THE LEG WE EXPECT

1594
01:11:36,211 --> 01:11:40,215
INTEGRIN TO BE HYPERACTIVATED SO

1595
01:11:40,215 --> 01:11:45,020
UPREGULATED SO THAT SHAPE IS

1596
01:11:45,020 --> 01:11:48,223
READY TO MIGRATE.

1597
01:11:48,223 --> 01:11:49,391
SICKLE CELL FORMATION IS ANOTHER

1598
01:11:49,391 --> 01:11:52,528
ONE WE WORK ON ACTIVELY, THAT

1599
01:11:52,528 --> 01:11:59,434
THERE IS A SINGLE MUTATION IN

1600
01:11:59,434 --> 01:12:02,571
THE HEMOGLOBIN UNDER THE LACK OF

1601
01:12:02,571 --> 01:12:05,607
OXYGEN HEMOGLOBIN START MAKING

1602
01:12:05,607 --> 01:12:10,846
THE FILAMENT, THE FILAMENT

1603
01:12:10,846 --> 01:12:11,613
EVENTUALLY REACHED CELL,

1604
01:12:11,613 --> 01:12:12,915
CRESCENT SHAPE, EVENTUALLY TO

1605
01:12:12,915 --> 01:12:13,549
BREAK DOWN.

1606
01:12:13,549 --> 01:12:16,451
WE WANT ALSO TO HAVE A LOOK AT

1607
01:12:16,451 --> 01:12:19,054
HOW THIS CAN HAPPEN AND HOW WE

1608
01:12:19,054 --> 01:12:20,389
CAN PREVENT IT.

1609
01:12:20,389 --> 01:12:23,926
AND ALSO FINALLY THE NEURONAL

1610
01:12:23,926 --> 01:12:25,294
CELL LOSING CONNECTION, THAT

1611
01:12:25,294 --> 01:12:27,296
MEANS IT CAN BE INJURED, THAT

1612
01:12:27,296 --> 01:12:29,398
MEANS IT'S A BRAIN INJURY, SO WE

1613
01:12:29,398 --> 01:12:32,067
TRY TO UNDERSTAND THE PROCESS OF

1614
01:12:32,067 --> 01:12:34,269
IT AND HOW WE CAN CONTROL IT OR

1615
01:12:34,269 --> 01:12:37,472
AT LEAST TO UNDERSTAND WHAT IS

1616
01:12:37,472 --> 01:12:39,308
GOING TO HAPPEN AT THE MOLECULAR

1617
01:12:39,308 --> 01:12:39,942
RESOLUTION.

1618
01:12:39,942 --> 01:12:42,244
THAT'S WHAT WE'RE TRYING TO

1619
01:12:42,244 --> 01:12:42,811
ADDRESS.

1620
01:12:42,811 --> 01:12:44,046
OKAY.

1621
01:12:44,046 --> 01:12:49,718
SO, NOW THIS IS OUR KIND OF

1622
01:12:49,718 --> 01:12:51,453
SHOWCASE EXAMPLE, SHOWING HOW

1623
01:12:51,453 --> 01:12:52,588
NEURONAL CELL CHANGING THE SHAPE

1624
01:12:52,588 --> 01:12:58,727
SO YOU CAN SEE HERE THIS IS A

1625
01:12:58,727 --> 01:13:01,697
NEW NEUROIDE COMING OUT, THIS IS

1626
01:13:01,697 --> 01:13:07,236
THE FIRST TIME WE SEE DIRECTLY

1627
01:13:07,236 --> 01:13:08,503
WHAT'S HAPPENING WITHOUT

1628
01:13:08,503 --> 01:13:09,438
FILTERING FLUORESCENT LEVELING,

1629
01:13:09,438 --> 01:13:10,372
WE SEE EVERYTHING HERE.

1630
01:13:10,372 --> 01:13:13,408
NOW WHAT WAS QUITE INTERESTING

1631
01:13:13,408 --> 01:13:17,479
TO SEE AS MITOCHONDRIA HERE,

1632
01:13:17,479 --> 01:13:21,717
YELLOW SHOWN HERE E.R., E.R. IS

1633
01:13:21,717 --> 01:13:22,217
HOLDING MITOCHONDRIA SO

1634
01:13:22,217 --> 01:13:25,454
MITOCHONDRIA DOESN'T RUN AWAY

1635
01:13:25,454 --> 01:13:26,955
FROM THE ROOT OF THE NEURON

1636
01:13:26,955 --> 01:13:28,323
PORTION OF THE CELL.

1637
01:13:28,323 --> 01:13:30,292
IN ORDER TO MAKE THE PROTEINS

1638
01:13:30,292 --> 01:13:34,229
THAT ARE NECESSARY TO MAKE THE

1639
01:13:34,229 --> 01:13:37,165
NEURITE, YOU SEE A LOT OF BLUE

1640
01:13:37,165 --> 01:13:39,801
DOTS OF THE RIBOSOME, SO THIS

1641
01:13:39,801 --> 01:13:42,738
WAS ACTUALLY AN UNEXPECTED

1642
01:13:42,738 --> 01:13:46,008
SURPRISE BECAUSE PEOPLE HAVE

1643
01:13:46,008 --> 01:13:47,442
NEVER SEEN RIBOSOME IN AXON

1644
01:13:47,442 --> 01:13:50,946
BEFORE, THE FIRST EXAMPLE, THIS

1645
01:13:50,946 --> 01:13:52,381
IS THE RIBOSOME, IT'S ONLY AT

1646
01:13:52,381 --> 01:13:56,051
THE AREA WHERE THE NEW FORMATION

1647
01:13:56,051 --> 01:14:01,056
OF THE LIKE MANY CELL  PROTRUSIN

1648
01:14:01,056 --> 01:14:02,791
TO START HAPPENING SO THIS WAS

1649
01:14:02,791 --> 01:14:03,558
FULFILLING EXPERIENCE FOR US,

1650
01:14:03,558 --> 01:14:05,661
JUST TO HAVE A LOOK, AND THEN TO

1651
01:14:05,661 --> 01:14:09,364
HAVE A SURPRISE OF IT.

1652
01:14:09,364 --> 01:14:12,834
SO, WHY DO WE SEE EVERYTHING

1653
01:14:12,834 --> 01:14:14,136
USING CryoEM TECHNOLOGY AS

1654
01:14:14,136 --> 01:14:16,338
OPPOSED TO NORMAL VOLUME OF EM

1655
01:14:16,338 --> 01:14:17,105
AND SO ON?

1656
01:14:17,105 --> 01:14:20,876
I WANT TO GIVE A LITTLE BIT OF

1657
01:14:20,876 --> 01:14:24,246
EXPLANATION ABOUT IT USING THIS

1658
01:14:24,246 --> 01:14:24,446
VIDEO.

1659
01:14:24,446 --> 01:14:26,315
SO JUST EMERGING THIS IS YOUR

1660
01:14:26,315 --> 01:14:28,817
CELL, THIS IS YOUR TISSUE, YOU

1661
01:14:28,817 --> 01:14:32,454
CAN EMBED IT OR GO ON EM GRID,

1662
01:14:32,454 --> 01:14:35,023
AND THEN YOU SEE NOW THEY ARE

1663
01:14:35,023 --> 01:14:36,525
FROZEN AT MINUS 180 DEGREES AND

1664
01:14:36,525 --> 01:14:44,266
THEN THIS IS AN EM GRID,

1665
01:14:44,266 --> 01:14:46,201
LITERALLY GOES INSIDE

1666
01:14:46,201 --> 01:14:50,906
MICROSCOPE, TO BE COLLECTED SO

1667
01:14:50,906 --> 01:14:53,675
THE TOMOGRAPHY IS HAPPENING, NOW

1668
01:14:53,675 --> 01:14:57,546
COMBINED, PROJECTED INTO THE 3D

1669
01:14:57,546 --> 01:15:00,082
RECONSTRUCTION, YOU SEE DENSITY

1670
01:15:00,082 --> 01:15:02,451
BUT THIS DENSITY IS LITERALLY

1671
01:15:02,451 --> 01:15:05,554
THE DIFFERENCE OF THE MOLECULE,

1672
01:15:05,554 --> 01:15:14,196
SO THIS MEANS THAT YOU WOULD SEE

1673
01:15:14,196 --> 01:15:16,031
EVERYTHING, IT IS TRANSPARENT

1674
01:15:16,031 --> 01:15:19,301
BECAUSE THERE IS NOTHING

1675
01:15:19,301 --> 01:15:20,702
COVERING, NOTHING FIXING, ALSO

1676
01:15:20,702 --> 01:15:23,438
IT HAS POTENTIAL OF THE

1677
01:15:23,438 --> 01:15:24,139
RESOLUTION OF ATOMIC RESOLUTION,

1678
01:15:24,139 --> 01:15:26,708
OF COURSE IF YOU DO GOOD JOB

1679
01:15:26,708 --> 01:15:28,643
WITH THE SAMPLE PREPARATION AND

1680
01:15:28,643 --> 01:15:31,513
HAVE THE RIGHT SAMPLE.

1681
01:15:31,513 --> 01:15:37,119
THIS IS NOT THE EVERYDAY, BUT

1682
01:15:37,119 --> 01:15:38,186
POTENTIAL IS VERY HIGH.

1683
01:15:38,186 --> 01:15:40,655
I SAID ALREADY IT IS NOT

1684
01:15:40,655 --> 01:15:42,724
EVERYBODY'S METHOD BUT WE TRY

1685
01:15:42,724 --> 01:15:44,760
OUR BEST TO OPTIMIZE IT.

1686
01:15:44,760 --> 01:15:48,096
AND IT IS A DEVELOPING FIELD SO

1687
01:15:48,096 --> 01:15:50,832
THIS MEANS THAT EVERY PROJECT

1688
01:15:50,832 --> 01:15:51,900
REQUIRES PIPELINE OPTIMIZATION,

1689
01:15:51,900 --> 01:15:54,503
SO IT'S NOT GREAT BUT WE TRY OUR

1690
01:15:54,503 --> 01:15:59,441
BEST BECAUSE THE FRUIT IS VERY

1691
01:15:59,441 --> 01:16:00,409
AMAZING.

1692
01:16:00,409 --> 01:16:07,649
SO FAR SAMPLE  PREPARATION,

1693
01:16:07,649 --> 01:16:11,253
OPTIMIZATION, IDENTIFY AREA OF

1694
01:16:11,253 --> 01:16:18,293
INTEREST, COMPOSED OF THICKNESS,

1695
01:16:18,293 --> 01:16:20,128
10 OR 20 MICROMETER LENS, THE

1696
01:16:20,128 --> 01:16:22,364
SIZE, IF YOU HAVE THE THICKNESS

1697
01:16:22,364 --> 01:16:25,534
OF 1 MICRO METER, YOU NEED TO

1698
01:16:25,534 --> 01:16:28,603
TRIM NICELY AND TAR GET IT TO

1699
01:16:28,603 --> 01:16:29,604
KNOW EXACTLY WHERE YOU'RE

1700
01:16:29,604 --> 01:16:31,072
LOOKING AT BECAUSE IT'S GOING TO

1701
01:16:31,072 --> 01:16:33,809
BE DIFFICULT TO FIND.

1702
01:16:33,809 --> 01:16:35,343
SO WHAT WE TYPICALLY DO FREEZE A

1703
01:16:35,343 --> 01:16:40,081
SAMPLE AND THEN WE HAVE A LOOK

1704
01:16:40,081 --> 01:16:41,216
USING CREATIVE MICROSCOPE, SO WE

1705
01:16:41,216 --> 01:16:44,386
CAN LABEL ONE OF THE FAVORITE

1706
01:16:44,386 --> 01:16:46,588
PROTEIN TO THE RIGHT LOCATION

1707
01:16:46,588 --> 01:16:54,529
AND THEN YOU DO SOMETHING CALLED

1708
01:16:54,529 --> 01:16:54,963
CRYOMEETING.

1709
01:16:54,963 --> 01:16:56,531
QUITE A BIT OF MEETING HAPPENING

1710
01:16:56,531 --> 01:17:06,241
IN THIS TINY AREA THAT REMAINED,

1711
01:17:06,241 --> 01:17:07,776
AND THEN 100-NANOMETER OF THE

1712
01:17:07,776 --> 01:17:10,078
FILAMENT THAT'S PRODUCED.

1713
01:17:10,078 --> 01:17:12,647
NOW, THIS IS GOING TO BE -- THE

1714
01:17:12,647 --> 01:17:14,149
DATA IS COLLECTED USING THIS

1715
01:17:14,149 --> 01:17:17,385
LAMINA AND THEN YOU GET

1716
01:17:17,385 --> 01:17:17,886
RECONSTRUCTION.

1717
01:17:17,886 --> 01:17:20,755
NOW WE NEED TO DO THE ANALYSIS,

1718
01:17:20,755 --> 01:17:22,157
ANOTHER SUPER ACTIVE AREA OF

1719
01:17:22,157 --> 01:17:24,926
RESEARCH BECAUSE WE NEED TO DO A

1720
01:17:24,926 --> 01:17:26,161
LOT OF QUANTIFICATION AND A LOT

1721
01:17:26,161 --> 01:17:28,396
OF DATA ANALYSIS TO SQUEEZE OUT

1722
01:17:28,396 --> 01:17:29,998
ALL THE INFORMATION.

1723
01:17:29,998 --> 01:17:32,734
IF YOU'RE EXTREMELY LUCKY YOU

1724
01:17:32,734 --> 01:17:34,236
MIGHT GET NEAR ATOMIC RESOLUTION

1725
01:17:34,236 --> 01:17:36,071
OF THE OBJECT THAT YOU ARE

1726
01:17:36,071 --> 01:17:38,006
LOOKING BUT IF NOT AT LEAST YOU

1727
01:17:38,006 --> 01:17:40,375
GET THE NICE CONTEXT WHICH COULD

1728
01:17:40,375 --> 01:17:41,476
ALSO BE EQUALLY INTERESTING.

1729
01:17:41,476 --> 01:17:44,312
SO NOW I'M GOING TO TELL YOU TWO

1730
01:17:44,312 --> 01:17:47,349
EXAMPLES OF PLOD SYSTEM THAT WE

1731
01:17:47,349 --> 01:17:49,084
HAVE -- BLOOD SYSTEM WE'VE BEEN

1732
01:17:49,084 --> 01:17:50,318
WORKING ON, REALLY ONGOING

1733
01:17:50,318 --> 01:17:52,187
PROJECT, SO WE DON'T HAVE THE

1734
01:17:52,187 --> 01:17:54,456
CONCLUSION YET BUT I WANT TO

1735
01:17:54,456 --> 01:17:56,892
GIVE YOU THE FLAVOR.

1736
01:17:56,892 --> 01:18:01,496
SO, FIRST EXAMPLE I WANT TO TELL

1737
01:18:01,496 --> 01:18:04,599
YOU, TO UNDERSTAND THE MECHANISM

1738
01:18:04,599 --> 01:18:05,734
OF SICKLE CELL FORMATION.

1739
01:18:05,734 --> 01:18:08,236
I ALREADY INTRODUCE YOU ABOUT

1740
01:18:08,236 --> 01:18:09,538
THE SICKLE CELL FORMATION, SO

1741
01:18:09,538 --> 01:18:14,543
WHAT WE DO, SO THIS IS IN

1742
01:18:14,543 --> 01:18:18,146
COLLABORATION WITH NHLBI, SHE'S

1743
01:18:18,146 --> 01:18:19,114
A CLINICAL INVESTIGATOR, SHE

1744
01:18:19,114 --> 01:18:20,582
KNOWS A LOT ABOUT THE DISEASE

1745
01:18:20,582 --> 01:18:24,386
ITSELF AND A LOT ABOUT THE

1746
01:18:24,386 --> 01:18:32,294
SICKLE CELL TOGETHER WITH

1747
01:18:32,294 --> 01:18:34,396
BIOPHYSICALLIST, EATON, COLLECT

1748
01:18:34,396 --> 01:18:36,464
THE SAMPLE FROM PATIENT, THEN WE

1749
01:18:36,464 --> 01:18:37,098
HAVE SPECIAL CHAMBER.

1750
01:18:37,098 --> 01:18:39,968
SO EVERYTHING IS DONE IN THIS

1751
01:18:39,968 --> 01:18:42,704
CHAMBER BECAUSE WE CAN MAKE

1752
01:18:42,704 --> 01:18:43,672
DEOXYGENIZATION AND PUT NITROGEN

1753
01:18:43,672 --> 01:18:46,007
INTO THE ENVIRONMENT.

1754
01:18:46,007 --> 01:18:50,979
SO THEN WE HAVE THE CYCLING

1755
01:18:50,979 --> 01:18:52,747
FORMATION MIMICKED HERE, 45

1756
01:18:52,747 --> 01:18:55,684
MINUTES, CELLS START BECOMING

1757
01:18:55,684 --> 01:18:55,917
SPIKEY.

1758
01:18:55,917 --> 01:18:58,219
AFTER 4 HOURS THE COMPLETION OF

1759
01:18:58,219 --> 01:19:02,023
SICKLE FORMATION IS HAPPENING.

1760
01:19:02,023 --> 01:19:08,763
NOW FREEZING THE SAMPLE, HERE IS

1761
01:19:08,763 --> 01:19:11,032
THE FROZEN SAMPLE, HERE YOU CAN

1762
01:19:11,032 --> 01:19:13,902
SEE THE FROZEN SAMPLE, THIS AREA

1763
01:19:13,902 --> 01:19:14,569
IS EMPTY.

1764
01:19:14,569 --> 01:19:15,403
THIS HAPPENS.

1765
01:19:15,403 --> 01:19:20,809
LOOKING AT THIS AREA YOU CAN SEE

1766
01:19:20,809 --> 01:19:21,343
SOMETHING FROZEN.

1767
01:19:21,343 --> 01:19:22,877
THIS IS THE SICKLE CELL.

1768
01:19:22,877 --> 01:19:27,716
WE DO THE MEETING, SO TO LOOK

1769
01:19:27,716 --> 01:19:29,751
INTO THE INSIDE, TARGETING WITH

1770
01:19:29,751 --> 01:19:31,286
THE MILLING, THEN BEAUTIFULLY WE

1771
01:19:31,286 --> 01:19:35,657
MANAGED TO GET THE FIRST TIME

1772
01:19:35,657 --> 01:19:38,426
VISUALIZATION OF THE FILAMENT.

1773
01:19:38,426 --> 01:19:39,894
YEAH, LOOKING LIKE THIS.

1774
01:19:39,894 --> 01:19:45,400
SO, NOW YOU CAN SEE IT IS FULL

1775
01:19:45,400 --> 01:19:46,701
OF FILAMENT INSIDE THE SICKLE

1776
01:19:46,701 --> 01:19:47,235
CELL.

1777
01:19:47,235 --> 01:19:49,804
WE NEED TO DO A LOT OF ANALYSIS.

1778
01:19:49,804 --> 01:19:51,606
IT TOOK US MORE THAN ONE YEAR TO

1779
01:19:51,606 --> 01:19:52,507
GET TO THIS STAGE.

1780
01:19:52,507 --> 01:19:55,377
NOW IT'S THE TIME THAT WE DO

1781
01:19:55,377 --> 01:19:57,579
ANALYSIS, FOR EXAMPLE, WHAT

1782
01:19:57,579 --> 01:19:58,647
WOULD BE THE DISTANCE BETWEEN

1783
01:19:58,647 --> 01:20:01,483
TWO FILAMENT OF WHAT WOULD BE

1784
01:20:01,483 --> 01:20:03,351
THE MECHANISM OF THE FILAMENT

1785
01:20:03,351 --> 01:20:05,420
BUNDLING, WHAT WOULD BE THE

1786
01:20:05,420 --> 01:20:07,355
MECHANISM OF THIS FILAMENT

1787
01:20:07,355 --> 01:20:09,424
POKING INTO THE INNER MEMBRANE

1788
01:20:09,424 --> 01:20:11,493
OF THE PLASMA MEMBRANE ENOUGH

1789
01:20:11,493 --> 01:20:13,528
THAT IT IS GETTING FRAGILE, SO

1790
01:20:13,528 --> 01:20:18,566
THIS KIND OF INFORMATION WE ARE

1791
01:20:18,566 --> 01:20:21,136
GOING TO ASK. 

1792
01:20:21,136 --> 01:20:29,778
HOW DO I KNOW? 

1793
01:20:29,778 --> 01:20:31,479
YES, IT'S A GOOD QUESTION.

1794
01:20:31,479 --> 01:20:34,816
ONE THING I CAN SAY, TRAINED.

1795
01:20:34,816 --> 01:20:37,185
AND SECOND A CONTROL.

1796
01:20:37,185 --> 01:20:39,154
IF IT'S NOT SICKLE, IT IS

1797
01:20:39,154 --> 01:20:40,288
ABSOLUTELY NOTHING.

1798
01:20:40,288 --> 01:20:41,656
SO YOU SEE THE DOTS.

1799
01:20:41,656 --> 01:20:44,426
FOR YOU, YOU MIGHT SAY THIS IS

1800
01:20:44,426 --> 01:20:45,427
DOTS.

1801
01:20:45,427 --> 01:20:49,564
BUT THEN I RECOGNIZE, FOR

1802
01:20:49,564 --> 01:20:52,300
EXAMPLE, YEAH, A FILAMENT HERE,

1803
01:20:52,300 --> 01:20:55,503
HERE A FILAMENT, HERE A

1804
01:20:55,503 --> 01:20:56,237
FILAMENT.

1805
01:20:56,237 --> 01:21:02,477
SO, THEN WE CAN INDEPENDENTLY

1806
01:21:02,477 --> 01:21:04,045
ALSO RECOGNIZE, THE PROTEIN

1807
01:21:04,045 --> 01:21:06,815
STRUCTURE IS KNOWN.

1808
01:21:06,815 --> 01:21:13,021
AND STRUCTURE OF THE -- SO

1809
01:21:13,021 --> 01:21:14,055
THERE'S CRYSTALGRAPHIC PACKING

1810
01:21:14,055 --> 01:21:20,662
THAT ALLOWS US , HOW IT'S

1811
01:21:20,662 --> 01:21:23,832
HAPPENING, WE CAN ALSO USE THAT,

1812
01:21:23,832 --> 01:21:25,700
WE HAVE EDUCATED GUESS HOW THE

1813
01:21:25,700 --> 01:21:27,502
FILAMENT SHOULD LOOK LIKE AND

1814
01:21:27,502 --> 01:21:30,772
THIS SEEMS TO BE THE CASE SO WE

1815
01:21:30,772 --> 01:21:31,906
CAN VALIDATE THAT AND SO WHAT

1816
01:21:31,906 --> 01:21:34,175
WE'RE TRYING TO DO IS NOT JUST

1817
01:21:34,175 --> 01:21:37,378
TO LOOK AT IT BUT TRY TO

1818
01:21:37,378 --> 01:21:38,079
UNDERSTAND THE MOLECULAR

1819
01:21:38,079 --> 01:21:39,013
ORGANIZATION HOW THEY ARE

1820
01:21:39,013 --> 01:21:40,548
HAPPENING SO THIS IS ONLY

1821
01:21:40,548 --> 01:21:42,350
STARTING TO HAPPEN NOW.

1822
01:21:42,350 --> 01:21:46,688
SO MAYBE NEXT YEAR I COME BACK

1823
01:21:46,688 --> 01:21:47,288
HERE.

1824
01:21:47,288 --> 01:21:47,555
OKAY.

1825
01:21:47,555 --> 01:21:48,957
SO THEN THE NEXT EXAMPLE THAT I

1826
01:21:48,957 --> 01:21:59,501
WANT TO SHOW YOU, WE FOUND THIS

1827
01:21:59,868 --> 01:22:06,441
LIGAND, SO THIS LIGAND IS

1828
01:22:06,441 --> 01:22:07,242
RECOGNIZED BY INTEGRIN, VERY

1829
01:22:07,242 --> 01:22:09,778
MUCH EXPRESSED ON THE SURFACE OF

1830
01:22:09,778 --> 01:22:13,615
THE PLATELET. 

1831
01:22:13,615 --> 01:22:20,522
SO THIS MEANS YOU MIGHT EXPECT

1832
01:22:20,522 --> 01:22:23,224
INTEGRIN IS ACTIVATED SO IF YOU

1833
01:22:23,224 --> 01:22:25,527
COMPARE THE PLATELET OF THE

1834
01:22:25,527 --> 01:22:29,564
NORMAL CONDITION AND THE TEST

1835
01:22:29,564 --> 01:22:32,033
CONDITION, YOU WOULD SEE A LOT

1836
01:22:32,033 --> 01:22:38,473
OF PLATELET GETTING ACTIVATED.

1837
01:22:38,473 --> 01:22:41,743
NOW WE WANTED TO HAVE A LOOK,

1838
01:22:41,743 --> 01:22:43,578
PARTICULARLY INTERESTED IN

1839
01:22:43,578 --> 01:22:45,613
INITIATION PROCESS OF ACTIVATION

1840
01:22:45,613 --> 01:22:47,148
OF THE PLATELET, AT THE

1841
01:22:47,148 --> 01:22:49,384
BEGINNING WHAT WE SAW IS THE

1842
01:22:49,384 --> 01:22:52,253
FORMATION OF THE SUPER ELONGATED

1843
01:22:52,253 --> 01:22:54,656
PLATELETS, THIS WAY.

1844
01:22:54,656 --> 01:22:57,392
SO, BEFORE OPENING UP INTO THE

1845
01:22:57,392 --> 01:23:00,762
SHAPE SOME SEE A LOT ELONGATED

1846
01:23:00,762 --> 01:23:01,162
PLATELET.

1847
01:23:01,162 --> 01:23:05,233
SO WE HAD A LOOK AT THIS ON THE

1848
01:23:05,233 --> 01:23:05,700
CryoEM.

1849
01:23:05,700 --> 01:23:10,071
YOU CAN SEE HERE THIS IS

1850
01:23:10,071 --> 01:23:11,873
ACTUALLY PLATELET.

1851
01:23:11,873 --> 01:23:17,712
LIKE THIS. 

1852
01:23:17,712 --> 01:23:22,016
SO, NOW HAVING, DO TOMOGRAPHY,

1853
01:23:22,016 --> 01:23:23,051
APPROXIMATELY ONE MICROMETER IN

1854
01:23:23,051 --> 01:23:23,685
SIZE.

1855
01:23:23,685 --> 01:23:25,587
THIS IS THE RECONSTRUCTION.

1856
01:23:25,587 --> 01:23:27,689
YOU SEE HERE THIS IS THE

1857
01:23:27,689 --> 01:23:29,991
MEMBRANE, PLASMA MEMBRANE OF THE

1858
01:23:29,991 --> 01:23:35,230
PLATELET AND INSIDE THERE IS A

1859
01:23:35,230 --> 01:23:36,831
BUNDLE OF ACTIN WITH PROTEIN

1860
01:23:36,831 --> 01:23:38,199
DENSITY WE DON'T KNOW WHAT BUT

1861
01:23:38,199 --> 01:23:42,570
TO HAVE FIND IT OUT.

1862
01:23:42,570 --> 01:23:46,741
THAT BINDING OF THE LIGAND ON

1863
01:23:46,741 --> 01:23:48,343
PLATELET SURFACE, QUITE NICE, I

1864
01:23:48,343 --> 01:23:50,745
SHOWED PREVIOUSLY MAYBE 10

1865
01:23:50,745 --> 01:23:52,847
MINUTES AGO ABOUT THE ADHESION

1866
01:23:52,847 --> 01:23:54,515
MACHINERY THAT WE ARE

1867
01:23:54,515 --> 01:23:56,417
RECONSTITUTING, THAT MEANS WE

1868
01:23:56,417 --> 01:24:01,623
CAN START TO SEE POTENTIALLY THE

1869
01:24:01,623 --> 01:24:04,092
CONNECTION BETWEEN THE ACTIVATED

1870
01:24:04,092 --> 01:24:06,928
INTEGRIN COMPLEX, FROM THE IN

1871
01:24:06,928 --> 01:24:09,764
SITU, AND COMBINE IT WITH THE

1872
01:24:09,764 --> 01:24:11,633
PURIFIED COMPONENTS SO WE CAN

1873
01:24:11,633 --> 01:24:14,302
HAVE A COMPREHENSIVE VIEW.

1874
01:24:14,302 --> 01:24:17,805
SO, THIS IS AGAIN ONGOING.

1875
01:24:17,805 --> 01:24:18,273
OKAY.

1876
01:24:18,273 --> 01:24:19,574
FINALLY THE THIRD EXAMPLE I WANT

1877
01:24:19,574 --> 01:24:22,810
TO SHOW IS MORE THE COMPLETE

1878
01:24:22,810 --> 01:24:24,979
VERSION WHICH IS ABOUT THE

1879
01:24:24,979 --> 01:24:25,313
NEURITE.

1880
01:24:25,313 --> 01:24:27,749
NOW WHY I WANT TO SHOW YOU THIS

1881
01:24:27,749 --> 01:24:33,488
AS AN EXAMPLE IS WE DISCOVERED

1882
01:24:33,488 --> 01:24:35,256
SOMETHING BY VISUALIZING IT AND

1883
01:24:35,256 --> 01:24:38,359
ALSO ON DIRECT VISUALIZATION OF

1884
01:24:38,359 --> 01:24:39,294
NOVEL MECHANISTIC INSIGHTS YOU

1885
01:24:39,294 --> 01:24:44,732
CAN SHOWCASE FOR YOU USING THIS

1886
01:24:44,732 --> 01:24:45,033
EXAMPLE.

1887
01:24:45,033 --> 01:24:47,135
SO, CAN WE DIRECT AGAIN

1888
01:24:47,135 --> 01:24:54,108
MECHANISTIC INSIGHT JUST BY

1889
01:24:54,108 --> 01:24:55,910
LOOKING IN SITU IMAGES, THE

1890
01:24:55,910 --> 01:24:57,145
ANSWER IS YES.

1891
01:24:57,145 --> 01:25:00,081
SO, I'M GOING TO SHOW YOU MY

1892
01:25:00,081 --> 01:25:00,448
EXAMPLE.

1893
01:25:00,448 --> 01:25:04,852
SO WHAT I DID IS ACTUALLY THE

1894
01:25:04,852 --> 01:25:06,788
INJURY FORMATION OF AXON, SO

1895
01:25:06,788 --> 01:25:11,059
AXON IS THE LONGEST NEURITE OF

1896
01:25:11,059 --> 01:25:18,333
THE NEURON, IT IS IMPORTANT TO

1897
01:25:18,333 --> 01:25:20,335
SEE THE MOST POLARIZED CELL AS

1898
01:25:20,335 --> 01:25:21,502
AN EXAMPLE.

1899
01:25:21,502 --> 01:25:23,304
WE WANTED TO CHECK HOW THE

1900
01:25:23,304 --> 01:25:26,174
REACTION OF THE INJURY WOULD BE,

1901
01:25:26,174 --> 01:25:27,709
HOP REPAIR WOULD HAPPEN, HOW

1902
01:25:27,709 --> 01:25:33,247
DECISION MAKING OF THE AXON IS

1903
01:25:33,247 --> 01:25:36,084
REGENERATING OR DEGENERATING.

1904
01:25:36,084 --> 01:25:44,492
AND THIS IS IMPORTANT

1905
01:25:44,492 --> 01:25:47,295
BIOPHYSICALALLY AND CLINICALLY.

1906
01:25:47,295 --> 01:25:49,263
AXON INJURY IS ACTUALLY WHICH

1907
01:25:49,263 --> 01:25:50,398
MEANS BRAIN INJURY.

1908
01:25:50,398 --> 01:25:52,800
SO WHEN THE BRAIN INJURY HAPPENS

1909
01:25:52,800 --> 01:25:54,902
IS WHEN YOU HAVE THE CONCUSSION,

1910
01:25:54,902 --> 01:25:58,473
WHEN YOU HAVE THE HEAD INJURY,

1911
01:25:58,473 --> 01:26:02,310
ESPECIALLY WHEN YOU HAVE THE

1912
01:26:02,310 --> 01:26:03,811
BRAIN INJURY IN THE PORTION OF

1913
01:26:03,811 --> 01:26:06,514
BRAIN AT THE CENTRAL NERVE

1914
01:26:06,514 --> 01:26:08,850
SYSTEM, IT IS KNOWN THAT NEURONS

1915
01:26:08,850 --> 01:26:09,684
NEVER REGENERATE.

1916
01:26:09,684 --> 01:26:11,252
SO THIS IS A PROGRAM BECAUSE

1917
01:26:11,252 --> 01:26:14,889
ONCE YOU HAVE THE INJURY, YOU

1918
01:26:14,889 --> 01:26:17,291
GET UNCONSCIOUS, YOU HAVE A

1919
01:26:17,291 --> 01:26:18,459
COGNITIVE PROBLEM AND COULD DIE

1920
01:26:18,459 --> 01:26:20,261
OUT OF IT SO IT IS IMPORTANT TO

1921
01:26:20,261 --> 01:26:21,829
FIND OUT WHAT'S HAPPENING, HOW

1922
01:26:21,829 --> 01:26:26,834
WE CAN PREVENT OR HOW WE CAN

1923
01:26:26,834 --> 01:26:29,771
EVEN INDUCE THE REGENERATION.

1924
01:26:29,771 --> 01:26:31,739
SO WE ARE LOOKING AT INJURY

1925
01:26:31,739 --> 01:26:35,209
REACTION OF THE NEURONAL CELLS.

1926
01:26:35,209 --> 01:26:39,580
NOW I TELL YOU HOW MOLECULARLY

1927
01:26:39,580 --> 01:26:40,748
WHAT'S HAPPENING.

1928
01:26:40,748 --> 01:26:43,017
WHEN THE INJURY ON THE AXON

1929
01:26:43,017 --> 01:26:46,054
HAPPENS, THAT MEANS MEMBRANE IS

1930
01:26:46,054 --> 01:26:52,760
BROKEN, THAT MEANS THAT THE

1931
01:26:52,760 --> 01:26:55,930
CYTOSKELETON COMPONENTS LEAK

1932
01:26:55,930 --> 01:26:56,431
OUT.

1933
01:26:56,431 --> 01:26:58,099
GETS BROKEN.

1934
01:26:58,099 --> 01:27:00,435
THE MEMBRANE CLOSES AS YOU CAN

1935
01:27:00,435 --> 01:27:03,137
SEE HERE.

1936
01:27:03,137 --> 01:27:06,507
CALCIUM GOES IN, MICROTUBULES

1937
01:27:06,507 --> 01:27:09,143
SHRINK, THAT'S THE SCIENCE FOR

1938
01:27:09,143 --> 01:27:10,511
REGENERATION OF THE AXON.

1939
01:27:10,511 --> 01:27:19,821
SOMETIME AGO, 5 YEARS AGO, A

1940
01:27:19,821 --> 01:27:23,124
GROUP SHOWED REPAIRING THE

1941
01:27:23,124 --> 01:27:28,963
AXONAL INJURY OR REPAIR THE

1942
01:27:28,963 --> 01:27:31,132
SPINAL CORD INJURY.

1943
01:27:31,132 --> 01:27:34,402
EPO-B IS KNOWN AS ANTI-CANCER

1944
01:27:34,402 --> 01:27:42,643
DRUG TO FREEZE THE  CELL CYCLE,

1945
01:27:42,643 --> 01:27:45,680
BINDING ON MICROTUBAL, CAN BE

1946
01:27:45,680 --> 01:27:49,050
REPURPOSED BUT STILL NOT KNOWN

1947
01:27:49,050 --> 01:27:53,087
HOW EPO-B CAN ACT FOR THE

1948
01:27:53,087 --> 01:27:53,488
REGENERATION.

1949
01:27:53,488 --> 01:27:56,190
WE DECIDED TO WORK ON THAT BY

1950
01:27:56,190 --> 01:27:57,658
MAKING THE PIPELINE.

1951
01:27:57,658 --> 01:28:03,297
SO WE USED THE THALAMUS, TRAIN

1952
01:28:03,297 --> 01:28:04,665
TISSUE, DISSECTION.

1953
01:28:04,665 --> 01:28:10,204
YOU CAN SEE HERE WE MADE THE

1954
01:28:10,204 --> 01:28:12,006
SPECIAL TISSUE, EXPLANT, THE

1955
01:28:12,006 --> 01:28:13,441
CENTER BRAIN TISSUE AND THESE

1956
01:28:13,441 --> 01:28:15,243
ARE THE NEURITES.

1957
01:28:15,243 --> 01:28:17,612
WHAT IS VERY NICE IN THIS SYSTEM

1958
01:28:17,612 --> 01:28:19,580
IS THAT EVERYTHING SINGLE

1959
01:28:19,580 --> 01:28:21,482
NEURITE WE GET, AXONS, WE CAN

1960
01:28:21,482 --> 01:28:24,819
GET EVERYTHING WE LIKE AS

1961
01:28:24,819 --> 01:28:26,521
OPPOSED TO NORMAL ISOLATED

1962
01:28:26,521 --> 01:28:30,892
NEURON THAT HAS DENDRITE AS

1963
01:28:30,892 --> 01:28:31,292
WELL.

1964
01:28:31,292 --> 01:28:33,661
WE ALSO CULTIVATE THIS EXPLANT

1965
01:28:33,661 --> 01:28:35,663
ONTO EM GRID AND ALSO YOU CAN

1966
01:28:35,663 --> 01:28:39,800
SEE THIS IS THE EXPLANT UNDER

1967
01:28:39,800 --> 01:28:41,035
LIGHT MICROSCOPE, VISUALIZE AND

1968
01:28:41,035 --> 01:28:45,306
MAKE A FUNCTIONAL AND STRUCTURAL

1969
01:28:45,306 --> 01:28:50,411
ANALYSIS NOW WHAT WE DO IS

1970
01:28:50,411 --> 01:28:52,113
SOMETHING WHICH MEANS WE MAKE

1971
01:28:52,113 --> 01:28:54,315
THE INJURY ONTO EM GRID SO WE

1972
01:28:54,315 --> 01:28:56,117
DEVELOP THIS SPECIAL METHOD

1973
01:28:56,117 --> 01:28:58,352
USING THE NEEDLE, AND THEN TO

1974
01:28:58,352 --> 01:28:59,787
MAKE AN INJURY ONTO AXON AND WE

1975
01:28:59,787 --> 01:29:02,290
CAN HAVE A LOOK AT THE REACTION

1976
01:29:02,290 --> 01:29:06,360
AT A MOLECULAR RESOLUTION USING

1977
01:29:06,360 --> 01:29:06,928
CryoEM.

1978
01:29:06,928 --> 01:29:09,430
SO, NOW JUST TO TEST, SO

1979
01:29:09,430 --> 01:29:14,135
FUNCTIONALLY WHAT'S HAPPENING

1980
01:29:14,135 --> 01:29:15,336
YOU CAN SEE HERE INJURY

1981
01:29:15,336 --> 01:29:17,872
HAPPENING NOW, HERE IS THE

1982
01:29:17,872 --> 01:29:28,416
NEURITE, AND HERE IS ALL THE CUT

1983
01:29:30,017 --> 01:29:32,486
AXON, WITHOUT EPO-B, IT GROWS,

1984
01:29:32,486 --> 01:29:36,657
WE CAN SEE AT CELLULAR LEVEL

1985
01:29:36,657 --> 01:29:37,525
EPO-B IS WORKING.

1986
01:29:37,525 --> 01:29:41,362
NOW LET'S HAVE A LOOK AT HOW THE

1987
01:29:41,362 --> 01:29:42,863
REGENERATION HAPPENS MORE

1988
01:29:42,863 --> 01:29:44,498
CLEARLY.

1989
01:29:44,498 --> 01:29:49,704
THIS IS THE CUT AXON, BUT THEN

1990
01:29:49,704 --> 01:29:51,005
AFTER SOME TIME IT STARTS THIS.

1991
01:29:51,005 --> 01:29:55,243
I DON'T KNOW IF YOU NOTICED,

1992
01:29:55,243 --> 01:29:58,246
LIKE THIS, AFTER 90 MINUTES TO

1993
01:29:58,246 --> 01:29:59,780
TWO HOURS ACTUALLY, THERE IS

1994
01:29:59,780 --> 01:30:00,448
NOTHING HERE.

1995
01:30:00,448 --> 01:30:04,585
IT'S ONLY LIKE A STICK THAT IS

1996
01:30:04,585 --> 01:30:05,119
REGENERATING.

1997
01:30:05,119 --> 01:30:08,189
AND AFTER TWO HOURS THERE'S THIS

1998
01:30:08,189 --> 01:30:15,997
MORPHOLOGY COMING OUT, NORMAL

1999
01:30:15,997 --> 01:30:18,165
WAY OF AXON GROWING, AND UP TO

2000
01:30:18,165 --> 01:30:21,702
TWO HOURS IT'S NOT NORMAL SO

2001
01:30:21,702 --> 01:30:23,204
SOMEHOW AXON IS REGENERATING IN

2002
01:30:23,204 --> 01:30:26,274
THE ABNORMAL WAY.

2003
01:30:26,274 --> 01:30:30,811
SO WE HYPOTHESIS THIS MUST HAVE

2004
01:30:30,811 --> 01:30:36,450
SOMETHING TO DO WITH EPO-B,

2005
01:30:36,450 --> 01:30:37,952
LIKELY MICROTUBULES.

2006
01:30:37,952 --> 01:30:44,792
MAKE THE MICROTUBE TUBULE IS PUG

2007
01:30:44,792 --> 01:30:47,428
THE MEMBRANE, SO HERE YOU CAN

2008
01:30:47,428 --> 01:30:52,867
ALSO SEE THE SAME THING. 

2009
01:30:52,867 --> 01:30:58,039
SO TO TEST THIS HYPOTHESIS,

2010
01:30:58,039 --> 01:30:59,740
OKAY, WE MEASURED MEMBRANE,

2011
01:30:59,740 --> 01:31:01,242
AFTER REGENERATING THE SITE HOW

2012
01:31:01,242 --> 01:31:04,211
THE MEMBRANE TENSION IS

2013
01:31:04,211 --> 01:31:08,082
CHANGING, SO IF REGENERATION IS

2014
01:31:08,082 --> 01:31:09,183
HAPPENING, PUSHING THE MEMBRANE,

2015
01:31:09,183 --> 01:31:11,218
MAYBE THE TENSION IS HIGHER SO

2016
01:31:11,218 --> 01:31:14,322
WE USED A DYE TO MEASURE THE

2017
01:31:14,322 --> 01:31:16,324
MEMBRANE TENSION, REGENERATING

2018
01:31:16,324 --> 01:31:17,958
FRONT YOU SEE MEMBRANE TENSION

2019
01:31:17,958 --> 01:31:21,495
IS HIGHER AFTER ONE HOUR, BUT

2020
01:31:21,495 --> 01:31:24,799
AFTER FOUR HOURS YOU SEE IT GETS

2021
01:31:24,799 --> 01:31:31,205
NORMALIZED SO THIS MEANS THAT

2022
01:31:31,205 --> 01:31:32,473
MEMBRANE GETS NORMALIZED, WHEN

2023
01:31:32,473 --> 01:31:34,141
GROWTH CON CAME BACK.

2024
01:31:34,141 --> 01:31:36,010
YOU CAN SEE CONTROL ALSO THE

2025
01:31:36,010 --> 01:31:36,544
SAME.

2026
01:31:36,544 --> 01:31:38,446
THIS MEANS BETWEEN ONE HOUR TO

2027
01:31:38,446 --> 01:31:41,215
FOUR HOURS OF THE REGENERATION,

2028
01:31:41,215 --> 01:31:42,650
SOMETHING IS CHANGED, SOMETHING

2029
01:31:42,650 --> 01:31:44,452
IS ACTING UP.

2030
01:31:44,452 --> 01:31:47,988
SO, WE DECIDED TO HAVE A LOOK

2031
01:31:47,988 --> 01:31:48,622
USING CryoEM.

2032
01:31:48,622 --> 01:31:51,859
HERE MAYBE YOU CAN SEE A NEURITE

2033
01:31:51,859 --> 01:31:55,529
AXON, AND NOW WE WILL PERFORM A

2034
01:31:55,529 --> 01:31:56,931
MICROSURGERY ON EM GRID.

2035
01:31:56,931 --> 01:32:01,102
YOU CAN SEE THIS DOT, THIS IS

2036
01:32:01,102 --> 01:32:02,370
ONE MICROMETER SMALL HOLE

2037
01:32:02,370 --> 01:32:04,505
TYPICALLY WE USE FOR THE IMAGING

2038
01:32:04,505 --> 01:32:07,908
BUT FOR THE CASE OF AXON WE

2039
01:32:07,908 --> 01:32:09,844
DON'T REALLY -- AXON REALLY

2040
01:32:09,844 --> 01:32:11,912
DON'T FOLLOW THIS SO WE JUST

2041
01:32:11,912 --> 01:32:16,717
COLLECTED DATA  -- COLLECT THE

2042
01:32:16,717 --> 01:32:18,619
DATA WHEREVER WE CAN FIND.

2043
01:32:18,619 --> 01:32:19,520
SURGERY HAPPEN.

2044
01:32:19,520 --> 01:32:22,456
THE NEEDLE, THEY CUT THE AXON.

2045
01:32:22,456 --> 01:32:25,860
AFTER THE CUT OF THE AXON WHAT

2046
01:32:25,860 --> 01:32:28,696
HAPPENS, HERE YOU CAN SEE THIS

2047
01:32:28,696 --> 01:32:31,298
IS AXON, THEN YOU CAN SEE THE

2048
01:32:31,298 --> 01:32:32,433
GROWTH IS HAPPENING.

2049
01:32:32,433 --> 01:32:39,640
SO ON THE EM GRIDDLES WE CAN SEE

2050
01:32:39,640 --> 01:32:41,242
REGENERATION REPRODUCED.

2051
01:32:41,242 --> 01:32:42,943
NOW CRYOOBSERVATION, HERE IS THE

2052
01:32:42,943 --> 01:32:45,312
TISSUE OF THE BRAIN, HERE IS THE

2053
01:32:45,312 --> 01:32:45,513
AXON.

2054
01:32:45,513 --> 01:32:48,949
SO LET'S LOOK AT THIS AREA.

2055
01:32:48,949 --> 01:32:51,952
TWO AXONS, WE CUT BOTH AXONS, ON

2056
01:32:51,952 --> 01:32:57,825
THIS ONE DID NOT GROW BACK SO

2057
01:32:57,825 --> 01:32:59,093
THIS IS DEGENERATING.

2058
01:32:59,093 --> 01:33:00,428
ON THIS ONE SEEMS TO BE

2059
01:33:00,428 --> 01:33:01,796
REGENERATING SO SOMETHING IS

2060
01:33:01,796 --> 01:33:05,099
HAPPENING HERE SO WE HAD A LOOK

2061
01:33:05,099 --> 01:33:08,769
MORE CAREFULLY, SOMETHING THERE.

2062
01:33:08,769 --> 01:33:11,105
SO HERE IS THE MONTAGE THAT YOU

2063
01:33:11,105 --> 01:33:11,906
CAN SEE.

2064
01:33:11,906 --> 01:33:16,243
HERE IS THE CUT SIDE. 

2065
01:33:16,243 --> 01:33:17,211
AND THERE'S SOMETHING

2066
01:33:17,211 --> 01:33:18,179
REGENERATING.

2067
01:33:18,179 --> 01:33:23,984
YOU CAN SEE HERE MUCH EASIER, SO

2068
01:33:23,984 --> 01:33:26,787
MICROTUBULES, GREEN, AND RED IS

2069
01:33:26,787 --> 01:33:32,359
THE ACTIN SHOWN HERE. 

2070
01:33:32,359 --> 01:33:38,065
SO COMPONENTS COMING OUT.

2071
01:33:38,065 --> 01:33:40,167
14 MICROMETER WITHIN ONE HOUR

2072
01:33:40,167 --> 01:33:41,869
CAME BACK DRASTICALLY, WE KNOW

2073
01:33:41,869 --> 01:33:43,938
THE ANSWER NOW THAT PLASMA

2074
01:33:43,938 --> 01:33:47,842
MEMBRANE WAS MISSING, PRECISELY

2075
01:33:47,842 --> 01:33:50,845
WHERE THE AX OTOMY HAPPENS, THIS

2076
01:33:50,845 --> 01:33:54,982
MEMBRANE WAS SO MUCH PUSHED OR

2077
01:33:54,982 --> 01:33:57,718
STRETCHED DURING THE CryoEM

2078
01:33:57,718 --> 01:33:58,886
PREPARATION, PLASMA MEMBRANE,

2079
01:33:58,886 --> 01:34:01,989
BUT THAT ACTUALLY WAS QUITE AN

2080
01:34:01,989 --> 01:34:03,424
ADVANTAGE THING FOR US BECAUSE

2081
01:34:03,424 --> 01:34:11,365
WE HAVE A VERY GOOD

2082
01:34:11,365 --> 01:34:12,233
SIGNAL-TO-NOISE RATIO KNOWING

2083
01:34:12,233 --> 01:34:14,201
WHERE THE CUT HAPPENED AND

2084
01:34:14,201 --> 01:34:17,938
DECIDED TO COLLECT THE DATA,

2085
01:34:17,938 --> 01:34:19,340
SINGLE PARTICLE ANALYSIS, SPA,

2086
01:34:19,340 --> 01:34:20,341
TRYING TO REACH HIGH RESOLUTION

2087
01:34:20,341 --> 01:34:22,209
INFORMATION OUT OF IT.

2088
01:34:22,209 --> 01:34:24,778
SO HERE YOU CAN SEE THIS IS THE

2089
01:34:24,778 --> 01:34:26,447
AXON, ALL THE AXONS ARE GOING TO

2090
01:34:26,447 --> 01:34:27,515
THE SAME DIRECTION BECAUSE WE

2091
01:34:27,515 --> 01:34:32,453
KNOW WHERE THE SOURCE IS.

2092
01:34:32,453 --> 01:34:35,789
IT'S THE TISSUE. 

2093
01:34:35,789 --> 01:34:39,326
WE DID LARGER AXOTOMY, AND LET

2094
01:34:39,326 --> 01:34:40,327
REGENERATION HAPPEN.

2095
01:34:40,327 --> 01:34:43,430
WHEN WE DO THE CRYOOPERATION

2096
01:34:43,430 --> 01:34:45,533
WHATEVER WE SEE BEYOND THIS

2097
01:34:45,533 --> 01:34:46,166
POINT IS REGENERATING POINT OF

2098
01:34:46,166 --> 01:34:48,836
THE NEURON.

2099
01:34:48,836 --> 01:34:54,308
WE COLLECTED DATA,  3,000 IMAGES

2100
01:34:54,308 --> 01:34:58,078
OF THE REGENERATING AXON AND

2101
01:34:58,078 --> 01:35:00,180
BOUGHT THIS BEAUTIFUL

2102
01:35:00,180 --> 01:35:00,981
TOMOGRAPHY, PLASMA MEMBRANE,

2103
01:35:00,981 --> 01:35:01,448
MICROTUBULES.

2104
01:35:01,448 --> 01:35:04,985
FROM NOW ON I'M GOING TO FOCUS

2105
01:35:04,985 --> 01:35:07,254
ON THE DESCRIPTION OF THE

2106
01:35:07,254 --> 01:35:07,955
MICROTUBULES.

2107
01:35:07,955 --> 01:35:11,058
NOW YOU CAN SEE HERE THIS IS A

2108
01:35:11,058 --> 01:35:14,028
STRUCTURE OF THE MICROTUBULES OF

2109
01:35:14,028 --> 01:35:18,532
THE AXONAL MICROTUBULE IN SITU

2110
01:35:18,532 --> 01:35:21,402
THAT'S REGENERATING. 

2111
01:35:21,402 --> 01:35:26,707
WHAT'S AMAZING FOR US, ALL THE

2112
01:35:26,707 --> 01:35:29,043
MICROTUBULE HAVE 13 PROTEIN

2113
01:35:29,043 --> 01:35:29,677
FILAMENT ARRANGEMENT,

2114
01:35:29,677 --> 01:35:34,848
PHYSIOLOGICALLY RELEVANT. 

2115
01:35:34,848 --> 01:35:39,887
WHEN YOU RECONSTITUTE

2116
01:35:39,887 --> 01:35:41,121
MICROTUBEEL YOU GET GET 14, A

2117
01:35:41,121 --> 01:35:45,125
STABLE FORM OF THE MICROTUBULE,

2118
01:35:45,125 --> 01:35:47,995
THAT MEANS CHAPERONE OR SOME

2119
01:35:47,995 --> 01:35:49,997
TEMPLATE IS MAKING REGENERATIVE

2120
01:35:49,997 --> 01:35:52,266
MICROTUBULE SO IT IS SET TO 13

2121
01:35:52,266 --> 01:35:54,602
PROTEIN FILAMENT.

2122
01:35:54,602 --> 01:35:56,370
WE CAN ALSO SEE THIS

2123
01:35:56,370 --> 01:35:59,006
REGENERATING PORTION OF THE

2124
01:35:59,006 --> 01:36:02,076
AXON, OR THE MICROTUBULE HAVE

2125
01:36:02,076 --> 01:36:04,345
SAME DIRECTIONALITY, ALL HAVE,

2126
01:36:04,345 --> 01:36:14,021
HALLMARK OF THE AXON. 

2127
01:36:14,021 --> 01:36:16,090
IT HAS AXONAL IDENTITY.

2128
01:36:16,090 --> 01:36:18,792
NOW RESOLUTION WAS 3.6-ANGSTROM,

2129
01:36:18,792 --> 01:36:21,261
WE CAN SEE WHAT'S HAPPENING

2130
01:36:21,261 --> 01:36:22,663
WITHIN THE MICROTUBULE OF

2131
01:36:22,663 --> 01:36:27,701
REGENERATING AXON. 

2132
01:36:27,701 --> 01:36:30,270
WE MEASURED THE DISTANCE,

2133
01:36:30,270 --> 01:36:31,171
83.3-ANGSTROM, SO THIS MEANS

2134
01:36:31,171 --> 01:36:34,575
THIS IS AN IN VITRO

2135
01:36:34,575 --> 01:36:35,909
RECONSTITUTED MICROTUBULE

2136
01:36:35,909 --> 01:36:37,511
PUBLISHED SOMETIME AGO, WHEN IT

2137
01:36:37,511 --> 01:36:43,717
IS FORCED TO BE STABILIZED, IT

2138
01:36:43,717 --> 01:36:47,988
STRETCHES TO HAVE 84-ANGSTROM,

2139
01:36:47,988 --> 01:36:51,325
DYNAMIC, UNSTABLE FORM,

2140
01:36:51,325 --> 01:36:52,860
81.8-ANGSTROM WHICH MEANS

2141
01:36:52,860 --> 01:36:54,595
REGENERATING IS STABILIZED, WHY

2142
01:36:54,595 --> 01:36:56,630
IS THAT?

2143
01:36:56,630 --> 01:37:00,234
LIKELY BECAUSE OF THE EPO-B

2144
01:37:00,234 --> 01:37:01,335
ENGAGING TO STABILIZE.

2145
01:37:01,335 --> 01:37:04,238
HOWEVER WHEN YOU LOOK INTO THE

2146
01:37:04,238 --> 01:37:06,974
SKINNIER DENSITY OF THE

2147
01:37:06,974 --> 01:37:09,476
MICROTUBULE, THIS IS SUPPOSED TO

2148
01:37:09,476 --> 01:37:12,312
BE THE EPO-B DRUG IS SUPPOSED TO

2149
01:37:12,312 --> 01:37:12,546
ATTACH.

2150
01:37:12,546 --> 01:37:14,281
WE DIDN'T SEE IT.

2151
01:37:14,281 --> 01:37:16,717
WHEN WE CHANGE THE DENSITY WE DO

2152
01:37:16,717 --> 01:37:20,187
SEE IT SO WE CAN REALLY SEE

2153
01:37:20,187 --> 01:37:23,691
EPO-B THE DRUG ENGAGED ON THE

2154
01:37:23,691 --> 01:37:25,759
MICROTUBULE REGENERATING AT THE

2155
01:37:25,759 --> 01:37:27,027
REGENERATING AXON WHICH IS

2156
01:37:27,027 --> 01:37:29,563
EXCITE AMAZING.

2157
01:37:29,563 --> 01:37:35,502
EVEN MORE  AMAZING, THE

2158
01:37:35,502 --> 01:37:38,806
CONCENTRATION IS 20 MICROMOLAR

2159
01:37:38,806 --> 01:37:40,541
IN NEURONS, WHICH MEANS 20,000

2160
01:37:40,541 --> 01:37:43,177
TIMES LESS AMOUNT OF THE DRUG

2161
01:37:43,177 --> 01:37:47,314
THAN ESTIMATED THAT YOU CAN SEE

2162
01:37:47,314 --> 01:37:47,881
HERE.

2163
01:37:47,881 --> 01:37:50,751
YOU SEE THE DENSITY OF EPO-B,

2164
01:37:50,751 --> 01:37:53,587
THERE'S EFFECTIVE CONCENTRATION

2165
01:37:53,587 --> 01:37:56,857
OF THE EPO-B AT THE REGENERATING

2166
01:37:56,857 --> 01:37:58,092
AXON SO STABILIZATION HAPPEN AND

2167
01:37:58,092 --> 01:38:01,729
REGENERATION CAN BE SWITCHED

2168
01:38:01,729 --> 01:38:03,030
OFF. 

2169
01:38:03,030 --> 01:38:04,732
SORRY, SWITCHED ON.

2170
01:38:04,732 --> 01:38:07,568
SO NOW WHERE ARE THE

2171
01:38:07,568 --> 01:38:10,471
MICROTUBULES COMING FROM?

2172
01:38:10,471 --> 01:38:13,607
WE ASKED OURSELVES THREE

2173
01:38:13,607 --> 01:38:14,408
HYPOTHESES.

2174
01:38:14,408 --> 01:38:16,477
FIRST MAYBE THE TUBULIN IS

2175
01:38:16,477 --> 01:38:17,511
SYNTHESIZED AT THE REGENERATING

2176
01:38:17,511 --> 01:38:17,845
SITE.

2177
01:38:17,845 --> 01:38:23,517
WHY WE THINK SO IS BECAUSE WHEN

2178
01:38:23,517 --> 01:38:26,587
WE LOOK NEW NEURITE FORMATION,

2179
01:38:26,587 --> 01:38:28,155
RIBOSOMES ARE ACCUMULATED,

2180
01:38:28,155 --> 01:38:36,096
LIKELY MAKING THE ACTIN HERE.

2181
01:38:36,096 --> 01:38:39,399
SO WE WONDER IF RIBOSOME CAN BE

2182
01:38:39,399 --> 01:38:41,902
SHOWN REGENERATING, THE ANSWER

2183
01:38:41,902 --> 01:38:44,671
IS KNOW, MICROTUBULES OR TUBULIN

2184
01:38:44,671 --> 01:38:46,507
IS NOT SYNTHESIZED AT THE SITE

2185
01:38:46,507 --> 01:38:49,743
BUT CARRIED FROM THE DOWNSTREAM

2186
01:38:49,743 --> 01:38:55,015
OF THE NEURON.

2187
01:38:55,015 --> 01:38:59,586
YOU CAN SEE HERE ACTUALLY THIS

2188
01:38:59,586 --> 01:39:02,623
IS REGENERATING AXON, STAINED

2189
01:39:02,623 --> 01:39:07,494
TUBULIN YOU SAW, CLUSTER OF

2190
01:39:07,494 --> 01:39:09,363
MICROTUBULE TUBULIN TO THE

2191
01:39:09,363 --> 01:39:11,732
REGENERATING SITE, IS THIS

2192
01:39:11,732 --> 01:39:14,468
MICROTUBULE OR TUBULIN CLUSTER?

2193
01:39:14,468 --> 01:39:19,173
SO WE TESTED THAT, TO DO THAT WE

2194
01:39:19,173 --> 01:39:20,707
TAKE ADVANTAGE OF THIS MATERIAL,

2195
01:39:20,707 --> 01:39:22,910
WE DON'T KNOW THE IDENTITY YET

2196
01:39:22,910 --> 01:39:29,683
BUT WE HAVE A LOT INSIGHT.

2197
01:39:29,683 --> 01:39:31,852
IF THE MICROTUBULES ARE CARRIED

2198
01:39:31,852 --> 01:39:34,421
TO THE REGENERATING SITE WE

2199
01:39:34,421 --> 01:39:36,490
EXPECT SPOTS TO BE ALSO PRESENT

2200
01:39:36,490 --> 01:39:38,192
AT THE REGENERATING SITE.

2201
01:39:38,192 --> 01:39:44,431
NOW YOU CAN SEE HERE THIS IS

2202
01:39:44,431 --> 01:39:45,899
REGENERATION, 24 HOUR, YOU SEE

2203
01:39:45,899 --> 01:39:48,769
THE DENSITY OF THE INNER LUMEN,

2204
01:39:48,769 --> 01:39:52,506
MUCH LESS AT THE BEGINNING OF

2205
01:39:52,506 --> 01:39:56,443
THE REGENERATION, YOU EVEN SEE

2206
01:39:56,443 --> 01:39:59,413
IT ULTIMATELY AT THE MICROTUBULE

2207
01:39:59,413 --> 01:40:01,915
WHERE THE REGENERATION FRONT IS.

2208
01:40:01,915 --> 01:40:05,819
YOU SEE NOTHING INSIDE OF THE

2209
01:40:05,819 --> 01:40:07,487
MICROTUBULE AS OPPOSED TO

2210
01:40:07,487 --> 01:40:12,626
PROXIMAL PORTION, INDICATES THIS

2211
01:40:12,626 --> 01:40:14,161
IS A NEWLY POLYMERIZED TUBEIN AT

2212
01:40:14,161 --> 01:40:15,362
THE SITE RATHER THAN FROM THE

2213
01:40:15,362 --> 01:40:17,097
OTHER SITE OF THE NEURON.

2214
01:40:17,097 --> 01:40:21,902
SO THAT MEANS WE SHOULD BE

2215
01:40:21,902 --> 01:40:25,639
LOOKING FOR THE CLUSTER TUBULIN

2216
01:40:25,639 --> 01:40:34,848
THAT GETS CARRIED TO THE END OF

2217
01:40:34,848 --> 01:40:38,752
THE REGENERATING AXON. 

2218
01:40:38,752 --> 01:40:45,025
ONE MOMENT.

2219
01:40:45,025 --> 01:40:52,332
SO THEN WE FOUND IT HERE.

2220
01:40:52,332 --> 01:40:55,602
AGAIN WE SEE ALL OLIGOMERS

2221
01:40:55,602 --> 01:40:57,604
SHOWING HERE LIKE THIS.

2222
01:40:57,604 --> 01:41:06,179
THESE ARE MICROTUBULES.

2223
01:41:06,179 --> 01:41:08,282
IF YOU LOOK AT THE SIZE THIS IS

2224
01:41:08,282 --> 01:41:11,451
EXACTLY SAME AS WHAT HAS BEEN

2225
01:41:11,451 --> 01:41:13,320
OBSERVED IN VITRO, THE CLUSTER

2226
01:41:13,320 --> 01:41:16,623
OF TUBULIN AND THAT CAN BE

2227
01:41:16,623 --> 01:41:17,457
RECONSTITUTED USING PURIFIED

2228
01:41:17,457 --> 01:41:19,660
TUBULIN SO WE HAVE QUITE

2229
01:41:19,660 --> 01:41:21,662
CONFIDENT THIS IS THE TUBULIN.

2230
01:41:21,662 --> 01:41:25,198
YOU CAN ALSO SEE THE SEGMENTS

2231
01:41:25,198 --> 01:41:29,403
AND THEN VISUALIZE EACH OF THE

2232
01:41:29,403 --> 01:41:31,605
DOT, LOOKING AT THE SPIRAL,

2233
01:41:31,605 --> 01:41:35,442
MEASURING THE  SIZE OF THE

2234
01:41:35,442 --> 01:41:38,245
SPIRAL, EACH OF THE MOLECULE,

2235
01:41:38,245 --> 01:41:41,615
IT'S EXACTLY SAME SIZE AS

2236
01:41:41,615 --> 01:41:43,150
TUBULIN YOU SEE IN MICROTUBULES

2237
01:41:43,150 --> 01:41:45,452
OR THE SIZE IS DIFFERENT FROM

2238
01:41:45,452 --> 01:41:49,189
ACTIN SO THIS IS A VISUALIZATION

2239
01:41:49,189 --> 01:41:51,258
METHOD BY LOOKING AT IMAGE WE

2240
01:41:51,258 --> 01:41:56,096
CAN DISTINGUISH THE SIZE OF THE

2241
01:41:56,096 --> 01:41:59,700
ACTIN, 5-NANOMETER AND TUBULIN

2242
01:41:59,700 --> 01:42:01,301
WHICH IS 4-NANOMETER.

2243
01:42:01,301 --> 01:42:08,008
NOW YOU CAN SEE IN SITU

2244
01:42:08,008 --> 01:42:08,608
MICROTUBULE POLYMERIZATION

2245
01:42:08,608 --> 01:42:09,977
HAPPENING, SO SHOWN HERE FOR

2246
01:42:09,977 --> 01:42:13,080
EXAMPLE YOU SEE CLUSTER OR THE

2247
01:42:13,080 --> 01:42:14,915
SPIRAL OF THE TUBULIN STARTING

2248
01:42:14,915 --> 01:42:20,153
TO ATTACH, SOME YOU CAN SEE IT

2249
01:42:20,153 --> 01:42:22,122
STARTS STRAIGHTENING, WE CAN

2250
01:42:22,122 --> 01:42:24,624
VISUALIZE POLYMERIZATION PROCESS

2251
01:42:24,624 --> 01:42:27,561
OF THE MICROTUBULE AS

2252
01:42:27,561 --> 01:42:28,428
REGENERATING AXON.

2253
01:42:28,428 --> 01:42:31,698
THE CONCLUSION OF THE STUDY,

2254
01:42:31,698 --> 01:42:37,504
TUBULIN CLUSTER IS MADE BECAUSE

2255
01:42:37,504 --> 01:42:39,573
OF THE EPO-B, AND THEN OLIGOMERS

2256
01:42:39,573 --> 01:42:41,174
ARE MADE, THAT WOULD BE

2257
01:42:41,174 --> 01:42:41,775
TRANSPARTED.

2258
01:42:41,775 --> 01:42:45,278
WE KNOW IT IS TRANSPORTED, WE

2259
01:42:45,278 --> 01:42:47,180
DID A STUDY ALREADY, WE DO NOT

2260
01:42:47,180 --> 01:42:49,516
KNOW AT THIS POINT WHAT IS THE

2261
01:42:49,516 --> 01:42:53,420
TRIGGER OF IT BUT WE DO KNOW IT

2262
01:42:53,420 --> 01:42:57,190
GETS CARRIED TO THE TIP OF THE

2263
01:42:57,190 --> 01:42:59,059
REGENERATING AXON AND

2264
01:42:59,059 --> 01:43:03,463
MICROTUBULES ARE POLYMERIZED, AT

2265
01:43:03,463 --> 01:43:04,765
THE REGENERATION, REGENERATING

2266
01:43:04,765 --> 01:43:11,138
PORTION, 10 TO 20 MICROMETER OF

2267
01:43:11,138 --> 01:43:13,073
THE ELONGATION.

2268
01:43:13,073 --> 01:43:13,306
OKAY.

2269
01:43:13,306 --> 01:43:18,945
QUALITY CONTROL  AFTER 24 HOURS

2270
01:43:18,945 --> 01:43:20,781
IT GOT QUITE LONG, CAN YOU SEE

2271
01:43:20,781 --> 01:43:22,416
QUALITY CONTROL HOW THE AXON

2272
01:43:22,416 --> 01:43:24,451
LOOK LIKE AFTER 24 HOURS OF THE

2273
01:43:24,451 --> 01:43:26,153
REGENERATION, THAT SEEMS TO BE A

2274
01:43:26,153 --> 01:43:28,555
NORMAL AXON ACTUALLY THAT YOU

2275
01:43:28,555 --> 01:43:33,293
CAN ALSO SEE THAT IT ENDS WITH

2276
01:43:33,293 --> 01:43:34,761
THE GROWTH CONE.

2277
01:43:34,761 --> 01:43:37,464
SO, WITH THAT I'M GOING TO GIVE

2278
01:43:37,464 --> 01:43:41,435
YOU A LITTLE SUMMARY.

2279
01:43:41,435 --> 01:43:45,205
YEAH, SO WHEN THE MEMBRANE GETS

2280
01:43:45,205 --> 01:43:46,840
INJURED ON THE AXON THEN --

2281
01:43:46,840 --> 01:43:51,845
FIRST TIME, SORRY.

2282
01:43:51,845 --> 01:43:53,947
I HOPE YOU UNDERSTAND BASED ON

2283
01:43:53,947 --> 01:43:55,549
MY EXPLANATION WHAT'S HAPPENING

2284
01:43:55,549 --> 01:43:58,752
BUT ANYWAY THE MEMBRANE GETS

2285
01:43:58,752 --> 01:44:00,787
CUT, TUBULIN CLUSTER THAT'S

2286
01:44:00,787 --> 01:44:02,089
HAPPENING, MEMBRANE GETS CLOSED,

2287
01:44:02,089 --> 01:44:12,032
AND THEN MICROTUBULE STABILIZED,

2288
01:44:12,032 --> 01:44:12,999
SHUTTLING CONTINUOUSLY

2289
01:44:12,999 --> 01:44:16,503
HAPPENING. 

2290
01:44:16,503 --> 01:44:19,106
NOW WE CAN SEE THE MECHANISM OF

2291
01:44:19,106 --> 01:44:19,473
IT.

2292
01:44:19,473 --> 01:44:22,609
SO THIS WAS AN EXAMPLE IT WAS

2293
01:44:22,609 --> 01:44:24,211
QUITE SATISFYING BECAUSE WE SEE

2294
01:44:24,211 --> 01:44:25,912
EVERYTHING AND WE CAN ALSO

2295
01:44:25,912 --> 01:44:28,748
COMBINE IT WITH THE DYNAMIC, IT

2296
01:44:28,748 --> 01:44:34,621
SEEMS TO BE QUITE IMPORTANT FOR

2297
01:44:34,621 --> 01:44:37,324
REGENERATION OF THE NEURON.

2298
01:44:37,324 --> 01:44:41,161
SO WE ARE WORKING ON DIFFERENT

2299
01:44:41,161 --> 01:44:41,828
INTERESTING PROJECTS, SIMILAR

2300
01:44:41,828 --> 01:44:45,398
WAY TRYING TO MAKE THE PIPELINE,

2301
01:44:45,398 --> 01:44:52,272
TRYING TO MAKE THE MECHANISTIC

2302
01:44:52,272 --> 01:44:54,574
UNDERSTANDING, SOMETIMES WE FIND

2303
01:44:54,574 --> 01:44:55,075
UNEXPECTED DISCOVERIES,

2304
01:44:55,075 --> 01:44:56,676
SOMETIMES WE HAVE A NICE

2305
01:44:56,676 --> 01:44:58,078
MECHANISM SHOWING UP SO THIS IS

2306
01:44:58,078 --> 01:45:00,313
A VERY NICE METHOD AND IT'S A

2307
01:45:00,313 --> 01:45:04,151
VERY NICE TIME FOR THE CryoEM

2308
01:45:04,151 --> 01:45:04,417
FIELD.

2309
01:45:04,417 --> 01:45:06,953
WITH THAT I WOULD LIKE TO FINISH

2310
01:45:06,953 --> 01:45:08,622
MY TALK, HERE IS THE MEMBER OF

2311
01:45:08,622 --> 01:45:14,127
THE LAB AND I JUST  LISTED

2312
01:45:14,127 --> 01:45:17,531
COLLABORATOR AND PEOPLE IN THE

2313
01:45:17,531 --> 01:45:18,331
LAB ON THE DIRECTORY INVOLVED

2314
01:45:18,331 --> 01:45:20,767
WITH THE PROJECT I SHOWED YOU.

2315
01:45:20,767 --> 01:45:23,537
YOU CAN SEE I HAVE SOME GRANT IN

2316
01:45:23,537 --> 01:45:26,540
GERMANY, BECAUSE MY PROGRAM IS A

2317
01:45:26,540 --> 01:45:30,177
CONTINUATION I WOULD LIKE TO

2318
01:45:30,177 --> 01:45:33,313
ACKNOWLEDGE THE FUNDING RESOURCE

2319
01:45:33,313 --> 01:45:36,983
AND ALSO NIH AND NHLBI.

2320
01:45:36,983 --> 01:45:39,085
THANK YOU FOR YOUR ATTENTION.

2321
01:45:39,085 --> 01:45:49,663
HAPPY TO TAKE QUESTIONS. 

2322
01:45:49,663 --> 01:45:50,363
 

2323
01:45:50,363 --> 01:45:53,400
>> ANY COMMENTS OR
QUESTIONS?

2324
01:45:53,400 --> 01:45:53,700
>> GREAT.

2325
01:45:53,700 --> 01:45:56,269
THANK YOU FOR THE TALK, VERY

2326
01:45:56,269 --> 01:45:56,870
COOL STUFF.

2327
01:45:56,870 --> 01:46:00,140
MY QUESTION, YOU TALKED ABOUT

2328
01:46:00,140 --> 01:46:00,607
INTEGRINS AND ADHESION

2329
01:46:00,607 --> 01:46:02,342
COMPLEXES, ARE YOU ABLE TO USE

2330
01:46:02,342 --> 01:46:04,244
THE SAME TECHNOLOGY TO VISUALIZE

2331
01:46:04,244 --> 01:46:07,414
MATRIX DEPOSITION AND MATRIX

2332
01:46:07,414 --> 01:46:09,649
MATURATION AND MATRIX

2333
01:46:09,649 --> 01:46:10,150
REMODELING?

2334
01:46:10,150 --> 01:46:12,052
>> I IMAGINE SO.

2335
01:46:12,052 --> 01:46:14,521
I HAVEN'T TOUCHED THE

2336
01:46:14,521 --> 01:46:15,188
EXTRACELLULAR PORTION YET BUT

2337
01:46:15,188 --> 01:46:16,723
THAT WILL BE INTERESTING.

2338
01:46:16,723 --> 01:46:20,193
BUT IN THIS CASE THEN I WOULD

2339
01:46:20,193 --> 01:46:24,130
LIKE TO ADD INFERENCE OF THE

2340
01:46:24,130 --> 01:46:24,731
FOLDS.

2341
01:46:24,731 --> 01:46:28,969
INFERENCE OF THE FOLDS, YEAH. 

2342
01:46:28,969 --> 01:46:34,007
YEAH, YEAH, YEAH. 

2343
01:46:34,007 --> 01:46:38,878
>> ANYONE ELSE? 

2344
01:46:38,878 --> 01:46:39,246
OKAY.

2345
01:46:39,246 --> 01:46:41,948
THANK YOU VERY MUCH.

2346
01:46:41,948 --> 01:46:45,185
>> THANK YOU.

2347
01:46:45,185 --> 01:46:46,419
>> WE'RE NOW AT THE
PORTION

2348
01:46:46,419 --> 01:46:53,526
WHERE WE'LL HAVE A REFRESHER OF

2349
01:46:53,526 --> 01:46:54,928
DECISION LENS TOOLS, BEFORE

2350
01:46:54,928 --> 01:46:58,798
CONCEPTS, A REVIEW AND THEN

2351
01:46:58,798 --> 01:47:00,100
WE'LL START WITH CONCEPTS.

2352
01:47:00,100 --> 01:47:10,677
I'LL TURN THIS OVER TO THE TEAM 

2353
01:47:50,183 --> 01:47:51,551
>> LOOKING TO SHARE ON THE
TEAMS

2354
01:47:51,551 --> 01:47:54,054
REAL QUICK.

2355
01:47:54,054 --> 01:48:00,026
 

2356
01:48:00,026 --> 01:48:10,070
 

2357
01:52:13,446 --> 01:52:14,714
>> COUNCIL MEMBERS CAN SEE
ON

2358
01:52:14,714 --> 01:52:18,751
THEIR SCREENS BUT WE'RE HAVING

2359
01:52:18,751 --> 01:52:20,019
DIFFICULTY SHARING ON THE BIG

2360
01:52:20,019 --> 01:52:20,286
SCREEN.

2361
01:52:20,286 --> 01:52:21,387
WE'LL TALK YOU THROUGH IT AND

2362
01:52:21,387 --> 01:52:24,290
YOU'LL BE ABLE TO WATCH ON YOUR

2363
01:52:24,290 --> 01:52:25,291
MONITORS.

2364
01:52:25,291 --> 01:52:25,558
THANK YOU.

2365
01:52:25,558 --> 01:52:26,059
>> THANK YOU.

2366
01:52:26,059 --> 01:52:28,161
AGAIN, THANKS FOR HAVING US

2367
01:52:28,161 --> 01:52:28,962
BACK.

2368
01:52:28,962 --> 01:52:29,329
GOOD AFTERNOON.

2369
01:52:29,329 --> 01:52:31,230
I'LL BE GOING THROUGH THE

2370
01:52:31,230 --> 01:52:32,298
DECISION LENS REFRESHER

2371
01:52:32,298 --> 01:52:32,599
TRAINING.

2372
01:52:32,599 --> 01:52:34,701
WHAT I DROPPED IN THE CHAT OF

2373
01:52:34,701 --> 01:52:36,903
THE TEAMS IS THE LINK TO

2374
01:52:36,903 --> 01:52:39,305
DIRECTLY GET TO THE VOTING

2375
01:52:39,305 --> 01:52:42,075
SCREEN. 

2376
01:52:42,075 --> 01:52:43,810
YOU SHOULD HAVE RECEIVED AN

2377
01:52:43,810 --> 01:52:46,946
E-MAIL LETTING YOU KNOW THE TASK

2378
01:52:46,946 --> 01:52:48,548
IS OPEN, USE THAT E-MAIL TO GET

2379
01:52:48,548 --> 01:52:49,649
TO THE SAME LOCATION.

2380
01:52:49,649 --> 01:52:51,117
ONCE YOU USE THE LINK YOU'LL BE

2381
01:52:51,117 --> 01:52:54,120
ABLE TO GET TO THE LOG-IN

2382
01:52:54,120 --> 01:52:54,454
SCREEN.

2383
01:52:54,454 --> 01:52:55,788
WE'LL USE E-MAIL AND PASSWORD,

2384
01:52:55,788 --> 01:52:57,590
IF YOU NEED HELP REMEMBERING

2385
01:52:57,590 --> 01:52:58,725
THAT OR RESETTING THAT LET ME

2386
01:52:58,725 --> 01:53:00,226
KNOW AND I CAN HELP.

2387
01:53:00,226 --> 01:53:02,095
AFTER YOU LOG IN, YOU SHOULD GET

2388
01:53:02,095 --> 01:53:04,764
TO A SCREEN THAT I'M SHARING IN

2389
01:53:04,764 --> 01:53:08,267
THE TEAMS CURRENTLY, YOU'LL SEE

2390
01:53:08,267 --> 01:53:11,671
A RATE ALTERNATIVE TASK AT THE

2391
01:53:11,671 --> 01:53:11,871
TOP.

2392
01:53:11,871 --> 01:53:14,107
CLICK ON THAT, THAT BRINGS YOU

2393
01:53:14,107 --> 01:53:16,809
TO ANOTHER PAGE OF THE DECISION

2394
01:53:16,809 --> 01:53:17,610
LENS RATING SCREEN.

2395
01:53:17,610 --> 01:53:20,046
WHAT WE'LL HAVE YOU DO IS CLICK

2396
01:53:20,046 --> 01:53:22,382
ON THE FIRST CONCEPT THAT WE'LL

2397
01:53:22,382 --> 01:53:23,683
BE RATING, STRENGTHENING HEALTH

2398
01:53:23,683 --> 01:53:26,619
SYSTEMS HERE AT THE TOP OF THE

2399
01:53:26,619 --> 01:53:26,919
LIST.

2400
01:53:26,919 --> 01:53:30,390
THIS WILL BRING UP YOUR FIRST

2401
01:53:30,390 --> 01:53:32,925
CONCEPT WE'LL BE VOTING ON AND

2402
01:53:32,925 --> 01:53:33,192
REVIEWING.

2403
01:53:33,192 --> 01:53:35,028
YOU'LL SEE THE CONCEPT NAME

2404
01:53:35,028 --> 01:53:42,769
LISTED AT THE TOP IN THE BLUE

2405
01:53:42,769 --> 01:53:44,971
TEXT, CLICK AND YOU'LL SEE THE

2406
01:53:44,971 --> 01:53:47,073
SIDE CAR CLICK UP ON, I.D. AND

2407
01:53:47,073 --> 01:53:47,340
PRESENTER.

2408
01:53:47,340 --> 01:53:49,042
ONCE YOU READ THE INFORMATION

2409
01:53:49,042 --> 01:53:50,143
ABOUT THE CONCEPTS, YOU'LL MOVE

2410
01:53:50,143 --> 01:53:52,211
DOWN THE PAGE AND MAKE YOUR

2411
01:53:52,211 --> 01:53:54,580
ASSESSMENT AGAINST EACH OF THE

2412
01:53:54,580 --> 01:53:54,847
CRITERIA.

2413
01:53:54,847 --> 01:53:56,449
THE CRITERIA ARE LISTED IN

2414
01:53:56,449 --> 01:53:56,683
PURPLE.

2415
01:53:56,683 --> 01:53:59,919
IF YOU WANT TO SEE THE FULL

2416
01:53:59,919 --> 01:54:02,689
CRITERIA DEFINITION, CLICK ON

2417
01:54:02,689 --> 01:54:03,589
THE PURPLE TEXT.

2418
01:54:03,589 --> 01:54:05,692
PURPLE TEXT WILL PROVIDE YOU THE

2419
01:54:05,692 --> 01:54:07,560
FULL DESCRIPTION ON THE SIDE.

2420
01:54:07,560 --> 01:54:10,129
ONCE YOU'RE READY TO MAKE YOUR

2421
01:54:10,129 --> 01:54:11,197
SELECTION, YOU'LL CLICK INTO THE

2422
01:54:11,197 --> 01:54:16,936
BOX THAT YOU WISH TO MAKE YOUR

2423
01:54:16,936 --> 01:54:17,970
JUDGMENT.

2424
01:54:17,970 --> 01:54:19,405
YOU'LL NOTICE THAT IT SAVES.

2425
01:54:19,405 --> 01:54:28,448
ONE MOMENT AS WE GET PLUGGED IN.

2426
01:54:28,448 --> 01:54:28,848
GREAT.

2427
01:54:28,848 --> 01:54:30,516
YOU'LL NOTICE YOUR RATING HAS

2428
01:54:30,516 --> 01:54:34,153
SAVED WHEN IT'S HIGHLIGHTED IN

2429
01:54:34,153 --> 01:54:35,788
GREEN.

2430
01:54:35,788 --> 01:54:37,256
EVERYTHING WILL AUTO SAVE IF YOU

2431
01:54:37,256 --> 01:54:38,725
GET DISCONNECTED OR LOGGED OUT,

2432
01:54:38,725 --> 01:54:40,193
YOU'LL BE ABLE TO JUMP BACK IN

2433
01:54:40,193 --> 01:54:43,329
AND PICK  PICK UP WHERE YOU LEF.

2434
01:54:43,329 --> 01:54:49,202
THERE'S A. COMMENTING FEATURE.

2435
01:54:49,202 --> 01:54:51,404
IF YOU LEAVE A COMMENT,

2436
01:54:51,404 --> 01:54:52,538
QUESTION, FEEDBACK, YOU CAN

2437
01:54:52,538 --> 01:54:55,208
LEAVE THAT BY CLICKING THE

2438
01:54:55,208 --> 01:54:56,976
COMMENT BUBBLE HERE.

2439
01:54:56,976 --> 01:54:58,911
TYPING IN YOUR COMMENT.

2440
01:54:58,911 --> 01:55:01,247
AND THEN POSTING THE ADD COMMENT

2441
01:55:01,247 --> 01:55:01,748
BUTTON.

2442
01:55:01,748 --> 01:55:03,750
YOU'LL PROCEED TO GO DOWN THE

2443
01:55:03,750 --> 01:55:05,551
ENTIRE PAGE, MAKING YOUR

2444
01:55:05,551 --> 01:55:08,488
JUDGMENTS, AGAIN THEY WILL BE

2445
01:55:08,488 --> 01:55:09,655
HIGHLIGHTING IN GREEN KNOWING

2446
01:55:09,655 --> 01:55:11,591
THEY ARE SAVING IN THE SCREEN.

2447
01:55:11,591 --> 01:55:13,459
ONCE YOU REACH THE BOTTOM YOU'LL

2448
01:55:13,459 --> 01:55:17,497
SEE THE NEXT BUTTON AT THE

2449
01:55:17,497 --> 01:55:18,898
BUTTON, HIGHLIGHTED IN ORANGE.

2450
01:55:18,898 --> 01:55:20,533
IF YOU CLICK ON THAT IT WILL

2451
01:55:20,533 --> 01:55:24,003
BRING UP THE NEXT CONCEPT.

2452
01:55:24,003 --> 01:55:25,805
YOU'LL BE ABLE TO CHECK YOUR

2453
01:55:25,805 --> 01:55:27,540
OVERALL PROGRESS IN THE TOP

2454
01:55:27,540 --> 01:55:28,841
RIGHT-HAND CORNER, AS WE WORK

2455
01:55:28,841 --> 01:55:30,576
OUR WAY THROUGH WE'LL BE ABLE TO

2456
01:55:30,576 --> 01:55:32,278
SEE IF EVERYONE IS ON TRACK.

2457
01:55:32,278 --> 01:55:36,983
IF YOU  MISS A JUDGMENT I MIGHT

2458
01:55:36,983 --> 01:55:40,386
TAP ON YOU THE SHOULDER AND LET

2459
01:55:40,386 --> 01:55:42,755
YOU KNOW SO YOU CAN ENTER THAT

2460
01:55:42,755 --> 01:55:42,955
VOTE.

2461
01:55:42,955 --> 01:55:47,326
IF YOU HAVE QUESTIONS I'LL BE

2462
01:55:47,326 --> 01:55:47,960
RIGHT HERE.

2463
01:55:47,960 --> 01:55:49,796
RAISE YOUR HAND AND COME FIND

2464
01:55:49,796 --> 01:55:49,962
ME.

2465
01:55:49,962 --> 01:55:52,465
THANK YOU.

2466
01:55:52,465 --> 01:56:01,073
 

2467
01:56:01,073 --> 01:56:07,647
>> WE'RE GOING TO MAKE
SURE  DR.

2468
01:56:07,647 --> 01:56:12,819
MENSAH, IN TERMS OF ORDER,

2469
01:56:12,819 --> 01:56:15,221
PRESENTING CONCEPTS, SO THEN

2470
01:56:15,221 --> 01:56:24,197
WE'LL COME BACK --

2471
01:56:24,197 --> 01:56:26,365
MAURA IS GOING TO LET US KNOW

2472
01:56:26,365 --> 01:56:27,567
WHERE COUNCIL MEMBERS ARE IN

2473
01:56:27,567 --> 01:56:29,302
TERMS OF COMPLETING THEIR VOTING

2474
01:56:29,302 --> 01:56:31,537
AFTER EACH CONCEPT.

2475
01:56:31,537 --> 01:56:34,040
WE'LL LOOK TO HER AND GO TO THE

2476
01:56:34,040 --> 01:56:41,581
NEXT CONCEPT. 

2477
01:56:41,581 --> 01:56:45,484
 

2478
01:56:45,484 --> 01:56:51,958
 

2479
01:56:51,958 --> 01:56:52,992
 

2480
01:56:52,992 --> 01:56:54,493
>> OKAY.

2481
01:56:54,493 --> 01:56:54,794
>> THANKS.

2482
01:56:54,794 --> 01:56:58,731
I THOUGHT I WOULD SHARE THAT WE

2483
01:56:58,731 --> 01:57:00,166
REALLY APPRECIATE COMMENTS AND

2484
01:57:00,166 --> 01:57:01,601
SUGGESTIONS YOU'RE PUTTING IN

2485
01:57:01,601 --> 01:57:02,501
THE FIELD.

2486
01:57:02,501 --> 01:57:04,203
SO I STRONGLY ENCOURAGE YOU TO

2487
01:57:04,203 --> 01:57:07,907
TAKE ADVANTAGE OF IT AND ADD

2488
01:57:07,907 --> 01:57:09,141
YOUR COMMENTS.

2489
01:57:09,141 --> 01:57:13,312
THE CENTER FOR TRANSLATIONAL

2490
01:57:13,312 --> 01:57:22,555
RESEARCH AND IMPLEMENTATION

2491
01:57:22,555 --> 01:57:24,857
SCIENCE FIRST THREE, 5147, 48

2492
01:57:24,857 --> 01:57:26,893
AND 50, ALL THREE CONCEPTS ARE

2493
01:57:26,893 --> 01:57:30,062
PART OF THE GLOBAL ALLIANCE FOR

2494
01:57:30,062 --> 01:57:31,097
CHRONIC DISEASE INITIATIVE,

2495
01:57:31,097 --> 01:57:36,002
WHICH FOR THIS PRESENTATION I

2496
01:57:36,002 --> 01:57:37,937
WOULD ABBREVIATE GACD, THEY HAVE

2497
01:57:37,937 --> 01:57:40,406
NIH-WIDE SUPPORT, ALIGN WITH THE

2498
01:57:40,406 --> 01:57:42,074
GOAL TO REDUCE MORBIDITY AND

2499
01:57:42,074 --> 01:57:43,676
MORTALITY OF CHRONIC DISEASE

2500
01:57:43,676 --> 01:57:44,844
ACROSS THE LIFESPAN.

2501
01:57:44,844 --> 01:57:48,080
WE ARE ASKING YOU TO EVALUATE

2502
01:57:48,080 --> 01:57:49,415
EACH CONCEPT SEPARATELY, EVEN

2503
01:57:49,415 --> 01:57:54,687
THOUGH THEY SHARE A COMMON

2504
01:57:54,687 --> 01:57:55,521
BACKGROUND.

2505
01:57:55,521 --> 01:58:00,026
SO 5147 SUPPORTS IMPLEMENT

2506
01:58:00,026 --> 01:58:01,227
RESEARCH STRENGTHENING HEALTH

2507
01:58:01,227 --> 01:58:02,628
SYSTEMS, 5148 ADDRESSES

2508
01:58:02,628 --> 01:58:05,464
STRATEGIES BEYOND TRADITIONAL

2509
01:58:05,464 --> 01:58:07,466
HEALTH CARE SETTINGS, AND 5150

2510
01:58:07,466 --> 01:58:10,336
TARGETS EARLY INTERVENTION FOR

2511
01:58:10,336 --> 01:58:12,138
CHILDREN AND YOUTH.

2512
01:58:12,138 --> 01:58:15,908
OVERARCHING MISSION TO USE

2513
01:58:15,908 --> 01:58:17,443
IMPLEMENT RESEARCH IN LOW- AND

2514
01:58:17,443 --> 01:58:18,678
MIDDLE-INCOME COUNTRIES TO FIRST

2515
01:58:18,678 --> 01:58:20,613
OVERCOME BARRIERS TO SCALEUP AND

2516
01:58:20,613 --> 01:58:23,349
SPREAD OF PROVEN STRATEGIES, AND

2517
01:58:23,349 --> 01:58:25,451
SECOND TO BUILD RESILIENT HEALTH

2518
01:58:25,451 --> 01:58:27,386
SYSTEMS FOR CHRONIC DISEASE

2519
01:58:27,386 --> 01:58:29,755
PREVENTION AND CONTROL.

2520
01:58:29,755 --> 01:58:31,157
I'LL PROVIDE A BRIEF BACKGROUND

2521
01:58:31,157 --> 01:58:32,858
FOR ALL THREE AND WILL TAKE THEM

2522
01:58:32,858 --> 01:58:36,796
ONE BY ONE AND ASK YOU TO

2523
01:58:36,796 --> 01:58:42,702
PROVIDE YOUR COMMENTS AND TO

2524
01:58:42,702 --> 01:58:43,336
EVALUATE.

2525
01:58:43,336 --> 01:58:44,136
BACKGROUND, GACD IS

2526
01:58:44,136 --> 01:58:45,371
INTERNATIONAL COLLABORATION OF

2527
01:58:45,371 --> 01:58:47,273
LEADING PUBLIC HEALTH RESEARCH

2528
01:58:47,273 --> 01:58:48,774
FUNDING AGENCIES, THAT WORK

2529
01:58:48,774 --> 01:58:51,978
TOGETHER TO ADDRESS THE GLOBAL

2530
01:58:51,978 --> 01:58:54,013
BURDEN OF NON-COMMUNICABLE

2531
01:58:54,013 --> 01:58:54,714
CHRONIC DISEASES.

2532
01:58:54,714 --> 01:58:57,283
NIH IS THE FOUNDING MEMBER OF

2533
01:58:57,283 --> 01:58:59,785
GACD AND HAS BEEN REPRESENTED IN

2534
01:58:59,785 --> 01:59:01,554
THE ALLIANCE BY THE NHLBI

2535
01:59:01,554 --> 01:59:03,889
DIRECTOR AND DIRECTOR OF THE

2536
01:59:03,889 --> 01:59:06,559
FOGARTY INTERNATIONAL CENTER.

2537
01:59:06,559 --> 01:59:12,665
OVER THE PAST 14 YEARS THE

2538
01:59:12,665 --> 01:59:14,233
ALLIANCE HAS INVESTED OVER $370

2539
01:59:14,233 --> 01:59:17,269
MILLION IN 37 RESEARCH PROJECTS,

2540
01:59:17,269 --> 01:59:19,605
YIELDED MORE THAN 400

2541
01:59:19,605 --> 01:59:21,073
PUBLICATIONS, AND MOST

2542
01:59:21,073 --> 01:59:23,909
IMPORTANTLY THE GACD RESEARCH

2543
01:59:23,909 --> 01:59:26,112
FINDINGS LED TO POLICY CHANGES

2544
01:59:26,112 --> 01:59:28,848
WITH REAL WORLD IMPLICATIONS IN

2545
01:59:28,848 --> 01:59:30,049
GHANA, NIGERIA, PERU.

2546
01:59:30,049 --> 01:59:33,919
WE CAN SHARE MORE EXAMPLES WITH

2547
01:59:33,919 --> 01:59:34,420
YOU.

2548
01:59:34,420 --> 01:59:38,524
THE PREVIOUS OR PAST NHLBI

2549
01:59:38,524 --> 01:59:41,394
SUPPORTED RESEARCH HAS ADDRESSED

2550
01:59:41,394 --> 01:59:43,129
HYPERTENSION, CHRONIC DISEASES

2551
01:59:43,129 --> 01:59:44,764
IN URBAN ENVIRONMENTS, AND

2552
01:59:44,764 --> 01:59:45,865
MULTI-MORBIDITY MANAGEMENT BUT

2553
01:59:45,865 --> 01:59:48,534
IN ALL OF THESE EFFORTS THE

2554
01:59:48,534 --> 01:59:51,570
CENTRAL COMMITMENT HAS BEEN THE

2555
01:59:51,570 --> 01:59:53,639
DEVELOPMENT OF COMPREHENSIVE

2556
01:59:53,639 --> 01:59:56,142
SCALABLE SOLUTIONS FOR EACH OF

2557
01:59:56,142 --> 01:59:58,310
THE THREE INITIATIVES, NHLBI NOW

2558
01:59:58,310 --> 02:00:02,281
PLANS TO SUPPORT UP TO ONE

2559
02:00:02,281 --> 02:00:02,915
HIGH-QUALITY APPLICATION FROM A

2560
02:00:02,915 --> 02:00:04,917
LOW AND MIDDLE INCOME COUNTRY.

2561
02:00:04,917 --> 02:00:08,254
I WILL NOW BRIEFLY DESCRIBE THE

2562
02:00:08,254 --> 02:00:09,288
THREE INDIVIDUAL CONCEPTS AND

2563
02:00:09,288 --> 02:00:13,459
THEN ASK FOR YOUR COMMENTS AND

2564
02:00:13,459 --> 02:00:14,427
YOUR VOTING.

2565
02:00:14,427 --> 02:00:18,531
5147 AS I MENTIONED IS TARGETED

2566
02:00:18,531 --> 02:00:20,466
FISCAL YEAR 2026 ON

2567
02:00:20,466 --> 02:00:21,967
STRENGTHENING HEALTH SYSTEMS.

2568
02:00:21,967 --> 02:00:24,670
THE PRIMARY OBJECTIVE IN THIS

2569
02:00:24,670 --> 02:00:30,476
CONCEPT IS TO DEVELOP

2570
02:00:30,476 --> 02:00:31,243
CONTEXT-SPECIFIC STRATEGIES

2571
02:00:31,243 --> 02:00:32,578
USING IMPLEMENTATION SCIENCE TO

2572
02:00:32,578 --> 02:00:34,647
TRANSFORM HEALTH SYSTEMS AND

2573
02:00:34,647 --> 02:00:38,884
REDUCE BURDEN OF CHRONIC

2574
02:00:38,884 --> 02:00:40,453
DISEASES, EXAMPLES OF INTEREST

2575
02:00:40,453 --> 02:00:44,356
IMPORTANT AREAS THAT FOCUS ON

2576
02:00:44,356 --> 02:00:47,126
RESEARCH TO SUPPORT BUILDING

2577
02:00:47,126 --> 02:00:49,595
RESILIENT HEALTH SYSTEMS

2578
02:00:49,595 --> 02:00:53,065
ENHANCING WORKFORCE CAPACITY,

2579
02:00:53,065 --> 02:00:54,567
EFFECTIV TECHNOLOGY INTEGRATION,

2580
02:00:54,567 --> 02:00:57,970
INCORPORATING INNOVATIONS SUCH

2581
02:00:57,970 --> 02:00:59,405
AS PRACTICE FACILITATION, TEST

2582
02:00:59,405 --> 02:01:01,507
SHARING, ALL OF THESE STRATEGIES

2583
02:01:01,507 --> 02:01:05,344
SO THAT WE CAN IMPLEMENT

2584
02:01:05,344 --> 02:01:06,078
CULTURALLY TAILORED

2585
02:01:06,078 --> 02:01:07,113
COMMUNITY-INFORMED SOLUTIONS TO

2586
02:01:07,113 --> 02:01:09,682
ACCESS TO CARE AND TO CONTINUE

2587
02:01:09,682 --> 02:01:13,819
THE CARE, THAT'S THE FIRST ONE.

2588
02:01:13,819 --> 02:01:19,358
THE SECOND NUMBER 5148 IS

2589
02:01:19,358 --> 02:01:21,427
TARGETED FOR FISCAL YEAR 2027

2590
02:01:21,427 --> 02:01:24,029
GOES BEYOND TRADITIONAL HEALTH

2591
02:01:24,029 --> 02:01:24,463
SYSTEM.

2592
02:01:24,463 --> 02:01:26,098
IT SUPPORTS IMPLEMENTATION

2593
02:01:26,098 --> 02:01:28,200
RESEARCH THAT WOULD EXTEND

2594
02:01:28,200 --> 02:01:29,869
CHRONIC DISEASE PREVENTION

2595
02:01:29,869 --> 02:01:31,137
STRATEGIES BEYOND TRADITIONAL

2596
02:01:31,137 --> 02:01:36,609
SETTINGS WITH THE FOCUS ON

2597
02:01:36,609 --> 02:01:37,109
LEVERAGING CROSS-SECTOR

2598
02:01:37,109 --> 02:01:38,410
ENGAGEMENT IN LOW- AND

2599
02:01:38,410 --> 02:01:39,445
MIDDLE-INCOME COUNTRIES.

2600
02:01:39,445 --> 02:01:42,815
EXAMPLES OF KEY SEARCH AREAS

2601
02:01:42,815 --> 02:01:45,050
INCLUDE BUILDING STRATEGIC

2602
02:01:45,050 --> 02:01:46,452
PARTNERSHIPS WITH SECTORS LIKE

2603
02:01:46,452 --> 02:01:49,088
SCHOOLS WITHIN THE EDUCATION

2604
02:01:49,088 --> 02:01:51,190
SECTOR, HOUSING AND COMMUNITY

2605
02:01:51,190 --> 02:01:54,460
DEVELOPMENT THAT WOULD HELP

2606
02:01:54,460 --> 02:01:55,694
ADDRESS SOCIAL DETERMINANTS OF

2607
02:01:55,694 --> 02:01:57,196
HEART, LUNG, BLOOD, SLEEP

2608
02:01:57,196 --> 02:01:57,663
DISORDERS.

2609
02:01:57,663 --> 02:02:00,799
IT WOULD ALSO SUPPORT RESEARCH

2610
02:02:00,799 --> 02:02:04,136
TO PROMOTE WELLNESS THROUGH

2611
02:02:04,136 --> 02:02:05,037
EVIDENCE-INFORMED COMMUNITY

2612
02:02:05,037 --> 02:02:08,073
ENGAGEMENT IN ORDER TO ADVANCE

2613
02:02:08,073 --> 02:02:11,944
COMMUNITY HEALTH INTERVENTIONS.

2614
02:02:11,944 --> 02:02:14,813
THE FINAL CONCEPT 5150 TARGETED

2615
02:02:14,813 --> 02:02:16,815
FOR FISCAL YEAR 2028, ADDRESSES

2616
02:02:16,815 --> 02:02:21,654
HOW WE SCALE UP AND SPREAD EARLY

2617
02:02:21,654 --> 02:02:21,987
INTERVENTIONS.

2618
02:02:21,987 --> 02:02:23,856
IT WOULD SUPPORT RESEARCH TO

2619
02:02:23,856 --> 02:02:26,292
DEVELOP AND TEST THE SCALING UP

2620
02:02:26,292 --> 02:02:28,427
OF THESE INTERVENTIONS

2621
02:02:28,427 --> 02:02:31,063
SPECIFICALLY TARGETING CHILDREN

2622
02:02:31,063 --> 02:02:31,564
AND YOUTH IN LOW- AND

2623
02:02:31,564 --> 02:02:33,332
MIDDLE-INCOME COUNTRIES AND

2624
02:02:33,332 --> 02:02:36,168
WOULD BUILD ON INSIGHTS FROM

2625
02:02:36,168 --> 02:02:37,570
PREVIOUSLY FUNDED GACD WORK IN

2626
02:02:37,570 --> 02:02:39,371
THIS POPULATION.

2627
02:02:39,371 --> 02:02:40,973
SOME EXAMPLES ARE INTEGRATION OF

2628
02:02:40,973 --> 02:02:44,376
HEART LUNG BLOOD AND SLEEP

2629
02:02:44,376 --> 02:02:46,979
PREVENTION INTO SCHOOLS,

2630
02:02:46,979 --> 02:02:48,514
PEDIATRIC HEALTH SERVICES,

2631
02:02:48,514 --> 02:02:50,216
ACTIVE INVOLVEMENT ENGAGEMENT OF

2632
02:02:50,216 --> 02:02:53,285
FAMILIES AND PEERS, IN SHAPING

2633
02:02:53,285 --> 02:02:55,955
HEALTHY BEHAVIORS, AND USE OF

2634
02:02:55,955 --> 02:02:58,490
INTERACTIVE AND DIGITAL TOOLS TO

2635
02:02:58,490 --> 02:03:05,164
BOOST YOUTH ENGAGEMENT IN

2636
02:03:05,164 --> 02:03:05,831
PREVENTION.

2637
02:03:05,831 --> 02:03:07,933
THESE CONCEPTS ARE VITAL FOR

2638
02:03:07,933 --> 02:03:09,235
ACCELERATING PREVENTION AND

2639
02:03:09,235 --> 02:03:12,204
CONTROL OF CHRONIC DISEASES IN

2640
02:03:12,204 --> 02:03:16,475
THESE COUNTRIES, THEY HELP BRING

2641
02:03:16,475 --> 02:03:17,142
TOGETHER MULTI-DISCIPLINE

2642
02:03:17,142 --> 02:03:18,043
RESEARCH TEAMS, STRATEGIC

2643
02:03:18,043 --> 02:03:20,279
PARTNERS FOR MULTIPLE SECTORS TO

2644
02:03:20,279 --> 02:03:22,481
USE IMPLEMENTATION SCIENCE TO

2645
02:03:22,481 --> 02:03:24,683
HELP TRANSLATE RESEARCH INTO

2646
02:03:24,683 --> 02:03:25,184
PRACTICE.

2647
02:03:25,184 --> 02:03:27,353
THEY ALSO HELP REDUCE LONG-TERM

2648
02:03:27,353 --> 02:03:30,789
BURDEN AND RISK BY ADDRESSING

2649
02:03:30,789 --> 02:03:33,158
CRITICAL DEVELOPMENTAL STAGES BY

2650
02:03:33,158 --> 02:03:36,395
EMBEDDING PREVENTION STRATEGIES

2651
02:03:36,395 --> 02:03:41,900
EARLY IN LIFE AND BUILD -- THEY

2652
02:03:41,900 --> 02:03:43,869
ALIGN WITH NHLBI STRATEGIC

2653
02:03:43,869 --> 02:03:46,071
OBJECTIVES, AS YOU HEARD THIS

2654
02:03:46,071 --> 02:03:47,473
MORNING FROM DR. GIBBONS'

2655
02:03:47,473 --> 02:03:49,241
DIRECTOR'S REPORT AND ALSO

2656
02:03:49,241 --> 02:03:52,845
DIRECTLY SUPPORT THE NIH AND HHS

2657
02:03:52,845 --> 02:03:54,280
PRIORITIES FOR CHRONIC DISEASES,

2658
02:03:54,280 --> 02:03:56,248
ESPECIALLY IN CHILDREN AND

2659
02:03:56,248 --> 02:03:56,582
YOUTH.

2660
02:03:56,582 --> 02:03:59,184
I'LL STOP HERE TO SEE IF YOU

2661
02:03:59,184 --> 02:04:01,086
HAVE ANY CLARIFYING QUESTIONS OR

2662
02:04:01,086 --> 02:04:03,255
COMMENTS OR SUGGESTIONS.

2663
02:04:03,255 --> 02:04:05,524
AND THEN WE CAN ENCOURAGE YOU TO

2664
02:04:05,524 --> 02:04:07,393
PUT IN YOUR VOTES AND YOUR

2665
02:04:07,393 --> 02:04:07,893
COMMENTS.

2666
02:04:07,893 --> 02:04:13,966
THANK YOU.

2667
02:04:13,966 --> 02:04:16,702
AND I CANNOT SEE THE SCREEN SO

2668
02:04:16,702 --> 02:04:18,570
IF YOU COULD HELP ME WITH THE

2669
02:04:18,570 --> 02:04:20,372
COMMENTS ON THE SCREEN.

2670
02:04:20,372 --> 02:04:28,447
>> I HAVE ONE QUESTION. 

2671
02:04:28,447 --> 02:04:29,748
MAY I PROCEED?

2672
02:04:29,748 --> 02:04:31,684
>> IF THERE ARE QUESTIONS
GO

2673
02:04:31,684 --> 02:04:33,285
AHEAD AND VOTE.

2674
02:04:33,285 --> 02:04:33,719
PLEASE REMEMBER --

2675
02:04:33,719 --> 02:04:35,054
>> I HAVE A QUESTION.

2676
02:04:35,054 --> 02:04:39,158
YOU GUYS CAN'T HEAR ME?

2677
02:04:39,158 --> 02:04:45,497
 

2678
02:04:45,497 --> 02:04:47,800
HELLO?

2679
02:04:47,800 --> 02:04:51,770
>> DR. MENSAH, CAN YOU
HEAR THE

2680
02:04:51,770 --> 02:04:54,673
DOCTOR, IN THE ROOM?

2681
02:04:54,673 --> 02:04:58,510
 

2682
02:04:58,510 --> 02:05:01,480
>> CHECK ONE, TWO, TEST.

2683
02:05:01,480 --> 02:05:11,557
 

2684
02:05:11,557 --> 02:05:14,259
LET ME CHECK ON THE CONNECTION.

2685
02:05:14,259 --> 02:05:24,403
>> OKAY.

2686
02:06:03,876 --> 02:06:04,843
>> WHO HAS A QUESTION?

2687
02:06:04,843 --> 02:06:05,844
>> I HAVE A QUESTION.

2688
02:06:05,844 --> 02:06:09,948
CAN YOU HEAR ME NOW?

2689
02:06:09,948 --> 02:06:10,783
>> YES.

2690
02:06:10,783 --> 02:06:13,152
>> THANK YOU.

2691
02:06:13,152 --> 02:06:15,721
DR. MENSAH, THAT WAS ELOQUENTLY

2692
02:06:15,721 --> 02:06:17,623
DESCRIBED BUT I CAN'T HELP

2693
02:06:17,623 --> 02:06:19,291
MYSELF AND ASK THIS QUESTION.

2694
02:06:19,291 --> 02:06:24,096
THREE OF THESE CONCEPTS ARE ON

2695
02:06:24,096 --> 02:06:24,496
GLOBAL HEALTH.

2696
02:06:24,496 --> 02:06:26,031
AND LOW- AND MIDDLE-INCOME

2697
02:06:26,031 --> 02:06:26,865
COUNTRIES, TRIBAL POPULATIONS,

2698
02:06:26,865 --> 02:06:28,934
SO MY QUESTION IS ONE THAT I'M

2699
02:06:28,934 --> 02:06:30,369
SURE MY COLLEAGUES ARE ALSO

2700
02:06:30,369 --> 02:06:32,638
THINKING ABOUT.

2701
02:06:32,638 --> 02:06:34,773
GIVEN THE CURRENT POSTURE THAT

2702
02:06:34,773 --> 02:06:37,075
WE'RE GETTING FROM THE

2703
02:06:37,075 --> 02:06:38,043
GOVERNMENT ABOUT PROGRAMS LIKE

2704
02:06:38,043 --> 02:06:42,080
THIS, AND I KNOW COLLEAGUES OF

2705
02:06:42,080 --> 02:06:47,252
MINE WHO HAD GLOBAL HEALTH

2706
02:06:47,252 --> 02:06:49,822
PROGRAMS REDEFINED, SOME BEING

2707
02:06:49,822 --> 02:06:51,790
CANCELED, SO CAN THE INSTITUTE

2708
02:06:51,790 --> 02:06:58,197
GIVE US AN ASSURANCE THAT THESE

2709
02:06:58,197 --> 02:06:59,264
CONCEPTS WILL PROGRESS AND

2710
02:06:59,264 --> 02:07:01,733
BECOME AVAILABLE FOR FOLKS TO

2711
02:07:01,733 --> 02:07:08,273
ACTUALLY COMPETE FOR FUNDING?

2712
02:07:08,273 --> 02:07:10,776
>> THANK YOU VERY MUCH,
VERY

2713
02:07:10,776 --> 02:07:12,744
THOUGHTFUL QUESTION.

2714
02:07:12,744 --> 02:07:14,279
WAS DR. GIBBONS GETTING READY TO

2715
02:07:14,279 --> 02:07:14,847
BEYOND?

2716
02:07:14,847 --> 02:07:21,286
I CERTAINLY YIELD TO DR.

2717
02:07:21,286 --> 02:07:21,520
GIBBONS.

2718
02:07:21,520 --> 02:07:22,521
>> THROW ME THE SOFTBALL,

2719
02:07:22,521 --> 02:07:26,425
GEORGE.

2720
02:07:26,425 --> 02:07:30,028
>> SOLOMON, I APPRECIATE
YOU

2721
02:07:30,028 --> 02:07:32,698
BRINGING UP YOUR QUESTIONS.

2722
02:07:32,698 --> 02:07:37,369
QUITE APPROACH IT,

2723
02:07:37,369 --> 02:07:37,836
UNDERSTANDABLE.

2724
02:07:37,836 --> 02:07:39,438
AND WE RECOGNIZE THAT THERE HAVE

2725
02:07:39,438 --> 02:07:45,377
BEEN A NUMBER OF TERMINATIONS IN

2726
02:07:45,377 --> 02:07:50,249
THE SPACE.

2727
02:07:50,249 --> 02:07:53,285
I THINK CLEARLY, I WOULD

2728
02:07:53,285 --> 02:07:55,287
CERTAINLY, BASED ON PRIOR

2729
02:07:55,287 --> 02:07:57,122
GUIDANCE FROM THIS

2730
02:07:57,122 --> 02:07:57,789
ADMINISTRATION, IT'S CLEARLY AN

2731
02:07:57,789 --> 02:08:01,159
ISSUE WITH WHAT THEY CALL

2732
02:08:01,159 --> 02:08:04,229
COUNTRIES OF CONCERN, GIVEN THE

2733
02:08:04,229 --> 02:08:05,864
ADMINISTRATION'S CONCERN ABOUT

2734
02:08:05,864 --> 02:08:10,002
THE NATIONAL SECURITY, STEALING

2735
02:08:10,002 --> 02:08:11,203
OF INTELLECTUAL PROPERTY, AND

2736
02:08:11,203 --> 02:08:14,506
OTHER ELEMENTS OF THAT.

2737
02:08:14,506 --> 02:08:23,215
SO THERE IS A -- I'LL SAY A

2738
02:08:23,215 --> 02:08:24,182
CIRCUMSPECTION ABOUT GLOBAL

2739
02:08:24,182 --> 02:08:30,489
COLLABORATIONS, WHERE THEY ARE,

2740
02:08:30,489 --> 02:08:31,990
WHO WE'RE COLLABORATING WITH

2741
02:08:31,990 --> 02:08:33,559
WITH TAXPAYER MONEY, FAIR TO

2742
02:08:33,559 --> 02:08:35,294
SAY, AND THERE'S THERE'S

2743
02:08:35,294 --> 02:08:35,994
SCRUTINY.

2744
02:08:35,994 --> 02:08:39,464
THE SECOND LAYER IS RELATED TO

2745
02:08:39,464 --> 02:08:41,533
THE SUBAWARD ISSUE, IS THAT MANY

2746
02:08:41,533 --> 02:08:43,702
OF THE STRUCTURES THAT WE DEAL

2747
02:08:43,702 --> 02:08:46,471
WITH IN THESE INTERNATIONAL

2748
02:08:46,471 --> 02:08:47,873
COLLABORATIONS, THE SUBAWARD MAY

2749
02:08:47,873 --> 02:08:50,842
BE IN A FOREIGN COUNTRY AND TO

2750
02:08:50,842 --> 02:08:55,280
THE DEGREE TO WHICH WE -- THE

2751
02:08:55,280 --> 02:08:57,683
ADMINISTRATION BELIEVES WE HAVE

2752
02:08:57,683 --> 02:09:00,686
PROBABLY LESS THAN OPTIMAL

2753
02:09:00,686 --> 02:09:02,154
OVERSIGHT OF THOSE SUBAWARDS,

2754
02:09:02,154 --> 02:09:03,555
THAT'S WHERE THERE'S BEEN A

2755
02:09:03,555 --> 02:09:05,924
SENSE OF MAYBE TAKING A STEP

2756
02:09:05,924 --> 02:09:11,730
BACK TO SEE HOW WE CAN REFINE

2757
02:09:11,730 --> 02:09:13,632
THAT CAPABILITY, AND SO WHAT'S

2758
02:09:13,632 --> 02:09:16,134
STILL UNCERTAIN WHETHER THERE'S

2759
02:09:16,134 --> 02:09:18,403
A PAUSE AS THAT'S GOING ON, BOTH

2760
02:09:18,403 --> 02:09:22,040
THE VETTING AS WELL AS DEFINING

2761
02:09:22,040 --> 02:09:24,610
THE OPERATIONAL PATH FORWARD,

2762
02:09:24,610 --> 02:09:26,011
VERSUS A COMPLETE ELIMINATION.

2763
02:09:26,011 --> 02:09:30,716
THOUGH I DO HEAR YOUR CONCERN,

2764
02:09:30,716 --> 02:09:33,919
AND CERTAINLY I THINK WE CAN BE

2765
02:09:33,919 --> 02:09:34,987
TRANSPARENT WITH THE PRESIDENT'S

2766
02:09:34,987 --> 02:09:35,420
BUDGET.

2767
02:09:35,420 --> 02:09:39,157
I DON'T THINK THERE WAS FUNDING

2768
02:09:39,157 --> 02:09:42,494
FOR FOGARTY IN THAT BUDGET.

2769
02:09:42,494 --> 02:09:46,264
AND SO THAT MAY REFLECT THIS

2770
02:09:46,264 --> 02:09:48,734
ADMINISTRATION'S POSITION BUT I

2771
02:09:48,734 --> 02:09:55,007
WOULD ALSO SAY THAT IN THE

2772
02:09:55,007 --> 02:09:55,974
REORGANIZATION STRATEGY THERE

2773
02:09:55,974 --> 02:09:59,478
COULD BE A SENSE OF MAINTAINING

2774
02:09:59,478 --> 02:10:00,512
CERTAIN FUNCTIONALITIES, EVEN IF

2775
02:10:00,512 --> 02:10:03,348
IT DIDN'T STILL CONTINUE TO

2776
02:10:03,348 --> 02:10:07,552
RESIDE IN A PARTICULAR CENTER,

2777
02:10:07,552 --> 02:10:09,054
LIKE FOGARTY.

2778
02:10:09,054 --> 02:10:12,090
AND JAY I THINK HAS BEEN ON THE

2779
02:10:12,090 --> 02:10:13,792
RECORD AS GENERALLY SUPPORTING

2780
02:10:13,792 --> 02:10:14,393
INTERNATIONAL COLLABORATIONS.

2781
02:10:14,393 --> 02:10:19,331
I THINK IT IS MORE THE HOW THAN

2782
02:10:19,331 --> 02:10:19,665
NEVER.

2783
02:10:19,665 --> 02:10:22,000
AT LEAST THAT'S OUR INITIAL

2784
02:10:22,000 --> 02:10:22,501
IMPRESSIONS.

2785
02:10:22,501 --> 02:10:25,504
BUT IT'S STILL EARLY.

2786
02:10:25,504 --> 02:10:26,038
IT'S FLUID.

2787
02:10:26,038 --> 02:10:28,473
AND TO THE DEGREE TO WHICH IT IS

2788
02:10:28,473 --> 02:10:30,509
EARLY AND FLUID, I THINK IT'S

2789
02:10:30,509 --> 02:10:32,911
PRUDENT FOR US TO CONTINUE TO

2790
02:10:32,911 --> 02:10:37,082
MAKE THE CASE FOR THIS RESEARCH

2791
02:10:37,082 --> 02:10:40,018
AND AS DR. MENSAH, AS YOU SAID,

2792
02:10:40,018 --> 02:10:41,353
ELOQUENTLY OUTLINED I THINK THE

2793
02:10:41,353 --> 02:10:43,655
GOOD CASE CAN BE MADE THAT THIS

2794
02:10:43,655 --> 02:10:47,259
IS IN LINE WITH ADDRESSING THE

2795
02:10:47,259 --> 02:10:50,529
BURDEN OF CHRONIC DISEASE,

2796
02:10:50,529 --> 02:10:52,464
RECOGNIZING ITS INTERNATIONAL

2797
02:10:52,464 --> 02:10:53,932
CHARACTER THAT INDEED THE

2798
02:10:53,932 --> 02:10:55,333
SECRETARY'S POINTED OUT,

2799
02:10:55,333 --> 02:10:57,536
COMPARING OURSELVES WITH WEALTHY

2800
02:10:57,536 --> 02:10:57,803
COUNTRIES.

2801
02:10:57,803 --> 02:11:01,640
IT IS ALSO I THINK

2802
02:11:01,640 --> 02:11:04,309
SCIENTIFICALLY SOUND TO ALSO

2803
02:11:04,309 --> 02:11:06,545
INCLUDE LOW- AND MIDDLE-INCOME

2804
02:11:06,545 --> 02:11:08,246
COUNTRIES TO ELUCIDATE THE

2805
02:11:08,246 --> 02:11:09,815
STRATEGIES TO ADDRESS CHRONIC

2806
02:11:09,815 --> 02:11:10,115
DISEASE.

2807
02:11:10,115 --> 02:11:14,219
SO WE'RE FOCUSED ON MAINTAINING

2808
02:11:14,219 --> 02:11:15,420
THE SCIENTIFIC ARGUMENT, AND

2809
02:11:15,420 --> 02:11:17,389
QUITE FRANKLY THIS WILL BE A

2810
02:11:17,389 --> 02:11:18,490
TEST CASE.

2811
02:11:18,490 --> 02:11:21,660
WE'RE GOING TO SEE WHERE THE

2812
02:11:21,660 --> 02:11:23,228
PRIORITIES FALL OUT, AND BUT

2813
02:11:23,228 --> 02:11:24,596
WE'RE HOPEFUL.

2814
02:11:24,596 --> 02:11:27,399
I HOPE THAT ADDRESSES A VERY

2815
02:11:27,399 --> 02:11:28,600
LEGITIMATE QUESTION, SOLOMON.

2816
02:11:28,600 --> 02:11:29,601
>> IT DOES.

2817
02:11:29,601 --> 02:11:32,404
THANK YOU SO MUCH.

2818
02:11:32,404 --> 02:11:33,939
>> THANKS, DR. GIBBONS.

2819
02:11:33,939 --> 02:11:36,341
LET ME ENCOURAGE YOU TO PLEASE

2820
02:11:36,341 --> 02:11:39,511
REMEMBER TO PUT YOUR COMMENTS

2821
02:11:39,511 --> 02:11:40,746
FOR ALL THREE INDIVIDUALLY AND

2822
02:11:40,746 --> 02:11:42,914
THEN WE'LL TRY AND GET YOU OUT

2823
02:11:42,914 --> 02:11:44,049
OF HERE ON TIME.

2824
02:11:44,049 --> 02:11:44,349
THANKS.

2825
02:11:44,349 --> 02:11:46,651
>> I THINK YOU CAN MOVE
ALONG.

2826
02:11:46,651 --> 02:11:56,194
I'M OVER HERE NOW. 

2827
02:11:56,194 --> 02:11:57,429
>> EXCELLENT. 

2828
02:11:57,429 --> 02:11:58,864
I WILL TAG YOU.

2829
02:11:58,864 --> 02:12:00,932
>> NOW WE'RE MOVING TO THE

2830
02:12:00,932 --> 02:12:05,670
CONCEPT OF MY DIVISION,

2831
02:12:05,670 --> 02:12:07,506
CARDIOVASCULAR SCIENCES.

2832
02:12:07,506 --> 02:12:12,677
THE FIRST ONE, IDS NUMBER 5139,

2833
02:12:12,677 --> 02:12:16,248
STRONG HEART STUDY RENEWAL.

2834
02:12:16,248 --> 02:12:18,016
SO THE OBJECTIVE AIMS TO

2835
02:12:18,016 --> 02:12:19,918
CONTINUE THE STRONG HEART STUDY

2836
02:12:19,918 --> 02:12:23,121
WHICH IS THE LONGEST-RUNNING AND

2837
02:12:23,121 --> 02:12:25,257
LARGEST MULTI-CENTER PER OF

2838
02:12:25,257 --> 02:12:26,158
STUDY OF AMERICAN INDIANS.

2839
02:12:26,158 --> 02:12:29,828
WE WANT TO ENSURE IT REMAINS A

2840
02:12:29,828 --> 02:12:31,930
VITAL RESOURCE FOR ONGOING

2841
02:12:31,930 --> 02:12:33,698
EPIDEMIOLOGIC RESEARCH ON HEART,

2842
02:12:33,698 --> 02:12:34,866
LUNG, BLOOD, SLEEP DISORDERS AND

2843
02:12:34,866 --> 02:12:36,802
BEYOND AS WELL AS RELATED RISK

2844
02:12:36,802 --> 02:12:39,738
FACTORS AND DISEASES IN THIS

2845
02:12:39,738 --> 02:12:40,405
POPULATION.

2846
02:12:40,405 --> 02:12:42,107
THE STRONG HEART STUDY IS

2847
02:12:42,107 --> 02:12:44,276
CONDUCTED IN PARTNERSHIP WITH

2848
02:12:44,276 --> 02:12:46,511
TRIBAL GOVERNMENTS, AND

2849
02:12:46,511 --> 02:12:48,980
COMMUNITY PARTICIPANTS, FROM 12

2850
02:12:48,980 --> 02:12:49,915
TRIBAL COMMUNITIES IN THREE

2851
02:12:49,915 --> 02:12:54,553
GEOGRAPHIC AREAS OF THE U.S.,

2852
02:12:54,553 --> 02:12:56,955
INCLUDES DAKOTAS, OKLAHOMA, AND

2853
02:12:56,955 --> 02:12:57,189
ARIZONA.

2854
02:12:57,189 --> 02:12:58,857
AND WITH OVER 540 PUBLICATIONS

2855
02:12:58,857 --> 02:13:01,026
MANY IN HIGH IMPACT JOURNALS,

2856
02:13:01,026 --> 02:13:03,094
THE STUDY WAS INSTRUMENTAL OF

2857
02:13:03,094 --> 02:13:04,729
IDENTIFYING DIABETES AS THE

2858
02:13:04,729 --> 02:13:07,766
STRONGEST RISK FACTOR FOR

2859
02:13:07,766 --> 02:13:09,267
CARDIOVASCULAR DISEASE IN

2860
02:13:09,267 --> 02:13:11,236
AMERICAN INDIAN POPULATIONS AND

2861
02:13:11,236 --> 02:13:11,870
FOR IMPLEMENTING PROGRAMS BY

2862
02:13:11,870 --> 02:13:14,706
INDIAN HEALTH SERVICE TO REDUCE

2863
02:13:14,706 --> 02:13:16,241
THE BUFFERED OF DIABETES AND

2864
02:13:16,241 --> 02:13:18,310
CARDIOVASCULAR DISEASE IN THIS

2865
02:13:18,310 --> 02:13:18,777
POPULATION.

2866
02:13:18,777 --> 02:13:20,178
WE'RE PROPOSING THE NEXT PHASE

2867
02:13:20,178 --> 02:13:22,447
WILL CONTINUE TO BUILD UPON

2868
02:13:22,447 --> 02:13:24,082
REALLY SIGNIFICANT ACHEEVMENTS

2869
02:13:24,082 --> 02:13:26,351
OF THE STUDY OVER THE PAST 35

2870
02:13:26,351 --> 02:13:29,054
YEARS, BY SUPPORTING THE

2871
02:13:29,054 --> 02:13:30,055
CONTINUED COLLECTION OF ROBUST

2872
02:13:30,055 --> 02:13:32,891
DATA THAT IDENTIFIES HEALTH

2873
02:13:32,891 --> 02:13:35,493
NEEDS AND CHALLENGES FACED BY

2874
02:13:35,493 --> 02:13:36,828
AGING AMERICAN INDIAN

2875
02:13:36,828 --> 02:13:39,464
POPULATIONS AND ALSO ADDING DATA

2876
02:13:39,464 --> 02:13:43,368
COLLECTION FROM A YOUNGER

2877
02:13:43,368 --> 02:13:45,470
GENERATION TO SHAPE CULTURALLY

2878
02:13:45,470 --> 02:13:46,771
SPECIFIC PREVENTION AND

2879
02:13:46,771 --> 02:13:48,173
TREATMENT STRATEGIES ACROSS THE

2880
02:13:48,173 --> 02:13:48,473
LIFESPAN.

2881
02:13:48,473 --> 02:13:51,409
THE STRONG HEART STUDY HAS A

2882
02:13:51,409 --> 02:13:53,278
SUCCESSFUL TRACK RECORD IN

2883
02:13:53,278 --> 02:13:55,480
PUBLICATIONS BUT HAS COMMUNITY

2884
02:13:55,480 --> 02:13:59,184
ENGAGEMENTS THAT ARE STRONG WITH

2885
02:13:59,184 --> 02:14:01,019
PARTICIPATING TRIBAL COMMUNITIES

2886
02:14:01,019 --> 02:14:02,754
AND RENEWAL WILL ENSURE THESE

2887
02:14:02,754 --> 02:14:05,023
EFFORTS CONTINUE MOVING FORWARD.

2888
02:14:05,023 --> 02:14:07,092
AND THIS WILL CONTINUE THROUGH

2889
02:14:07,092 --> 02:14:08,727
DISSEMINATION OF RESULTS,

2890
02:14:08,727 --> 02:14:09,861
RELEVANT HEALTH INFORMATION VIA

2891
02:14:09,861 --> 02:14:12,530
ONLINE AND PRINTED MATERIALS,

2892
02:14:12,530 --> 02:14:14,065
COMMUNITY EVENTS, COMMUNITY

2893
02:14:14,065 --> 02:14:15,867
ENGAGED PROJECTS BY IMPLEMENTING

2894
02:14:15,867 --> 02:14:17,335
BEST PRACTICES AND AND

2895
02:14:17,335 --> 02:14:19,804
CONNECTIONS, WE'LL WORK AND

2896
02:14:19,804 --> 02:14:21,273
LEVERAGE ONGOING RESOURCES

2897
02:14:21,273 --> 02:14:24,609
PROVIDED BY NIH-WIDE INITIATIVES

2898
02:14:24,609 --> 02:14:26,144
SUCH AS COMMUNITY ENGAGEMENT

2899
02:14:26,144 --> 02:14:26,711
ALLIANCE, OR CEAL.

2900
02:14:26,711 --> 02:14:29,347
THE STUDY WILL CONTINUE TO TRAIN

2901
02:14:29,347 --> 02:14:31,449
AND MENTOR EARLY CAREER

2902
02:14:31,449 --> 02:14:32,550
RESEARCHERS AND HEALTHCARE

2903
02:14:32,550 --> 02:14:34,119
PROFESSIONALS INTERESTED IN

2904
02:14:34,119 --> 02:14:37,455
ADDRESSING THE NEEDS AND

2905
02:14:37,455 --> 02:14:38,690
CONDITIONS IN TRIBAL

2906
02:14:38,690 --> 02:14:39,424
COMMUNITIES.

2907
02:14:39,424 --> 02:14:40,659
IN SUMMARY THIS PROPOSED RENEWAL

2908
02:14:40,659 --> 02:14:42,527
OF THE STRONG HEART STUDY SEEKS

2909
02:14:42,527 --> 02:14:44,963
TO WORK IN PARTNERSHIP TO BEST

2910
02:14:44,963 --> 02:14:49,634
SERVE HEALTH NEEDS OF THE NATIVE

2911
02:14:49,634 --> 02:14:51,169
AMERICAN COMMUNITIES BY

2912
02:14:51,169 --> 02:14:53,104
CONTINUING THE COHORT OF

2913
02:14:53,104 --> 02:14:55,040
PARTICIPANTS WHILE EXPANDING TO

2914
02:14:55,040 --> 02:14:57,275
INCLUDE YOUNGER PARTICIPANTS.

2915
02:14:57,275 --> 02:14:58,443
WE WILL STRENGTHEN

2916
02:14:58,443 --> 02:14:59,611
COLLABORATIONS WITH INTERESTED

2917
02:14:59,611 --> 02:15:01,212
EXTERNAL RESEARCHERS IN THE

2918
02:15:01,212 --> 02:15:03,982
CONDUCT OF ANCILLARY PROJECTS AS

2919
02:15:03,982 --> 02:15:05,150
WELL, MAINTAINING COMMUNITY

2920
02:15:05,150 --> 02:15:06,651
ENGAGEMENT EFFORTS AND INVEST

2921
02:15:06,651 --> 02:15:09,387
TRAINING IN THE NEXT GENERATION

2922
02:15:09,387 --> 02:15:10,555
OF HEALTH PROFESSIONALS TO

2923
02:15:10,555 --> 02:15:17,562
ADDRESS TRIBAL HEALTH NEEDS.

2924
02:15:17,562 --> 02:15:19,164
THANK YOU.

2925
02:15:19,164 --> 02:15:22,033
HAPPY TO ANSWER QUESTIONS OR

2926
02:15:22,033 --> 02:15:24,102
HEAR ANY COMMENTS.

2927
02:15:24,102 --> 02:15:26,137
AND IF NOT, PLEASE FEEL FREE TO

2928
02:15:26,137 --> 02:15:29,074
CAST YOUR VOTE.

2929
02:15:29,074 --> 02:15:34,245
THANKS. 

2930
02:15:34,245 --> 02:15:36,548
>> A LOT OF QUESTIONS, IS
THE

2931
02:15:36,548 --> 02:15:37,615
PERCEIVED BENEFIT WORTH THE

2932
02:15:37,615 --> 02:15:37,882
COST.

2933
02:15:37,882 --> 02:15:39,084
I SHOULD HAVE ASKED FOR THE

2934
02:15:39,084 --> 02:15:39,818
OTHER ONE.

2935
02:15:39,818 --> 02:15:46,358
DO WE KNOW THE COST? 

2936
02:15:46,358 --> 02:15:48,660
JUST ANSWER THE QUESTION?

2937
02:15:48,660 --> 02:15:50,929
>> I PERSONALLY THINK YOU
SHOULD

2938
02:15:50,929 --> 02:15:53,164
BUT YOU SHOULD CERTAINLY KNOW

2939
02:15:53,164 --> 02:15:59,237
WHAT IT COST IN THE PREVIOUS

2940
02:15:59,237 --> 02:15:59,437
CYCLE.

2941
02:15:59,437 --> 02:16:00,338
>> AND IDS WRITE-UP, COST

2942
02:16:00,338 --> 02:16:02,841
ESTIMATES ARE IN THE WRITE-UPS,

2943
02:16:02,841 --> 02:16:06,544
YOU SHOULD HAVE ACCESS TO BUT WE

2944
02:16:06,544 --> 02:16:08,546
CAN PULL THAT UP AND BRING THAT

2945
02:16:08,546 --> 02:16:10,715
ON THE TABLE HERE.

2946
02:16:10,715 --> 02:16:11,816
>> YEAH, OR, GINA, IF YOU
WANT

2947
02:16:11,816 --> 02:16:14,652
TO TELL THEM WHAT IT IS.

2948
02:16:14,652 --> 02:16:17,255
>> SURE, I CAN PULL THAT
UP.

2949
02:16:17,255 --> 02:16:27,532
>> THE RANGE. 

2950
02:16:29,501 --> 02:16:32,871
>> THIS IS A PROCEDURAL

2951
02:16:32,871 --> 02:16:33,138
QUESTION.

2952
02:16:33,138 --> 02:16:34,839
>> YEAH, IN GENERAL, NOT
THIS

2953
02:16:34,839 --> 02:16:37,575
ONE SPECIFIC, BUT IS PERCEIVED

2954
02:16:37,575 --> 02:16:39,044
BENEFIT WORTH THE COST.

2955
02:16:39,044 --> 02:16:42,213
>> YES, WHEN I WAS READING
THE

2956
02:16:42,213 --> 02:16:44,749
RUBRIC IT LOOKED LIKE IS THIS

2957
02:16:44,749 --> 02:16:47,318
WORTH FUND OF THIS IN LIEU OF

2958
02:16:47,318 --> 02:16:49,387
FUNDING A SEPARATE R01 OR OTHER

2959
02:16:49,387 --> 02:16:52,524
FUNDING MECHANISMS, SO IF IT'S

2960
02:16:52,524 --> 02:16:55,527
ABOUT EQUIVALENT, IT'S

2961
02:16:55,527 --> 02:16:56,995
EQUIVALENT, IF IT'S WORTH UNION

2962
02:16:56,995 --> 02:16:58,263
REDUCING ONE R01 TO FUND THIS,

2963
02:16:58,263 --> 02:17:01,566
ET CETERA, IS THAT THE RIGHT

2964
02:17:01,566 --> 02:17:04,102
UNDERSTANDING?

2965
02:17:04,102 --> 02:17:05,103
>> YEAH, YOU GOT IT.

2966
02:17:05,103 --> 02:17:07,105
>> TO A CERTAIN EXTENT WE
ALL

2967
02:17:07,105 --> 02:17:08,640
HAVE BEEN ON BOTH SIDES.

2968
02:17:08,640 --> 02:17:17,882
AND SO WHEN YOU HAVE

2969
02:17:17,882 --> 02:17:18,516
INSTITUTE-SOLICITED ACTIVITIES

2970
02:17:18,516 --> 02:17:21,252
SOMETIMES AT THE EXPENSE OF

2971
02:17:21,252 --> 02:17:23,088
R01S, AND THAT'S OFTEN A USEFUL

2972
02:17:23,088 --> 02:17:26,057
BAROMETER AS TO HOW YOU ALL

2973
02:17:26,057 --> 02:17:27,892
WOULD FEEL ABOUT SOMETHING IN

2974
02:17:27,892 --> 02:17:29,928
TERMS OF OUR INVESTMENT

2975
02:17:29,928 --> 02:17:30,361
STRATEGY.

2976
02:17:30,361 --> 02:17:36,101
IS THIS WORTH MOVING IN THIS

2977
02:17:36,101 --> 02:17:38,203
AREA, WITH INSTITUTE

2978
02:17:38,203 --> 02:17:39,404
SOLICITATION RATHER THAN

2979
02:17:39,404 --> 02:17:41,039
INVESTIGATOR.

2980
02:17:41,039 --> 02:17:42,040
>> IT'S NOT FINANCIAL COST

2981
02:17:42,040 --> 02:17:43,174
IT'S OPPORTUNITY COST.

2982
02:17:43,174 --> 02:17:46,744
>> AND BOTH ARE ELEMENTS
OF YOUR

2983
02:17:46,744 --> 02:17:57,055
JUDGMENT, EXACTLY.

2984
02:18:04,496 --> 02:18:14,873
>> ANOTHER SECOND OR TWO.

2985
02:18:23,615 --> 02:18:25,350
>> SURE.

2986
02:18:25,350 --> 02:18:26,618
>> YOU CAN MOVE FORWARD.

2987
02:18:26,618 --> 02:18:27,452
>> ALL RIGHT.

2988
02:18:27,452 --> 02:18:32,724
MOVE TO THE SECOND ONE.

2989
02:18:32,724 --> 02:18:38,763
THAT IS IDS 5149, CARDIOTHORACIC

2990
02:18:38,763 --> 02:18:46,037
SURGICAL TRIALS NETWORK RENEWAL.

2991
02:18:46,037 --> 02:18:48,973
RENEWAL OF IMPACTFUL

2992
02:18:48,973 --> 02:18:49,908
CARDIOTHORACIC NETWORK, CTSN,

2993
02:18:49,908 --> 02:18:50,675
LARGEST CARDIAC SURGICAL

2994
02:18:50,675 --> 02:18:53,611
RESEARCH NETWORK IN THE WORLD.

2995
02:18:53,611 --> 02:18:55,547
TRIAL RESULTS INFLUENCED

2996
02:18:55,547 --> 02:18:56,915
NATIONAL AND INTERNATIONAL

2997
02:18:56,915 --> 02:18:57,949
GUIDELINES AND CLINICAL

2998
02:18:57,949 --> 02:18:58,216
PRACTICE.

2999
02:18:58,216 --> 02:19:00,385
SO THE AIM OF THE CURRENT

3000
02:19:00,385 --> 02:19:01,553
INITIATIVE TO EXPAND THE SCOPE

3001
02:19:01,553 --> 02:19:05,857
OF THE NETWORK WHICH FOCUSES ON

3002
02:19:05,857 --> 02:19:07,559
HEART SURGERY, INTERVENTIONAL

3003
02:19:07,559 --> 02:19:08,493
CARDIOLOGY, RELATED

3004
02:19:08,493 --> 02:19:10,361
PERIOPERATIVE CARE TO INCLUDE

3005
02:19:10,361 --> 02:19:13,097
GREATER EMPHASIS ON

3006
02:19:13,097 --> 02:19:14,499
IMPLEMENTATION SCIENCE,

3007
02:19:14,499 --> 02:19:15,833
CIRCADIAN MEDICINE, MECHANISTIC

3008
02:19:15,833 --> 02:19:16,501
SCIENCE EFFORTS.

3009
02:19:16,501 --> 02:19:20,004
AT THE SAME TIME YOU WANT TO

3010
02:19:20,004 --> 02:19:21,606
STREAMLINE THE PROCESSES IN

3011
02:19:21,606 --> 02:19:22,707
CENTRALIZED TRAINING THAT WOULD

3012
02:19:22,707 --> 02:19:25,210
LEAD TO REDUCTION IN COST FROM

3013
02:19:25,210 --> 02:19:29,948
THE PREVIOUS RENEWAL.

3014
02:19:29,948 --> 02:19:33,084
JUST BRIEFLY CONDUCTS TIMELY

3015
02:19:33,084 --> 02:19:34,919
EFFECTIVENESS TRIALS WITH

3016
02:19:34,919 --> 02:19:36,054
PATIENT CENTERED OUTCOMES THAT

3017
02:19:36,054 --> 02:19:38,089
INDUSTRY WILL NOT TYPICALLY DO,

3018
02:19:38,089 --> 02:19:46,231
SO THEIR FOCUS IS ON OBTAINING

3019
02:19:46,231 --> 02:19:47,732
REGULATORY APPROVAL, AND JUST TO

3020
02:19:47,732 --> 02:19:50,068
BRAG ABOUT HOW SUCCESSFUL THIS

3021
02:19:50,068 --> 02:19:53,605
NETWORK HAS BEEN, IT HAS BEEN

3022
02:19:53,605 --> 02:19:55,707
TREMENDOUSLY SUCCESSFUL.

3023
02:19:55,707 --> 02:19:56,808
FOR EXAMPLE, TRAINED

3024
02:19:56,808 --> 02:19:58,543
APPROXIMATELY 100 CLINICAL

3025
02:19:58,543 --> 02:20:00,878
IMPLEMENTATION SCIENCE

3026
02:20:00,878 --> 02:20:02,513
INVESTIGATORS ACROSS

3027
02:20:02,513 --> 02:20:04,115
SPECIALTIES, INCLUDING ADULT,

3028
02:20:04,115 --> 02:20:09,287
PEDIATRIC CARDIAC SURGERY,

3029
02:20:09,287 --> 02:20:11,556
CARDIOLOGY, ICU, BIOSTATS, 538

3030
02:20:11,556 --> 02:20:13,191
PAPERS BY THESE TRAINEES,

3031
02:20:13,191 --> 02:20:14,659
PUBLISHED 24 PRIMARY OUTCOME

3032
02:20:14,659 --> 02:20:16,327
PAPERS IN HIGH-IMPACT JOURNALS

3033
02:20:16,327 --> 02:20:20,765
AS WELL AS 76 SECONDARY

3034
02:20:20,765 --> 02:20:21,165
ANALYSES.

3035
02:20:21,165 --> 02:20:22,600
RAPIDLY PIVOTED IN 2020 TO

3036
02:20:22,600 --> 02:20:25,570
BECOME A LEAD ENROLLER IN

3037
02:20:25,570 --> 02:20:26,738
MULTIPLE COVID-19 TRIALS,

3038
02:20:26,738 --> 02:20:28,840
PROVING IMENSURE VALUE OF HAVING

3039
02:20:28,840 --> 02:20:31,709
AN ALREADY EXISTING NETWORK TO

3040
02:20:31,709 --> 02:20:32,910
BENEFIT PUBLIC HEALTH

3041
02:20:32,910 --> 02:20:33,444
EMERGENCIES.

3042
02:20:33,444 --> 02:20:38,149
IN THIS CURRENT OR THIRD CYCLE,

3043
02:20:38,149 --> 02:20:41,119
DOUBLED FUNDING BY COLLABORATING

3044
02:20:41,119 --> 02:20:42,287
WITH INTERNATIONAL FUNDERS,

3045
02:20:42,287 --> 02:20:43,354
SMALL BUSINESS INVESTIGATORS,

3046
02:20:43,354 --> 02:20:44,989
OBTAINING ADDITIONAL GRANTS

3047
02:20:44,989 --> 02:20:48,459
THROUGH OUR NORMATIVE PROCESSES.

3048
02:20:48,459 --> 02:20:50,428
AND COLLECTIVELY THIS NETWORK

3049
02:20:50,428 --> 02:20:53,097
HAS WORKED WITH OVER 800

3050
02:20:53,097 --> 02:20:54,732
INVESTIGATORS, WHO ENROLLED OVER

3051
02:20:54,732 --> 02:20:59,604
5,000 PARTICIPANTS IN  RANDOMIZD

3052
02:20:59,604 --> 02:21:05,176
CONTROLLED TRIALS, 14,000

3053
02:21:05,176 --> 02:21:06,311
PARTICIPANTS, 550 IN REGISTRIES

3054
02:21:06,311 --> 02:21:07,278
WORLDWIDE.

3055
02:21:07,278 --> 02:21:09,814
I WANT TO MENTION THAT NHLBI

3056
02:21:09,814 --> 02:21:14,585
RECONVENED AN EXPERT PANEL IN

3057
02:21:14,585 --> 02:21:15,453
2024 THAT UNANIMOUSLY

3058
02:21:15,453 --> 02:21:16,554
RECOMMENDED WE CONTINUE TO

3059
02:21:16,554 --> 02:21:19,791
INVEST PUBLIC MONEY INTO THIS

3060
02:21:19,791 --> 02:21:21,893
CTSN TO BUILD UPON THE

3061
02:21:21,893 --> 02:21:22,794
CONTRIBUTION THIS WORK HAS MADE

3062
02:21:22,794 --> 02:21:26,497
IN TERMS OF CARE FOR THE

3063
02:21:26,497 --> 02:21:29,167
PARTICIPANTS WITH CARDIOVASCULAR

3064
02:21:29,167 --> 02:21:29,600
DISEASE.

3065
02:21:29,600 --> 02:21:31,369
THEY HAVE PROPOSED 19 CHILD

3066
02:21:31,369 --> 02:21:32,837
CONCEPTS TO ADDRESS IN

3067
02:21:32,837 --> 02:21:35,473
GUIDELINES, WE WON'T BE PUTTING

3068
02:21:35,473 --> 02:21:36,708
ALL THAT IN OUR RENEWAL.

3069
02:21:36,708 --> 02:21:37,642
WE'RE GOING TO BE ASKING

3070
02:21:37,642 --> 02:21:40,812
INVESTIGATORS TO COME UP WITH

3071
02:21:40,812 --> 02:21:43,381
THOSE IDEAS AND FUND SEPARATELY

3072
02:21:43,381 --> 02:21:44,248
THAT WAY.

3073
02:21:44,248 --> 02:21:47,618
SPECIFICALLY, I WANT TO MENTION

3074
02:21:47,618 --> 02:21:48,252
FOR THIS PARTICULAR CYCLE

3075
02:21:48,252 --> 02:21:50,822
THERE'S GOING TO BE A

3076
02:21:50,822 --> 02:21:54,559
STREAMLINED PROCESS TO INCREASE

3077
02:21:54,559 --> 02:21:56,260
EFFICIENCY, DONE BY REORGANIZING

3078
02:21:56,260 --> 02:21:58,896
CTSN INFRASTRUCTURE TO BE A

3079
02:21:58,896 --> 02:22:00,898
SINGLE AWARD FOR DATA AND

3080
02:22:00,898 --> 02:22:02,667
COORDINATING CENTER AND THAT

3081
02:22:02,667 --> 02:22:04,969
WILL CONTRACT WITH CLINICAL

3082
02:22:04,969 --> 02:22:05,403
SITES.

3083
02:22:05,403 --> 02:22:08,206
YOU ALL HAVE THE CURRENT

3084
02:22:08,206 --> 02:22:09,874
PROPOSAL, DOES HAVE SEED FUNDING

3085
02:22:09,874 --> 02:22:13,177
PROPOSED TO CONDUCT TWO TO THREE

3086
02:22:13,177 --> 02:22:13,911
INVESTIGATOR-INITIATED TRIALS

3087
02:22:13,911 --> 02:22:15,847
AND COORDINATE THE TRAINING.

3088
02:22:15,847 --> 02:22:18,182
AND AS FAR AS -- AS WELL I

3089
02:22:18,182 --> 02:22:19,851
MENTION THIS WILL BROADEN

3090
02:22:19,851 --> 02:22:23,054
RESEARCH AND INTERVENTION

3091
02:22:23,054 --> 02:22:25,223
CARDIOLOGY AND CONTINUE TO

3092
02:22:25,223 --> 02:22:27,692
ATTRACT ADDITIONAL FUNDING FROM

3093
02:22:27,692 --> 02:22:28,626
BROAD STAKEHOLDERS INCLUDING

3094
02:22:28,626 --> 02:22:29,961
ACADEMIA, PROFESSIONAL

3095
02:22:29,961 --> 02:22:32,563
SOCIETIES, ET CETERA, AND

3096
02:22:32,563 --> 02:22:34,499
INTERNATIONAL RESEARCH ENTITIES.

3097
02:22:34,499 --> 02:22:36,267
FINALLY WE'LL EXPAND

3098
02:22:36,267 --> 02:22:37,235
IMPLEMENTATION SCIENCE EFFORTS

3099
02:22:37,235 --> 02:22:39,670
AS WELL AS MECHANISTIC AND

3100
02:22:39,670 --> 02:22:41,606
CIRCADIAN MEDICINE RESEARCH

3101
02:22:41,606 --> 02:22:43,474
THROUGH COLLECTION OF

3102
02:22:43,474 --> 02:22:44,976
BIOSPECIMENS, IMAGING DATA,

3103
02:22:44,976 --> 02:22:45,610
WEARABLES.

3104
02:22:45,610 --> 02:22:49,714
SO IN SUMMARY WE'RE PROPOSING TO

3105
02:22:49,714 --> 02:22:51,115
RENEW, WHICH GENERATED NUMEROUS

3106
02:22:51,115 --> 02:22:54,752
TRIALS RESULTS, THAT CHANGED

3107
02:22:54,752 --> 02:22:55,853
NATIONAL AND INTERNATIONAL

3108
02:22:55,853 --> 02:22:56,521
GUIDELINES IN INFLUENCING

3109
02:22:56,521 --> 02:22:58,556
CLINICAL PROGRAM WITHOUT THIS

3110
02:22:58,556 --> 02:23:06,664
RENEWAL WE WORK CLINICIANS COULD

3111
02:23:06,664 --> 02:23:08,766
GO BACKWARDS TO EARLIER DAYS

3112
02:23:08,766 --> 02:23:11,035
CONDUCTING PROCEDURES WITHOUT

3113
02:23:11,035 --> 02:23:12,437
EFFICACY AND SAFETY.

3114
02:23:12,437 --> 02:23:14,305
THANK YOU FOR YOUR ATTENTION.

3115
02:23:14,305 --> 02:23:16,073
>> ONE QUESTION, IN
LOOKING AT

3116
02:23:16,073 --> 02:23:19,143
SOME OF THESE TRIALS, THEY LOOK

3117
02:23:19,143 --> 02:23:24,015
LIKE THEY WERE INVESTIGATING

3118
02:23:24,015 --> 02:23:25,049
KIND OF NOVEL THINGS THAT WOULD

3119
02:23:25,049 --> 02:23:27,151
HAVE BEEN -- THERE WOULD BE SOME

3120
02:23:27,151 --> 02:23:28,820
ADVANTAGE FOR THE COMPANIES THAT

3121
02:23:28,820 --> 02:23:30,455
MAKE THOSE VALVES, FOR EXAMPLE,

3122
02:23:30,455 --> 02:23:32,790
IS THERE A SEPARATE FUNDING

3123
02:23:32,790 --> 02:23:33,991
MECHANISM FOR THAT, YOU KNOW, IN

3124
02:23:33,991 --> 02:23:37,562
ORDER TO BE PART OF CTSN BUT THE

3125
02:23:37,562 --> 02:23:39,464
TRIAL PARTLY FUNDED BY THOSE

3126
02:23:39,464 --> 02:23:40,164
ORGANIZATIONS?

3127
02:23:40,164 --> 02:23:41,466
>> YEAH, THANK YOU FOR
THAT.

3128
02:23:41,466 --> 02:23:44,602
I'LL DO MY BEST TO ANSWER.

3129
02:23:44,602 --> 02:23:47,405
SO, WE HAVE SEVERAL OTHER

3130
02:23:47,405 --> 02:23:48,906
MECHANISMS FOR -- LIKE SMALL

3131
02:23:48,906 --> 02:23:52,477
BUSINESS, FOR EXAMPLE, THAT CAN

3132
02:23:52,477 --> 02:23:57,682
TEST THOSE AND DEVELOP THOSE

3133
02:23:57,682 --> 02:23:58,783
PROCEDURES OR WHATEVER IT IS

3134
02:23:58,783 --> 02:24:00,518
THAT'S DEVELOPED.

3135
02:24:00,518 --> 02:24:03,454
SO, YEAH, I THINK BEFORE THEY

3136
02:24:03,454 --> 02:24:04,755
ACTUALLY COME TO CTSN THEY NEED

3137
02:24:04,755 --> 02:24:10,995
TO BE TESTED IN SOME WAY, SO WE

3138
02:24:10,995 --> 02:24:13,631
WOULDN'T BE USING, AT LEAST I

3139
02:24:13,631 --> 02:24:18,703
DON'T THINK SO, WOULDN'T BE

3140
02:24:18,703 --> 02:24:20,071
USING FOR FIRST IN HUMAN TRIALS

3141
02:24:20,071 --> 02:24:24,275
BUT MORE OF A BROADER --

3142
02:24:24,275 --> 02:24:26,978
>> WHAT I CAN ADD, IS THAT
THERE

3143
02:24:26,978 --> 02:24:28,880
ARE PROTOCOLS DONE IN CTSNs

3144
02:24:28,880 --> 02:24:32,149
THAT ARE INDUSTRY FUNDED SO

3145
02:24:32,149 --> 02:24:34,619
THE -- WE FUND SOME TRIALS IN

3146
02:24:34,619 --> 02:24:39,524
CTSN BUT NOT ALL THE TRIALS IN

3147
02:24:39,524 --> 02:24:40,091
CTSA.

3148
02:24:40,091 --> 02:24:42,660
THAT'S SOMETHING WE WANT THE

3149
02:24:42,660 --> 02:24:43,761
INVESTIGATORS TO BE

3150
02:24:43,761 --> 02:24:45,496
ENTREPRENEURIAL AND IF WE INVEST

3151
02:24:45,496 --> 02:24:48,432
IN THE NETWORK AND THEY HAVE

3152
02:24:48,432 --> 02:24:49,967
THEM, THE INFRASTRUCTURE AND

3153
02:24:49,967 --> 02:24:51,402
CAPACITY, WE THINK THEY SHOULD

3154
02:24:51,402 --> 02:24:52,770
BECOME A GO-TO PLACE FOR

3155
02:24:52,770 --> 02:24:56,340
INDUSTRY TO COME AND SAY WE WANT

3156
02:24:56,340 --> 02:24:58,442
TO TEST OUR APPROACHES HERE.

3157
02:24:58,442 --> 02:25:04,849
NOW, WHAT WE SEE OFTEN IS THAT

3158
02:25:04,849 --> 02:25:07,184
THE INVESTIGATORS ARE INTERESTED

3159
02:25:07,184 --> 02:25:08,219
IN COMPARATIVE EFFECTIVENESS,

3160
02:25:08,219 --> 02:25:10,621
COMPANIES ARE NOT INTERESTED IN

3161
02:25:10,621 --> 02:25:11,222
COMPARATIVE EFFECTIVENESS

3162
02:25:11,222 --> 02:25:11,489
RESEARCH.

3163
02:25:11,489 --> 02:25:12,790
IF THEY HAVE A NEW VALVE THEY

3164
02:25:12,790 --> 02:25:15,259
DON'T WANT TO TEST AGAINST

3165
02:25:15,259 --> 02:25:16,427
ANOTHER VALVE, THEY JUST WANT TO

3166
02:25:16,427 --> 02:25:17,595
SEE DOES THEIR VALVE WORK.

3167
02:25:17,595 --> 02:25:19,997
THAT'S NOT THE QUESTION MOST OF

3168
02:25:19,997 --> 02:25:20,765
THESE INVESTIGATORS WITH

3169
02:25:20,765 --> 02:25:21,098
INTERESTED IN.

3170
02:25:21,098 --> 02:25:22,600
THEY WANT TO KNOW DOES IT WORK

3171
02:25:22,600 --> 02:25:24,835
BETTER THAN OR AS WELL AS

3172
02:25:24,835 --> 02:25:25,636
SOMETHING THAT'S ALREADY

3173
02:25:25,636 --> 02:25:25,903
AVAILABLE.

3174
02:25:25,903 --> 02:25:30,508
SO THEY ARE MORE INTERESTED IN

3175
02:25:30,508 --> 02:25:32,076
COMPARATIVE EFFECTIVENESS, SO

3176
02:25:32,076 --> 02:25:32,910
SOMETIMES THE DIVISIONS AND

3177
02:25:32,910 --> 02:25:38,049
MISSIONS DON'T ALIGN BUT WHEN

3178
02:25:38,049 --> 02:25:48,526
THEY DO THERE'S PARTNERSHIP.

3179
02:25:48,893 --> 02:25:50,428
>> WE JUST HAVE SOME
PEOPLE

3180
02:25:50,428 --> 02:25:53,431
FINISHING UP THEIR VOTING.

3181
02:25:53,431 --> 02:25:59,437
 

3182
02:25:59,437 --> 02:26:09,480
 

3183
02:26:32,036 --> 02:26:37,108
>> WE HAVE THE PROGRAM
OFFICIAL

3184
02:26:37,108 --> 02:26:39,844
HERE FROM CTSN, DR. KATHLEEN

3185
02:26:39,844 --> 02:26:41,612
FENTON, TO GIVE A LITTLE BIT

3186
02:26:41,612 --> 02:26:43,147
MORE ANSWER.

3187
02:26:43,147 --> 02:26:44,448
>> I WANTED TO ADD --
THANK YOU

3188
02:26:44,448 --> 02:26:46,951
FOR THE QUESTION, APPRECIATE IT.

3189
02:26:46,951 --> 02:26:48,686
ON THIS FUNDING CYCLE FOR

3190
02:26:48,686 --> 02:26:49,920
EXAMPLE THE CURRENT FUNDING

3191
02:26:49,920 --> 02:26:51,956
CYCLE WE HAVE HAD TWO TRIALS

3192
02:26:51,956 --> 02:26:54,558
THAT WERE BROUGHT IN BY SMALL

3193
02:26:54,558 --> 02:26:56,160
BUSINESSES, AND THE TRIAL

3194
02:26:56,160 --> 02:26:56,994
RESULTS HELPED THE BUSINESSES,

3195
02:26:56,994 --> 02:26:58,295
SORRY ABOUT THAT, I DON'T KNOW

3196
02:26:58,295 --> 02:27:01,966
HOW TO FIX IT, CONTRIBUTE TO THE

3197
02:27:01,966 --> 02:27:04,769
REGULATORY PAPERWORK FOR FDA.

3198
02:27:04,769 --> 02:27:12,343
ONE OF THEM WAS A TRIAL LOOKING

3199
02:27:12,343 --> 02:27:15,079
AT SOMATIC STEM CELLS, AND

3200
02:27:15,079 --> 02:27:18,816
ANOTHER ONE WAS LOOKING AT A

3201
02:27:18,816 --> 02:27:20,117
DEVICE.

3202
02:27:20,117 --> 02:27:21,185
SO AS DAVID MENTIONED, THE

3203
02:27:21,185 --> 02:27:23,521
BIG -- MOST OF THE BIG COMPANIES

3204
02:27:23,521 --> 02:27:25,322
LIKE MEDTRONIC AND ABBOTT HAVE

3205
02:27:25,322 --> 02:27:26,223
THEIR OWN TRIAL NETWORKS ALREADY

3206
02:27:26,223 --> 02:27:28,125
AND THEY HAVE THEIR WHOLE

3207
02:27:28,125 --> 02:27:28,359
SYSTEM.

3208
02:27:28,359 --> 02:27:29,260
SOME OF OUR INVESTIGATORS

3209
02:27:29,260 --> 02:27:31,829
ACTUALLY WORK WITH THEM AND WORK

3210
02:27:31,829 --> 02:27:33,097
WITH THE CTSN.

3211
02:27:33,097 --> 02:27:34,765
BUT THE SMALL COMPANIES REALLY

3212
02:27:34,765 --> 02:27:36,801
BENEFIT FROM BEING ABLE TO BRING

3213
02:27:36,801 --> 02:27:39,336
THINGS IN AND DO SORT OF SMALLER

3214
02:27:39,336 --> 02:27:41,205
TRIALS WITH US, IT'S NOT A

3215
02:27:41,205 --> 02:27:46,811
3,000-PATIENT TRIAL. 

3216
02:27:46,811 --> 02:27:57,154
IT'S A SMALL TRIAL.

3217
02:27:59,423 --> 02:28:01,559
>> THIRD ONE, 5128, THE
NEW

3218
02:28:01,559 --> 02:28:03,227
HEART HEALTH STUDY RENEWAL.

3219
02:28:03,227 --> 02:28:07,832
YOU HEARD ABOUT THIS FROM DR.

3220
02:28:07,832 --> 02:28:11,235
GIBBONS EARLIER TODAY AS WELL.

3221
02:28:11,235 --> 02:28:13,971
OBJECTIVE OF THE NEW MOM 2 BE IS

3222
02:28:13,971 --> 02:28:16,273
FOLLOW THIS RICHLY PHENOTYPED

3223
02:28:16,273 --> 02:28:18,242
COHORT OF WOMEN WHO HAVE BEEN

3224
02:28:18,242 --> 02:28:21,512
PART SINCE THE FIRST PREGNANCY,

3225
02:28:21,512 --> 02:28:24,448
FURTHER UNDERSTAND RELATIONSHIP

3226
02:28:24,448 --> 02:28:25,549
BETWEEN ADVERSE PREGNANCY

3227
02:28:25,549 --> 02:28:26,584
OUTCOMES AND CARDIOVASCULAR

3228
02:28:26,584 --> 02:28:30,488
DISEASE, BY ADVERSE WE MEAN

3229
02:28:30,488 --> 02:28:33,924
STILLBIRTH, SMALL FOR

3230
02:28:33,924 --> 02:28:36,427
GESTATIONAL AGE, PRE-TERM,

3231
02:28:36,427 --> 02:28:38,729
DISEASES PREGNANCY, GESTATIONAL

3232
02:28:38,729 --> 02:28:39,730
DIABETES.

3233
02:28:39,730 --> 02:28:41,031
WOMEN DONATED BIOSPECIMENS AND

3234
02:28:41,031 --> 02:28:43,701
DATA SINCE THIS STUDY INCEPTION

3235
02:28:43,701 --> 02:28:44,401
15 YEARS AGO.

3236
02:28:44,401 --> 02:28:46,103
AS A RESULT IMPORTANT

3237
02:28:46,103 --> 02:28:47,138
DISCOVERIES HAVE BEEN GLEANED

3238
02:28:47,138 --> 02:28:52,243
INCLUDING WHAT YOU HEARD EARLIER

3239
02:28:52,243 --> 02:28:57,681
SEMINAL FINDING WOMEN WITH

3240
02:28:57,681 --> 02:28:59,416
ADVERSE OUTCOMES 45% MORE RISK

3241
02:28:59,416 --> 02:29:01,152
THAN THOSE WITHOUT WITHOUT

3242
02:29:01,152 --> 02:29:04,488
ADVERSE PREGNANCY OUTCOMES TO

3243
02:29:04,488 --> 02:29:05,523
DEVELOP NEW ONSET HYPERTENSION

3244
02:29:05,523 --> 02:29:11,061
IN AS LITTLE AS 2 TO 7 YEARS

3245
02:29:11,061 --> 02:29:13,164
AFTER FIRST PREGNANCY, WOMEN

3246
02:29:13,164 --> 02:29:19,503
WITH AVERAGE OUTCOME MORE LIKELY

3247
02:29:19,503 --> 02:29:20,271
TO HAVE ATHEROGENIC

3248
02:29:20,271 --> 02:29:28,946
CHARACTERISTICS, HIGHER BLOOD

3249
02:29:28,946 --> 02:29:29,780
PRESSURES, GLUCOSE, LOWER

3250
02:29:29,780 --> 02:29:32,249
HDLs, IN PARTICULAR FOUND

3251
02:29:32,249 --> 02:29:37,788
HIGHER GLUCOSE AND HIGH

3252
02:29:37,788 --> 02:29:39,890
SENSITIVITY CRP WITH HIGHER RISK

3253
02:29:39,890 --> 02:29:41,158
OF HYPERTENSION 2 TO 7 YEARS

3254
02:29:41,158 --> 02:29:42,126
AFTER PREGNANCY.

3255
02:29:42,126 --> 02:29:45,129
THE PURPOSE OF THIS RENEWAL

3256
02:29:45,129 --> 02:29:45,496
SEVERAL FOLD.

3257
02:29:45,496 --> 02:29:48,666
NUMBER ONE, FURTHER ENHANCE AND

3258
02:29:48,666 --> 02:29:49,567
UNDERSTAND RISK FACTOR

3259
02:29:49,567 --> 02:29:51,235
PROGRESSION FROM ADVERSE

3260
02:29:51,235 --> 02:29:55,906
PREGNANCY OUTCOMES TO CARDIO AND

3261
02:29:55,906 --> 02:29:57,074
CEREBROVASCULAR DISEASE IN

3262
02:29:57,074 --> 02:29:57,641
PARTICIPANTS.

3263
02:29:57,641 --> 02:29:59,944
SECOND TO PROMOTE ADOPTION OF

3264
02:29:59,944 --> 02:30:01,579
HEALTHY LIFESTYLE BEHAVIORS

3265
02:30:01,579 --> 02:30:03,781
THROUGH HEALTH EDUCATION, VIA

3266
02:30:03,781 --> 02:30:05,616
VARIETY OF MODALITIES.

3267
02:30:05,616 --> 02:30:07,251
THIRD PROVIDE STATISTICAL POWER

3268
02:30:07,251 --> 02:30:09,320
TO PERFORM ANALYSES OF

3269
02:30:09,320 --> 02:30:11,822
PREDICTORS OF CLINICAL EVENTS.

3270
02:30:11,822 --> 02:30:15,826
FOURTH, STUDY PROGRESSION OF

3271
02:30:15,826 --> 02:30:16,827
SUBCLINICAL TO CLINICAL

3272
02:30:16,827 --> 02:30:18,629
CARDIOVASCULAR DISEASE, FIFTH TO

3273
02:30:18,629 --> 02:30:22,466
IDENTIFY NEW RISK FACTORS FOR

3274
02:30:22,466 --> 02:30:23,968
INTERACTIONS SUCH AS

3275
02:30:23,968 --> 02:30:26,470
PERIMENOPAUSE AMONG FACTORS THAT

3276
02:30:26,470 --> 02:30:27,338
INFORM DISEASE PATHOPHYSIOLOGY.

3277
02:30:27,338 --> 02:30:29,707
SO IN SUMMARY THIS RENEWAL WILL

3278
02:30:29,707 --> 02:30:33,277
CONTINUE THE FOLLOW-UP AND

3279
02:30:33,277 --> 02:30:33,911
REPEAT CLINICAL EXAMINATIONS

3280
02:30:33,911 --> 02:30:36,881
THAT WILL ADD TO RICH DATA AND

3281
02:30:36,881 --> 02:30:38,449
SAMPLES ALREADY AMASSED AND

3282
02:30:38,449 --> 02:30:41,719
ENABLE CAPTURE OF ADDITIONAL

3283
02:30:41,719 --> 02:30:43,387
DATA AS WOMEN ENTER

3284
02:30:43,387 --> 02:30:44,355
PERIMENOPAUSE AND MENOPAUSE, AN

3285
02:30:44,355 --> 02:30:45,589
IMPORTANT STAGE IN THEIR

3286
02:30:45,589 --> 02:30:48,459
LIFESPAN FOR STUDY TO UNCOVER

3287
02:30:48,459 --> 02:30:51,262
IMPACT OF BOTH PRIOR PREGNANCY

3288
02:30:51,262 --> 02:30:52,329
OUTCOMES AND NEW HORMONAL

3289
02:30:52,329 --> 02:30:55,032
CHANGES ON CARDIOVASCULAR HEALTH

3290
02:30:55,032 --> 02:30:57,635
AND OUTCOMES.

3291
02:30:57,635 --> 02:30:59,570
SO THAT WE WANT TO CAPTURE

3292
02:30:59,570 --> 02:31:01,038
CHANGES TO ADDRESS QUESTIONS

3293
02:31:01,038 --> 02:31:03,407
ABOUT THE DEVELOPMENT AND

3294
02:31:03,407 --> 02:31:04,608
PROGRESSION OF CLINICAL

3295
02:31:04,608 --> 02:31:05,676
CARDIOVASCULAR DISEASE AND

3296
02:31:05,676 --> 02:31:06,176
RELATED CONDITIONS.

3297
02:31:06,176 --> 02:31:08,913
SO THANK YOU FOR YOUR ATTENTION.

3298
02:31:08,913 --> 02:31:10,948
THIS CONCEPT IS OPEN FOR

3299
02:31:10,948 --> 02:31:14,318
COMMENTS, DISCUSSIONS, VOTING.

3300
02:31:14,318 --> 02:31:15,786
>> I HAVE A QUESTION.

3301
02:31:15,786 --> 02:31:20,624
CAN YOU COMMENT ON THE BUDGETARY

3302
02:31:20,624 --> 02:31:21,959
PLAN, LIKE THE CONTRACTING OUT

3303
02:31:21,959 --> 02:31:24,194
AND WHAT THE THOUGHT PROCESS FOR

3304
02:31:24,194 --> 02:31:30,167
THAT IS?

3305
02:31:30,167 --> 02:31:30,567
>> YES.

3306
02:31:30,567 --> 02:31:36,740
THIS IS MEANT TO BE -- THANK

3307
02:31:36,740 --> 02:31:46,850
YOU. 

3308
02:31:49,019 --> 02:31:50,421
THIS IS OPEN SESSION, RIGHT?

3309
02:31:50,421 --> 02:31:52,723
I WANT TO MAKE SURE.

3310
02:31:52,723 --> 02:31:55,426
OKAY.

3311
02:31:55,426 --> 02:32:03,467
SORRY, WHY ARE WE BEING -- YES,

3312
02:32:03,467 --> 02:32:06,303
SO THIS IS GOING TO BE CHANGED,

3313
02:32:06,303 --> 02:32:07,571
CURRENTLY COOPERATIVE AGREEMENT,

3314
02:32:07,571 --> 02:32:09,073
WE'RE CHANGING -- PROPOSING TO

3315
02:32:09,073 --> 02:32:12,776
HAVE IT CHANGED TO A CONTRACT.

3316
02:32:12,776 --> 02:32:14,712
AND ALSO PROPOSED TO BE A SINGLE

3317
02:32:14,712 --> 02:32:17,648
CONTRACT AND THEN WILL HAVE

3318
02:32:17,648 --> 02:32:19,984
SUBCONTRACTS TO THE DIFFERENT

3319
02:32:19,984 --> 02:32:21,251
CENTERS THAT COLLECT THE DATA.

3320
02:32:21,251 --> 02:32:22,920
DOES THAT ANSWER YOUR QUESTION?

3321
02:32:22,920 --> 02:32:31,061
>> YES. 

3322
02:32:31,061 --> 02:32:32,162
>> [OFF MICROPHONE].

3323
02:32:32,162 --> 02:32:35,032
>> YES, WE WANT TO KEEP
THE --

3324
02:32:35,032 --> 02:32:40,070
FOR NOW WE WANT TO KEEP THE

3325
02:32:40,070 --> 02:32:41,638
STRUCTURE SIMILAR TO THE

3326
02:32:41,638 --> 02:32:42,272
COOPERATIVE AGREEMENT.

3327
02:32:42,272 --> 02:32:44,908
THE CURRENT IS THE SAME THING,

3328
02:32:44,908 --> 02:32:45,876
WHERE THE CENTERS --

3329
02:32:45,876 --> 02:32:47,711
COORDINATING CENTERS ARE THE

3330
02:32:47,711 --> 02:32:50,347
PRIMARY FUNDERS AND THEN THEY

3331
02:32:50,347 --> 02:32:53,150
PAY OUT THE FIELD CENTERS.

3332
02:32:53,150 --> 02:32:54,218
SO, YEAH.

3333
02:32:54,218 --> 02:32:54,718
THANKS.

3334
02:32:54,718 --> 02:32:56,820
>> SO I THINK THE QUESTION
MIGHT

3335
02:32:56,820 --> 02:32:58,789
BE WHY CHANGE FROM COOPERATIVE

3336
02:32:58,789 --> 02:32:59,656
AGREEMENT TO CONTRACT, AND THIS

3337
02:32:59,656 --> 02:33:02,593
IS KIND OF NORMATIVE WITH OUR

3338
02:33:02,593 --> 02:33:03,427
OTHER LARGE COHORTS.

3339
02:33:03,427 --> 02:33:09,133
SO IF YOU THINK ABOUT OUR COHORT

3340
02:33:09,133 --> 02:33:13,270
PORTFOLIO, FRAMINGHAM, JACKSON,

3341
02:33:13,270 --> 02:33:14,104
MESA, ERICK, CARDIA, SOUL, THEY

3342
02:33:14,104 --> 02:33:15,873
ARE CONTRACTS.

3343
02:33:15,873 --> 02:33:17,474
THE REASON WE TAKE THIS

3344
02:33:17,474 --> 02:33:21,612
APPROACH, BEFORE I GOT HERE, SO

3345
02:33:21,612 --> 02:33:23,981
IT'S HISTORICAL IN NATURE, IT

3346
02:33:23,981 --> 02:33:25,549
PROVIDES A COUPLE -- MANY

3347
02:33:25,549 --> 02:33:28,152
ADVANTAGES TO THE INSTITUTE.

3348
02:33:28,152 --> 02:33:33,323
ONE IS WE HAVE GREATER ABILITY

3349
02:33:33,323 --> 02:33:35,959
TO PARTICIPATE ACTIVELY IN THE

3350
02:33:35,959 --> 02:33:39,596
SCIENCE OF THE CONTRACT IN TERMS

3351
02:33:39,596 --> 02:33:41,632
OF GUIDING WHAT HAPPENS WITHIN

3352
02:33:41,632 --> 02:33:42,466
THE COHORT.

3353
02:33:42,466 --> 02:33:50,274
WE ALSO -- DATA AND BIOSPECIMENS

3354
02:33:50,274 --> 02:33:51,341
WE MAIN UNDER MORE GOVERNMENTAL

3355
02:33:51,341 --> 02:33:52,776
CONTROL, IF YOU WILL, IN TERMS

3356
02:33:52,776 --> 02:33:56,080
OF LONG-TERM MANAGEMENT OF THE

3357
02:33:56,080 --> 02:33:58,082
RESEWERS. -- RESOURCE.

3358
02:33:58,082 --> 02:34:01,351
AT THE END OF SUN SETTING THE

3359
02:34:01,351 --> 02:34:03,954
COHORT THE BIOSPECIMENS AND THE

3360
02:34:03,954 --> 02:34:05,456
DATA ARE ACTUALLY GOVERNMENT

3361
02:34:05,456 --> 02:34:08,058
PROPERTY AS DELIVERABLES FROM

3362
02:34:08,058 --> 02:34:08,725
THE CONTRACT.

3363
02:34:08,725 --> 02:34:14,465
IT ALSO MAKES IT POSSIBLE FOR US

3364
02:34:14,465 --> 02:34:20,938
TO REALLY KIND OF GUARD AGAINST

3365
02:34:20,938 --> 02:34:22,106
VAGARIES OF ASSIGNMENT OF

3366
02:34:22,106 --> 02:34:25,609
APPLICATIONS FOR CORE SUPPORT

3367
02:34:25,609 --> 02:34:28,712
FOR THE COHORTS TO PEER REVIEW.

3368
02:34:28,712 --> 02:34:29,913
NOW, THE SCIENTIFIC COMPONENTS

3369
02:34:29,913 --> 02:34:36,487
GET ADDED ON BY ANCILLARY

3370
02:34:36,487 --> 02:34:36,720
STUDIES.

3371
02:34:36,720 --> 02:34:39,923
AND THAT GETS INFORMED BY PEER

3372
02:34:39,923 --> 02:34:41,458
REVIEW, BUT THE CORE

3373
02:34:41,458 --> 02:34:46,130
INFRASTRUCTURE OF THE COHORT,

3374
02:34:46,130 --> 02:34:47,131
ONGOING FOLLOW-UP, RETENTION,

3375
02:34:47,131 --> 02:34:49,566
MANAGEMENT OF THE DATA

3376
02:34:49,566 --> 02:34:50,267
REPOSITORY AND BIOREPOSITORY,

3377
02:34:50,267 --> 02:34:52,236
THOSE ARE IN THE BEST INTEREST

3378
02:34:52,236 --> 02:34:58,275
ST INSTITUTE AND WE BELIEVE THE

3379
02:34:58,275 --> 02:34:59,510
TAXPAYERS TO MAINTAIN UNDER

3380
02:34:59,510 --> 02:35:01,145
CONTRACT MECHANISM WHILE

3381
02:35:01,145 --> 02:35:02,546
ALLOWING THE SCIENCE TO EVOLVE

3382
02:35:02,546 --> 02:35:07,184
AND BE THE BEST SCIENCE

3383
02:35:07,184 --> 02:35:08,819
INVESTIGATORS CAN PROPOSE

3384
02:35:08,819 --> 02:35:09,620
THROUGH THE

3385
02:35:09,620 --> 02:35:10,187
INVESTIGATOR-INITIATED PEER

3386
02:35:10,187 --> 02:35:11,221
REVIEW SYSTEM.

3387
02:35:11,221 --> 02:35:13,657
SO I HOPE THAT HELPS IN

3388
02:35:13,657 --> 02:35:16,527
DESCRIBING WHY WE HAVE CORE

3389
02:35:16,527 --> 02:35:17,127
CONTRACTS FOR INFRASTRUCTURE

3390
02:35:17,127 --> 02:35:19,897
LAYERED ON TOP OF THAT ANCILLARY

3391
02:35:19,897 --> 02:35:21,832
STUDIES TO R01s TO STRENGTHEN

3392
02:35:21,832 --> 02:35:24,134
THE SCIENCE.

3393
02:35:24,134 --> 02:35:27,204
 

3394
02:35:27,204 --> 02:35:28,438
>> THANK YOU.

3395
02:35:28,438 --> 02:35:30,307
AND THANK YOU, I THINK IN TERMS

3396
02:35:30,307 --> 02:35:32,075
OF THE CONFLICT WE FOUND OUT

3397
02:35:32,075 --> 02:35:41,618
THAT IT WAS OKAY FOR -- SHE JUST

3398
02:35:41,618 --> 02:35:43,020
CAN'T VOTE, I THINK THAT'S

3399
02:35:43,020 --> 02:35:44,788
SQUARED AWAY.

3400
02:35:44,788 --> 02:35:47,457
READY TO MOVE ON.

3401
02:35:47,457 --> 02:35:50,194
THOSE THREE ARE PRETTY MUCH THE

3402
02:35:50,194 --> 02:35:51,795
HUGE INITIATIVES, AS YOU

3403
02:35:51,795 --> 02:35:52,496
NOTICED.

3404
02:35:52,496 --> 02:35:57,534
I'M GOING TO GO ON WITH

3405
02:35:57,534 --> 02:35:59,136
SECONDARY PARTICIPATION.

3406
02:35:59,136 --> 02:36:02,839
SO THIS IS IDS 51378 SECONDARY

3407
02:36:02,839 --> 02:36:04,441
PARTICIPATION IN RENEWAL,

3408
02:36:04,441 --> 02:36:08,045
LIMITED COMPETITION FOR NATIONAL

3409
02:36:08,045 --> 02:36:09,346
SWINE CENTER, SECONDARY

3410
02:36:09,346 --> 02:36:10,914
PARTICIPATION OF AN INITIATIVE

3411
02:36:10,914 --> 02:36:14,117
LED BY THE NIH OFFICE OF

3412
02:36:14,117 --> 02:36:14,952
RESEARCH INFRASTRUCTURE PROGRAM,

3413
02:36:14,952 --> 02:36:16,453
NIH OFFICE OF DIRECTOR.

3414
02:36:16,453 --> 02:36:18,889
THE PURPOSE OF THIS INITIATIVE

3415
02:36:18,889 --> 02:36:21,225
IS TO PROVIDE CONTINUOUS SUPPORT

3416
02:36:21,225 --> 02:36:23,860
FOR NATIONAL SWINE RESOURCE AND

3417
02:36:23,860 --> 02:36:27,030
RESEARCH CENTER.

3418
02:36:27,030 --> 02:36:30,167
TO INCREASE UNDERSTANDING OF

3419
02:36:30,167 --> 02:36:31,702
HUMAN HEALTH AND DISEASE YOU

3420
02:36:31,702 --> 02:36:34,538
BOUGH SWINE MODELS FOR

3421
02:36:34,538 --> 02:36:38,242
BIOMEDICAL RESEARCH, CREATES

3422
02:36:38,242 --> 02:36:41,578
GENETICALLY MODIFIED MODELS AS

3423
02:36:41,578 --> 02:36:43,180
REQUESTED BY SCIENTIFIC

3424
02:36:43,180 --> 02:36:44,214
COMMUNITY, REPOSITORY AND

3425
02:36:44,214 --> 02:36:45,882
DISTRIBUTION CENTER, AS WELL AS

3426
02:36:45,882 --> 02:36:48,352
OTHER RESOURCES SUCH AS REAGENTS

3427
02:36:48,352 --> 02:36:51,054
AND CULTURES INCLUDING CELLS,

3428
02:36:51,054 --> 02:36:52,856
TISSUES, ORGANS, THAT SERVE THE

3429
02:36:52,856 --> 02:36:54,324
BIOMEDICAL COMMUNITY AT LARGE.

3430
02:36:54,324 --> 02:36:57,961
THE CENTER IS THE ONLY PUBLICLY

3431
02:36:57,961 --> 02:36:59,763
FUNDED SWINE FACILITY TO SERVE

3432
02:36:59,763 --> 02:37:02,532
AS A REPOSITORY FOR NEW SWINE

3433
02:37:02,532 --> 02:37:05,602
MODELS GENERATED BY ACADEMIC

3434
02:37:05,602 --> 02:37:11,742
RESEARCHERS AND RESOURCE FOR

3435
02:37:11,742 --> 02:37:13,343
INBRED OR GENETICALLY ALTERED

3436
02:37:13,343 --> 02:37:13,777
MODELS.

3437
02:37:13,777 --> 02:37:15,746
THERE'S A GROWING AWARENESS OF

3438
02:37:15,746 --> 02:37:22,119
LARGE ANIMAL MODELS FOR USE IN

3439
02:37:22,119 --> 02:37:24,855
EXPEDITING BASIC RESEARCH TO

3440
02:37:24,855 --> 02:37:26,156
FIND CURES AND THERAPIES FOR

3441
02:37:26,156 --> 02:37:26,590
HOME.

3442
02:37:26,590 --> 02:37:28,025
THEY ARE CLOSELY RELATED TO

3443
02:37:28,025 --> 02:37:32,262
HUMANS IN TERMS OF ANATOMY,

3444
02:37:32,262 --> 02:37:33,130
GENETICS, PHYSIOLOGY, WITH

3445
02:37:33,130 --> 02:37:41,605
ORGANS SHARING COMMON FUNCTIONAL

3446
02:37:41,605 --> 02:37:43,640
FEATURES, IDEAL MODEL, A

3447
02:37:43,640 --> 02:37:46,043
CLINICAL RESOURCE FOR

3448
02:37:46,043 --> 02:37:48,679
UNDERSTANDING HUMAN BIOLOGY TO

3449
02:37:48,679 --> 02:37:50,447
REDUCE CORONARY ARTERY DISEASE,

3450
02:37:50,447 --> 02:37:52,249
DIABETES, OBESITY, HYPERTENSION,

3451
02:37:52,249 --> 02:37:58,021
HEART AND LUNG TRANSPLANTATION,

3452
02:37:58,021 --> 02:37:59,790
XENOTRANSPLANTATION, HEMOPHILIA

3453
02:37:59,790 --> 02:38:01,224
AND OTHER DISEASES, RESOURCE OF

3454
02:38:01,224 --> 02:38:01,925
INFLAMMATION AND TRAINING

3455
02:38:01,925 --> 02:38:04,428
RELATED TO USE OF THESE ANIMALS

3456
02:38:04,428 --> 02:38:06,096
IN BIOMEDICAL RESEARCH AS MODELS

3457
02:38:06,096 --> 02:38:08,465
OF HUMAN HEALTH AND DISEASE FOR

3458
02:38:08,465 --> 02:38:10,400
THE BROADER RESEARCH COMMUNITY.

3459
02:38:10,400 --> 02:38:13,036
AND HAVE FORMED CUTTING EMBEDDED

3460
02:38:13,036 --> 02:38:14,204
RESEARCH TO ADVANCE TECHNOLOGY

3461
02:38:14,204 --> 02:38:15,472
IN THIS AREA.

3462
02:38:15,472 --> 02:38:17,808
IN SUMMARY WE'RE PROPOSING TO

3463
02:38:17,808 --> 02:38:19,409
CO-FUND RENEWAL OF THE CENTER,

3464
02:38:19,409 --> 02:38:21,778
SO IT CAN CONTINUE TO SERVE AS

3465
02:38:21,778 --> 02:38:24,614
CENTRAL RESOURCE FOR THE

3466
02:38:24,614 --> 02:38:27,250
CREATION OF GENETICALLY MODIFIED

3467
02:38:27,250 --> 02:38:29,453
SWINE REAGENTS AND PROCUREMENT,

3468
02:38:29,453 --> 02:38:31,254
PRESERVATION, DISTRIBUTION OF

3469
02:38:31,254 --> 02:38:32,989
SWINE AND BIOLOGICAL MATERIALS

3470
02:38:32,989 --> 02:38:34,358
TO INVESTIGATORS THROUGHOUT THE

3471
02:38:34,358 --> 02:38:34,725
COUNTRY.

3472
02:38:34,725 --> 02:38:36,193
THANK YOU FOR YOUR ATTENTION.

3473
02:38:36,193 --> 02:38:46,370
THIS IS OPEN FOR COMMENTS,

3474
02:38:46,370 --> 02:38:49,005
QUESTIONS, VOTING.

3475
02:38:49,005 --> 02:38:49,172
YES.

3476
02:38:49,172 --> 02:38:51,141
 

3477
02:38:51,141 --> 02:38:53,777
>> [OFF MICROPHONE].

3478
02:38:53,777 --> 02:38:59,783
 

3479
02:38:59,783 --> 02:39:09,826
 

3480
02:39:12,262 --> 02:39:13,096
>> THE QUESTION, WHAT

3481
02:39:13,096 --> 02:39:15,465
PROPORTION, IT LOOKED LIKE A LOT

3482
02:39:15,465 --> 02:39:18,602
OF INSTITUTES ARE BENEFITING

3483
02:39:18,602 --> 02:39:19,503
FROM THE SWINE MODEL.

3484
02:39:19,503 --> 02:39:24,141
DO YOU KNOW WHAT  PORTION IS

3485
02:39:24,141 --> 02:39:25,509
COVERED BY NHLBI VERSUS OTHER

3486
02:39:25,509 --> 02:39:27,811
INSTITUTES?

3487
02:39:27,811 --> 02:39:30,080
 

3488
02:39:30,080 --> 02:39:32,015
>> I WAS GOING TO LOOK IT
UP.

3489
02:39:32,015 --> 02:39:33,583
THANK YOU.

3490
02:39:33,583 --> 02:39:36,286
19% IS THE ANSWER.

3491
02:39:36,286 --> 02:39:38,388
 

3492
02:39:38,388 --> 02:39:40,924
>> A QUICK QUESTION
REGARDING

3493
02:39:40,924 --> 02:39:41,958
THE COMPETITION.

3494
02:39:41,958 --> 02:39:44,694
>> YES PLEASE, GO AHEAD.

3495
02:39:44,694 --> 02:39:48,532
>> I KNOW YOU SAY LIMITED

3496
02:39:48,532 --> 02:39:51,368
COMPETITION, I'VE SEEN LIMITED

3497
02:39:51,368 --> 02:39:53,170
COMPETITION APPLICATIONS ONLY

3498
02:39:53,170 --> 02:39:57,641
ONE ENTITY OR INSTITUTION WAS

3499
02:39:57,641 --> 02:40:00,143
ALLOWED TO APPLY.

3500
02:40:00,143 --> 02:40:02,712
HOW MANY INSTITUT NATIONAL

3501
02:40:02,712 --> 02:40:03,814
TUITIONS OR ENTITIES ARE ALLOWED

3502
02:40:03,814 --> 02:40:05,482
IN THIS?

3503
02:40:05,482 --> 02:40:07,150
>> LIMITED COMPETITION IS
FOR

3504
02:40:07,150 --> 02:40:09,786
THE CENTER, TO RENEW CENTER TO

3505
02:40:09,786 --> 02:40:10,821
PROVIDE RESOURCE.

3506
02:40:10,821 --> 02:40:13,356
SO ONCE IT'S RENEWED THEN PRETTY

3507
02:40:13,356 --> 02:40:16,193
MUCH OPENED UP THE APPLICATIONS,

3508
02:40:16,193 --> 02:40:18,462
RESOURCES OPEN UP TO THE ENTIRE

3509
02:40:18,462 --> 02:40:19,763
U.S., THE RESEARCH COMMUNITY,

3510
02:40:19,763 --> 02:40:20,697
HOPE THAT HELPS.

3511
02:40:20,697 --> 02:40:21,131
>> IT DOES.

3512
02:40:21,131 --> 02:40:29,539
THANK YOU. 

3513
02:40:29,539 --> 02:40:39,583
 

3514
02:40:54,698 --> 02:40:58,335
>> MOVING TO CONCEPT FIVE.

3515
02:40:58,335 --> 02:41:01,037
THIS IS IDS 5127, STIMULATING

3516
02:41:01,037 --> 02:41:06,776
ACCESS TO RESEARCH AND RESIDENCY

3517
02:41:06,776 --> 02:41:09,513
TRANSFER SCHOLAR, START FOR

3518
02:41:09,513 --> 02:41:09,846
SHORT.

3519
02:41:09,846 --> 02:41:12,616
MOVING, OBJECTIVE GOAL OF THE K

3520
02:41:12,616 --> 02:41:15,919
88 STIMULATING ACCESS TO

3521
02:41:15,919 --> 02:41:17,387
RESEARCH AND RESIDENCY

3522
02:41:17,387 --> 02:41:19,122
TRANSITION SCHOLAR, START,

3523
02:41:19,122 --> 02:41:19,956
CAREER DEVELOPMENT PROGRAM TO

3524
02:41:19,956 --> 02:41:23,059
HELP ENSURE MULTIPLE POOLS OF

3525
02:41:23,059 --> 02:41:24,361
HIGHLY TRAINED SCIENTISTS

3526
02:41:24,361 --> 02:41:25,495
AVAILABLE IN APPROPRIATE

3527
02:41:25,495 --> 02:41:27,130
SCIENTIFIC DISCIPLINES TO

3528
02:41:27,130 --> 02:41:29,399
ADDRESS THE NATION'S BIOMEDICAL,

3529
02:41:29,399 --> 02:41:30,834
BEHAVIORAL, CLINICAL RESEARCH

3530
02:41:30,834 --> 02:41:31,167
NEEDS.

3531
02:41:31,167 --> 02:41:34,237
AS YOU KNOW, NIH INSTITUTES AND

3532
02:41:34,237 --> 02:41:37,274
CENTERS SUPPORT A VARIETY OF

3533
02:41:37,274 --> 02:41:39,442
MENTORED AND NON-MENTORED CAREER

3534
02:41:39,442 --> 02:41:41,611
DEVELOPMENT AWARD PROGRAMS,

3535
02:41:41,611 --> 02:41:43,880
DESIGNED TO FOSTER TRANSITION OF

3536
02:41:43,880 --> 02:41:48,251
NEW INVESTIGATORS TO RESEARCH

3537
02:41:48,251 --> 02:41:50,687
INDEPENDENCE AND ALSO SUPPORT IN

3538
02:41:50,687 --> 02:41:52,389
ACHIVING OBJECTIVES.

3539
02:41:52,389 --> 02:41:57,661
SO THE PURPOSE FOR THIS

3540
02:41:57,661 --> 02:41:58,061
PARTICULAR --

3541
02:41:58,061 --> 02:42:08,305
[ NO AUDIO ] 

3542
02:42:08,672 --> 02:42:10,106
HERE WE GO.

3543
02:42:10,106 --> 02:42:12,442
THIS PROGRAM PROVIDES INDIVIDUAL

3544
02:42:12,442 --> 02:42:14,844
MENTORED AWARDS TO RETAIN AND

3545
02:42:14,844 --> 02:42:17,347
SUPPORT CLINICIAN INVESTIGATORS

3546
02:42:17,347 --> 02:42:19,983
WHO HAVE SUCCESSFULLY COMPLETED

3547
02:42:19,983 --> 02:42:22,652
AND R 38 STAR PROGRAM, FOCUSED

3548
02:42:22,652 --> 02:42:25,789
ON RESIDENCY PREFERRED.

3549
02:42:25,789 --> 02:42:28,258
SO TO PROVIDE OPPORTUNITIES FOR

3550
02:42:28,258 --> 02:42:30,961
ADDITIONAL RESEARCH AND CAREER

3551
02:42:30,961 --> 02:42:32,362
DEVELOPMENT DURING SUBSEQUENT

3552
02:42:32,362 --> 02:42:33,830
CLINICAL FELLOWSHIPS OR EARLY

3553
02:42:33,830 --> 02:42:36,466
CAREER FACULTY, ANTICIPATED THAT

3554
02:42:36,466 --> 02:42:39,169
THE K 38 STAR PROGRAM WILL

3555
02:42:39,169 --> 02:42:41,605
PROVIDE PATHWAY TO RETAIN NEWLY

3556
02:42:41,605 --> 02:42:43,540
CREATED POOL OF INVESTIGATORS

3557
02:42:43,540 --> 02:42:46,276
GENERATED IN THE R 36 STAR

3558
02:42:46,276 --> 02:42:46,843
PROGRAM.

3559
02:42:46,843 --> 02:42:48,078
GRANTEES WOULD RECEIVE SUPPORT

3560
02:42:48,078 --> 02:42:49,913
FOR CONTINUED RESEARCH AND

3561
02:42:49,913 --> 02:42:51,247
CAREER DEVELOPMENT OPPORTUNITIES

3562
02:42:51,247 --> 02:42:56,319
AND BASIC CLINICAL AND/OR

3563
02:42:56,319 --> 02:42:57,621
TRANSLATIONAL RESEARCH,

3564
02:42:57,621 --> 02:42:59,022
PROVIDING POTENTIAL TO

3565
02:42:59,022 --> 02:42:59,556
ACCELERATE TRANSITION TO

3566
02:42:59,556 --> 02:43:01,558
INDEPENDENT RESEARCH CAREERS.

3567
02:43:01,558 --> 02:43:03,960
THIS AWARD SUPPORTS UP TO 28

3568
02:43:03,960 --> 02:43:05,662
MONTHS OF RESEARCH IN CAREER

3569
02:43:05,662 --> 02:43:08,164
DEVELOPMENT WITH SAME OR NEW

3570
02:43:08,164 --> 02:43:11,234
PRIMARY MENTOR DEPARTMENT AND/OR

3571
02:43:11,234 --> 02:43:16,272
INSTITUTION, AS THAT OF THE R

3572
02:43:16,272 --> 02:43:16,940
38.

3573
02:43:16,940 --> 02:43:19,242
PROVIDING A 75% OF SUPPORTED

3574
02:43:19,242 --> 02:43:20,477
TIME WHILE FACULTY ARE PROVIDED

3575
02:43:20,477 --> 02:43:22,245
50% AT THE SUPPORTED TIME FROM

3576
02:43:22,245 --> 02:43:23,780
THE AWARD.

3577
02:43:23,780 --> 02:43:26,282
THE AWARD INCLUDES RESEARCH

3578
02:43:26,282 --> 02:43:28,485
DEVELOPMENT FUNDS TO UNCOVER

3579
02:43:28,485 --> 02:43:30,320
COST OF RESEARCH SUPPLIES,

3580
02:43:30,320 --> 02:43:31,221
PROFESSIONAL DEVELOPMENT

3581
02:43:31,221 --> 02:43:32,288
ACTIVITIES, APPLICANTS ARE

3582
02:43:32,288 --> 02:43:34,524
STRONGLY ENCOURAGED TO PREPARE

3583
02:43:34,524 --> 02:43:36,393
AND SUBMIT APPLICATION FOR

3584
02:43:36,393 --> 02:43:39,362
ANOTHER MENTOR RESEARCH CAREER

3585
02:43:39,362 --> 02:43:46,569
DEVELOPMENT AWARD SUCH AS K01,

3586
02:43:46,569 --> 02:43:47,704
K23, ET CETERA, BEFORE THE END

3587
02:43:47,704 --> 02:43:49,205
OF THE PROGRAM.

3588
02:43:49,205 --> 02:43:53,043
TO DATE 15 OF THE R 38 PROGRAM

3589
02:43:53,043 --> 02:43:56,012
GRADUATES APPLIED TO THIS K 38

3590
02:43:56,012 --> 02:43:58,882
PROGRAM WITH 12 SUCCESSFULLY

3591
02:43:58,882 --> 02:44:00,283
OBTAINING FUNDING, ADDITIONAL

3592
02:44:00,283 --> 02:44:05,755
FIVE HAVE APPLIED IN FY 25, SO

3593
02:44:05,755 --> 02:44:08,458
THIS NUMBER OF APPLICATIONS WITH

3594
02:44:08,458 --> 02:44:10,427
THE K 38 REFLECTS APPROXIMATELY

3595
02:44:10,427 --> 02:44:13,697
30% OF THE ELIGIBLE R 38

3596
02:44:13,697 --> 02:44:15,632
GRADUATES, AND SO A LARGE

3597
02:44:15,632 --> 02:44:16,633
PROPORTION REMAIN IN FELLOWSHIP

3598
02:44:16,633 --> 02:44:18,968
TRAINING AND HAVE YET TO PURSUE

3599
02:44:18,968 --> 02:44:24,507
ANY GRANT FUNDING YET WHILE MANY

3600
02:44:24,507 --> 02:44:29,112
OTHERS OBTAINED T32, K12s, ET

3601
02:44:29,112 --> 02:44:29,546
CETERA.

3602
02:44:29,546 --> 02:44:31,081
WE'RE LOOKING FORWARD TO

3603
02:44:31,081 --> 02:44:32,282
RENEWING TO OPEN UP THIS

3604
02:44:32,282 --> 02:44:32,582
OPPORTUNITY.

3605
02:44:32,582 --> 02:44:35,985
THANK YOU.

3606
02:44:35,985 --> 02:44:38,188
>> I LOVE THIS.

3607
02:44:38,188 --> 02:44:40,156
I REALLY THINK SUPPORTING OUR

3608
02:44:40,156 --> 02:44:42,358
PIPELINE IS CRITICAL.

3609
02:44:42,358 --> 02:44:44,360
YOU'VE ALREADY PRE-SELECTED BY

3610
02:44:44,360 --> 02:44:48,298
THE FACT THESE ARE TRAINEES WHO

3611
02:44:48,298 --> 02:44:50,033
ALREADY SUCCESSFULLY HAVE GONE

3612
02:44:50,033 --> 02:44:53,903
THROUGH THE R 38 PROGRAM, SO I

3613
02:44:53,903 --> 02:44:55,805
THINK DEVELOPING A MECHANISM TO

3614
02:44:55,805 --> 02:44:57,574
CONTINUE THEIR SUPPORT IS SO

3615
02:44:57,574 --> 02:44:59,042
IMPORTANT, AND EVEN MORE

3616
02:44:59,042 --> 02:45:01,911
IMPORTANT IN THESE CURRENT

3617
02:45:01,911 --> 02:45:03,179
TIMES.

3618
02:45:03,179 --> 02:45:09,919
THANK YOU. 

3619
02:45:09,919 --> 02:45:20,430
>> THANK YOU, DR. SCHNAPP.

3620
02:45:30,039 --> 02:45:31,574
>> WE'RE HAVING A PROBLEM
WITH

3621
02:45:31,574 --> 02:45:40,483
THE MICS.

3622
02:45:40,483 --> 02:45:41,651
SOMETHING'S HAPPENING OVERALL.

3623
02:45:41,651 --> 02:45:44,420
WE'LL BE SHARING UNTIL THEY CAN

3624
02:45:44,420 --> 02:45:52,962
FIGURE OUT SOMETHING. 

3625
02:45:52,962 --> 02:46:03,006
 

3626
02:46:16,953 --> 02:46:20,657
>> I'M GOING TO DO CONCEPT
8.

3627
02:46:20,657 --> 02:46:26,095
THIS IS ALSO ONE WHERE NHLBI IS

3628
02:46:26,095 --> 02:46:27,964
PRIMARY, SECONDARY ANALYSIS OF

3629
02:46:27,964 --> 02:46:29,299
EXISTING DATASETS, HEART, LUNG

3630
02:46:29,299 --> 02:46:33,503
AND BLOOD DISEASES AND SLEEP

3631
02:46:33,503 --> 02:46:33,937
DISORDERS.

3632
02:46:33,937 --> 02:46:39,509
SO THIS IS AN NHLBI-LED R21,

3633
02:46:39,509 --> 02:46:42,345
RENEWAL OF INITIATIVE AIMS TO

3634
02:46:42,345 --> 02:46:44,681
CONTINUE ENCOURAGING INNOVATIVE

3635
02:46:44,681 --> 02:46:45,682
SECONDARY DATA ANALYSIS TO

3636
02:46:45,682 --> 02:46:48,151
ADDRESS GAPS IN KNOWLEDGE AND

3637
02:46:48,151 --> 02:46:49,219
IMPORTANT SCIENTIFIC QUESTIONS

3638
02:46:49,219 --> 02:46:51,688
WITHIN OUR MISSION.

3639
02:46:51,688 --> 02:46:54,090
IT SEEKS TO PROVIDE

3640
02:46:54,090 --> 02:46:55,024
INVESTIGATORS ESPECIALLY EARLY

3641
02:46:55,024 --> 02:46:57,427
STAGE INVESTIGATORS WITH ABILITY

3642
02:46:57,427 --> 02:47:04,701
TO OBTAIN PRELIMINARY DATA

3643
02:47:04,701 --> 02:47:05,835
FOSTERING DEVELOPMENT OF

3644
02:47:05,835 --> 02:47:07,503
PROJECTS AND FURTHERING RESEARCH

3645
02:47:07,503 --> 02:47:08,104
CAREERS.

3646
02:47:08,104 --> 02:47:10,874
THIS PROGRAM WHICH INITIALLY

3647
02:47:10,874 --> 02:47:12,642
STARTED IN 2012 SUPPORTS R21

3648
02:47:12,642 --> 02:47:15,144
AWARDS FOR TWO YEARS WITH NO

3649
02:47:15,144 --> 02:47:17,180
MORE THAN $75,000 IN DIRECT COST

3650
02:47:17,180 --> 02:47:19,682
ALLOWED IN ANY SINGLE YEAR.

3651
02:47:19,682 --> 02:47:22,518
IT'S BEEN IMMENSELY POPULAR WITH

3652
02:47:22,518 --> 02:47:23,186
THE INVESTIGATOR COMMUNITY.

3653
02:47:23,186 --> 02:47:26,389
OVER THE PAST DECADE OR SO THE

3654
02:47:26,389 --> 02:47:28,491
PROGRAM HAS RECEIVED ALMOST 1500

3655
02:47:28,491 --> 02:47:31,527
APPLICATIONS WITH 25% COMING

3656
02:47:31,527 --> 02:47:35,832
FROM ESIs, EARLY STAGE

3657
02:47:35,832 --> 02:47:38,301
INVESTIGATORS, 181 GRANTS, 20%

3658
02:47:38,301 --> 02:47:39,736
TO EARLY STAGE INVESTIGATORS.

3659
02:47:39,736 --> 02:47:41,204
THE NUMBER OF APPLICATIONS

3660
02:47:41,204 --> 02:47:43,606
SUBMITTED YEARLY CONTINUES TO BE

3661
02:47:43,606 --> 02:47:46,342
AROUND 100 OR MORE.

3662
02:47:46,342 --> 02:47:48,011
THE PROGRAM HAS SUCCESSFULLY

3663
02:47:48,011 --> 02:47:52,515
INCREASED DATA USAGE WITH OVER

3664
02:47:52,515 --> 02:47:55,385
250 DATASETS AND HAS SUPPORTED

3665
02:47:55,385 --> 02:47:57,387
R01 PROJECTS WITH SECONDARY

3666
02:47:57,387 --> 02:47:58,888
ANALYSIS CONTENT.

3667
02:47:58,888 --> 02:48:01,925
ADDITIONALLY THE INITIATIVE HAS

3668
02:48:01,925 --> 02:48:04,527
GENERATED OVER 750 SCIENTIFIC

3669
02:48:04,527 --> 02:48:05,628
PUBLICATIONS, VARIOUS RESOURCES

3670
02:48:05,628 --> 02:48:10,300
INCLUDING STATISTICAL AND IMAGE

3671
02:48:10,300 --> 02:48:12,835
AND METHODOLOGIES, SOFTWARE,

3672
02:48:12,835 --> 02:48:13,269
DATASETS.

3673
02:48:13,269 --> 02:48:14,971
NEW DATA AVAILABILITY SUCH AS

3674
02:48:14,971 --> 02:48:21,577
FROM NHLBI BIODATA CATALYST OR

3675
02:48:21,577 --> 02:48:22,845
"ALL OF US" WILL ENHANCE

3676
02:48:22,845 --> 02:48:24,213
OPPORTUNITIES MAKING PROGRAMS

3677
02:48:24,213 --> 02:48:27,750
LIKE THIS QUITE VALUABLE TO HAVE

3678
02:48:27,750 --> 02:48:28,718
INVESTIGATORS LEVERAGE RESOURCES

3679
02:48:28,718 --> 02:48:31,321
FOR HEART, LUNG, AND BLOOD

3680
02:48:31,321 --> 02:48:31,788
DISORDERS.

3681
02:48:31,788 --> 02:48:32,989
GIVEN COST EFFECTIVENESS AND

3682
02:48:32,989 --> 02:48:34,924
PRODUCTIVITY WE'RE PROPOSING TO

3683
02:48:34,924 --> 02:48:36,893
RENEW THIS INITIATIVE FOR

3684
02:48:36,893 --> 02:48:37,460
ANOTHER THREE YEARS.

3685
02:48:37,460 --> 02:48:40,630
THANK YOU FOR YOUR ATTENTION.

3686
02:48:40,630 --> 02:48:43,433
THIS CONCEPT IS OPEN FOR

3687
02:48:43,433 --> 02:48:51,874
QUESTIONS, COMMENTS, VOTING. 

3688
02:48:51,874 --> 02:49:01,918
 

3689
02:49:12,795 --> 02:49:15,598
I THINK WE'RE DONE.

3690
02:49:15,598 --> 02:49:19,102
BUT NOT QUITE YET.

3691
02:49:19,102 --> 02:49:26,809
 

3692
02:49:26,809 --> 02:49:30,580
ALL RIGHT. 

3693
02:49:30,580 --> 02:49:32,515
THE FINAL TWO CONCEPTS, ONE

3694
02:49:32,515 --> 02:49:34,884
FOCUSES ON CAREER DEVELOPMENT, K

3695
02:49:34,884 --> 02:49:38,521
AWARDEES, THE OTHER ON

3696
02:49:38,521 --> 02:49:41,758
FIRST-TIME RPG AWARDEES.

3697
02:49:41,758 --> 02:49:44,560
FIRST IS CONCEPT 5144,

3698
02:49:44,560 --> 02:49:45,161
ADMINISTRATIVE SUPPLEMENT TO

3699
02:49:45,161 --> 02:49:47,463
PROMOTE RESEARCH CONTINUITY AND

3700
02:49:47,463 --> 02:49:49,399
RETENTION OF NIH MENTORED CAREER

3701
02:49:49,399 --> 02:49:51,834
DEVELOPMENT AWARD RECIPIENTS AND

3702
02:49:51,834 --> 02:49:52,268
SCHOLARS.

3703
02:49:52,268 --> 02:49:55,071
I WILL GO AHEAD.

3704
02:49:55,071 --> 02:49:58,141
SO THIS ONE, THE OBJECTIVE OF

3705
02:49:58,141 --> 02:50:01,144
THE SECONDARY SIGN-ON TO PROVIDE

3706
02:50:01,144 --> 02:50:03,980
ADDITIONAL RESOURCES TO OUR

3707
02:50:03,980 --> 02:50:06,349
CAREER DEVELOPMENT OR K AWARDEES

3708
02:50:06,349 --> 02:50:09,552
FOR FACING CRITICAL LIFE EVENT

3709
02:50:09,552 --> 02:50:11,220
THAT TAKES THEM IN RESEARCH FOR

3710
02:50:11,220 --> 02:50:14,590
EXTENDED PERIODS OF TIME DURING

3711
02:50:14,590 --> 02:50:16,325
THIS VULNERABLE CAREER STAGE,

3712
02:50:16,325 --> 02:50:18,694
THIS SUPPLEMENT PROGRAM ENHANCES

3713
02:50:18,694 --> 02:50:20,096
RETENTION OF INVESTIGATORS

3714
02:50:20,096 --> 02:50:22,698
FACING CRITICAL LIFE EVENTS

3715
02:50:22,698 --> 02:50:24,333
INCLUDING CHILD BIRTH, ADOPTION,

3716
02:50:24,333 --> 02:50:26,869
CARE OF IMMEDIATE FAMILY MEMBERS

3717
02:50:26,869 --> 02:50:29,472
WHO ARE ILL OR SEVERE PERSONAL

3718
02:50:29,472 --> 02:50:30,339
HEALTH ISSUE.

3719
02:50:30,339 --> 02:50:32,742
THESE CAN LEAD TO SIGNIFICANT

3720
02:50:32,742 --> 02:50:34,143
DISRUPTIONS DURING MENTORED

3721
02:50:34,143 --> 02:50:36,879
CAREER DEVELOPMENT AWARDS, AND

3722
02:50:36,879 --> 02:50:39,515
HINDER TRANSITION TO RESEARCH

3723
02:50:39,515 --> 02:50:40,049
INDEPENDENCE.

3724
02:50:40,049 --> 02:50:41,417
THROUGH THE SUPPLEMENTS NHLBI

3725
02:50:41,417 --> 02:50:43,052
CAREER DEVELOPMENT AWARDEES CAN

3726
02:50:43,052 --> 02:50:44,821
REQUEST ADDITIONAL FUNDS TO

3727
02:50:44,821 --> 02:50:45,855
SUPPORT THEIR RESEARCH WHILE

3728
02:50:45,855 --> 02:50:47,757
THEY ARE AWAY FROM THE LAB.

3729
02:50:47,757 --> 02:50:49,826
THESE FUNDS CAN BE USED TO

3730
02:50:49,826 --> 02:50:51,961
HIGHER PERSONNEL TO HELP WITH

3731
02:50:51,961 --> 02:50:54,464
PATIENT RECRUITMENT, LAB WORK,

3732
02:50:54,464 --> 02:50:57,300
DATA ANALYSIS, OR PURCHASE

3733
02:50:57,300 --> 02:51:00,670
EQUIPMENT OR SUPPLIES TO

3734
02:51:00,670 --> 02:51:02,205
ACCELERATE PROJECT COMPLETION.

3735
02:51:02,205 --> 02:51:07,477
THE PROGRAM IS INTENDED TO

3736
02:51:07,477 --> 02:51:09,779
SUPPORT CONTINUITY AMONG

3737
02:51:09,779 --> 02:51:12,048
RECIPIENTS BY PROVIDING

3738
02:51:12,048 --> 02:51:14,016
SUPPLEMENTAL RESEARCH SUPPORT TO

3739
02:51:14,016 --> 02:51:16,652
HELP SUSTAIN INVESTIGATORS'

3740
02:51:16,652 --> 02:51:17,753
FUTURE'S MOMENTUM DURING A

3741
02:51:17,753 --> 02:51:19,355
VULNERABLE STAGE OF THEIR

3742
02:51:19,355 --> 02:51:24,060
CAREER, SO BY -- WE ARE HOPING

3743
02:51:24,060 --> 02:51:26,629
THAT BY MITIGATING IMPACT OF

3744
02:51:26,629 --> 02:51:28,397
CRITICAL LIFE EVENTS THE

3745
02:51:28,397 --> 02:51:30,800
AWARDEES WILL HAVE RESOURCES TO

3746
02:51:30,800 --> 02:51:31,801
REMAIN COMPETITIVE FOR FUTURE

3747
02:51:31,801 --> 02:51:34,604
FUNDING SO WE CAN HELP ENCOURAGE

3748
02:51:34,604 --> 02:51:42,812
RETENTION OF THE NEXT GENERATION

3749
02:51:42,812 --> 02:51:44,180
OF HLBS RESEARCHERS.

3750
02:51:44,180 --> 02:51:45,915
I CAN PAUSE AND SEE IF PEOPLE

3751
02:51:45,915 --> 02:51:47,450
HAVE COMMENTS FOR THIS ONE.

3752
02:51:47,450 --> 02:51:51,888
OR I CAN GO TO THE NEXT.

3753
02:51:51,888 --> 02:52:00,196
DID YOU WANT TO SAY SOMETHING? 

3754
02:52:00,196 --> 02:52:01,764
 

3755
02:52:01,764 --> 02:52:02,465
>> MINOR.

3756
02:52:02,465 --> 02:52:03,966
GIVEN THE COMMENTS ON THE

3757
02:52:03,966 --> 02:52:08,804
FEDERAL LEVEL SHOULD WE CHANGE

3758
02:52:08,804 --> 02:52:11,174
TO MALE-FEMALE, INSTEAD OF

3759
02:52:11,174 --> 02:52:12,875
MEN-WOMEN OR DO YOU THINK IT

3760
02:52:12,875 --> 02:52:16,646
WON'T MAKE A DIFFERENCE WITH IT

3761
02:52:16,646 --> 02:52:18,447
BEING SCOPED OUT USING A.I.?

3762
02:52:18,447 --> 02:52:22,251
I THINK IT'S VERY IMPORTANT, I'M

3763
02:52:22,251 --> 02:52:24,086
SORRY, I'M WONDERING IF IT'S

3764
02:52:24,086 --> 02:52:26,122
WORTH MAKING IT MALE-FEMALE.

3765
02:52:26,122 --> 02:52:28,457
>> I WOULD DEFER TO
PROGRAM ON

3766
02:52:28,457 --> 02:52:29,192
THAT.

3767
02:52:29,192 --> 02:52:32,028
I HEAR YOUR SENSIBILITY.

3768
02:52:32,028 --> 02:52:35,198
AND QUITE FRANKLY, THERE HAVE

3769
02:52:35,198 --> 02:52:36,999
BEEN SOME INITIATIVES MAYBE

3770
02:52:36,999 --> 02:52:38,668
RELATED TO THE OTHER ONE,

3771
02:52:38,668 --> 02:52:41,170
MATERNAL HEALTH, WHERE THERE WAS

3772
02:52:41,170 --> 02:52:42,038
LANGUAGE ABOUT PREGNANT PEOPLE.

3773
02:52:42,038 --> 02:52:45,775
I THINK IT'S FAIR TO SAY THAT

3774
02:52:45,775 --> 02:52:49,011
HAS BEEN ALTERED IN THAT CONTEXT

3775
02:52:49,011 --> 02:52:52,148
AND YOU'RE ALLUDING TO OTHER

3776
02:52:52,148 --> 02:52:53,983
DEFINITIONS OF GENDER AND

3777
02:52:53,983 --> 02:52:59,522
IDENTITY WHICH AGAIN GIVEN THE

3778
02:52:59,522 --> 02:53:00,690
TRANSITION IS BEING CONSIDERED

3779
02:53:00,690 --> 02:53:03,559
IN LIGHT OF THE EXECUTIVE

3780
02:53:03,559 --> 02:53:03,793
ORDERS.

3781
02:53:03,793 --> 02:53:05,261
IN THIS CONTEXT THOUGH I DO

3782
02:53:05,261 --> 02:53:07,296
THINK IT RELATES TO BOTH SEXES.

3783
02:53:07,296 --> 02:53:09,832
I THINK WE'RE ACTUALLY TRYING TO

3784
02:53:09,832 --> 02:53:12,268
BE A LITTLE BIT MORE 21ST

3785
02:53:12,268 --> 02:53:14,270
CENTURY THAT WHETHER YOU'RE THE

3786
02:53:14,270 --> 02:53:16,239
DAD OR YOU'RE THE MOM HAVING A

3787
02:53:16,239 --> 02:53:18,541
CHILD IS A LIFE EVENT, AND IT

3788
02:53:18,541 --> 02:53:20,176
MAY AFFECT YOUR WORK.

3789
02:53:20,176 --> 02:53:23,446
SO IT IS SOMETHING THAT WE'VE

3790
02:53:23,446 --> 02:53:25,815
AWARDED BOTH MEN AND WOMEN.

3791
02:53:25,815 --> 02:53:28,951
SO, I THINK WE'RE OKAY, AS LONG

3792
02:53:28,951 --> 02:53:32,288
AS --  I APPRECIATE YOUR QUESTIN

3793
02:53:32,288 --> 02:53:42,832
AND THIS IS THE TIMES WE'RE IN. 

3794
02:53:43,733 --> 02:53:45,334
>> AGAIN, SUPPORTING OUR

3795
02:53:45,334 --> 02:53:47,069
PIPELINE AT THE RELATIVELY

3796
02:53:47,069 --> 02:53:49,338
MODEST COST WITH TREMENDOUS

3797
02:53:49,338 --> 02:53:50,573
IMPACT ON THE INVESTIGATORS

3798
02:53:50,573 --> 02:53:52,775
IMPACTED BY IT SO I THINK IT'S A

3799
02:53:52,775 --> 02:53:55,478
GREAT INVESTMENT OF OUR

3800
02:53:55,478 --> 02:54:03,719
RESOURCES.

3801
02:54:03,719 --> 02:54:04,420
>> I APPRECIATE YOU
SPREADING

3802
02:54:04,420 --> 02:54:05,087
THE WORD.

3803
02:54:05,087 --> 02:54:06,889
WE GET A GOOD RESPONSE.

3804
02:54:06,889 --> 02:54:08,324
I SOMETIMES WONDER WHETHER

3805
02:54:08,324 --> 02:54:16,832
EVERYBODY'S AWARE OF IT.

3806
02:54:16,832 --> 02:54:20,269
>> LAST ONE, 5145, THIS IS
ALSO

3807
02:54:20,269 --> 02:54:23,239
THE ADMINISTRATIVE SUPPLEMENT

3808
02:54:23,239 --> 02:54:26,008
FOR CONTINUITY OF THE LIFE

3809
02:54:26,008 --> 02:54:28,611
EVENTS, THIS ONE IN PARTICULAR

3810
02:54:28,611 --> 02:54:30,780
IS FOR FIRST-TIME RECIPIENTS OF

3811
02:54:30,780 --> 02:54:34,050
NIH RESEARCH PROJECT GRANT

3812
02:54:34,050 --> 02:54:34,617
AWARDS.

3813
02:54:34,617 --> 02:54:35,951
AND SO I'LL BRIEFLY TALK ABOUT

3814
02:54:35,951 --> 02:54:37,787
THIS BECAUSE YOU HEARD MOST OF

3815
02:54:37,787 --> 02:54:40,423
THE RATIONALE FROM THE OTHER

3816
02:54:40,423 --> 02:54:41,223
ONE.

3817
02:54:41,223 --> 02:54:43,025
SO OBJECTIVE ALSO SECONDARY

3818
02:54:43,025 --> 02:54:45,461
SIGN-ON TO PROVIDE ADDITIONAL

3819
02:54:45,461 --> 02:54:48,331
RESOURCES TO NHLBI FIRST-TIME

3820
02:54:48,331 --> 02:54:50,433
RPG AWARDEES, AGAIN THESE ARE

3821
02:54:50,433 --> 02:54:51,133
THOSE FACING CRITICAL LIFE

3822
02:54:51,133 --> 02:54:53,102
EVENTS THAT CAN TAKE THEM AWAY

3823
02:54:53,102 --> 02:54:54,637
FROM RESEARCH FOR EXTENDED

3824
02:54:54,637 --> 02:54:55,938
PERIOD OF TIME.

3825
02:54:55,938 --> 02:54:57,773
THIS AIDS IN RETENTION OF

3826
02:54:57,773 --> 02:54:58,774
TALENTED YOUNG INVESTIGATORS

3827
02:54:58,774 --> 02:55:00,743
WITHIN OUR MISSION AND CRITICAL

3828
02:55:00,743 --> 02:55:04,680
COMPONENT IN THE DEVELOPMENT OF

3829
02:55:04,680 --> 02:55:05,281
FUTURE RESEARCHERS.

3830
02:55:05,281 --> 02:55:06,982
AND THE OVERARCHING GOAL TO HELP

3831
02:55:06,982 --> 02:55:09,185
MAINTAIN PRODUCTIVITY OF THESE

3832
02:55:09,185 --> 02:55:13,289
CURRENT FIRST-TIME RECIPIENTS OF

3833
02:55:13,289 --> 02:55:14,423
RPGs, DEALING WITH CRITICAL

3834
02:55:14,423 --> 02:55:17,526
LIFE EVENTS SUCH AS CHILD BIRTH,

3835
02:55:17,526 --> 02:55:18,694
ADOPTION, CARE OF IMMEDIATE

3836
02:55:18,694 --> 02:55:21,597
FAMILY MEMBERS WHO ARE ILL OR

3837
02:55:21,597 --> 02:55:23,532
WHO THEMSELVES HAVE HEALTH

3838
02:55:23,532 --> 02:55:26,035
ISSUES, TO HELP NEWLY

3839
02:55:26,035 --> 02:55:27,136
INDEPENDENT INVESTIGATORS WE

3840
02:55:27,136 --> 02:55:29,071
MAIN COMPETITIVE FOR FIRST

3841
02:55:29,071 --> 02:55:30,139
RENEWAL OR SECOND RESEARCH

3842
02:55:30,139 --> 02:55:31,807
PROJECT GRANT AWARD BY PROVIDING

3843
02:55:31,807 --> 02:55:34,377
FLEXIBLE FUNDING THAT CAN BE

3844
02:55:34,377 --> 02:55:38,614
USED FOR PERSONNEL, RESEARCH,

3845
02:55:38,614 --> 02:55:39,115
EQUIPMENT, SUPPLIES, AND

3846
02:55:39,115 --> 02:55:40,583
EQUIPMENT AND SUPPLIES.

3847
02:55:40,583 --> 02:55:42,318
RETAINING INVESTIGATORS IN THIS

3848
02:55:42,318 --> 02:55:44,086
CRITICAL PERIOD WILL PROTECT THE

3849
02:55:44,086 --> 02:55:45,855
RESEARCH INVESTMENT ALREADY MADE

3850
02:55:45,855 --> 02:55:49,058
VIA THE PARENT NIH AWARD.

3851
02:55:49,058 --> 02:55:52,862
AND SO I THINK I'LL END BY

3852
02:55:52,862 --> 02:55:55,498
SAYING THIS SUPPLEMENT PROGRAM

3853
02:55:55,498 --> 02:55:57,066
REPRESENTS STRATEGIC INVESTMENT

3854
02:55:57,066 --> 02:55:59,535
IN OUR WORKFORCE BY SUSTAINING

3855
02:55:59,535 --> 02:56:01,370
RESEARCH AND CAREER PRODUCTIVITY

3856
02:56:01,370 --> 02:56:07,810
DURING A CRITICAL LIFE EVENT.

3857
02:56:07,810 --> 02:56:10,413
THIS IS OPEN FOR DISCUSSION

3858
02:56:10,413 --> 02:56:18,687
AND/OR VOTING. 

3859
02:56:18,687 --> 02:56:22,958
 

3860
02:56:22,958 --> 02:56:28,798
>> ARE WE READY TO GO?

3861
02:56:28,798 --> 02:56:38,841
 

3862
02:56:48,484 --> 02:56:52,154
>> THANK YOU.

3863
02:56:52,154 --> 02:56:52,555
100%.

3864
02:56:52,555 --> 02:56:55,057
>> CONCEPTS FOR DIVISION
OF LUNG

3865
02:56:55,057 --> 02:56:58,894
DISEASES WE HAVE THREE, THE

3866
02:56:58,894 --> 02:57:05,201
FIRST ONE IS IDS 5124, SECONDARY

3867
02:57:05,201 --> 02:57:06,535
PARTICIPATION FOR HUMAN ORGANS

3868
02:57:06,535 --> 02:57:09,038
AND TISSUES.

3869
02:57:09,038 --> 02:57:10,606
COMPETITION RENEWALS U 42.

3870
02:57:10,606 --> 02:57:14,844
HUMAN TISSUE AND ORGAN RESEARCH

3871
02:57:14,844 --> 02:57:19,482
RESOURCE WILL SERVE AS

3872
02:57:19,482 --> 02:57:20,983
BIOREPOSITORY FOR RECEIPT,

3873
02:57:20,983 --> 02:57:21,784
STORAGE, DISTRIBUTION ACROSS

3874
02:57:21,784 --> 02:57:23,018
CLINICAL SITES.

3875
02:57:23,018 --> 02:57:25,154
DATA AND BIOSPECIMENS WILL BE

3876
02:57:25,154 --> 02:57:27,323
SHARED BY A PUBLIC ACCESS

3877
02:57:27,323 --> 02:57:30,960
PLATFORM THROUGH NATIONAL

3878
02:57:30,960 --> 02:57:31,894
DISEASE RESEARCH INTERCHANGE AND

3879
02:57:31,894 --> 02:57:33,762
RESOURCES DURING AND AFTER THE

3880
02:57:33,762 --> 02:57:36,232
END OF THE STUDY.

3881
02:57:36,232 --> 02:57:41,003
HTOR WILL FOCUS ON SICKLE CELL

3882
02:57:41,003 --> 02:57:42,104
DISEASE, HEMOPHILIA,

3883
02:57:42,104 --> 02:57:44,707
SARCOIDOSIS, HEART DISEASE,

3884
02:57:44,707 --> 02:57:46,075
INCLUDING HEART FAILURE, IN

3885
02:57:46,075 --> 02:57:47,076
CONSULTATION WITH BLOOD

3886
02:57:47,076 --> 02:57:50,746
DIVISION, TISSUES THAT WILL BE

3887
02:57:50,746 --> 02:57:52,481
FOCUSING ON SICKLE CELL DISEASE

3888
02:57:52,481 --> 02:57:55,017
INCLUDE FROM THE LUNGS, LIVER,

3889
02:57:55,017 --> 02:57:58,354
KIDNEYS, HEART, EYES, BONES,

3890
02:57:58,354 --> 02:58:01,390
JOINTS, BRAIN, SPLEEN,

3891
02:58:01,390 --> 02:58:06,328
HEMOPHILIA TO STUDY LIVER

3892
02:58:06,328 --> 02:58:09,732
ISSUES, INCLUDES HEART FAILURE

3893
02:58:09,732 --> 02:58:14,870
TISSUE SAMPLES, WILL COMPLEMENT

3894
02:58:14,870 --> 02:58:17,740
BIODATACATALYST, BioLINCC

3895
02:58:17,740 --> 02:58:19,375
WHILE HIGHLIGHTING A GAP, LIVING

3896
02:58:19,375 --> 02:58:25,281
TISSUES, WITH FOCUS ON RARE

3897
02:58:25,281 --> 02:58:25,548
DISEASES.

3898
02:58:25,548 --> 02:58:26,348
FIVE-YEAR BUDGET IS

3899
02:58:26,348 --> 02:58:31,153
1.250 MILLION, AIMS TO FUND A

3900
02:58:31,153 --> 02:58:35,691
U42 AWARD AT $250,000 PER YEAR,

3901
02:58:35,691 --> 02:58:40,062
HTOR IS CO-FUNDED AT  $100,000

3902
02:58:40,062 --> 02:58:45,100
TOTAL COST PER YEAR AND RECEIVED

3903
02:58:45,100 --> 02:58:50,306
87 HEART TISSUES, 16 BRAIN

3904
02:58:50,306 --> 02:58:51,740
TISSUES, 43 BLOOD SAMPLES, OTHER

3905
02:58:51,740 --> 02:58:55,678
ORGAN TISSUES IN TWO YEARS, SO

3906
02:58:55,678 --> 02:58:56,812
REQUEST FOR CONTINUED FUNDING.

3907
02:58:56,812 --> 02:59:04,887
ANY QUESTIONS?

3908
02:59:04,887 --> 02:59:09,592
I GUESS WE MAY PROCEED FOR

3909
02:59:09,592 --> 02:59:19,868
DECISION LENS. 

3910
02:59:22,071 --> 02:59:24,239
ALL RIGHT.

3911
02:59:24,239 --> 02:59:25,741
GREAT.

3912
02:59:25,741 --> 02:59:28,577
NEXT CONCEPT IS IDS 5146 RENEWAL

3913
02:59:28,577 --> 02:59:30,512
FOR LIMITED COMPETITION SMALL

3914
02:59:30,512 --> 02:59:41,056
GRANT PROGRAM FOR NHLBI, AND THE

3915
02:59:41,290 --> 02:59:51,767
PURPOSE OF THIS NOFO TO SOLICIT

3916
02:59:52,468 --> 02:59:53,702
K01s, SOME K25s FOR SMALL

3917
02:59:53,702 --> 02:59:57,072
GRANT SUPPORT TO EXPAND CURRENT

3918
02:59:57,072 --> 02:59:57,706
RESEARCH OBJECTIVES OR BRANCH

3919
02:59:57,706 --> 03:00:00,009
OUT RESULTING FROM THE RESEARCH

3920
03:00:00,009 --> 03:00:02,878
CONDUCTED UNDER K AWARDS.

3921
03:00:02,878 --> 03:00:06,515
THE OVERALL OBJECTIVES IS

3922
03:00:06,515 --> 03:00:08,384
PROVIDE A STEP-STONE FOR

3923
03:00:08,384 --> 03:00:09,885
AWARDEES WITH HIGH POTENTIAL BUT

3924
03:00:09,885 --> 03:00:12,154
FACE CHALLENGES AND NEED SUPPORT

3925
03:00:12,154 --> 03:00:16,692
TO HELP GENERATE CRITICAL DATA

3926
03:00:16,692 --> 03:00:19,528
AND/OR PUBLICATIONS TO

3927
03:00:19,528 --> 03:00:27,670
FACILITATE K TO R 2 TRANSITION,

3928
03:00:27,670 --> 03:00:37,913
MAJORITY  ARE

3929
03:00:38,180 --> 03:00:38,580
PHYSICIAN-SCIENTISTS.

3930
03:00:38,580 --> 03:00:40,349
THIS PROGRAM HAS BEEN AROUND FOR

3931
03:00:40,349 --> 03:00:44,086
10 YEARS AND CURRENT NOFO WILL

3932
03:00:44,086 --> 03:00:46,321
EXPIRE ON JANUARY 8, 2026.

3933
03:00:46,321 --> 03:00:50,426
BETWEEN FISCAL YEAR 16 AND 24,

3934
03:00:50,426 --> 03:00:56,165
TOTAL OF 160 AWARDS MADE WITH

3935
03:00:56,165 --> 03:01:01,637
SUCCESS RATE OF 47%, 20 NEW

3936
03:01:01,637 --> 03:01:03,405
AWARDS PER YEAR, AWARDEES ARE

3937
03:01:03,405 --> 03:01:06,442
MORE LIKELY TO APPLY FOR AND

3938
03:01:06,442 --> 03:01:08,844
OBTAIN SUBSEQUENT R01 OR

3939
03:01:08,844 --> 03:01:09,445
EQUIVALENT INDEPENDENT GRANTS

3940
03:01:09,445 --> 03:01:12,648
AND LESS LIKELY TO DROP OUT FROM

3941
03:01:12,648 --> 03:01:12,981
RESEARCH.

3942
03:01:12,981 --> 03:01:15,617
WE BELIEVE THIS PROGRAM IS

3943
03:01:15,617 --> 03:01:18,320
ACHIEVING STATED GOAL PROMOTING

3944
03:01:18,320 --> 03:01:21,657
RESEARCH INDEPENDENCE FOR NHLBI

3945
03:01:21,657 --> 03:01:22,758
AWARDEES.

3946
03:01:22,758 --> 03:01:25,260
OBJECTIVE IS TO CONTINUE THE

3947
03:01:25,260 --> 03:01:31,266
PROGRAM TO K TO R TRANSITION

3948
03:01:31,266 --> 03:01:31,734
WITH MINOR REVISIONS.

3949
03:01:31,734 --> 03:01:41,577
FOR EXAMPLE IN RESPONSE TO

3950
03:01:41,577 --> 03:01:43,312
INFLATION, DIRECT COST FROM

3951
03:01:43,312 --> 03:01:46,381
$75,000 TO $85,000 A YEAR,

3952
03:01:46,381 --> 03:01:50,119
THERE'S BEEN A DECREASE IN R03

3953
03:01:50,119 --> 03:01:53,222
SUCCESS RATE, THERE'S A NEED FOR

3954
03:01:53,222 --> 03:01:54,056
INCREASING APPLICATIONS FROM

3955
03:01:54,056 --> 03:01:56,458
SOME OF THE OTHER DIVISIONS.

3956
03:01:56,458 --> 03:01:58,093
AS A RESULT SIGNIFICANT INCREASE

3957
03:01:58,093 --> 03:02:00,362
IN FUTURE APPLICATIONS IS

3958
03:02:00,362 --> 03:02:00,662
ANTICIPATED.

3959
03:02:00,662 --> 03:02:01,764
TO PREVENT FURTHER REDUCTION IN

3960
03:02:01,764 --> 03:02:03,732
SUCCESS RATE AND MEET K AWARDEE

3961
03:02:03,732 --> 03:02:05,467
COMMUNITY NEED WE PROPOSE TO

3962
03:02:05,467 --> 03:02:07,302
INCREASE TOTAL NUMBERS OF NEW

3963
03:02:07,302 --> 03:02:09,605
AWARDS FROM 20 TO 29 PER YEAR,

3964
03:02:09,605 --> 03:02:12,040
ADDING THREE MORE FOR EACH

3965
03:02:12,040 --> 03:02:13,575
COUNCIL ROUND.

3966
03:02:13,575 --> 03:02:16,445
CURRENT NOFO ALLOWS K AWARDEES

3967
03:02:16,445 --> 03:02:18,247
TO APPLY FROM SECOND YEAR OF K

3968
03:02:18,247 --> 03:02:19,548
AWARD PROJECT PERIOD BECAUSE

3969
03:02:19,548 --> 03:02:23,719
IT'S TOO EARLY TO EVALUATE IF AN

3970
03:02:23,719 --> 03:02:25,821
R03 IS NEEDED TO SUPPORT K TO R,

3971
03:02:25,821 --> 03:02:27,589
THIS HAS BEEN ONGOING FOR ONE

3972
03:02:27,589 --> 03:02:30,959
YEAR, WE PROPOSE TO DELAY THE

3973
03:02:30,959 --> 03:02:31,860
ELIGIBILITY FROM SECOND TO THIRD

3974
03:02:31,860 --> 03:02:35,030
YEAR OF THE PROJECT PERIOD, TO

3975
03:02:35,030 --> 03:02:39,701
GIVE ENOUGH TIME TO PREPARE FOR

3976
03:02:39,701 --> 03:02:40,302
R01 OR EQUIVALENT GRANT

3977
03:02:40,302 --> 03:02:41,970
APPLICATIONS, IN THE FOURTH TO

3978
03:02:41,970 --> 03:02:44,072
FIFTH YEAR USUALLY OF THE K

3979
03:02:44,072 --> 03:02:45,574
AWARD PERIOD.

3980
03:02:45,574 --> 03:02:48,243
AGAIN, WHAT WE'RE PROPOSING OR

3981
03:02:48,243 --> 03:02:51,547
REQUESTING IS RENEWAL FOR THIS

3982
03:02:51,547 --> 03:02:52,581
R03 LIMITED COMPETITION PROGRAM.

3983
03:02:52,581 --> 03:03:01,056
ANY QUESTIONS? 

3984
03:03:01,056 --> 03:03:04,593
WE MAY PROCEED TO DECISION LENS

3985
03:03:04,593 --> 03:03:14,703
THEN. 

3986
03:03:22,644 --> 03:03:32,621
 

3987
03:03:34,690 --> 03:03:36,425
>> THANK YOU.

3988
03:03:36,425 --> 03:03:39,361
THIRD AND LAST IS 5142,

3989
03:03:39,361 --> 03:03:40,395
SECONDARY PARTICIPATION IN HIV

3990
03:03:40,395 --> 03:03:42,264
AND AGING BASIC SCIENCE

3991
03:03:42,264 --> 03:03:44,233
INITIATIVE, R21 CLINICAL TRIAL

3992
03:03:44,233 --> 03:03:44,666
NOT ALLOWED.

3993
03:03:44,666 --> 03:03:50,739
AND THIS IS A NEW SECONDARY

3994
03:03:50,739 --> 03:03:53,709
SIGN-ON.

3995
03:03:53,709 --> 03:03:55,310
50 AND OLDER, THIS NUMBER IS

3996
03:03:55,310 --> 03:03:59,314
EXPECTED TO BE GREATER THAN 50%

3997
03:03:59,314 --> 03:04:03,051
BY 2030 ACCORDING TO CDC DATA.

3998
03:04:03,051 --> 03:04:04,620
THE LAST PATIENTS LIVING WITH

3999
03:04:04,620 --> 03:04:08,290
HIV IS SIMILAR TO THOSE WITHOUT

4000
03:04:08,290 --> 03:04:14,863
HIV, HEALTH SPAN HAS NOT

4001
03:04:14,863 --> 03:04:16,431
SIGNIFICANTLY CHANGED, AGING

4002
03:04:16,431 --> 03:04:19,001
WITH HIV PRESENTS PERSISTENT

4003
03:04:19,001 --> 03:04:19,968
CHALLENGES FOR MANY OLDER ADULTS

4004
03:04:19,968 --> 03:04:23,538
AS WELL AS PEOPLE WHO ARE

4005
03:04:23,538 --> 03:04:26,608
LIFETIME AND LONG-TERM SURVIVORS

4006
03:04:26,608 --> 03:04:28,810
AND MANAGING BOTH HIV AND HEALTH

4007
03:04:28,810 --> 03:04:29,077
CONCERNS.

4008
03:04:29,077 --> 03:04:32,281
THIS IS VERY COMPLEX.

4009
03:04:32,281 --> 03:04:34,182
THIS INITIATIVE USES R21

4010
03:04:34,182 --> 03:04:36,885
MECHANISM TO CULTIVATE A GROUP

4011
03:04:36,885 --> 03:04:37,920
OF INTERDISCIPLINARY

4012
03:04:37,920 --> 03:04:39,087
INVESTIGATORS ALREADY

4013
03:04:39,087 --> 03:04:40,989
ESTABLISHED IN EITHER HIV OR

4014
03:04:40,989 --> 03:04:42,624
AGING RESEARCH TO ADDRESS

4015
03:04:42,624 --> 03:04:44,493
MECHANISMS FOR THE INCREASED

4016
03:04:44,493 --> 03:04:46,361
INCIDENCE OF CO-MORBIDITIES IN

4017
03:04:46,361 --> 03:04:48,263
PEOPLE LIVING WITH HIV.

4018
03:04:48,263 --> 03:04:51,199
THE PROGRAM IS UNIQUE IN THAT

4019
03:04:51,199 --> 03:04:52,601
APPLICATIONS WILL REQUIRE

4020
03:04:52,601 --> 03:04:53,936
IDENTIFICATION OF SUITABLE

4021
03:04:53,936 --> 03:04:56,204
EXPERTS IN AREAS WHERE THE

4022
03:04:56,204 --> 03:04:57,506
PRINCIPAL INVESTIGATOR HAS LESS

4023
03:04:57,506 --> 03:05:00,008
EXPERIENCE WITH HIV OR AGING.

4024
03:05:00,008 --> 03:05:03,045
AND THIS NEW COLLABORATORS WILL

4025
03:05:03,045 --> 03:05:04,079
DEVELOP AND EXECUTE

4026
03:05:04,079 --> 03:05:05,480
COLLABORATIVE AND COMPLEMENTARY

4027
03:05:05,480 --> 03:05:09,151
RESEARCH PLAN THAT COMPLEMENTS

4028
03:05:09,151 --> 03:05:15,357
AND COMPLETES THE DESIGN STUDY

4029
03:05:15,357 --> 03:05:16,892
AIMS.

4030
03:05:16,892 --> 03:05:17,759
PROPOSED STUDIES WILL IMPROVE

4031
03:05:17,759 --> 03:05:21,263
UNDERSTANDING OF AGING IN

4032
03:05:21,263 --> 03:05:23,799
CARDIOVASCULAR, PULMONARY

4033
03:05:23,799 --> 03:05:28,804
SYSTEMS, WITH EMPHASIS --

4034
03:05:28,804 --> 03:05:33,875
[ NO AUDIO ] 

4035
03:05:33,875 --> 03:05:40,983
AND WITH EMPHASIS ON -- WHERE I

4036
03:05:40,983 --> 03:05:45,988
WAS? 

4037
03:05:45,988 --> 03:05:47,122
HERE IT IS.

4038
03:05:47,122 --> 03:05:50,092
EMPHASIS ON HOW HIV INFECTIONS

4039
03:05:50,092 --> 03:05:51,693
INFECT ASSOCIATED COMORBIDITIES.

4040
03:05:51,693 --> 03:05:53,562
PROPOSED STUDIES ARE EXPECTED TO

4041
03:05:53,562 --> 03:05:55,564
IDENTIFY PATHWAYS TO IMPROVE

4042
03:05:55,564 --> 03:05:57,099
RESILIENCE OF HIV-RELATED HEART,

4043
03:05:57,099 --> 03:05:59,201
LUNG, BLOOD AND SLEEP DISEASES

4044
03:05:59,201 --> 03:06:04,139
BY APPLYING CURRENT AGE AND

4045
03:06:04,139 --> 03:06:08,143
SCIENCE PARADIGMS.

4046
03:06:08,143 --> 03:06:10,912
SIMILAR TO OTHER KNOW NOFOS,

4047
03:06:10,912 --> 03:06:13,782
USING DATASETS FOR HIV AND

4048
03:06:13,782 --> 03:06:13,982
AGING.

4049
03:06:13,982 --> 03:06:15,250
OFFICE OF AIDS RESEARCH FUNDS

4050
03:06:15,250 --> 03:06:20,389
WILL BE USED IN TWO WAYS, FIRST

4051
03:06:20,389 --> 03:06:26,561
TO CROSS-CULTIVATE I.C. I.C. SUT

4052
03:06:26,561 --> 03:06:29,231
ACROSS INSTITUTES THAT SIGN TO

4053
03:06:29,231 --> 03:06:31,199
THE INITIATIVE, UP TO $2 MILLION

4054
03:06:31,199 --> 03:06:34,936
PER YEAR IN DIRECT COST FOR 2027

4055
03:06:34,936 --> 03:06:36,905
TO 2031 FISCAL YEARS.

4056
03:06:36,905 --> 03:06:39,408
SECOND IF COMPETITIVE

4057
03:06:39,408 --> 03:06:40,709
APPLICATIONS ARE RECEIVED THAT

4058
03:06:40,709 --> 03:06:42,811
ARE RELATED BUT NOT SUPPORTED BY

4059
03:06:42,811 --> 03:06:45,247
OAR UP TO THREE ADDITIONAL

4060
03:06:45,247 --> 03:06:46,148
APPLICATIONS PER RECEIPT DATE,

4061
03:06:46,148 --> 03:06:49,951
SO ONE PER YEAR, WILL BE

4062
03:06:49,951 --> 03:06:53,355
SUPPORTED BY NHLBI HIV OAR

4063
03:06:53,355 --> 03:06:58,894
ALLOCATED FUNDS, COMBINED BUDGET

4064
03:06:58,894 --> 03:07:03,198
MAY NOT EXCEED $275,000, NO MORE

4065
03:07:03,198 --> 03:07:05,500
THAN 200,000 REQUESTED IN A

4066
03:07:05,500 --> 03:07:07,369
SINGLE YEAR, BEGINNING IN 2027,

4067
03:07:07,369 --> 03:07:08,737
RUNNING FOR FIVE YEARS, THIS

4068
03:07:08,737 --> 03:07:11,306
WILL BE SUPPORTED FOR THREE

4069
03:07:11,306 --> 03:07:13,141
YEARS, WITH RENEWAL FOR FINAL

4070
03:07:13,141 --> 03:07:19,614
TWO YEARS. 

4071
03:07:19,614 --> 03:07:24,586
SO ANY QUESTIONS? 

4072
03:07:24,586 --> 03:07:28,323
>> I WILL SAY NOT HAVING
NHLBI

4073
03:07:28,323 --> 03:07:30,092
SUPPORT THIS INITIATIVE IN MY

4074
03:07:30,092 --> 03:07:34,029
VIEW IS A MAJOR GAP GIVEN THE

4075
03:07:34,029 --> 03:07:37,732
FACT THAT HEART AND LUNG

4076
03:07:37,732 --> 03:07:39,034
COMORBIDITIES ARE THE MAJOR

4077
03:07:39,034 --> 03:07:40,836
COMORBIDITIES IN PERSONS LIVING

4078
03:07:40,836 --> 03:07:44,773
WITH HIV AND THE TOP CAUSES OF

4079
03:07:44,773 --> 03:07:47,843
MORBIDITY AND MORTALITY IN THIS

4080
03:07:47,843 --> 03:07:48,376
POPULATION.

4081
03:07:48,376 --> 03:07:51,146
SO I THINK IT MAKES A TON OF

4082
03:07:51,146 --> 03:07:51,680
SENSE.

4083
03:07:51,680 --> 03:07:55,517
I CAN'T IMAGINE HAVING THIS

4084
03:07:55,517 --> 03:07:59,054
WITHOUT NHLBI, SO GLAD WE'RE

4085
03:07:59,054 --> 03:08:00,388
DOING IT NOW.

4086
03:08:00,388 --> 03:08:04,659
>> THANK YOU, LYNN.

4087
03:08:04,659 --> 03:08:07,229
>> MY OWN KNOWLEDGE GAP

4088
03:08:07,229 --> 03:08:08,363
QUESTION, WHY IS THIS LUNG

4089
03:08:08,363 --> 03:08:10,932
DISEASE AND NOT HEART DISEASE?

4090
03:08:10,932 --> 03:08:12,200
>> NO, IT'S COVERING
ACROSS

4091
03:08:12,200 --> 03:08:15,270
SPECTRUM OF HEART LUNG BLOOD AND

4092
03:08:15,270 --> 03:08:16,138
SLEEP DISORDERS.

4093
03:08:16,138 --> 03:08:18,974
IT'S ABOUT ALL OF IT.

4094
03:08:18,974 --> 03:08:22,110
APPLICANTS FROM ALL THOSE FIELDS

4095
03:08:22,110 --> 03:08:28,817
CAN APPLY.

4096
03:08:28,817 --> 03:08:30,218
>> ANY OTHER QUESTIONS?

4097
03:08:30,218 --> 03:08:34,956
WE LED LUNG LEAD  SOME OF THE

4098
03:08:34,956 --> 03:08:35,223
TIME.

4099
03:08:35,223 --> 03:08:36,958
AND WE DO REALLY GOOD.

4100
03:08:36,958 --> 03:08:38,493
>> I GUESS WE CAN PROCEED
TO

4101
03:08:38,493 --> 03:08:48,837
DECISION LENS THEN. 

4102
03:09:20,635 --> 03:09:21,203
>> ALL RIGHT.

4103
03:09:21,203 --> 03:09:27,209
NOW,  WE'LL CONTINUE PRESENTING

4104
03:09:27,209 --> 03:09:27,642
CONCEPTS.

4105
03:09:27,642 --> 03:09:29,411
>> THE FIRST OF THREE

4106
03:09:29,411 --> 03:09:33,415
INITIATIVES, BLOOD DIVISION WILL

4107
03:09:33,415 --> 03:09:35,784
PRESENT, IDS 5073, RENEWAL OF

4108
03:09:35,784 --> 03:09:38,053
THE MAXIMIZING SCIENTIFIC VALUE

4109
03:09:38,053 --> 03:09:41,456
OF THE NHLBI BIOLOGIC,

4110
03:09:41,456 --> 03:09:44,159
BIOSPECIMEN, BIOREPOSITORY.

4111
03:09:44,159 --> 03:09:46,127
SCIENTIFIC OPPORTUNITIES FOR

4112
03:09:46,127 --> 03:09:48,863
EXPLORATORY RESEARCH R21

4113
03:09:48,863 --> 03:09:51,600
MECHANISM, TO RENEW THIS

4114
03:09:51,600 --> 03:09:54,903
TRANSNHLBI R21, LAST RENEWED IN

4115
03:09:54,903 --> 03:09:56,771
FISCAL YEAR 2023, BIOSPECIMENS

4116
03:09:56,771 --> 03:10:00,842
FROM 62 CLINICAL STUDIES

4117
03:10:00,842 --> 03:10:03,011
CURRENTLY STORED IN THE NHLBI

4118
03:10:03,011 --> 03:10:05,547
BIOREPOSITORY, OPEN TO THE

4119
03:10:05,547 --> 03:10:07,282
COMMUNITY FOR NHLBI BioLINCC

4120
03:10:07,282 --> 03:10:09,517
WEB PORTAL AVAILABLE SAMPLES ARE

4121
03:10:09,517 --> 03:10:10,652
DISTRIBUTED TO RESEARCHERS AT

4122
03:10:10,652 --> 03:10:13,188
THE COST OF SHIPPING SOLELY.

4123
03:10:13,188 --> 03:10:15,290
THIS RFA HAS THREE OBJECTIVES,

4124
03:10:15,290 --> 03:10:16,324
TO PROVIDE SHORT-TERM FUNDING

4125
03:10:16,324 --> 03:10:23,064
FOR RESEARCHERS TO YOU THE  --

4126
03:10:23,064 --> 03:10:23,999
UTILIZES SPECIMENS, FOR

4127
03:10:23,999 --> 03:10:25,133
REGENERATION OF DATA FOR

4128
03:10:25,133 --> 03:10:28,903
RESEARCH WHICH WILL DEVELOP THE

4129
03:10:28,903 --> 03:10:30,071
SCIENTIFIC WORKFORCE AT ALL

4130
03:10:30,071 --> 03:10:31,840
LEVELS AND TO CONTINUE TO

4131
03:10:31,840 --> 03:10:35,510
MAXIMIZE SCIENTIFIC VALUE OF THE

4132
03:10:35,510 --> 03:10:38,213
UNIQUE BIOSPECIMEN COLLECTIONS

4133
03:10:38,213 --> 03:10:38,980
STOREDDED IN BIOSPECIMEN

4134
03:10:38,980 --> 03:10:39,514
REPOSITORY.

4135
03:10:39,514 --> 03:10:41,483
DURATION OF EACH AWARD IS TWO

4136
03:10:41,483 --> 03:10:44,052
YEARS, WITH AWARD BUDGET UP TO

4137
03:10:44,052 --> 03:10:47,489
$100,000 IN DIRECT COST PER YEAR

4138
03:10:47,489 --> 03:10:48,757
PER GRANT.

4139
03:10:48,757 --> 03:10:50,292
PAST EXPERIENCE DEMONSTRATED

4140
03:10:50,292 --> 03:10:52,327
UTILITY TO PROMOTE SCIENTIFIC

4141
03:10:52,327 --> 03:10:55,030
UTILITY OF THE ARCHIVES

4142
03:10:55,030 --> 03:10:56,197
COLLECTIONS FROM COMPLETED NHLBI

4143
03:10:56,197 --> 03:10:58,466
FUNDED CLINICAL TRIALS AND

4144
03:10:58,466 --> 03:10:59,501
OBSERVATIONAL STUDIES,

4145
03:10:59,501 --> 03:11:03,004
IMPORTANTLY TO BRING AWARENESS

4146
03:11:03,004 --> 03:11:04,439
OF THE BIOREPOSITORY TO THE

4147
03:11:04,439 --> 03:11:06,174
PUBLIC AND PROVIDES A RESOURCE

4148
03:11:06,174 --> 03:11:08,810
FOR EARLY STAGE INVESTIGATORS TO

4149
03:11:08,810 --> 03:11:11,746
OBTAIN PRELIMINARY DATA TO HELP

4150
03:11:11,746 --> 03:11:12,981
LAUNCH SCIENTIFIC CAREERS,

4151
03:11:12,981 --> 03:11:18,153
ROUGHLY 21% OF PRIOR AWARDEES

4152
03:11:18,153 --> 03:11:19,988
WERE EARLY STAGE INVESTIGATORS.

4153
03:11:19,988 --> 03:11:22,490
REVIEW SHOWS A GOOD DISTRIBUTION

4154
03:11:22,490 --> 03:11:25,193
OF RESEARCH AREAS REPRESENTATIVE

4155
03:11:25,193 --> 03:11:27,095
OF HEART, LUNG, BLOOD, SLEEP

4156
03:11:27,095 --> 03:11:28,296
RESEARCH AREAS, AWARDEES FUNDED

4157
03:11:28,296 --> 03:11:34,436
FROM THE LAST ITERATION

4158
03:11:34,436 --> 03:11:36,304
DEMONSTRATED CAREER DEVELOPMENT.

4159
03:11:36,304 --> 03:11:38,139
RECIPIENTS REMAINED IN THE

4160
03:11:38,139 --> 03:11:39,808
RESEARCH WORKFORCE.

4161
03:11:39,808 --> 03:11:42,944
THE RFA HAS SUCCESSFULLY BROUGHT

4162
03:11:42,944 --> 03:11:44,913
AWARENESS OF THE RESOURCE AS

4163
03:11:44,913 --> 03:11:46,247
REQUESTS INCREASED DURING AND

4164
03:11:46,247 --> 03:11:48,650
FOR THE PERIOD AFTER THAT ACTIVE

4165
03:11:48,650 --> 03:11:52,420
PERIOD OF THE RFA. 

4166
03:11:52,420 --> 03:11:56,691
CONTINUED SUPPORT OF THIS WILL

4167
03:11:56,691 --> 03:11:59,494
BOLSTER UTILIZATION AND IDENTIFY

4168
03:11:59,494 --> 03:12:02,330
NEW DIRECTIONS FOR HEART, LUNG,

4169
03:12:02,330 --> 03:12:03,598
SLEEP, AND BLOOD AREAS.

4170
03:12:03,598 --> 03:12:05,367
ANY QUESTIONS ON THIS INITIATIVE

4171
03:12:05,367 --> 03:12:15,610
FROM MEMBERS?

4172
03:12:52,881 --> 03:12:56,985
THE SECOND INITIATIVE FROM THE

4173
03:12:56,985 --> 03:13:01,689
DIVISION IS 5112, RENEWAL OF

4174
03:13:01,689 --> 03:13:03,691
BioLINCC RESOURCE CONTRACTS,

4175
03:13:03,691 --> 03:13:04,993
ESTABLISHED IN 2008, FACILITATE

4176
03:13:04,993 --> 03:13:09,063
ACCESS AND PROMOTE USE OF TWO

4177
03:13:09,063 --> 03:13:10,331
RESOURCES, REPOSITORY WHICH I

4178
03:13:10,331 --> 03:13:13,201
JUST SPOKE OF AND DATA

4179
03:13:13,201 --> 03:13:15,136
REPOSITORY MANAGED BY

4180
03:13:15,136 --> 03:13:16,738
EPIDEMIOLOGY BRANCH DIVISION OF

4181
03:13:16,738 --> 03:13:17,472
DCBS.

4182
03:13:17,472 --> 03:13:20,308
BioLINCC FITS WITHIN THE NHLBI

4183
03:13:20,308 --> 03:13:22,811
MISSION IN SEVERAL AREAS,

4184
03:13:22,811 --> 03:13:24,279
FACILITATING ACCESS TO RESOURCES

4185
03:13:24,279 --> 03:13:26,514
WHICH IN TURN INCREASES RETURN

4186
03:13:26,514 --> 03:13:28,383
ON INVESTMENT FOR NHLBI FUNDED

4187
03:13:28,383 --> 03:13:30,318
CLINICAL RESEARCH AND CONTINUING

4188
03:13:30,318 --> 03:13:32,787
TO MEET INSTITUTE PRIORITIES TO

4189
03:13:32,787 --> 03:13:33,688
ADDRESS CHANGING DATA SHARING

4190
03:13:33,688 --> 03:13:36,691
LANDSCAPE BY VIRTUE OF OUR

4191
03:13:36,691 --> 03:13:40,128
ONGOING INTEGRATION EFFORTS WITH

4192
03:13:40,128 --> 03:13:41,996
NHLBI BIODATA CATALYST CLOUD

4193
03:13:41,996 --> 03:13:42,263
RESOURCE.

4194
03:13:42,263 --> 03:13:44,666
CURRENT CONTRACT RENEWAL REQUEST

4195
03:13:44,666 --> 03:13:46,468
IS FOR ADDITIONAL FIVE YEARS,

4196
03:13:46,468 --> 03:13:48,336
OVERARCHING OBJECTIVES TO

4197
03:13:48,336 --> 03:13:50,572
MAINTAIN AND STRENGTHEN EXISTING

4198
03:13:50,572 --> 03:13:53,074
BIOLOGIC SPECIMEN AND DATA

4199
03:13:53,074 --> 03:13:54,609
REPOSITORY INFORMATION

4200
03:13:54,609 --> 03:13:55,677
COORDINATING CENTER PLATFORM,

4201
03:13:55,677 --> 03:13:57,378
MAXIMIZING THE SCIENTIFIC VALUE

4202
03:13:57,378 --> 03:13:59,547
AND UTILIZATION OF THESE

4203
03:13:59,547 --> 03:14:01,816
RESOURCES BY GREATER RESEARCH

4204
03:14:01,816 --> 03:14:02,183
COMMUNITY.

4205
03:14:02,183 --> 03:14:05,587
DATA AND BIOSPECIMENS USED FOR

4206
03:14:05,587 --> 03:14:07,789
GENERATING PILOT DATA,

4207
03:14:07,789 --> 03:14:09,691
FULFILLING AIMS, PERFORMING

4208
03:14:09,691 --> 03:14:11,259
META-ANALYSES, STATISTICAL

4209
03:14:11,259 --> 03:14:12,060
METHODS RESEARCH, QUANTITATIVE

4210
03:14:12,060 --> 03:14:16,931
APPROACHES TO CLINICAL TRIALS,

4211
03:14:16,931 --> 03:14:19,334
PREDICTION EQUATIONS, COHORT

4212
03:14:19,334 --> 03:14:19,934
CONTROLS.

4213
03:14:19,934 --> 03:14:21,369
CURRENTLY BioLINCC HOUSES

4214
03:14:21,369 --> 03:14:23,705
CLINICAL DATA FROM 233 CLINICAL

4215
03:14:23,705 --> 03:14:25,707
STUDIES FROM 61 STUDY

4216
03:14:25,707 --> 03:14:28,977
COLLECTIONS ROUGHLY 4 MILLION

4217
03:14:28,977 --> 03:14:31,246
VIALS FROM NHLBI-FUNDED STUDIES,

4218
03:14:31,246 --> 03:14:33,348
PROVEN INVALUABLE IN ALLOWING

4219
03:14:33,348 --> 03:14:42,223
RESEARCHERS TO PROBE  MECHANISM,

4220
03:14:42,223 --> 03:14:46,060
GREATER THAN 2,000 PUBLICATIONS

4221
03:14:46,060 --> 03:14:48,196
SINCE 2008, THREE-FOLD INCREASE

4222
03:14:48,196 --> 03:14:50,899
IN ACTIVE USERS SINCE LAST

4223
03:14:50,899 --> 03:14:53,835
RENEWAL IN 2018.

4224
03:14:53,835 --> 03:14:57,772
OF THESE USERS APPROXIMATELY 48%

4225
03:14:57,772 --> 03:14:59,807
ARE EARLY STAGE INVESTIGATORS.

4226
03:14:59,807 --> 03:15:02,076
DO ANY MEMBERS HAVE ANY

4227
03:15:02,076 --> 03:15:05,079
QUESTIONS OR WISH TO DISCUSS

4228
03:15:05,079 --> 03:15:14,022
MORE ON THIS INITIATIVE? 

4229
03:15:14,022 --> 03:15:24,065
 

4230
03:15:44,118 --> 03:15:50,925
WE'RE READY FOR THE THIRD AND

4231
03:15:50,925 --> 03:15:54,362
FINAL INITIATIVE, IDS NUMBER

4232
03:15:54,362 --> 03:16:00,868
5212, THIS NEW RFA TARGETS

4233
03:16:00,868 --> 03:16:02,837
IMPACT OF CLONAL HEMATOPOIESIS

4234
03:16:02,837 --> 03:16:05,173
ON HEART, LUNG, BLOOD AND SLEEP

4235
03:16:05,173 --> 03:16:09,410
DISEASES IN PEOPLE WITH LIVE.

4236
03:16:09,410 --> 03:16:15,550
CHIP REFERS TO SOMATIC MUTATIONS

4237
03:16:15,550 --> 03:16:21,489
GREATER THAN OR EQUAL TO 2% IN

4238
03:16:21,489 --> 03:16:26,227
BLOOD AND MARROW IN ABSENCE OF

4239
03:16:26,227 --> 03:16:27,528
MYELOID NEOPLASMS.

4240
03:16:27,528 --> 03:16:29,597
A TRIAL AIMED TO PREVENT

4241
03:16:29,597 --> 03:16:30,999
VASCULAR EVENTS IDENTIFIED CHIP

4242
03:16:30,999 --> 03:16:34,402
AMONGST THOSE LIVING WITH HIV.

4243
03:16:34,402 --> 03:16:36,104
THIS RFA SEEKS TO INVESTIGATE

4244
03:16:36,104 --> 03:16:37,639
THE DEVELOPMENT AND PROGRESSION

4245
03:16:37,639 --> 03:16:39,641
OF CHIP IN INDIVIDUALS LIVING

4246
03:16:39,641 --> 03:16:41,943
WITH HIV, AIMING TO UNDERSTAND

4247
03:16:41,943 --> 03:16:44,045
HOW CHRONIC INFLAMMATION AND

4248
03:16:44,045 --> 03:16:45,980
HIV-RELATED FACTORS CONTRIBUTE

4249
03:16:45,980 --> 03:16:48,016
TO CHIP.

4250
03:16:48,016 --> 03:16:50,785
ITS IMPACT ON DISEASES AND

4251
03:16:50,785 --> 03:16:52,720
BROADER BIOLOGICAL IMPLICATIONS

4252
03:16:52,720 --> 03:16:54,989
OF CHRONIC VIRAL INFECTIONS ON

4253
03:16:54,989 --> 03:16:57,492
HEMATOPOIETIC STEM CELL BIOLOGY

4254
03:16:57,492 --> 03:16:59,494
AND CLONAL EVOLUTION.

4255
03:16:59,494 --> 03:17:02,196
KEY SCIENTIFIC QUESTIONS INCLUDE

4256
03:17:02,196 --> 03:17:04,832
EXAMINING AGING AND DEMOGRAPHIC

4257
03:17:04,832 --> 03:17:06,134
FACTORS, BIOLOGICAL MECHANISMS

4258
03:17:06,134 --> 03:17:09,637
DRIVING CHIP, AND EFFECTS OF HIV

4259
03:17:09,637 --> 03:17:13,074
INFECTION AND LONG TEAM

4260
03:17:13,074 --> 03:17:19,480
ANTIRETROVIRAL THERAPY. 

4261
03:17:19,480 --> 03:17:21,182
AIMS TO COMPARE WITH

4262
03:17:21,182 --> 03:17:23,751
COMORBIDITIES TO CHIP IN NON-HIV

4263
03:17:23,751 --> 03:17:25,019
INDIVIDUALS WITH AGE-RELATED

4264
03:17:25,019 --> 03:17:27,188
HEART, LUNG, BLOOD, SLEEP

4265
03:17:27,188 --> 03:17:28,122
CONDITIONS TO IDENTIFY

4266
03:17:28,122 --> 03:17:30,091
DIFFERENCES AND PREFERENCE AND

4267
03:17:30,091 --> 03:17:30,558
PROGRESSION.

4268
03:17:30,558 --> 03:17:31,893
THE RFA WILL INVESTIGATE HOW

4269
03:17:31,893 --> 03:17:34,028
FACTORS UNIQUE TO PEOPLE LIVING

4270
03:17:34,028 --> 03:17:36,798
WITH HIV AND OVERALL

4271
03:17:36,798 --> 03:17:37,732
INFLAMMATORY STATE ASSOCIATED

4272
03:17:37,732 --> 03:17:39,734
WITH HIV CONTRIBUTE TO HIGHER

4273
03:17:39,734 --> 03:17:41,502
INCIDENCE OF CHIP.

4274
03:17:41,502 --> 03:17:43,705
LASTLY THE RFA SEEKS TO

4275
03:17:43,705 --> 03:17:47,508
DETERMINE WHETHER CHIP PRODUCES

4276
03:17:47,508 --> 03:17:52,280
CLONES THAT DRIVE  INFLAMMATION

4277
03:17:52,280 --> 03:17:54,348
IN PEOPLE WITH HIV, TO CLARIFY

4278
03:17:54,348 --> 03:17:56,150
RELATIONSHIP BETWEEN CHIP AND

4279
03:17:56,150 --> 03:17:57,885
INFLAMMATION IN THIS CONTEXT.

4280
03:17:57,885 --> 03:17:59,487
IN ADDITION TO RESEARCHING CHIP

4281
03:17:59,487 --> 03:18:02,824
IN CONTEXT OF HIV THIS WILL

4282
03:18:02,824 --> 03:18:04,125
PROVIDE BROADER BIOLOGICAL

4283
03:18:04,125 --> 03:18:07,729
INSIGHTS INTO HOW CHRONIC VIRAL

4284
03:18:07,729 --> 03:18:08,496
INFECTIONS INFLUENCE

4285
03:18:08,496 --> 03:18:10,164
HEMATOPOIETIC STEM CELL BIOLOGY

4286
03:18:10,164 --> 03:18:11,399
AND CLONAL EVOLUTION.

4287
03:18:11,399 --> 03:18:13,434
MOREOVER THERE ARE OTHER

4288
03:18:13,434 --> 03:18:15,203
RELEVANT HARD, LUNG, BLOOD,

4289
03:18:15,203 --> 03:18:16,671
SLEEP DISORDERS INFLAMMATORY IN

4290
03:18:16,671 --> 03:18:19,707
NATURE AND ASSOCIATED WITH

4291
03:18:19,707 --> 03:18:20,742
CLONAL HEMATOPOIESIS.

4292
03:18:20,742 --> 03:18:22,076
CHIP IS ASSOCIATED WITH

4293
03:18:22,076 --> 03:18:29,550
CONDITIONS SUCH AS

4294
03:18:29,550 --> 03:18:30,218
CARDIOVASCULAR DISEASE,

4295
03:18:30,218 --> 03:18:30,985
EMBOLISM, PULMONARY DISEASE,

4296
03:18:30,985 --> 03:18:33,588
THIS IS NOW OPEN TO MEMBERS FOR

4297
03:18:33,588 --> 03:18:35,456
DISCUSSION ON THIS CONCEPT IN

4298
03:18:35,456 --> 03:18:36,624
HIV, IN ADDITION I'M

4299
03:18:36,624 --> 03:18:37,258
PARTICULARLY INTERESTED IN

4300
03:18:37,258 --> 03:18:42,597
DISCUSSION ON THIS AREA OF

4301
03:18:42,597 --> 03:18:43,698
RESEARCH CLONAL HEMATOPOIESIS

4302
03:18:43,698 --> 03:18:45,767
AND INFLAMMATION AND IMPACT ON

4303
03:18:45,767 --> 03:18:47,735
OTHER HEART, LUNG, BLOOD, SLEEP

4304
03:18:47,735 --> 03:18:49,570
DISORDERS GIVEN KNOWN

4305
03:18:49,570 --> 03:18:50,905
ASSOCIATION WITH CARDIOVASCULAR

4306
03:18:50,905 --> 03:18:51,606
DISEASE, THROMBOSIS, LUNG

4307
03:18:51,606 --> 03:18:59,647
DISEASE. 

4308
03:18:59,647 --> 03:19:09,690
 

4309
03:19:20,868 --> 03:19:23,337
>> SO, I WAS REALLY HAPPY
TO

4310
03:19:23,337 --> 03:19:24,806
READ ABOUT THIS BECAUSE FOR

4311
03:19:24,806 --> 03:19:25,907
ANYONE WHO HAS FOLLOWED SICKLE

4312
03:19:25,907 --> 03:19:28,476
CELL IN THE PAST FEW YEARS KNOWS

4313
03:19:28,476 --> 03:19:29,477
THIS ISSUE OF CLONAL

4314
03:19:29,477 --> 03:19:30,778
HEMATOPOIESIS HAS COME UP QUITE

4315
03:19:30,778 --> 03:19:33,981
A BIT, AND THE DISCUSSION OF

4316
03:19:33,981 --> 03:19:35,983
OTHER INFLAMMATORY CONDITIONS

4317
03:19:35,983 --> 03:19:40,721
WOULD INCLUDE THINGS LIKE PNH,

4318
03:19:40,721 --> 03:19:41,222
APLASTIC ANEMIA,

4319
03:19:41,222 --> 03:19:41,956
UNDERAPPRECIATED AND WOULD BE

4320
03:19:41,956 --> 03:19:44,125
INTERESTING TO BE ABLE TO

4321
03:19:44,125 --> 03:19:45,226
COMPARE THOSE.

4322
03:19:45,226 --> 03:19:45,693
>> AGREED.

4323
03:19:45,693 --> 03:19:46,527
YEAH, WONDERFUL.

4324
03:19:46,527 --> 03:19:50,464
GOOD FURTHER EXAMPLES OF

4325
03:19:50,464 --> 03:19:51,766
POTENTIAL RELEVANT DISEASES.

4326
03:19:51,766 --> 03:19:53,201
ANY OTHER DISCUSSION FROM OTHER

4327
03:19:53,201 --> 03:19:56,070
MEMBERS ON THIS INITIATIVE?

4328
03:19:56,070 --> 03:20:05,046
 

4329
03:20:05,046 --> 03:20:07,148
>> I'LL RIF OFF ALLISON'S

4330
03:20:07,148 --> 03:20:08,850
COMMENT.

4331
03:20:08,850 --> 03:20:13,154
SORT OF BROADENING OUT FROM HIV,

4332
03:20:13,154 --> 03:20:15,356
NOW TO SEE AS WAS MENTIONED,

4333
03:20:15,356 --> 03:20:17,558
IT'S IN THE REPRIEVE TRIAL IN

4334
03:20:17,558 --> 03:20:23,130
HIV, BUT AS MANY ARE AWARE, CHIP

4335
03:20:23,130 --> 03:20:24,999
IS PROBABLY INVOLVED IN

4336
03:20:24,999 --> 03:20:25,967
ATHEROSCLEROSIS AS WELL,

4337
03:20:25,967 --> 03:20:29,337
GENERALLY WITHOUT THE HIV, AND

4338
03:20:29,337 --> 03:20:31,272
PERHAPS IT'S THAT THAT SYNERGY

4339
03:20:31,272 --> 03:20:34,275
IN REPRIEVE BETWEEN BASIC RISKS

4340
03:20:34,275 --> 03:20:38,112
OF ATHERO, PLUS HIV, AND SO I

4341
03:20:38,112 --> 03:20:39,447
THINK ONE QUESTION THAT MAYBE

4342
03:20:39,447 --> 03:20:42,717
COUNCIL CAN HELP US WITH IS

4343
03:20:42,717 --> 03:20:47,521
WHETHER THIS SHOULD BE BROADENED

4344
03:20:47,521 --> 03:20:49,690
TO NON-SORT OF HIV CONTEXT SORT

4345
03:20:49,690 --> 03:20:51,425
OF ALONG THE WAY, YOU WERE

4346
03:20:51,425 --> 03:20:54,762
SAYING, WOULD THAT BE SOMETHING

4347
03:20:54,762 --> 03:20:56,931
OF VALUE?

4348
03:20:56,931 --> 03:21:04,672
AND THIS IS OF SOME BROAD

4349
03:21:04,672 --> 03:21:05,506
INSTITUTE PERSPECTIVE BECAUSE

4350
03:21:05,506 --> 03:21:07,174
RESEARCH COMES FROM ALLOCATION

4351
03:21:07,174 --> 03:21:09,010
FROM THE AIDS PROGRAM, OAR,

4352
03:21:09,010 --> 03:21:17,652
WHERE  AS IF WE BROADENED WOULDN

4353
03:21:17,652 --> 03:21:22,523
THE OPTION OF BASE FUNDING, IN

4354
03:21:22,523 --> 03:21:22,990
DISORDERS NON-HIV.

4355
03:21:22,990 --> 03:21:28,062
WHAT IS THE SENSE OF THE COUNCIL

4356
03:21:28,062 --> 03:21:30,531
ABOUT THE OPPORTUNITIES?

4357
03:21:30,531 --> 03:21:33,634
>> I'LL KEEP GOING SINCE
MY MIC

4358
03:21:33,634 --> 03:21:34,435
IS WORKING.

4359
03:21:34,435 --> 03:21:37,238
I LIKE THE IDEA OF BROADENING

4360
03:21:37,238 --> 03:21:37,405
IT.

4361
03:21:37,405 --> 03:21:40,174
I WAS ONE OF THE PEOPLE THAT GOT

4362
03:21:40,174 --> 03:21:42,410
BROUGHT IN TO DISCUSS THE CLONAL

4363
03:21:42,410 --> 03:21:44,912
HEMATOPOIESIS WITH SICKLE CELL

4364
03:21:44,912 --> 03:21:47,081
WHEN IT FIRST EMERGED, AFTER THE

4365
03:21:47,081 --> 03:21:47,682
CURATIVE THERAPIES.

4366
03:21:47,682 --> 03:21:49,483
AND WE DIDN'T HAVE A TON OF DATA

4367
03:21:49,483 --> 03:21:51,018
TO GO OFF OF.

4368
03:21:51,018 --> 03:21:52,620
BUT I THINK THAT THERE'S GOOD

4369
03:21:52,620 --> 03:21:56,724
RATIONALE TO LOOK AT THIS, AND

4370
03:21:56,724 --> 03:21:57,391
MULTIPLE INFLAMMATORY STATES,

4371
03:21:57,391 --> 03:22:00,761
THEN WE WOULD HAVE BETTER

4372
03:22:00,761 --> 03:22:02,430
COMPARISONS ACROSS CONDITIONS.

4373
03:22:02,430 --> 03:22:04,665
AND GET A BETTER IDEA HOW MUCH

4374
03:22:04,665 --> 03:22:05,566
INFLAMMATION DRIVES VERSUS SOME

4375
03:22:05,566 --> 03:22:08,502
OF THE OTHER ISSUES.

4376
03:22:08,502 --> 03:22:10,504
>> A QUESTION ABOUT THAT.

4377
03:22:10,504 --> 03:22:12,273
I LIKE THE IDEA OF BROADENING.

4378
03:22:12,273 --> 03:22:14,008
MY QUESTION IS WHEN YOU PUT IN A

4379
03:22:14,008 --> 03:22:18,312
GRANT, IT HAS HIV IN IT, IT

4380
03:22:18,312 --> 03:22:19,613
USUALLY AUTOMATICALLY GETS

4381
03:22:19,613 --> 03:22:22,049
SHUNTED TO A PARTICULAR STUDY

4382
03:22:22,049 --> 03:22:22,350
SECTION.

4383
03:22:22,350 --> 03:22:25,052
AND I'M WONDERING IF THERE'S A

4384
03:22:25,052 --> 03:22:27,989
WAY, IF YOU BROADEN IT TO ENSURE

4385
03:22:27,989 --> 03:22:30,024
THAT HIV -- THOSE HIV GRANTS ARE

4386
03:22:30,024 --> 03:22:33,961
FOCUSED ON PEOPLE LIVING WITH

4387
03:22:33,961 --> 03:22:37,965
HIV, GOES TO THE PARENT STUDY

4388
03:22:37,965 --> 03:22:41,102
SECTION REVIEWING THESE GRANTS.

4389
03:22:41,102 --> 03:22:42,770
>> YEAH, AGAIN, THAT'S
SOMETHING

4390
03:22:42,770 --> 03:22:44,572
THE PROGRAM CAN THINK THROUGH,

4391
03:22:44,572 --> 03:22:46,674
BUT THAT'S ONE OF THE OTHER

4392
03:22:46,674 --> 03:22:50,311
THINGS WE MIGHT THINK OF IN A

4393
03:22:50,311 --> 03:22:53,147
NOFO OR TYPICALLY IN THE DAYS

4394
03:22:53,147 --> 03:22:54,215
WE'RE CURRENTLY IN, THAT WE

4395
03:22:54,215 --> 03:22:56,484
WOULD NEED TO HAVE THAT KIND OF

4396
03:22:56,484 --> 03:22:57,251
STRATEGY WORKED OUT, BECAUSE

4397
03:22:57,251 --> 03:22:59,453
THERE ARE A LOT OF OTHER

4398
03:22:59,453 --> 03:23:04,291
MECHANISMS TO DRIVE IT TO

4399
03:23:04,291 --> 03:23:05,126
INVESTIGATOR-INITIATED ARE ALSO

4400
03:23:05,126 --> 03:23:06,894
EVAPORATING, SO THIS IS WHY THIS

4401
03:23:06,894 --> 03:23:09,964
IS A GOOD DIALOGUE FOR PROGRAM

4402
03:23:09,964 --> 03:23:12,867
TO REALLY WEIGH THOSE DIFFERENT

4403
03:23:12,867 --> 03:23:14,368
CONSIDERATIONS BOTH SCIENTIFIC

4404
03:23:14,368 --> 03:23:16,904
OPPORTUNITIES OF BROADENING IT

4405
03:23:16,904 --> 03:23:19,740
AND REVIEW CONSIDERATIONS THAT

4406
03:23:19,740 --> 03:23:22,043
MAY COME FROM HOW WE STRUCTURE

4407
03:23:22,043 --> 03:23:29,984
THIS SO I APPRECIATE THAT.

4408
03:23:29,984 --> 03:23:32,319
>> THANK YOU FOR THE RICH

4409
03:23:32,319 --> 03:23:32,620
DISCUSSION.

4410
03:23:32,620 --> 03:23:33,487
THAT'S VERY HELPFUL.

4411
03:23:33,487 --> 03:23:41,195
I WILL HAND THIS OVER TO DR.

4412
03:23:41,195 --> 03:23:41,462
LAMAR.

4413
03:23:41,462 --> 03:23:42,163
OR GUS?

4414
03:23:42,163 --> 03:23:42,997
>> ALL RIGHT.

4415
03:23:42,997 --> 03:23:44,465
HERE WE GO.

4416
03:23:44,465 --> 03:23:48,235
THE LAST ONE, I'M PRESENTING A

4417
03:23:48,235 --> 03:23:53,641
CONCEPT FROM DIVISION OF

4418
03:23:53,641 --> 03:23:55,776
EXTRAMURAL RESEARCH ACTIVITIES,

4419
03:23:55,776 --> 03:24:01,382
DERA, 5129, SECONDARY SIGN-ON

4420
03:24:01,382 --> 03:24:02,817
SBIR/STTR READINESS PILOT,

4421
03:24:02,817 --> 03:24:04,318
TECHNICAL ASSISTANCE, LATE

4422
03:24:04,318 --> 03:24:04,685
DEVELOPMENT.

4423
03:24:04,685 --> 03:24:09,190
SB 1 CLINICAL TRIAL NOT ALLOWED.

4424
03:24:09,190 --> 03:24:10,724
SO THE COMMERCIALIZATION

4425
03:24:10,724 --> 03:24:13,461
READINESS PILOT PROGRAM CRP IS

4426
03:24:13,461 --> 03:24:16,831
TRANS-NIH PROGRAM MOST RECENTLY

4427
03:24:16,831 --> 03:24:20,601
AUTHORIZED BY 2022 SBIR AND STTR

4428
03:24:20,601 --> 03:24:22,236
EXTENSION ACT.

4429
03:24:22,236 --> 03:24:27,575
CRP FACILITATES TRANSITION OF

4430
03:24:27,575 --> 03:24:31,812
PREVIOUSLY FUNDED PHASE 2, 2B

4431
03:24:31,812 --> 03:24:33,114
PROJECTS BY PROVIDING SUPPORT

4432
03:24:33,114 --> 03:24:36,517
FOR LATHE LATER STAGE TECHNICAL

4433
03:24:36,517 --> 03:24:37,618
ASSISTANCE.

4434
03:24:37,618 --> 03:24:39,620
DUE TO UNIQUE MECHANISMS, AWARDS

4435
03:24:39,620 --> 03:24:43,591
UNDER THE CRP ARE NOT SUBJECT TO

4436
03:24:43,591 --> 03:24:44,992
THE SAME SUBCONTRACT RESTRICTION

4437
03:24:44,992 --> 03:24:47,528
AS 42 OR 44 AWARDS, ALLOWS

4438
03:24:47,528 --> 03:24:48,696
AWARDS TO COVER COST OF

4439
03:24:48,696 --> 03:24:50,631
ACTIVITIES THAT SHALL NOT

4440
03:24:50,631 --> 03:24:53,534
TYPICALLY SUPPORTED THROUGH

4441
03:24:53,534 --> 03:24:57,204
PHASE 2 OR PHASE 2B GRANTS OR

4442
03:24:57,204 --> 03:24:59,039
CONTRACTS BUT ARE NECESSARY

4443
03:24:59,039 --> 03:25:03,777
INCLUDING BUT NOT LIMITED TO

4444
03:25:03,777 --> 03:25:04,512
CHEMISTRY, MANUFACTURING,

4445
03:25:04,512 --> 03:25:05,746
CONTROL ACTIVITIES, VERIFICATION

4446
03:25:05,746 --> 03:25:10,918
AND VALIDATION STUDIES FOR

4447
03:25:10,918 --> 03:25:11,585
DEVICES, SOFTWARE, STUDIES,

4448
03:25:11,585 --> 03:25:13,821
CLINICAL TRIAL DESIGN AND

4449
03:25:13,821 --> 03:25:16,123
PLANNING, ANIMAL STUDIES TO

4450
03:25:16,123 --> 03:25:16,957
DEVELOP SURGICAL TECHNIQUES

4451
03:25:16,957 --> 03:25:19,093
RELEVANT TO NEW DEVICE AND

4452
03:25:19,093 --> 03:25:21,095
DEVELOPMENT AND VALIDATION OF

4453
03:25:21,095 --> 03:25:25,466
ASSAYS FOR CLINICAL TRIALS.

4454
03:25:25,466 --> 03:25:26,367
FURTHERMORE, THIS MECHANISM

4455
03:25:26,367 --> 03:25:31,238
ALLOWS 2 AND 2B GRANTEES TO

4456
03:25:31,238 --> 03:25:33,340
RECEIVE SUPPORT CONCURRENTLY.

4457
03:25:33,340 --> 03:25:35,876
BETWEEN 2016 AND FIST FISCAL

4458
03:25:35,876 --> 03:25:38,812
YEAR 2025, NHLBI HAS RECEIVED

4459
03:25:38,812 --> 03:25:41,348
105 APPLICATIONS FOR CRP LEADING

4460
03:25:41,348 --> 03:25:45,386
TO 22 FUNDED SB 1 PROJECTS,

4461
03:25:45,386 --> 03:25:49,456
SINCE THE LAST SIGN ON, MAY 22

4462
03:25:49,456 --> 03:25:51,058
COUNCIL MEETING, RECEIVED 35

4463
03:25:51,058 --> 03:25:54,195
APPLICATIONS, MADE 8 AWARDS TO

4464
03:25:54,195 --> 03:25:55,696
DATE.

4465
03:25:55,696 --> 03:25:57,831
NHLBI INNOVATION AND

4466
03:25:57,831 --> 03:25:58,532
COMMERCIALIZATION OFFICE

4467
03:25:58,532 --> 03:26:01,068
OBSERVED POSITIVE FINANCIAL AND

4468
03:26:01,068 --> 03:26:01,869
CLINICAL OUTCOMES ASSOCIATED

4469
03:26:01,869 --> 03:26:04,271
WITH CRP AWARDEES OVER MORE THAN

4470
03:26:04,271 --> 03:26:06,607
8 YEARS OF PARTICIPATION.

4471
03:26:06,607 --> 03:26:10,744
SOME EXAMPLES OF SUCCESSES ARE

4472
03:26:10,744 --> 03:26:12,213
AS FOLLOWS.

4473
03:26:12,213 --> 03:26:16,217
JANUARY 2024, IDE APPROVAL FOR

4474
03:26:16,217 --> 03:26:19,820
RCT TO DETERMINE EFFICACY OF THE

4475
03:26:19,820 --> 03:26:22,022
DEVICES IN ALLOWING CLINICIAN TO

4476
03:26:22,022 --> 03:26:24,158
ASSESS MATURATION, IN PATIENTS

4477
03:26:24,158 --> 03:26:25,392
UNDERGOING HEMODIALYSIS.

4478
03:26:25,392 --> 03:26:27,761
APPROVAL FOR THIS WAS RECEIVED

4479
03:26:27,761 --> 03:26:29,463
FOLLOWING POSITIVE RESULTS IN

4480
03:26:29,463 --> 03:26:33,467
INITIAL CLINICAL STUDY, ENDING

4481
03:26:33,467 --> 03:26:43,444
IN SEPTEMBER 2023.

4482
03:26:43,444 --> 03:26:45,613
CONSORTIUM AWARDED DARPA

4483
03:26:45,613 --> 03:26:46,080
CONTRACTS.

4484
03:26:46,080 --> 03:26:48,582
THIS PROGRAM ALLOWED THEM TO

4485
03:26:48,582 --> 03:26:56,223
CONTINUE DEVELOPMENT OF THEIR

4486
03:26:56,223 --> 03:26:58,392
RED BLOOD CELL PRODUCTS.

4487
03:26:58,392 --> 03:27:00,394
AND IN 2024, CLINICAL TRIALS,

4488
03:27:00,394 --> 03:27:05,966
EARLY CANDIDATE IN HEALTHY

4489
03:27:05,966 --> 03:27:06,767
VOLUNTEERS, RENEWED SECONDARY

4490
03:27:06,767 --> 03:27:12,906
PARTICIPATION IS CRUCIAL FOR

4491
03:27:12,906 --> 03:27:14,308
COMPLETING PRODUCT DEVELOPMENT

4492
03:27:14,308 --> 03:27:15,209
ACTIVITIES, ADVANCING NHLBI

4493
03:27:15,209 --> 03:27:17,444
STRATEGIC VISION THROUGH

4494
03:27:17,444 --> 03:27:19,913
DEVELOPING AND OPTIMIZING NOVEL

4495
03:27:19,913 --> 03:27:21,315
DIAGNOSTICS AND STRATEGIES TO

4496
03:27:21,315 --> 03:27:25,152
PREVENT, TREAT, CURE, HEART,

4497
03:27:25,152 --> 03:27:28,155
LUNG, BLOOD, SLEEP DISEASES.

4498
03:27:28,155 --> 03:27:31,659
WE PROPOSE COUNCIL APPROVE NHLBI

4499
03:27:31,659 --> 03:27:32,459
SECONDARY PARTICIPATION OR

4500
03:27:32,459 --> 03:27:35,796
REQUEST AND THIS WILL BE FOR

4501
03:27:35,796 --> 03:27:37,398
CONTINUED SECONDARY

4502
03:27:37,398 --> 03:27:38,666
PARTICIPATION AND ALLOWS $2

4503
03:27:38,666 --> 03:27:42,703
MILLION PER YEAR FISCAL YEAR 26

4504
03:27:42,703 --> 03:27:48,909
AND 2.2 MILLION FROM 2027 TO

4505
03:27:48,909 --> 03:27:52,046
2029 FROM NHLBI SBIR AND STTR

4506
03:27:52,046 --> 03:27:52,680
BUDGET.

4507
03:27:52,680 --> 03:27:53,647
DO ANY COUNCIL MEMBERS HAVE

4508
03:27:53,647 --> 03:28:01,689
QUESTIONS? 

4509
03:28:01,689 --> 03:28:02,189
 

4510
03:28:02,189 --> 03:28:12,633
WE MAY PROCEED TO VOTING.

4511
03:28:15,436 --> 03:28:16,303
AFTERWARDS, DR. LAMAR, I'LL

4512
03:28:16,303 --> 03:28:24,511
RETURN IT TO YOU. 

4513
03:28:24,511 --> 03:28:26,580
>> SO, WE'RE ALMOST DONE
WITH

4514
03:28:26,580 --> 03:28:28,182
THE VOTING ON THIS.

4515
03:28:28,182 --> 03:28:32,653
WE REACHED THE END OF THE DAY.

4516
03:28:32,653 --> 03:28:35,622
I'LL TURN IT OVER TO DR. GIBBONS

4517
03:28:35,622 --> 03:28:37,524
FOR FINAL COMMENTS OR IF COUNCIL

4518
03:28:37,524 --> 03:28:42,129
HAS FINAL COMMENTS OR QUESTIONS.

4519
03:28:42,129 --> 03:28:44,865
>> LIKE THE MICROPHONES, I
THINK

4520
03:28:44,865 --> 03:28:46,233
WE'RE ALL ABOUT WORN OUT AFTER A

4521
03:28:46,233 --> 03:28:48,268
LONG DAY OF DOING THIS.

4522
03:28:48,268 --> 03:28:49,203
REALLY APPRECIATE YOU GUYS

4523
03:28:49,203 --> 03:28:53,307
HANGING IN THERE AND PROVIDING

4524
03:28:53,307 --> 03:28:55,476
SUCH VALUABLE INPUT.

4525
03:28:55,476 --> 03:28:58,912
AND I KNOW YOU'RE READY TO

4526
03:28:58,912 --> 03:28:59,146
TRAVEL.

4527
03:28:59,146 --> 03:29:00,581
SO SAFE TRAVELS.

4528
03:29:00,581 --> 03:29:01,815
AGAIN, MUCH GRATITUDE.

4529
03:29:01,815 --> 03:29:02,950
I GUESS WE'RE ADJOURNED.

4530
03:29:02,950 --> 03:29:03,784
HERE IS MY GAVEL.

4531
03:29:03,784 --> 03:29:06,420
[END OF PROGRAM]

4532
03:29:06,420 --> 03:29:12,426
 

4533
03:29:12,426 --> 03:29:22,469